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Campylobacter jejuni is the most frequent cause of bacterial foodborne gastroenteritis worldwide and 
is thought to affect ~ 600, 000 people in the UK each year alone. The preparation and consumption of 
poultry meat remains the single source of human Campylobacter infection. With over 60 % of UK retail 
chicken carcasses showing Campylobacter contamination, the poultry sector represents a crucial 
reservoir for human disease. Having been previously considered a commensal within avian species, 
infection biology of C. jejuni within the broiler chicken shows limited understanding. Despite numerous 
efforts to develop both on-farm and post-slaughter controls, these have all proven to be of limited 
efficacy. Therefore, an improved understanding of the infection biology of Campylobacter in the 
chicken and effective control methods are a priority 
 
Here we used in vivo experimental methods to develop our understanding of the complex infection 
dynamics and host-microbe interactions associated with prolonged Campylobacter infection within a 
commonly used broiler chicken breed. Sampled between 2 & 28 days post-infection (d.p.i), 
bacteriological analysis revealed rapid C. jejuni colonisation of the chicken gastrointestinal tract, 
persisting at a high burden within the caecal crypts once established. While infrequent, evidence of 
systemic spread of C. jejuni to liver and splenic tissues was observed in all experimental trials, further 
confirming the invasive ability within the chicken. Early C. jejuni colonisation was associated with early 
upregulation of pro-inflammatory and Th-17 immune mediators (IL-1β, IL-6, IL17A and CXCLi2) (p < 
0.05) caecal and caecal tonsil tissue. Prolonged C. jejuni colonisation from 7 d.p.i onward was instead 
associated with regulatory immune mediators, IL-10 and TGFβ4 (p < 0.05).  
 
Modulation of the intestinal microbiome has been proposed as a potential control strategy for 
foodborne bacterial pathogens within poultry production, particularly as commercial chickens are 
reared in hatcheries with no maternal contact to develop an early or pioneer microbiome. We 
examined whether the at-hatch delivery of adult chicken caecal microflora (CMT) would lead to a more 
natural ‘avian’ microbiota which, in-turn, could drive an improvement in chicken gut health and reduce 
susceptibility to C. jejuni infection. Delivery of 0.1 - 0.2 ml CMT preparation (derived from 7-week old 
broiler chickens) within 4 hours post-hatch subsequently resulted in reduced within-flock transmission 
of C. jejuni and a reduced caecal C. jejuni burden (p < 0.05) following experimental infection compared 
to control birds. This response was consistently reproducible and sustained until commercial slaughter 
age. Compared to a commercial competitive exclusion microflora preparation (Aviguard®), CMT 
administration was significantly more protective against C. jejuni colonisation of the caeca (p < 0.05). 
16S rRNA Illumina MiSEQ analysis showed caecal content of birds treated with CMT had higher relative 
abundance of Firmicutes taxa – namely Ruminococcaceae (p < 0.05) compared to untreated control and 
Aviguard® treated birds. Caecal content of CMT treated chicks showed higher community richness 
compared to caecal content of both control (p < 0.001) and Aviguard® treated chicks (p < 0.001). These 
findings indicate that a novel, at-hatch transplantation of an adult chicken microbiota might 
prematurely drive successional development of the chick microbiota and reduce chicken susceptibility 



















































EVOLUTION OF THE MODERN BROILER CHICKEN 
 
It is thought that domestication of the modern chicken (Gallus gallus domesticus) originated 
in Southeast Asia nearly 10,000 years ago (Sawai et al., 2010). While this is undisputed, a 
defined ancestry remains under discussion (Stevens, 1991).  Charles Darwin is said to have 
attributed the evolution of the chicken to a single origin - that of the Red Jungle Fowl (Gallus 
gallus)(Sawai et al., 2010). While this conjecture was supported within an array of subsequent 
research (Delany, 2004; Fumihito et al., 1994; Lapennas & Reeves, 1983; Lawal et al., 2018), 
debate continued as to if this was in-fact an accurate evolutionary portrayal (Elferink et al., 
2012), with many stating genetic contributions from other wild jungle fowl breeds including 
Gallus varius (green jungle fowl), Gallus sonnerati (grey jungle fowl) and gallus lafayettei 
(Ceylon jungle fowl) (Haas et al., 2011). Irrespective of the precise phylogenetic history that 
defined the modern chicken, it was their fundamental adaptability to the range of global 
climates that cemented their dominance over many other domesticated livestock species 
(Siegel, 2014). With no natural migratory behaviors and a relatively small environmental 
range, the extensive global geographical distribution of the domesticated chicken is 
intrinsically linked to human mediated dispersal (Storey et al., 2012).  
 
Showing little reflection of current trends in poultry management, it is unlikely that the first 
domesticated chickens were domesticated for their ability to produce eggs or meat (Nicol, 
2015). Early ancestors of todays’ species would likely produce only five – six eggs within a 
single breeding season (Nicol, 2015). Interestingly, Liu et al. (2006) shows how distribution of 
chickens from a specific branch on the evolutionary tree was emulated by the distribution of 
the practice of cockfighting, long-outdated in many cultures, although still persisting in a 
number of regions including the Philippines and Thailand. It Is thought that this role in 
entertainment alongside religious practice provided a continued drive for domestication and 
distribution of fowl worldwide until mid-1800 (Al-Nasser et al., 2007; Miao et al., 2013). The 
transition toward the use of poultry for ornamental entertainment was likely a distinct 
evolutionary time-point of phylogenetic divergence (Megens & Groenen, 2012). Targeted 
breeding to intensify desired characteristics created specific morphological, physiological and 
behavioral phenotypes allowing for the creation of some 500 economical and fancy chicken 
breeds available today (Megens & Groenen, 2012). While some chicken breeds continued to 
show particular favor within poultry exhibition, others developed carcass and egg laying 
characteristics that would lend themselves toward intensive farming that would provide a 




commercialization of chickens for these specialized production characteristics first emerged 
in the 19th century, this handful of breeding lines dominate almost all of today’s commercial 
chicken population. It is thought that some of the earliest commercialized chicken breeds used 
in agriculture, such as White and Brown Leghorn and Rhode Island Red, were those that we 
today associate with intensive egg production practices (Griffin & Goddard, 1994). Continued 
poultry breeding to improve egg production generated an unwanted population of male 
chickens, as these could not be differentiated according to sex until approximately seven 
weeks of age (Griffin & Goddard, 1994). As such, the generation of the broiler meat industry 
was first demonstrated as a by-product of the egg-laying industry (Griffin & Goddard, 1994). 
Introduction of vent sexing technologies proved to be a point of divergence whereby breeding 
of chicken for meat was no longer constrained by the egg-laying industries (Griffin & Goddard, 
1994). With the emergence of this distinct arm of poultry production, selection for desirable 
meat-producing traits gave rise to specialized broiler chicken breeds often used today. Broiler 
breeds began to emanate across Europe (EU) and the United States (US), largely due to their 
remarkably fast muscle growth and hence, ability to increase body weight within relatively 
short periods of time (Ganabadi et al., 2009).  Today, over 100 million tonnes of poultry meat 
is produced each year, with comparably few specific breeds accounting for almost all of this 
production (Mottet & Tempio, 2017).  
 
Initial breeding selected for traits such as growth rate, feed conversion efficiency and muscle 
depth relatively crudely based on observable characteristics, and so breeding pairs were often 
simply the largest male and female individuals available (Elfick, 2006). Although conceptually 
simple, this process, called mass phenotypic selection, created a pure line of selected animals 
and allowed for rapid generation of fast-growing broiler breeds over relatively few 
generations (Elfick, 2006; Wolc et al., 2015). Over approximately 60 years, the growth rate of 
the commercial broiler chicken has increased by over 400 % (Zuidhof et al., 2014), with a 16 
week production period to market in 1950 being now reduced to just 6 – 7 weeks (Schmidt et 
al., 2009). This is largely thought to be a result of  a 50 % improvement in the measure of 
efficiency of food conversion to live weight gain (Food conversion ratio) with 25 g weight gain 
per day in the 1950s to 100 g per day in the modern chicken (Tickle et al., 2014). It soon 
became clear that accompanying this continued streamlining in poultry meat production 
came an associated decline in reproductive performance of these individuals (Thiruvenkadan 
et al., 2011). The negative correlation between increase body weight of the domestic chicken 




of which could be compensated for by alterations in management practices (Thiruvenkadan 
et al. 2011). Gradually, more emphasis was placed outside the phenotypic characteristics of 
an individual and onto genotypic characteristics of immediate relatives known as the 
‘Selection Index’ (Hazel, 1943; Nicol, 2015). Genetic improvement of modern commercial 
broilers is now largely achieved through the selection of genetic traits by only three sizeable 
primary broiler breeding companies – Cobb-Vantress, Aviagen and Hubbard (USDA, 2013). 
 
THE POULTRY INDUSTRY  
 
From the early evolution of the poultry industry, it has become the fastest growing agricultural 
sector worldwide. With short production cycles and food to muscle conversion efficiencies far 
outreaching those seen from red meat production systems, poultry benefit not only those of 
developed global regions, but also those limited in resource (FAO, 2013). It is in these regions 
that the production of poultry represents additional economic security, socio-cultural and 
religious importance (FAO, 2013). This being said, global production of chicken meat is 
dominated by China, the United States, the European Union and Brazil with this production 
heavily supplemented by low feed prices and rising domestic consumption (USDA, 2013).  
Global poultry meat consumption was recorded at 111 million tonnes in 2015, with this 
projected to almost 133 million tonnes by 2024 (FAO, 2013). It is thought that, of this, 89 % 
would be attributed solely to chicken meat to create a consumption of almost 118 million 
tonnes.  
 
In the United Kingdom (UK) production of broiler chickens has continued to grow year-on -
year from the first data sets publicly available in 1994 (NAW, 2018). Total poultry meat 
production in April 2018 was 182,800 tonnes, with broilers accounting or 90 % of total 
production, turkey (5%), boiling fowl (spent hens and spent breeders, 3 %) and duck (1%). A 
total in excess of a billion animals per annum. The value of the UK poultry industry is 
undeniable, with this being an industry continuing to evolve and contribute to the economy.  
 
THE CHICKEN DIGESTIVE TRACT 
 
It is the digestive system of any given animal that plays a vital role in conversion of feed intake 
into bioavailable nutrients that can be used for growth, maintenance and production 




their importance to modern society, it is essential to understand the first point of contact 
between feed and broiler chicken – the avian gastrointestinal tract (GIT). While it is not 
possible to describe all variations between the many avian species, it is important to describe 
key physiological and anatomical differences between birds and mammals, and how this may 
contribute to various beneficial phenotypes (Denbow, 2015). The chicken digestive system is 
a continuous tract from the mouth (beak) to the cloaca and comprises the oesophagus, crop 
(extension of the oesophagus), proventriculus (glandular stomach), ventriculus or gizzard 
(muscular stomach), small and large intestines, caeca and rectum (Alshamy et al., 2018; 
Klasing, 1999; Nasrin et al., 2012). Within each intestinal anatomical section we are able to 
identify several sequential periods of digestion, ultimately creating a utilisable end-product 
that can be absorbed by the host animal (Klasing, 1999).   
 
The oral cavity of the domestic chicken largely functions to mechanically and chemically 
process and lubricate ingested food, before its passage into the oesophagus. A distinct 
expansion of the oesophagus, commonly referred to as the crop, also exists for food storage 
(Klasing, 1999). The oesophagus continues from the oral cavity through to the thoracic cavity, 
where it terminates at the proventriculus (Madkour & Mohamed, 2019). The proventriculus, 
also known as the glandular stomach or ‘true’ stomach is the gastrointestinal site whereby 
digestion of the ingesta is initiated (Jacob & Pescatore, 2011). While no mechanical break-
down of feed occurs here, the secretion of hydrochloric acid (HCl) and digestive enzymes from 
the very glandular epithelial wall primes this intgesta for entry into the gizzard (Alshamy et al., 
2018). The gizzard, also known as the ventriculus or ‘mechanical’ stomach is a unique feature 
of the avian gastrointestinal tract that does not appear in mammalian anatomy (Jacob & 
Pescatore, 2011). With limited mechanical breakdown of feed within the mouth, the gizzard 
is the predominant site for such processes, with this increasing surface area available to 
previously added HCl and digestive enzymes (Klasing, 1999). Protecting the dense interior 
muscular arrangement of the gizzard from chemical digestion by these compounds is a thick 
protein rich secretory lining (Klasing, 1999). Specific shape and structure of the gizzard will 
vary between avian species according to diet, but is generally larger in size than the 
proventriculus within the broiler chicken (Svihus, 2014).  
 
The avian small intestine is largely homogenous in physiological form across different species, 
primarily due to the considerably reduced diversity in the physical nature of ingesta following 




intestinal is somewhat shorter than that of most mammalian species (Denbow, 2015). 
Irrespective of this disparity in size, as with mammals, the small intestine is the primary site 
of breakdown and absorption of carbohydrates, proteins and fatty acids (Lavin et al., 2008). 
The small intestine is made up of the duodenum and two further components, the jejunum 
and the ileum, which together form the lower small intestine (Gabriel et al., 2006). To combat 
the earlier addition of HCl, the pancreas secretes bicarbonate into the duodenum at point-of-
entry from the ventriculus (Jacob & Pescatore, 2011). Further digestion of proteins and lipids 
is aided by the additional secretion of digestive enzymes from both the pancreas and 
gallbladder, with this creating a readily available source of simple molecules that can then be 
passed through to lower sections of the intestinal system (Jacob & Pescatore, 2011). These 
molecules are absorbed in the duodenum and jejunum whereby the intestinal mucosa is 
specialized with epithelial folds, or villi, to facilitate maximal absorption. Here, the afore 
mentioned historic selection for specific developmental trains is emphasised, with divergent 
anatomical intestinal features evident between traditional broiler and chicken breeds 
(Yamauchi & Isshiki, 1991). Through comparison of broiler and layer breed intestinal villi 
structure, Yamauchi & Isshiki (1991) identify tendency toward larger and more densely packed 
structures within broiler breeds. However, common to all breeds is the increase in absorptive 
capacity of over 600-fold provided by these villi and associated microvilli (Alshamy et al., 
2018).  A zig-zag arrangement slows intestinal flow to increase contact time with the described 
epithelial border, supplementing this absorptive behaviour (Pelicano et al., 2005).  
 
Arising at the ileorectal junction are two blind-ended pouches known as the caecal crypts 
(Clench & Mathias, 1995). Exact functionality of the caeca remains relatively unexplored, 
although its importance in broiler nutrition is undeniable, with caecectomy procedures 
lowering food metabolisability and the digestibility of crude fibre (Denbow, 2015). It is in the 
caeca that water reabsorption and carbohydrate fermentation occur at maximal rate 
compared to other GIT regions (Svihus, 2014). A single cecum can be morphologically divided 
into three regions, with an epithelial layer that, although being continuous between regions, 
shows functional heterogeneity (Moretó & Planas, 1989). Caecal villi show greatest 
development at the region most proximal to the ileocecal junction, with these decreasing in 
size toward distal caecal regions (Svihus, 2014). Supplementary muscular structures located 
at ileocaecal junction are able to prevent the entrance of larger undigested molecules into the 




(Denbow, 2015). The caecal content is emptied into the large intestine for excretion up to 3 
times a day (Richards et al., 2019).   
 
The colon, occasionally referred to as the large intestine, is a section of the avian GIT linking 
the ileal tract with the cloacal vent whereby excreta is expelled (Denbow, 2015). Distinct to 
the mammalian colon, the avian colon contains a dense proportion of villi, although these are 
relatively flat compared to those seen in proximal intestine regions (Denbow, 2015). It is 
thought that the colon serves mainly in final water reabsorption as much of the utilizable 
nutrient source has already been derived from the faecal material by this stage (Georgaki, 
2014). The colon terminates at the cloaca, which forms the final tract of the digestive 
(coprodeum), urinary (urodeum) and reproductive (proctodeum) systems (Georgaki, 2014) 







Figure 1. Diagram displaying the chicken digestive tract from crop to cloaca with associated pH 
values for each given region. Diagram has been attained from Gabriel et al. 2006. 
 
 
THE CAECAL MICROBIAL COMMUNITY 
 
Inhabiting the gastrointestinal tract of the chicken are microbial communities, known 




community is comprised of bacteria, archaea, fungi, viruses and protozoa, however with 
anywhere up to 1013 bacteria inhabiting this system, these organisms predominate (Apajalahti 
et al., 2008). While all sections of the intestinal tract host vast microbial communities, these 
communities can be differentially quantified according to anatomical region (Gabriel et al., 
2006). Of these regions, the microorganisms may simply be located within the tract lumen or 
adhered to/embedded within the mucus layer (Albazaz & Buyukunal Bal, 2014). Of each of the 
GIT sites previously described, the crop and the caeca represent the primary sites of bacterial 
density, with 108 - 109 colony forming units per gram (CFU/g) bacteria in the crop compared 
to over 1011 within the caeca (Apajalahti et al., 2018). Accounting for all of the anatomical 
sections of the intestinal tract, the million-fold increases in bacterial density make the caeca 
an important region for microbial colonisation and as such, focus will be placed more heavily 
on understanding caecal microbiota as compared to other intestinal regions.  
 
Owing to recent advances in Next Generation Sequencing (NGS), accurate microbiota 
characterization has facilitated more investigation into the composition of the avian caecal 
microbiome than ever before (Stanley et al., 2015).  While early studies into the gut 
microbiome relied on bacteriological cultivation, we are now able to utilise an array of culture-
independent techniques, including genomics, transcriptomics, proteomics and metabolomics, 
to provide greater information about microbial community dynamics within the intestinal 
tract (Arnold et al., 2018). The requirement to culture bacterial groups to allow for their 
identification largely constrained our understanding of community taxonomic diversity, since 
many bacterial species are unable to grow under such artificial conditions (Mohd Shaufi et al., 
2015). With it now being understood that only 10 - 60 % of the caecal microbiota is cultivable, 
the introduction of more advanced molecular techniques during the early 2000s has since 
identified the complex chicken GIT as having over 600 bacterial species from more than 100 
bacterial genera (Torok et al., 2011). While a large number of these taxonomic genera and 
species remain unclassified, ever-more data is emerging discerning the known taxonomic 
groups inhabiting the caecal flora (Torok et al., 2011).  
 
One further facet that must be considered when performing taxonomic analysis of the broiler 
chicken microbiome, is the dynamic nature of this environment (Díaz-Sánchez et al., 2019). 
Breed, age and diet have all been identified as being strongly influential factors on the 
diversity and composition of the caecal microbiome (Ocejo et al., 2019). Additionally, even 




flocks, large inter-individual variation continues to exists within the bird caecal community 
structure (Torok et al., 2011).  However, the impact of this variation appears to be largely 
confined to taxonomic abundance as oppose to taxonomic diversity (Ocejo et al., 2019).  
 
It is well established that the pioneer microbiota forming within any animal occurs from 
parental and environmental sources immediately post - birth or hatch (Videnska et al., 2014). 
With a recognizable absence in parental influence upon chicks within commercial poultry 
rearing, the broiler chicken microbiome represents an ideal environment from which we can 
gain insight into the early influential behavior of specific bacterial taxons. Based on research 
by Ballou et al. (2016), the immature post-hatch broiler chicken caecal microbiome is 
characterized by low taxonomic diversity and overriding prevalence of gram negative 
Enterobacteriaceae (phylum Proteobacteria), with this finding commonly emulated by other 
research (Kubasova et al., 2019; Ocejo et al., 2019; Richards et al., 2019). Richards et al. (2019) 
observed taxonomic development of the caecal microbiota between 0 and 42 days post hatch 
(d.p.h), highlighting how this Enterobacteriaceae dominance may, however, be short lived, 
with peak relative abundance between 0 – 3 days post-hatch. The exact function of 
Enterobacteriaceae within the avian intestinal tract remains poorly determined (Grond et al., 
2018). Over time, a sharp decline in Enterobacteriaceae exists, forming a shift toward a more 
diverse microbial community incorporating more gram-positive bacterial groups, namely 
Clostridiales (phylum Firmicutes) (Ballou et al., 2016).  
 
By 14 d.p.h, Ruminococcaceae and Lachnospiraceae Families (phylum Firmicutes) comprise ~ 
90 % of the caecal microbiota (Ocejo et al., 2019; Videnska et al., 2014). Both Lachnospiraceae 
and Ruminococcaceae have received wide attention over recent years for their favorable 
ability to convert complex polysaccharides within digesta to a number of short chain fatty 
acids (SCFAs) – particularly butyrate (Oakley et al., 2014). With heavily proposed links to 
maintenance of gut homeostasis and intestinal epithelial integrity alongside favorable effects 
on host growth, this successional shift may represent significant benefit over primary caecal 
taxonomic communities (Oakley et al., 2014; Ocejo et al., 2019; Vital et al., 2014). This 
dominant Firmicutes presence remains for the remaining commercial broiler life-span, 
however, toward the end of the production cycle (~ 42 days post hatch), a proportion of these 
Firmicutes taxons are sequentially replaced by increases in Bacteroides (phylum 
Bacteroidetes) (Ocejo et al., 2019; Videnska et al., 2014). While this bacterial class also shows 




subsequent energy source for avian host, this energy source is produced in the form of 
propionate as oppose to the previously mentioned butyrate (Videnska et al., 2014). 
Propionate acts as a less available source of energy and is instead linked to a more sustainable 
chicken growth rate against energy acquisition (Ocejo et al., 2019). At this point in 
development, the number of genera forming the basis of the caecal community has more than 
doubled compared to that of the post hatch environment, with more than 200 genera 
identified (Oakley et al., 2014). As such, the final picture of the caecal community is dominated 
by anaerobes and fewer proportions of facultative bacteria, although many of these 
microorganisms are yet to be classified according to taxonomic name (Lu et al., 2003).   
 
The sequential replacement of specific taxonomic groups over time is thought to be a 
continual process throughout the life cycle of the commercial broiler chicken. The final picture 
of a caecal microbial environment dominated by Firmicutes with tendency toward later 
Bacteroidetes enrichment is strongly supported throughout literature, however it is 
undoubtable that this community structure can be influenced under the force of a number of 
confounding factors including breed, diet and antimicrobial use (Ocejo et al., 2019).  
 
FUNCTION OF THE CAECAL MICROBIAL COMMUNITY  
 
The bacterial population forming the intestinal microbiota contribute heavily to overall 
physiological homeostasis of the broiler chicken (Koutsos & Arias, 2006). With the immediate 
contact between this microbial community and the epithelial barrier of the avian host, the 
normal gut microbial community can have undoubted benefits, although such close contact 
will also be accompanied by associated physiological costs.  
 
One a major benefit of the microbial community is one based upon competitive exclusion (CE) 
(Shang et al., 2018). The basis of this competitive exclusion action can form one of two arms, 
direct or indirect (Grond et al., 2018). Simply, the great abundance of native bacteria form 
strong attachment to the enterocyte epithelial wall directly limiting the availability of binding 
sites and nutrients for opportunistic invading pathogenic bacterial groups (Shang et al., 2018). 
This direct interaction of pathogenic bacterial ecology extends further through the production 
of antimicrobial compounds and toxins from host bacterial communities with bactericidal 
activities (Grond et al., 2018; Kamada et al., 2013). In-vitro trials have previously found the 
bacteriocin Reuterin produced by Lactobacillus species has significant impact on growth of 




previously discussed, specific bacterial taxa commonly inhabiting the ‘healthy’ chicken 
microbiota, generate SCFAs such as propionate, butyrate, acetate and lactate as a by-product 
of anaerobic metabolism (Van Der Wielen et al., 2000). The use of these SCFAs as differentially 
available energy substrates for host tissues is well characterized (Bedford & Gong, 2018), 
however the ability of these organic acids to modulate the intestinal immune system is still 
being uncovered. As a direct means of activity, the presence of SCFAs creates a caecal 
environment of lower pH, considerably less favorable for growth of many invasive pathogenic 
bacteria (Mani-López et al., 2012). Indirectly, SCFAs are also able to contribute to the 
maintenance of intestinal epithelial protection and integrity, both being key factors negatively 
influenced during intestinal dysbiosis, that is, a movement away from intestinal homeostasis. 
Specifically, SCFAs are known to induce production of the glycoprotein Mucin within the 
protective intestinal mucosal layer (Willemsen et al., 2003). Additionally, SCFA production is 
heavily associated with an increased turnover of intestinal epithelial cells (Park et al., 2016) 
and upregulation of tight junction assembly (Peng et al., 2009). Through antagonistic 
modulation of both pro- and anti- inflammatory immune responses, SCFAs are capable of 
generating an intestinal environment of largely tolerogenic nature (Chakravarty et al., 2019). 
Downregulation of potentially harmful pro-inflammatory stimuli alongside induction of anti- 
inflammatory cytokine Interleukin-10 (IL-10) potentially limits the immunopathologies 
associated with dysbiosis of the intestinal microbiota (Chakravarty et al., 2019). Thought to be 
associated with more direct means of interaction with the intestinal immune system, the gut 
microbiota has undergone further experimental exploration over recent years (Grond et al., 
2018). Animals with experimentally induced germ-free intestinal tracts have been shown to 
have notably decreased cytokine production, systemic immunoglobulin abundance, mucus 
layer and relative amounts of gut-associated lymphoid tissues (GALT) (Tokuhara et al., 2019). 
As such, the commensal endogenous microbiota of the broiler chicken beneficially shapes the 
normal structure and function of the immune response to intestinal parasites (Broom & Kogut, 
2018).  The immediate contact of the commensal native gut flora with resident cells of the 
avian immune system, namely resident dendritic cells in the gut lamina propria promotes cell 
activation and maturation (Haghighi et al., 2005). Such activation is thought to have 
pronounced beneficial influence on activation of T-helper 1 (Th1) and Th2 responses, including 
cytokine secretion particularly associated with isotype switching of immunoglobulin classes.  
 
In the same instance, the modulatory action of the intestinal microbial environment on the 




intestinal microbiota far exceeds that of the host animal itself  and as such represents a large 
nutrient investment (Shang et al., 2018). Co-evolution largely maintains this nutrient 
competition between host and microbiota at a symbiotic nature since most host nutrient 
absorption occurs within the small intestine for the chicken, where bacterial density remains 
relatively low (Pan & Yu, 2014). However, if bacterial density within this intestinal region 
exceeds that of a homeostatic nature, nutrient availability tends first toward microbial species 
as oppose to host, creating nutrient deficit and depressed bird production efficiency (Pan & 
Yu, 2014; Shang et al., 2018). Extended periods of dysbiosis are thought to generate prolonged 
localized pro-inflammatory responses and further influence intestinal barrier function 
increasing the risk of pathogenic bacterial translocation across the intestinal epithelium 
(Shang et al., 2018).  
 
AVIAN INTESTINAL MUCOSAL IMMUNE SYSTEM 
 
Almost exclusively, invading pathogens will enter their host by breaching the protective 
surface associated with either the respiratory, reproductive or gastrointestinal tract (Kaspers 
et al., 2014). Since this surface area represents the largest source of contact between the host 
and the external environment, understanding the immunological control strategies employed 
as either preventative measures, or in response to pathogen breach is essential (Kaspers et 
al., 2014). This is of particular importance when discussing the commercial poultry industry, 
whereby large concentrated groups of animals exist in a localized environment, creating 
vulnerability of these broiler chickens for pathogenic bacteria to establish and rapidly 
proliferate throughout a flock. In this work we will discuss only those immune functions with 
relevance to pathogenic infections of the GIT. 
 
General organization of the avian intestinal immune tissues are somewhat similar to those of 
mammals, in that structure will largely vary according to physiological site along the length of 
the tract (Yegani & Korver, 2008). The intestinal barrier itself forms the primary, physical 
protection from infection and is largely composed of distinct anatomical regions based upon 
function and cellular component (Koutsos & Arias, 2006). Forming the intestinal mucosa is the 
single layer of epithelial cells, itself covered by a layer of protective mucus and the underlying 
lamina propria, housing widespread immune components (Kato and Owen 2005). The 
epithelial layer and its associated basement membrane form large hairpin protrusions, 
commonly referred to as villi, into the lumen of the intestinal cavity increasing the exposed 




of columnar cells is strengthened by intracellular junctional complexes, the most apical being 
tight junctions (TJ) (Guo et al., 2018). Serving to preserve the structural integrity and regulate 
paracellular permeability to larger molecules within the intestinal milieu, these multi-protein 
complexes are crucial to effective intestinal function (Awad et al., 2017).  
 
Nestled within this epithelial barrier are a series of specialized secretory cells, goblet cells, 
able to produce and secrete a mucus gel to overlay, lubricate and protect this barrier (Smirnov 
et al., 2005). Although thought to vary in thickness according to both intestinal site and avian 
species, the mucus layer is invariably predominated by a heavily modified glycoprotein, mucin 
(Koutsos & Arias, 2006; Zhang et al., 2015).  Acting largely as a physico-chemical barrier to 
infection, mucin works to prevent interaction between invading microbial agent and the host 
epithelial surface (Cornick et al., 2015; K. Zhang et al., 2015), with this theory supported by 
mouse models in work from Ermund et al. (2013). It has been suggested by Koutsos and Arias 
(2006) that this mucosal layer may also influence the lymphoid tissues underlying this 
epithelial barrier.  
 
The avian gut houses numerous types of immune cells, each differing in proportion and 
function; heterophils, macrophages, dendritic cells, natural killer (NK) cells, and B and T 
lymphocytes. Extending upon this is a group of intraepithelial lymphocytes comprising a series 
of Natural Killer (NK) cells and T-cells expressing either γδ or αβ form receptors (Lillehoj, 1994). 
T cell populations dominate such IEL communities, overshadowing both B cell and heterophil 
contribution (Smith & Beal, 2008). Underlying the epithelial layer described is the structural 
lamina propria, showing preference for B and T cell phenotypes, with these T cells largely 
being γδ type . γδ TCR are still subject to continuing research, however conjecture states their 
function in cytotoxicity and immunoregulation. The T cells inhabiting both the epithelial layers 
and associated lamina propria are thought to show localised polarization according to 
function, with CD8+ (Cytotoxic T cells) predominating within the epithelial layer and CD4+ (T 
helper cells) within the lamina propria (Koutsos & Arias, 2006). B cells located here secrete 
quantities of IgA into intestinal fluid.  
 
Forming one arm of the diverse mucosal associated lymphoid tissues (MALTs), the GALT is a 
series of both diffuse and structured aggregates scattered along the entirety of the intestinal 
tract (Lillehoj & Trout, 1996). Of note when discussing the avian lymphoid system, is the 




comprising structured tonsils at some anatomical locations (Casteleyn et al., 2010; Nochi et 
al., 2018; Smith et al., 2014). Focusing solely on distal GIT anatomical regions, the GALTs that 
functionally predominate are the Peyer’s patches (PP), caecal tonsils (CT), bursa of fabricius 
and diffuse lymphoid aggregates within the coprodeum and proctodeum (Casteleyn et al., 
2010; Yegani & Korver, 2008). The B and T lymphocytes that aggregate to form these tissues 
have migrated at the point of functional capability from two primary lymphoid organs – 
Bursa of fabricius (B lymphocytes) and the Thymus (T lymphocytes) (Sklan, 2005; Smith et 
al., 2014). PP’s are lymphoid aggregates found primarily within the lamina propria and 
comprise a specialized lymphoepithelial layer overlaying follicular structures (Lillehoj & 
Trout, 1996; Smith et al., 2014). Micro-fold (M) cells located within the lymphoepithelium 
are able to use apical projections to identify and present foreign antigenic material to the 
underlying lymphoid aggregations while also possessed a large quantity of vacuoles, 
reflecting their pinocytotic ability (Casteleyn et al., 2010). The trans-epithelial transport 
function of these cells has been highlighted in previous research, with M-cells representing a 
major route of entry across the gastrointestinal epithelial barrier for Salmonella species via 
trans-cellular endocytosis (Corr et al 2007). Such processes should also be considered for 
potential passage of Campylobacter jejuni from the intestinal lumen. It is within these PP 
sites that the primary induction of an IgA response to antigenic material is derived (Lillehoj & 
Trout, 1996). Thought to be largely similar in structure to the PP’s, CT tissues are located at 
the ileocaecal junction (Befus et al., 1980). Accompanying the T and B cell populations are 
differentiated B cells, or plasma cells, expressing surface IgM, IgY and IgA (Lillehoj & Trout, 
1996). The immune structures distributed along the intestinal tract work in accordance to 
induce appropriate immune-mediated responses to the continual array of challenge from 
ingested material and microorganisms that transition the intestinal system (Yegani & Korver, 
2008). It is thought that the GALT comprises more lymphocytes than the sum of all other 
lymphoid tissues collectively, highlighting the risk of exposure to pathogenic challenge 
comparable to other anatomical sites (Smith et al., 2014).  
 
CAMPYLOBACTER JEJUNI CHARACTERIZATION 
 
The earliest record of the genus Campylobacter is thought to stem from a series of articles 
published by Theodor Escherich in 1886 describing the isolation of a spiral bacteria from the 
colons of a number of children thought to have died from ‘cholera infantum’ (Escherich, 1886). 
However, culture of this novel bacterium was unsuccessful and much of this work remained 




attention was once again placed on this vibrio-link bacterium following diagnostic testing of a 
number of epizootic abortions in ewes by McFadyean and Stockman (Skirrow, 1994). Together 
with this, Jones et al., (1931) would later attribute an episode of winter dysentery in cattle to 
a ‘Vibrio’ bacterium given nomenclature Vibrio jejuni. The designation of Vibrio would later be 
renamed to Campylobacter (from the Greek and Latin meaning ‘curved rod’) In subsequent 
work published by Sebald & Veron (1963) following fermentative metabolism and DNA base 
composition testing distinguishing them from true Vibrio species (On, 2001). A further ten 
years later and four distinct Campylobacter species were described in comprehensive work by 
Veron & Chatelain (1973)– C. fetus, C coli, C. jejuni and C. sputorum.  
 
Campylobacter belongs to the Class epsilon Proteobacteria, a member of the Order 
Campylobacteriales (Young et al., 2007). At present, the genus Campylobacter has a total of 
39 names species and a further 16 subspecies (LPSN, 2019). The Genus Campylobacter 
encompasses Gram-negative, mostly microaerophilic bacterial species of small rod-like shape 
(0.2 - 0.8 µm x 0.5 - 5 µm) (Silva et al., 2011; Yi & Anderson, 2017).  The microaerophilic nature 
of these bacterial species makes them ideal candidates for occupying intestinal environmental 
niches of limited oxygen supply (D. J. Kelly, 2001). Generally, Campylobacter species have fast 
corkscrew-like motility emanating from unsheathe flagella located at one or both ends of the 
bacterium (Silva et al., 2011).  The Campylobacter species associated with human infection 
are thermophilic, with an optimal growth temperature of 41.5°C, although this is known to 
range anywhere from 30 – 46 °C (Silva et al., 2011).  
 
Since Campylobacter species are not readily culturable using conventional media, various 
selective culture medias have been developed largely on the basis of isolating Campylobacter 
jejuni from faeces during laboratory cultivation, with these forming moist, grey colonies on 
such media (Corry et al., 1995). Charcoal cefoperazone deoxycholate (CCDA) agars are most 
often the media utilised incubated at 42°C for 48 - hours, being able to culture comparatively 
more Campylobacter strains (Silva et al., 2011). CCDA media is often further supplemented 
with specific levels of antibiotics (mCCDA) allowing for further selective pressures (Silva et al., 
2011). Being obligate microaerophiles, Campylobacter species are grown under conditions off 
10 % CO2 and 5 % O2. 
 
Alternative diagnostic tools are often used to both rapidly identify and differentiate 
Campylobacter species. Most valuable to the food safety industry, molecular based methods 




organisms using a variety of species-specific gene sequences including 16S rRNA, glyA (serine 
hydroxymethyltransferase) and 23S rRNA (Ricke et al., 2019; Wang et al., 2002). Immune 
based methods such as Enzyme Linked Immunosorbent Assay (ELISA) and Flow cytometry 
testing are useful when large sample groups are processed, such as in epidemiological studies, 
however these methods require dedication of both increased time and expense (Ricke et al., 
2019) and often lack sensitivity due to cross-reactivity. More recent identification of 
Campylobacter species through matrix assisted laser desorption ionization-time of flight 
(MALDI-TOF) mass spectrometry has yielded both rapid and accurate means of identification 
(Bessède et al., 2011).  
 
ECONOMIC AND PUBLIC HEALTH IMPACT OF CAMPYLOBACTERIOSIS IN THE UK 
 
Campylobacter remains the leading cause of human foodborne bacterial gastroenteritis 
worldwide, referred to as campylobacteriosis upon diagnosis (Rushton et al., 2019). 
campylobacteriosis is commonly characterized by severe diarrhea and abdominal cramping 
and is generally self-limiting in nature (Barrett et al., 2018). While human cases of 
Campylobacter rarely exceed durations of one week, however, in some cases these symptoms 
can develop into post-infectious sequelae presenting as Guillan-Barré syndrome, reactive 
arthritis, and irritable bowel syndrome (Barrett et al., 2018). Of the numerous Campylobacter 
species previously highlighted, C. jejuni and C. coli are together the most common cause of 
campylobacteriosis cases comprising 80 % and 10 % of total human cases respectively 
(BIOHAZ, 2011).  
 
In 2017, Public Health England reported an infection rate within England and Wales of 95.57 
per 100, 000 population, with this equating to 56,729 campylobacteriosis cases over that 
same year (PHE, 2017). Incidence at this given level represents an increase on 2016 by 4,358 
cases (PHE, 2017). While this undoubtedly represents concern within the UK, of equal 
importance is the endemic nature of Campylobacter infection within those inhabiting 
developing countries (Barrett et al., 2018; Rushton et al., 2019). Most vulnerable to infection 
within these regions are infants of less than a year in age, with Rushton et al. (2019) reporting 
isolation rates of 8 to 21 % of all diarrhea samples.  
 
It is undeniable that Campylobacter is a causative agent of widespread morbidity and 
mortality. A commonly used metric to assess the burden of disease is the Disability Adjusted 




health of a specific population (Mangen et al., 2018). As of 2011, the DALY impact of 
campylobacteriosis across the EU was recorded as € 0.35 million per year, with a total 
economic burden of over € 2.4 billion (European Food Safety Authority, 2014). It is further 
estimated that the significant under-reporting of disease associated with campylobacteriosis 
creating disparity in the region of 10 to 100 times, with interpolated values of over 9 million 
cases of campylobacteriosis in the EU per year (European Food Safety Authority, 2014). 
Considering the high number of true campylobacteriosis cases, the burden of human 
Campylobacter infection cannot be underestimated (European Food Safety Authority, 2014). 
A comprehensive understanding of campylobacteriosis prevalence is essential in predicting 
the impact from disease burden. A seasonal pattern of Campylobacter contamination has 
been characterized in previous work, showing strong fluctuations in disease reporting 
according to calendar month (Friedrich et al., 2016). In western countries, seasonal peaks of 
Campylobacter reporting are observed in July, although this can also range to August in some 
climates (Rushton et al., 2019; Sibanda et al., 2018). The exact reasoning behind this seasonal 
fluctuation in human Campylobacter cases are still undefined, however, some inference has 
been lent toward specific changes in human behavior and environmental climate alongside an 
increase in pathogen vector reservoirs (Sibanda et al., 2018).  
 
SOURCES OF HUMAN CAMPYLOBACTERIOSIS  
 
It is thought that the majority of human campylobacteriosis cases can be attributed to a food 
or water-borne source (Mughini Gras et al., 2012; Pitkanen & Hanninen, 2017). Of these 
factors, food-borne transmission tends to dominate discussion, however the is growing 
evidence that environmental contamination of water sources with waste from C. jejuni 
infected animals has significant impact on levels of exposure (Wagenaar et al., 2013). While 
unable to grow in natural environments outside of the host species, survival of viable C. jejuni 
cells has been recorded for nearly 3 months in contaminated slurries and water containing 
contaminated animal waste (Nicholson et al., 2005). Direct contact with such contaminated 
animals has also been widely identified as a transmission pathway in human infection 
(Wagenaar et al., 2013) and further fly-borne transmission is likely to exacerbate such 
infection prevalence (Pitkanen & Hanninen, 2017). 
 
C. jejuni and C. coli are intestinal inhabitants within specific animal groups and have been 
isolated from a wide selection of warm-blooded species (Wagenaar et al., 2013). While the 




veterinary health, its carriage acts as an importance reservoir for human infection. Although 
this broad host range extends from wildlife to domesticated and pet animals, the particular 
burden found within commercial livestock animals cannot be negated. Using data collected 
during a national survey of livestock at slaughter in the UK (2003), either C. jejuni or C. coli 
were isolated from 54.6 % of cattle, 43.8 % of sheep and 69.3 % of pigs (Wagenaar et al., 
2015).  When assessing the capability of Campylobacter species to infiltrate food production 
systems, poultry in particular harbor vast Campylobacter burden (Wagenaar et al., 2015). It is 
thought that 50 - 80 % of all human cases of campylobacteriosis stem from the chicken 
Campylobacter reservoir, with 20 - 30 % solely emanating from preparation and consumption 
of broiler chicken meat (European Food Safety Authority, 2014). 
 
CAMPYLOBACTER IN THE BROILER CHICKEN  
 
Avian species, including commercial chicken breeds represent species with average body 
temperatures significantly above that of other mammalian animals (Duffy & Dykes, 2006). 
With stocking densities 0f 10,000 – 100,000 birds per house in commercial poultry farms 
across developed countries, this environment provides a perfect reservoir for optimal 
Campylobacter growth and transmission (Pitkanen & Hanninen, 2017). Over 30 years of 
epidemiological study has continued to portray chickens as the most important sources of 
human campylobacteriosis worldwide (Skirrow, 1994; Wagenaar et al., 2015). C. jejuni is both 
the most commonly isolated Campylobacter species in humans and chickens (Pielsticker et al., 
2012), reported to make up in excess of 65 % of chicken Campylobacter infection (Marotta et 
al., 2015).  
 
The term ‘farm-to-fork’ is often applied to the processes of meat production and encompasses 
all stages from primary production at rearing farms, transport, processing at slaughter, 
dressing and processing, retail and consumption of final meat products (Skarp et al., 2016). 
This integrated process provides multiple Campylobacter entry points and subsequent roles 
in transmission (Skarp et al., 2016). Ingestion of as little as 35 Colony Forming Units (CFU) of 
Campylobacter is sufficient to establish a colonizing population within 24 hours, with this 
showing rapid transmission throughout flocks (Stern et al., 1988). Once faecal shedding is 
established, almost all birds (> 95 %) within the flock of immediate contact will show 
colonisation in a matter of days (Stern, 2008). When established, colonisation tends to be 
sustained until the point of slaughter. While Campylobacter prevalence throughout the 




Campylobacter within positive flocks at slaughter is high, being approximately 80 % (European 
Food Safety Authority, 2014; Zhang et al., 2018). Further to this, cross-contamination during 
this post-processing period will have influence on the whole flock processed on a single line, 
with this increasing flock contamination prevalence (Hayama et al., 2011).  
 
Risk factors associated with broiler chicken C. jejuni infection 
 
 
Chicks are generally considered to be of Campylobacter-negative status at the point-of-hatch, 
with vertical transmission appearing to offer minimal contribution to Campylobacter spread 
(Camarda et al., 2000; European Food Safety Authority, 2014). Sibanda et al. (2018) indicates 
some ability of C. jejuni penetration through the surface of the egg when contaminated with 
faecal material, however this work requires further development to form a well-founded 
argument for vertical transmission from parent to offspring within the chicken. Longitudinal 
studies place most interest therefore, on horizontal transfer sources, largely exacerbated by 
the coprophagic nature of the chicken. While some horizontal risk factors appear at risk 
factors in many of the surveillance studies conducted into Campylobacter transmission within 
broiler chicken flocks, other secondary factors are dependent upon further variables (Table 
1). 
 
Table 1. Risk factors commonly cited amongst published literature as being important in 
C. jejuni colonisation of poultry flocks 
Risk factor Reasoning Citation 
Increasing age - Increase in prevalence from three weeks of age. 
- Increased risk of exposure with age and altered 
susceptibility. 
(Bouwknegt et al., 2004; 
European Food Safety 
Authority, 2014; McDowell 
et al., 2008; Sibanda et al., 
2018) 
Climate - Seasonal peak in colonisation between July-September 
alongside increases in temperature and rainfall 
- Increased ventilation and water consumption in warmer 
months 
- More flies acting as mechanical vectors 
(European Food Safety 
Authority, 2014; Hald et 
al.,  2008; Jore et al., 2010; 
Rushton et al., 2019) 
Thinning 
practices 
- Contamination of personnel and equipment 
- Stress promotes Campylobacter transmission 
(Hald et al., 2008; 




- Introduction of contamination from human traffic 
- Lack of due care with biosecurity processes 
(Agunos et al., 2014; 
Newell & Fearnley, 2003) 
Water and feed - Campylobacter is able to survive for long periods in water 
 - Contaminated or untreated water sources increase 
prevalence 
 - Use of nipple drinkers associated with increased 
prevalence 
 - Backtracking from contaminated drinkers to infect whole 
water line 
(Arsenault et al., 2007; 
Axelsson-olsson et al., 





LAG PHASE IN C. JEJUNI INFECTION OF THE CHICKEN 
 
With little to no evidence supporting the theory of vertical Campylobacter transmission from 
parent to offspring within the chicken, it is accepted conjecture that broiler chickens are 
hatched under a Campylobacter negative status (Berndtson et al., 1996; Newell & Fearnley, 
2003). Interestingly, epidemiological study suggests that this lack of detection persists until at 
least 10 days post-hatch under commercial production conditions, a biological characteristic 
distinct to Campylobacter infection within poultry species (Newell & Fearnley, 2003). The 
chick at point-of-hatch is protected by a relatively naive immune system with no established 
gastrointestinal microbiota or mucosal immune system (Hermans et al., 2014). While 
microbiota development begins immediately post-hatch, the first signs of immune 
development begin at around 4 – 7 days post-hatch (Hermans et al., 2014).  The source of 
protection during this period is yet to be uncovered, however its continued presence 
throughout longitudinal and experimental study has coined this period the name ‘lag-phase’. 
It is reported that the delay in Campylobacter colonisation of the commercial broiler chicken 
will most commonly last at least 2 weeks, at which point Campylobacter burden will increase 
until peak load at point of slaughter (6 – 7 weeks post-hatch) (Kalupahana et al., 2013; Newell 
& Fearnley, 2003; Sahin et al., 2003). Comprehensive research by Damjanova et al. (2011) 
assessed Campylobacter positivity of multiple animal and environmental samples at 2 and 7 
Insects   - Passive transfer of faeces from other houses and/or other 
livestock 
(Craven et al., 2000; Hald 
et al., 2008; Shane et al., 
1985) 
Wild animals  - Poor vermin control (Arsenault et al., 2007) 
Other livestock  - High risk of carriage from other positive farm livestock 
- Farming practices utilising multiple species have higher 
Campylobacter prevalence 
(Bouwknegt et al., 2004; 
Hansson et al., 2010; van 
de Giessen et al., 1998) 
Environmental 
contamination 
 - Contamination of environment can persist for many 
weeks 
- Free range flocks generally higher Campylobacter 
prevalence than conventionally raised 





- Inadequate disinfection of poultry house between flocks 
- Appears to have limited impact although may account for 
10 – 20 % of new flock infection 
(S. Smith et al., 2016)  
Antimicrobial 
use 
- Antimicrobial agents used as therapeutic agent to control 
disease   




 - Contradictory evidence exists between flock positivity and 
stocking density 
(Berndtson et al., 1996; 
Cardinale et al., 2004) 
Number of bird 
houses 
- Increased Campylobacter colonisation within each poultry 
house with increased number of total houses on site 
 - Cross-contamination from other houses 
(Arsenault et al., 2007; 
McDowell et al., 2008) 
Bird health Suggested association between Campylobacter flock 
positivity and bird health 




days post-hatch, including air, feed, water and faeces, with all samples returning no detectable 
contamination. By 6 weeks post-hatch, all birds within this study had detectable C. jejuni 
infection (Damjanova et al., 2011).  
 
While reasons underlying this so-called lag-phase remain unclear, Berndston et al. (1996) 
found day old chicks exposed to a more invasive Campylobacter strain exhibited pathological 
signs of diarrhea hours after artificial infection. This work infers that the lag-phase observed 
within poultry against Campylobacter infection might be associated with an inherent facet of 
poultry species instead of an ecological feature of the Campylobacter species (Newell & 
Fearnley, 2003). Adding to the complexity of the physiological basis behind this phenomenon 
is the dynamic nature of the avian intestinal niche during the early stages post-hatch (Newell 
& Fearnley, 2003). Maturation of the mucosal immune system, successional changes in the 
intestinal microbiota and changes in commercial production management processes create 
an array of confounding factors occurring throughout this period, with each having a yet 
unknown, impact on this age-related susceptibility of the chicken to infection (Newell & 
Fearnley, 2003).  
 
One concept, having been widely discussed in published literature, is the contribution of 
Campylobacter-specific maternally derived antibodies (MAB) found in abundance within 
chicks post-hatch before decline around 14 days post-hatch (Newell & Fearnley, 2003; Orhan 
Sahin et al., 2003). Sahin et al. (2003) highlighted how, of newly hatched chicks from five 
broiler chicken flocks, high levels of C. jejuni specific antibodies were detected in all chicks up 
to 7 days post-hatch. A series of experimental data sets present strong suggestion that MAB 
are able to target multiple loci on the outer membrane of C. jejuni supplemented by roles in 
complement mediated killing of these bacterial pathogens (Sahin et al., 2003). Of further 
interest are the commensal community assembly patterns associated with the developing 
chicken microbiota, with this thought to form further protective barrier in reducing 
susceptibility to infection. (Newell, 2002) provides evidence that specific pathogen free (SPF) 
birds are less resistant to experimental Campylobacter infection compared to commercial 
broiler chickens removed from production systems during the early lag phase. This 
understanding is further supported by Newell & Fearnley (2003) highlighting how 
Campylobacter-negative phenotype showed strong association with a birds’ ability to produce 




‘lag-phase’ period within the ecology of poultry Campylobacter infection could provide a vital 
basis from which future control strategies could be developed.  
 
CAMPYLOBACTER INFECTION IN THE CHICKEN: ACTING AS A PATHOGEN OR A 
COMMENSAL? 
 
While literature exists stressing the pathogenic nature of various opportunistic taxa known to 
invade the poultry gastrointestinal tract (Kaiser et al., 2006; Kaiser et al., 2000), the 
immunogenic ability of Campylobacter spp. has been significantly less explored (Meade et al., 
2009). As such, there exists continued contradiction within available literature as to the 
assignment of Campylobacter spp. within the chicken to either commensal or pathogenic 
ecologies (Wigley, 2015). Campylobacter is known to colonise the chicken via the fecal-oral 
route, establishing strong bacterial burdens within the lower GIT, particularly the caeca 
whereby it can colonise to levels up to 109 CFU/g caecal content (Sahin et al., 2015). It is 
thought that this colonisation can be established rapidly within the intestinal mucus, however 
Campylobacters may also be able to invade the intestinal epithelium and be further isolated 
from the bloodstream (Awad et al., 2018). As such, although the intestinal tract constitutes 
the main colonisation site of C. jejuni, dissemination and colonisation to a lesser extent has 
been observed in the liver, spleen, deep muscle, thymus and bursa of fabricius (Awad et al., 
2018; Chaloner et al., 2014; Humphrey et al., 2014), with this invasive ability also largely 
reliant on infecting Campylobacter strain (Awad et al., 2018; Chaloner et al., 2014).  
Colonisation of the broiler chicken with high burdens of C. jejuni is often in the absence of 
obvious clinical disease, resulting in a long-held opinion that colonisation is commensal and 
largely harmless (Humphrey et al 2014; Williams et al 2016). This poor immune activation 
would, in theory, result in the extensive persistence of Campylobacter colonisation 
throughout the intestinal system often seen (Meade et al. 2009; Awad et al. 2018). However, 
with increasing investigative research beyond that of the early descriptive studies, the 
stimulation of a pro-inflammatory response preceding that of a tolerogenic 
immunomodulatory nature has been associated with C. jejuni infection (Humphrey et al., 
2014; Li et al., 2010; Smith et al., 2005).  
 
This being said, work by Humphrey et al. (2014) indicates higher Campylobacter burden as a 
significant risk factor for welfare indications including hock marks and pododermatitis. Both 
hock marks and pododermatitis largely the result of high ammonia content on wet litter, and 




further eluded to in the work of Awad et al. (2018) whereby interaction of luminal C. jejuni 
with the intestinal epithelium is shown to decrease jejunal villus height and crypt depth, 
consequentially decreasing the available surface area for nutrient absorption. This can often 
result in notable decrease in animal productivity (Colles et al., 2016). 
 
INTESTINAL MUCOSAL SURFACE ASSOCIATION WITH C. JEJUNI  
 
The avian mucosal epithelial surface provides a physical barrier protecting the body’s 
interstitium from the external environment (Júnior & Júnior, 2016). Spanning the paracellular 
space between endothelial cells are a collection of tight junctions, with these controlling 
paracellular permeability. In-vitro studies by Lamb-Rosteski et al. (2008) were able to identify 
disruption in the claudin-4 protein of endothelial tight junctions following incubation with C. 
jejuni. This mechanism is thought to increase paracellular permeability, increasing likelihood 
of extra intestinal spread and fluid absorption (Júnior & Júnior, 2016; Lamb-Rosteski et al., 
2008).  
 
While commonly not adhering or invading the avian intestinal epithelial layer C. jejuni 
becomes largely associated with the mucus layer lining of the avian GIT (Looft et al., 2018). A 
core constituent of this mucosal layer are mucin proteins, with these glycoprotein units 
selectively influencing cellular adhesion, invasion and immune surveillance (Júnior & Júnior, 
2016). Having an active anti-inflammatory effect against Gram negative bacteria, Byrne et al. 
(2007) found dose-dependent attenuation C. jejuni using chicken intestinal mucus. While it 
has been observed throughout many in-vitro studies that C. jejuni is able to show invasive 
phenotypes against avian intestinal cells in-vitro, it has since been shown that addition of 
crude chicken mucus dampened such internalization (Byrne et al., 2007). This is in contrast to 
the results seen following the addition of human intestinal mucus, which showed contrasting 
hyper-internalization of C. jejuni (Byrne et al. 2007). Contribution of avian mucin glycoproteins 
to the attenuation of C. jejuni invasion within the chicken may provide some explanation as 
to its persistence within the avian intestinal tract.  
 
INNATE IMMUNITY TO CAMPYLOBACTER INFECTION IN THE CHICKEN 
 
As previously noted, the mature mucosal lining of the gastrointestinal tract constitutes one of 
the most immunocompetent region of the broiler chicken combining both innate and adaptive 
responses (Awad et al., 2018). It is the seqeuelae of events initiated during primary innate 




(Meade et al., 2009). Upon entry of Campylobacter, this innate immune response is 
responsible for recognizing these microbes as distinct from self, achieved through pattern 
recognition receptor (PRR) - dependent mechanisms of sentinel cells within the mucosal 
epithelia (Júnior & Júnior, 2016).  Of the PRR’s, it is the Toll-like receptor cells (TLRs) that are 
most commonly associated with Campylobacter infection and act to specifically recognize 
invading microbial components known as pathogen associated molecular patterns (PAMPs) 
(Otto et al., 2012). Once activated, phagocytosis of the pathogenic microbial is promoted, 
alongside the activation of a cell signaling cascade (Meade et al. 2009).  Work by De Zoete et 
al. 2010 found much of the TLR recognition of Campylobacter is reminiscent of that seen 
within human Campylobacter infection and predominated by TLR4 (De Zoete et al., 2010; 
Humphrey et al., 2014; Meade et al., 2009). Of particular importance is the activation of 
chicken TLR21, a recognition response not identified for the mammalian functional equivalent 
TLR9 during human infection (De Zoete et al., 2010; Humphrey et al., 2014; Meade et al., 2009; 
Shaughnessy et al., 2009). While the exact role of TLR21 following its identification of 
Campylobacter is yet to be defined, we have greater insight into the function of the more 
commonly referenced TLR4 (Awad et al., 2018). Activated by the gram-negative bacterial 
lipopolysaccharide (LPS) and bacterial DNA respectively, TLR4 and TLR21 have the ability to 
induce activation of multi-cellular pathways and production of antimicrobial peptides (AMPs) 
through production of a series of pro- and anti-inflammatory effector molecules (Awad et al., 
2018; Meade et al., 2009). Induction of inducible nitric oxide synthase (iNOS), and 
subsequently nitric oxide (NO), within chicken HD11 macrophage cell lines has been reported 
by He et al. (2012) resulting from chicken TL4 and TL21 activation. Chicken NO has known 
bactericidal activity and as such, represents an important localized innate immune response 
following infection (He et al., 2012). Conversely, studies by Meade et al. 2009 have linked 
increases in TLR21 expression to a concomitant downregulation of multiple avian β defensin 
(AvBD) genes. With the AvBD family known for being potent antimicrobial peptides, their 
downregulation in association with C. jejuni infection might contribute to the prolonged 
colonisation ecology (Meade et al. 2009).  
 
In mammalian epithelial and primary chick kidney cells expression of the pro-inflammatory 
cytokines interleukin-6 (IL-6) and IL-1β alongside the chemokine ligands CXCLi1 and CXCLi2 
(orthologues of the human chemokine IL-8) is increased in response to TLR4 and TLR21 
activation (Friis et al., 2009; Hermans et al., 2014). Up-regulation of the chemokine ligands 




sites of inflammation (Hermans et al., 2014) while IL-1β and IL-6 are common mediators of 
the innate immune response and further stimulate adaptive immune defenses. Although 
observable within the avian caecal crypts, this response is somewhat more dilute bar that of 
the chemoattractant chemokines CXCLi1 and CXCLi2 (Hermans et al., 2014). While debated as 
to its prevalence alongside C. jejuni infection, reports of infiltration of pro-inflammatory 
immune cells into the mucosal crypts may support this chemokine surge (Humphrey et al., 
2014; Larson et al., 2008).   
 
ADAPTIVE IMMUNITY TO CAMPYLOBACTER INFECTION IN THE CHICKEN 
 
Description of the adaptive responses to C. jejuni within the broiler chicken are limited within 
current research (Lacharme-Lora et al., 2017). Although sequential in timing, an adaptive 
response is also generated within the avian C. jejuni infection and is largely integrated with 
that of the innate response (Williams et al., 2016). Antigen presenting cells (APCs) within the 
mucosal epithelia are essential in recognizing and engulfing and presenting pathogen epitopes 
to naïve immune cells via protein structures known as major histocompatibility complex 
molecules (MHC) (Júnior & Júnior, 2016).  
 
The adaptive immune response consists of an antibody mediated and a cell mediated 
response (Erf, 2004). Cell mediated responses are associated with adaptive T cell mechanisms, 
with these being divided into two further T cell subdivisions known as T helper (Th) cells 
(CD4+) and T cytotoxic cells (CD8+) (Júnior & Júnior, 2016). Recognition of C. jejuni antigens 
by T cells is MHC-restricted, requiring antigen presentation and cytokine production (IL-6, IL-
12 and TNF-alpha) from APC’s to induce subsequent Th cell polarization (Júnior & Júnior 2016). 
This polarization will drive either a pro-inflammatory response profile (Th1) or an anti-
inflammatory response profile (Th2). More recently, a further Th17 pro-inflammatory 
response has been characterized. Upregulation of the Th1 profile correlated with increases in 
IFN-γ secretion from these cells while Th2 upregulation correlates with increases in Tumor 
Growth Factor- β (TGF-β), IL-4 and IL-10 secretion (Júnior & Júnior 2016). Th1 and Th17 guided 
responses are largely associated with attempted C. jejuni clearance while Th2 responses 
induce convalescence (Júnior & Júnior 2016).  The use of mathematical modelling approached 
couple with cytokine expression data show the relative importance of Th17 responses across 
broiler breeds with both high and low inflammatory responses (Reid et al. 2017).  As Th17 




increasing mucin and antimicrobial peptide production, it may be these responses are key to 
largely restricting infection to the gut. 
 
Humoral immune response to C. jejuni is reliant on B cell driven mechanisms, with these cells 
able to directly recognize soluble C. jejuni antigens by the B cell Receptor (BCR) without MHC 
mediated pathways (Júnior & Júnior 2016). Upon activation, B cells differentiate to form 
plasma cells that secrete BCR molecules more commonly referred to as antibodies, with these 
entering systemic circulation, mucosal surfaces and egg yolk (Júnior & Júnior 2016). Three 
immunoglobulin classes are known to exist, with these being avian orthologues of IgA, IgM 
and IgY (Júnior & Júnior 2016). IgM is largely homologous with that of the immunoglobulin 
group in mammals and is the first of the immunoglobulin classes produced during the humoral 
response (Janeway Jr, 2001). This early production is prior to cellular adaptation to the 
invading antigen and so is largely unspecific and of low affinity (Janeway Jr, 2001). However, 
IgM molecular are formed with pentomeric structure of 10 antigen-binding sites and as such, 
are effective activators of complement (Janeway Jr, 2001). This large pentomeric structure 
limits IgM localization largely to the blood (Wang et al., 2006). IgY largely works to opsonize 
antigenic material for immune cell phagocytosis, IgA works instead as a direct neutralizing 
antibody and is often the predominant immunoglobulin in secretions lining the mucosal tracts 
(Lamm, 1997). Of smaller size are the IgY and IgA isotypes, with these being of monomeric 
form (Janeway Jr, 2001). Intraepithelial lymphocytes (IELs) of the caecum, the primary site of 
C. jejuni colonisation within the chicken, have been assessed for thei potential function in local 
immune responses, however negligible changes in CD4+ and CD8α+ T cells have been 
observed (Pielsticker et al 2012). Later implication of breed effects on IEL response to 
Campylobacter in the chicken was implied by Han et al (2016) and may underly such findings. 
The same research observed significant effects of C. jejuni on LPL populations within the 
chicken caecum (Han et al., 2016)The exact nature of the immunoglobulin response to 
Campylobacter within the broiler chicken remains largely ill-defined and undeveloped (Wigley 
& Humphrey, 2014). Forming the basis of a significant portion of our knowledge is the 
evidentiary reaction between avian immunoglobulin classes and a number of C. jejuni outer 
membrane proteins (de Zoete et al., 2007). While such proteins are thought to include LPS 
and Lipooligosaccharides (LOS), the most notable remains C. jejuni flagellin (Sahin et al., 2001). 
While it is common for literature to correlate early chick MAB presence with the lag-phase 
commonly seen in Campylobacter infection of the chicken, functional studies into the exact 




avian immunoglobulin classes exist throughout the short commercial broiler life-cycle, it is 
generally accepted that Campylobacter colonisation of the chicken will induce an anti-
Campylobacter immunoglobulin response (Shoaf-Sweeney et al., 2008). However, this B 
lymphocyte mediated response may limit the overall extent of Campylobacter burden but 
shows little evidence of complete clearance of infection within the GIT, particularly the caeca 
(Sahin et al., 2003; Shoaf-Sweeney et al., 2008). The incline in immunoglobulin (namely IgY) 
production following Campylobacter challenge, as seen in the work of Myszewski & Stern, 
(1990) may serve mainly in clearance of infection of more proximal GIT sections, such as the 
ileum and jejunum, as oppose to clearance of the caecal crypts (Lacharme-Lora et al., 2017). 
Lacharme-Lora et al. (2017) suggests that, while not inhibiting initial passage of C. jejuni 
through these sections to the caeca, immunoglobulin mediated protection might instead 
protect against re-colonisation of the ileum and jejunum from more distal GIT sections. 
Targeted influence of these immunoglobulins on caecal C. jejuni colonisation is instead 
thought to occur at much later point in broiler development, usually outside the age remit 
seen for broiler chickens within the commercial poultry sector (Lacharme-Lora et al., 2017).  
 
CAMPYLOBACTER JEJUNI CONTROL METHODS 
 
Based on published literature reviews, Lin (2009) proposed three approaches to control of 
Campylobacter within the poultry industry, with these acting as distinct therapies in their own 
right, but also, strategies that can be amalgamated accordingly (Lin, 2009; Wagenaar et al.,  
2006). In essence, it is thought that Campylobacter can be controlled through; reduction in 
initial exposure, enhancement of poultry protection against colonisation post-exposure and 
therapeutic reduction in burden following colonisation (Lin, 2009), with a number of 






Table 2. Commonly referenced on-farm strategies for the control of C. jejuni within commercial broiler chicken farming. 
Factor Reasoning Potential limitations Reference 
Biosecurity 
measures 
General on-farm biosecurity measures including those 
regarding worker hygiene and physical farm barriers are 
required to prevent initial flock colonisation. While no one 
route, vehicle or vector has been identified in reducing 
Campylobacter colonisation, high biosecurity strategies 
have been correlated with Campylobacter absence.  
Sustaining such stringent biosecurity measures 
on large, established poultry farms may not be 
sustainable and would require complete 
cooperation from all farm workers.  
(Agunos et al., 2014; 
Lin, 2009; Meunier et 




Competitive exclusion therapies comprise defined or 
undefined preparations of commensal bacterial taxa. While 
the mechanisms are unclear, promising results have been 
observed in reducing poultry Salmonella infection, with 
contradictory results observed for Campylobacter.  
For commercial use within the poultry industry, 
more needs to be understood regarding 
mechanistic action, alongside full 
characterisation of the individual species 
present within the complex population.  
(Lin, 2009; Young et 
al., 2007) 
Vaccination  Vaccination strategies are were largely based of theory that 
initial lag phase protection from Campylobacter 
colonisation within the chicken was the result of maternally 
derived antibody presence. There has also been some 
reported correlation between reduced colonisation of C. 
jejuni with high antibody titres.  
Vaccination strategies are reliant on an 
increased understanding of avian 
immunological response to infection. The short 
production cycle used within the poultry 
industry limits potential efficacy of vaccine 
strategies employing humoral response 
strategies.  
(de Zoete et al., 2007) 
Genetic selection Differential colonisation of chickens has been observed 
between chicken breeds 
Individual variation in colonisation resistance is 
observed within-breed 
(Li et al., 2008; Stern 
et al., 1990) 
Bacteriophage  Bacteriophages (phages) are intracellular parasites able to 
target and lyse specific bacterial pathogens. Campylobacter 
models using oral Campylobacter infection of broiler 
chickens shows reduction in pathogen load ranging from 0 - 
5 log units.  
Reproducibility of beneficial impact on infection 
is poor, with some links being made to the 
development of target bacterial phage 
resistance. Widespread discontent amongst 
producers and consumers as to the phage 
(Carrillo et al., 2005; 
Clavijo & Flórez, 2018; 
Connerton et al., 





therapy safety has hampered its regulation and 
approval.  
Bacteriocin Bacteriocins are small molecular peptides produced by 
gram- positive and negative microorganisms. Several 
studies have reported a number of commensal bacterial 
species within the chicken that are able to produce 
bacteriocins against Campylobacter, with oral 
administration showed to reduce colonisation by 5 - 8 log 
units. 
Fear of resistance development  (Johnson et al., 2017; 




These are live commensal microbial preparations and non-
digestible food ingredients that promote beneficial 
bacterial growth within the gut. Probiotics, or 
probiotic/prebiotic combinations have shown promising 
results at preventing Campylobacter colonisation during 
primary production.  
Large discrepancy in trial outcomes based on 
variation in methodologies. Alterations in 
intestinal microflora communities following 
therapeutic administration appear to be 
relatively transient.  
(Kizerwetter-swida & 





COMPETITIVE EXCLUSION PRODUCTS 
 
For many years, the use of competitive enhancement products, such as those defined as 
prebiotics, probiotics and competitive exclusion products have largely been restricted to use 
within the poultry industry as means of growth promotion (Callaway et al., 2008). With 
continued bacterial resistance to commonly used antibiotics globally, the sub-therapeutic use 
of these antimicrobial agents within food production systems have come under increasing 
spotlight, with ever stringent legislature now in place to reduce its usage (Patterson & 
Burkholder, 2003). As understanding behind the importance of the gut microbiota in health 
and disease of living organism continues to grow, the area of competitive enhancement 
products in livestock industries is rapidly evolving and attracting significant investment as a 
viable alternative to antibiotic use.  
 
Microecology preparations can be employed in multiple different facets, most commonly 
ranging from prebiotics, defined Gibson & Roberfroid (1995) as ‘non-digestible food 
ingredients that have a beneficial effect on the host by selectively stimulating already existing 
bacterial species’ growth and/or activity’ to probiotics, defined by WHO  as ‘live 
microorganisms which when administered in adequate amounts will confer a health benefit 
on the host’ (FAO/WHO, 2001). While results of in vivo and in-vitro studies indicate efficacy of 
these pre- and probiotic formulations against Campylobacter infection of the broiler chicken 
(Ghareeb et al., 2012; Smialek et al., 2018), this opinion remains controversial. This variation 
in demonstrated effectiveness may be influenced by a multitude of factors, most notable 
being the exact source and compositional complexity of these pre- and probiotic formulations 
(Clavijo & Flórez, 2018). Following the observation that probiotic strains derived directly from 
chicken species were more effective in pathogen exclusion than those derived from alternate 
sources, use of a product representing a more ‘natural’ avian microbiota has been suggested 
as a more efficacious alternative (Clavijo & Flórez, 2018).   
 
The prospect of introducing a ‘normal’ microbial population from a host animal to that of the 
GI tract of a recipient has been defined as ‘competitive exclusion’ treatment and largely stems 
back to a pioneering study performed in 1973 (Callaway et al., 2008). Here, Nurmi & Rantala 
(1973) presented preliminary result demonstrating how administration of adult chicken 
microbiota could reduce establishment of experimental Salmonella spp infection when given 
early post-hatch. Four decades later and this principle has led to the development and 




While differences exist between the mechanistics of production and exact composition, each 
intervention has been formed off the basis of derivation from the caecal content and/or caecal 
wall of domestic poultry (Schneitz, 2005). The first known commercially available CE 
intervention, BROILACT® (Orion Corporation, Espoo, Finland), was launched across Finland 
and Sweden in 1987, with subsequent development in 1994 to a lyophilized formulation 
(Nakamura et al., 2002; Schneitz & Hakkinen, 1998). Composed of 32 strict and facultative 
anaerobic bacterial types, BROILACT® is a highly defined mixed culture derived from a single 
healthy hen (Nuotio et al., 2013). Since its release, BROILACT® has reported success in 
reducing Salmonella colonisation of commercial chickens in field conditions, alongside 
tentative links to protection from Campylobacter spp. (Palmu & Camelin, 1997; Schneitz, 
2005). However, continued large-scale use of BROILACT® has been somewhat restricted by a 
relatively short product shelf-life, allowing for the development of novel CE products with 
ability for extended periods of storage (Nakamura et al. 2002).  Aviguard® (Lallemand, 
Worcestershire, UK) Is a freeze-dried product of fermentation launched in 1993 and applied 
to chickens and turkeys via drinking water or spray application (Abudabos, 2013; Nakamura 
et al., 2002). Unlike BROILACT®, Aviguard® contains a mixture of live bacterial strains from the 
caeca of an adult healthy SPF chicken, with this commensal microflora only being partially 
characterized (Nakamura et al., 2002; Schneitz, 2005). Aviguard® is marketed as a CE product 
mainly associated with the reduction in colonisation of Salmonella spp., however protection 
from pathogenic E. coli has been reported.  
 
While the precise mechanistic action of CE interventions remains to be defined, effects are 
largely thought to be bacteriostatic by inhibiting the replication of intestinal pathogenic 
microorganisms within the caeca (Mead, 2000). While so much is yet to be discovered 
regarding avian pathogen interaction, alongside the microbe-microbe interactions of the 
intestinal tract, it is unlikely that we will truly understand the exact therapeutic actions behind 
these CE interventions for some time (Mead, 2000). However, five main modes of action have 
been postulated, described as (1) physical prevention of pathogen attachment and invasion, 
(2) nutritional competition direct and indirectly (3) production of biochemical antimicrobial 
products (e.g. SCFAs) (4) biological stimulation of the host immune system and (5) chemical 
reduction of the caecal pH creating a more hostile environment. With early studies (Soerjadi 
et al., 1981) stating protection of chicks from Salmonella colonisation as early as 1 – 4 hours 
after CE administration, it is largely considered that the physical process of direct competition 




likely to play an important protective role (Callaway et al. 2008; Mead 2000; Schneitz 2005). 
Physical competition processes are unlikely to form the sole processes by which CE therapies 
exert their effect, with pathogenic bacterial species with ecologies not requiring attachment 
to host epithelia also showing reduction in burden following CE exposure (Mead 2000). 
Production of SCFAs within the caecal crypt is also widely implicated in this protection through 
both direct and indirect means of reducing the competitive fitness of invading pathogenic 
bacteria (Callaway et al. 2008). Although clearly able to provide some degree of benefit to the 
commercial broiler chicken, this effect can often be transient allowing for subsequent 
infection at points of re-challenge (Cammarota et al., 2014). A practical basis for this limited 
establishment resilience could simply be due to initial exclusion product source and 
processing. With Aviguard® first isolated from SPF chickens before being fermented ex-vivo, 
crucial alterations in product composition could occur here, reducing the applicability as a 
truly ‘natural’ avian gut product.  
 
CAECAL MICROBIOTA TRANSPLANT (CMT) 
 
Fecal microbiota transplantation (FMT) refers to the transfer of a complete microbial 
environment from a healthy donor directly to recipient individual of the same species 
(Niederwerder et al., 2018). Unlike other microecological formulations described, FMT 
processes include the transfer of the complex fecal microbiota in its entirety, including 
bacteria, viruses, fungi, archaea, protozoa, metabolites and colonocytes (Bojanova & 
Bordenstein, 2016). This concept has led to the understanding that FMT is more than merely 
the transfer of beneficial microflora, but an entire organ transplantation in its own right 
(Borody & Khoruts, 2012). Previous work by Chapman et al. (2011) suggests that by increasing 
microecological preparation taxonomic complexity, an environment favoring establishment 
of the desired ‘probiotic’ taxa may be derived from other species much less in abundance, 
with these not going on to form strong colonisation footholds themselves. Since the caeca 
represents the intestinal region showing most dense microbial population within the chicken, 
this is the site of potentially most influence when considering donor microbiota for chicken 
microbiota transplantation (Sergeant et al., 2014). With the microbial taxonomic community 
structure significantly different between caecal and fecal content, use of caecal matter as 
donor material may be more representative of the ‘natural’ avian microbiota desired. As such, 
although this thesis will consider methodologies in regard to caecal microbiota 
transplantation (CMT) within the broiler chicken, published literature relating to this novel 




relating to FMT, in the understanding that identified theory within such research will be 
conceptually and functionally applicable to CMT methods.  
 
Although dating back to the 4th century, it is largely the clinical application of FMT in the 
treatment of human Clostridium difficile infection that has heralded its notoriety 
(Niederwerder et al., 2018). FMT application against antimicrobial non-responsive C. difficile 
infection was first described in 1983 and has since become highly successful as therapy 
administered across many mainstream hospitals (Niederwerder et al., 2018; Zeng et al., 2019). 
Alongside application to further human conditions including inflammatory bowel disease 
(IBD), Irritable bowel syndrome (IBS) amongst other conditions, FMT is widely utilized within 
veterinary medicine (Niederwerder et al. 2018).  Described in terms of transfaunication, FMT 
provided a means of restoring normal rumination within cattle following digestive or 
metabolic disorders (Niederwerder et al. 2018). Over time, implementation of FMT therapy 
has emerged in small animal practice as a means of treating canine parvovirus infection in 
puppies alongside colitis in horses (Pereira et al. 2018).  
 
While more complex in ecological composition, it is of largest inference that the mechanisms 
behind FMT function are simply an extension of the mechanisms described for CE based 
products described above. This being said, with the intestinal immune system showing great 
sensitivity to the microbial communities inhabiting both lumen and mucosal lining, the 
heightened complexity in infused transplantation microbiota might increase modulation of 
both innate and adaptive mucosal immune responses (Burrello et al., 2018). Studies by Hu et 
al. (2018) provides results on increase growth performance, intestinal barrier integrity and 
innate immune function in pigs orally gavaged with FMT therapy from donor pigs. Prophylactic 
use of FMT is more commonly associated with both porcine and poultry application, as oppose 
to therapeutic use described in most published literature associated with human use 
(Niederwerder et al., 2018).  With the infused fecal material given to therapy recipients of an 
undefined nature, the reliance on highly selective donor selection cannot be understated. 
While exact donor exclusion criteria will depend on species and indication, common screening 
practices consider genetic background, phenotypic characteristics, infectious disease, 







EARLY LIFE MICROBIOTA PROGRAMMING IN BROILERS  
 
While rapid production cycles of the commercial broiler chickens hamper the implementation 
of some disease control strategies, largely those relying on string adaptive immune response 
mechanisms, the nature of this system appears to offer an unusual opportunity for microbial 
based control strategies (Rubio, 2018). Post-oviposition, there is no contact between parent 
and offspring, completely eliminating the crucial influence this early experience has on 
offspring microbiota development (Rubio 2018). As previously stated, this early microbiota is 
able to rapidly establish unhindered and create an intestinal environment beneficial to their 
own requirements and a driver for the early immune development (Baldwin et al., 2018). The 
consequence of unnatural poultry hatching systems result in chicks earliest environmental 
exposure being that of non-avian bacterial sources such as human workers and transport 
crates (Rubio, 2018).  
 
The highly dynamic microbial variation is thought to exist only during early development, with 
Rubio 2018 stating continuation until 3 days post-hatch. The same work states clear 
differences in the at-hatch administration and of probiotic bacteria in the development of a 
stable, change resistant microbiota compared to natural environmental acquisition of the 
same bacterial taxa (Baldwin et al. 2018). 
 
SAFETY OF MICROFLORA PRODUCTS WITHIN THE POULTRY INDUSTRY 
 
Although modulation of the microbiota shows obvious promise in disease prevention, 
multiple areas of research have described increases in risk of disease associated with 
unnatural intestinal colonisation (Bartnicka et al., 2015).  One of the largest safety concerns 
associated with CMT introduction into regular clinical practice is the complexity associated 
with between-batch standardization and characterization. With substantial variation in 
microbial communities between individuals, reproducing specific active components cannot 
yet be assured (Bartnicka et al., 2015). Introducing microecological therapies of relatively 
undefined nature raises crucial safety concerns regarding the introduction of potentially 
pathogenic taxa to recipient species (Bartnicka et al., 2015).  
 
AIMS OF THIS THESIS  
 
While our understanding of the complex nature of Campylobacter infection within the broiler 




perceivably greatest importance to public health is the ability to reduce Campylobacter 
colonisation of the broiler chicken prior to point of slaughter. Here we use a collection of 
methodologies to first understand the ecology of Campylobacter infection within the broiler 
chicken, and subsequently, how frequency and severity of such infection can be minimized 
using novel microflora therapies.  
Using in vivo experimental models, Chapter 2 aims to describe the infection dynamics of 
Campylobacter infection within the broiler chicken until the commonly used commercial 
point-of-slaughter. This understanding can be used to supplement the further analysis of 
innate, adaptive and regulatory immune mechanisms associated with key time points post-
infection.  
 
Chapter 3 will form the initial proof-of-concept for the efficacy of CMT use within broiler 
chickens against Campylobacter infection at a flock level. Here we hope to define a basic 
mechanism of administration and outline the effects of this therapy on expressed chicken 
phenotype and disease resistance.  
 
As a progression from the preceding chapter, Chapter 4 both in vivo and in-vitro experimental 
protocols to uncover both the efficacy and potential immunological mechanisms of CMT 
action. With similarly derive CE products currently available but relatively seldom understood, 
direct comparisons will be drawn between the action of CMT and a commercial microflora 
product, Aviguard®.   
 
Finally, Chapter 5 will use genomic 16S rRNA techniques on the caecal samples taken from in 
vivo protocols of Chapter 4 to provide a basis of understanding in how both CE and CMT 
therapies work to modulate the chicken microbiota at early time points prior to infection. We 
can then draw comparison between these alterations in microbial structure and composition 














Chapter Two: A study into the dynamics of prolonged 

















Campylobacter continues to be the most common cause of bacterial foodborne 
gastroenteritis worldwide. Epidemiological reporting reports 250,161 laboratory confirmed 
cases of campylobacteriosis across 29 EU/EEA countries in 2017, marking a slight decrease 
compared to 2016 (ECDPC, 2019). Data on the prevalence of campylobacteriosis outside 
Europe and North America remains relatively sparse, however it is likely that infection is 
endemic in Africa, Asia and the middle east (Kaakoush  et al., 2015). Although incidence varies 
vastly from country to country, it is generally understood that true disease incidence is much 
higher than that recorded, largely due to under-detection and under-reporting (Wagenaar et 
al., 2013). Wagenaar et al. (2013) estimated that from the 198,252 EU campylobacteriosis 
cases reported in 2009, the true incidence of disease was 46.7 times this value, exceeding 
9 million cases. Furthermore, the economic burden to the EU of Campylobacter infection is 
thought to be in excess of € 2.4 billion per year in lost productivity (European Food Safety 
Authority, 2014). Of even greater concern is the prevalence of campylobacteriosis in the 
developing world, particularly amongst children < 5 years of age within these regions. One 
study reported infection rates as high as 60,000 per 100,000 population (Hanif et al., 2018). 
Poor sanitation, close contact with live animals and inefficient cooking of poultry meat are 
considered the key contributions to the hyperendemic nature of infection within the children 
of these countries (Zilbauer et al., 2008).  
 
Infection of Campylobacter in humans is largely associated with two reservoirs of infection; 
infected animals and birds and infected water sources. Links between untreated water and 
human campylobacteriosis are well established (Wilson et al., 2008). However, the 
contribution to disease resulting from this bacterial reservoir appears sporadic and highly 
seasonally dependent (Wilson et al., 2008). As such, infected water sources are thought to be 
a lesser public health risk, particularly in countries with a more developed sanitation 
infrastructure (Lin, 2009). Wilson et al. (2008) goes on to state that wild animal and 
environmental Campylobacter reservoirs are responsible for an estimated 3% of human 
campylobacteriosis cases, with these cases also peaking during warmer summer months. 
Regarded as the most important source of transmission, is the zoonotic transfer of 
Campylobacter from a domesticated animal host. Campylobacter has been isolated from the 
gut of multiple warm-blooded farm, wild animal and bird species (de Zoete et al., 2007). 
Despite this wide repertoire of hosts, chickens continue to be the largest source of infection, 




to 30% of cases could be solely attributed to the handling, preparation and consumption of 
broiler chicken meat (BIOHAZ, 2011).   
 
Despite a reported reduction in overall meat consumption across the EU over recent years, 
the poultry meat industry has continued to see production increase (BIOHAZ, 2011). Offering 
consumers, a cheap, lean and easily accessible source of protein has led to increased poultry 
meat consumption across countries both within and outside of Europe. With chicken being a 
natural vector of Campylobacter infection and estimated positivity within EU flocks sometimes 
reaching 90%, the Campylobacter reservoir harbored within the poultry industry confers a 
major public health concern (de Zoete et al., 2007). It is reasonable to believe that reduction 
in both the incidence and the level of Campylobacter contamination in commercial poultry 
meat would result in a considerable reduction in human campylobacteriosis. The European 
Food Safety Authority (EFSA), based on work by Rosenquist et al. (2003), predicts that half of 
all cases of human campylobacteriosis within the EU could be eliminated by reducing 
Campylobacter positivity within poultry flocks to 25 % per member state. Further to this, using 
the Rosenquist et al. (2003) risk assessment framework encompassing hazard identification, 
hazard characterisation, exposure assessment and risk characterisation on Dutch 
campylobacteriosis cases, it was suggested that simply reducing poultry carcass infection load 
by 100-fold could result in 30 times less campylobacteriosis incidence (Lin, 2009; Rosenquist 
et al., 2003). This prediction of the effects of specific mitigation strategies on the incidence of 
Campylobacter infection within humans has been used to inform both the Food Standards 
Agency (FSA) and EU policy on potential Campylobacter controls (FAO, 2009).Controlling 
infection within commercial poultry flocks is made more complex by the fact that broiler 
chickens rarely show obvious clinical signs of C. jejuni infection, despite levels of colonisation 
reaching an excess of 1010 CFU/g of caecal material (Ghunaim, 2009).   
 
Although more than 20 separate species of the Campylobacter genus have been identified 
within humans, the two species known to be the predominant cause of human 
campylobacteriosis are C. jejuni (~ 90%) and C. coli (~ 10%) (de Zoete et al., 2007) and 
therefore this study will primarily focus on C. jejuni.  Colonisation of commercial poultry flocks 
with C. jejuni generally begins from 2-3 weeks of age, although successful colonisation models 
have been described following experimental infection at a younger age (Sahin et al., 2002). 
Understanding of this apparent lag phase in infection remains limited, although many facets 




flora transition (Sahin et al., 2002). Once present within a flock, C. jejuni is able to rapidly and 
effectively colonise almost all birds (>95%) within only a period of several days (Hermans et 
al., 2014). The main site of C. jejuni colonisation within its avian host is the intestinal tract, 
with highest numbers primarily found at the distal end of the gastrointestinal tract (GIT) within 
the bind caecal crypts (Humphrey et al., 2014). Coward et al. (2008) found that within only 24 
hours of ingestion, C. jejuni was able to migrate to the caeca, multiply and establish a strong 
colonisation from only 35 CFU. Once established within the caecal crypts, C. jejuni can be 
found persistently within the caecal lumen and mucosal layer without adhering or invading 
the intestinal epithelial cell layer (de Zoete et al., 2007). Colonisation of the caeca shows little 
tendency towards clearance and as such, persistent colonisation is exhibited that extends until 
slaughter (Hermans et al., 2014). Colonisation of the avian intestinal tract has long been 
thought of as commensal in nature, lacking host associated intestinal inflammation and 
pathology (Mead, 2000). Such a concept has been queried over recent years, with Humphrey 
et al. (2014) proving C. jejuni colonisation leads to diarrhoea alongside compromises in the 
integrity of the mucosal epithelial barrier (Awad et al., 2017). Concomitantly, C. jejuni spread 
beyond the confines of the caeca has been observed, with bacteria recovered from the small 
intestine, crop, gizzard, liver and spleen (Chaloner et al., 2014). This ability to cause systemic 
infection has put further question onto the apparent benign infection model previously 
thought to be established by C. jejuni within avian hosts.  
 
With evidence that C. jejuni is able to traverse the intestinal epithelial barrier and enter 
systemic circulation the close interaction between bacterium and host suggested by this 
would likely induce local and systemic immune responses (Han et al., 2016; Smith et al., 2008). 
While little published evidence exists describing the nature of an innate immune response to 
C. jejuni within the chicken, some description of humoral response to infection is available 
(Lacharme-Lora et al., 2017). It has been suggested by Lacharme-Lora et al. (2017), that 
although immune clearance of C. jejuni may be somewhat attributed to antibody production 
within birds older than average commercial slaughter age, antibody-dependent clearance is 
negligible in birds younger than 8-weeks of age. Such clearance was also found to be largely 
localized within the ileum and jejunum, with limited influence within the caeca, implying 
antibody production in these more proximal gastrointestinal tract (GIT) sites will only prevent 
C. jejuni recolonisation locally, not affecting subsequent colonisation in more distal sites such 





To induce the adaptive immune responses discussed, it is first necessary for C. jejuni to elicit 
some degree of innate immune response (Smith et al., 2005). Much of the work characterizing 
these pathways have been developed in vitro using avian cell lines (Smith et al., 2005). 
However, observably distinct invasion capabilities are associated with use of C. jejuni in vitro 
using avian enterocyte lines (Smith et al., 2005). As such, although studies have made 
advances in identifying differential expression of immune transcripts associated with C. jejuni 
infection using these models, such data may not be truly reflective of an in vivo system. Of 
note is the work conducted by Reid et al. (2016), who utilized in vivo experimental challenge 
designs to assess time-dependent cytokine response to C. jejuni. Here, they highlight the 
overarching dominance of protective Th17 responses, such as IL-1ß and IL-6 in the stimulation 
of IL-17A. Other factors, such as those associated with T regulatory (Treg), pathways have also 
been investigated for their role in maintaining broiler chicken intestinal homeostasis 
(Humphrey et al., 2014). 
 
In order to enhance our current ability to control C. jejuni infection within commercial poultry 
industry worldwide, it is first essential to understand the biological infection dynamics and 
responses to infection within its natural avian host. With chicken being both a reservoir of 
C. jejuni and an important food source for humans across both the developing and developed 
world, in vivo poultry infection models act as tools in understanding aspects of host 
colonisation (Young et al., 2007). From this foundation in understanding, we would be more 
able to identify potential control strategies and when these should be implemented; either 
prior to or within the stages of C. jejuni colonisation.   
 
The aim of both experiments 1 and 2 within this study were to conduct in vivo poultry infection 
trials that would demonstrate the infection dynamics and host immune response to C. jejuni 
following a longer period of infection than that generally studied. From this we were hoping 
to elucidate when C. jejuni colonisation occurs within the small intestine and the caeca and 
whether such colonisation status would influence the profile of immune response generated. 
We were also looking to identify if extra-intestinal spread to the liver and spleen occurred 
within broiler chickens and whether this was correlated with level of C. jejuni load within the 






MATERIALS AND METHODS 
 
BACTERIAL ISOLATES AND GROWTH CONDITIONS 
 
Strain C. jejuni M1 was selected for use within this study, as it has a well characterized genetic 
background within published literature and is a strain associated with transmission from 
poultry to humans (Chaloner et al., 2014; Humphrey et al., 2014). C. jejuni M1 is of sequence 
type (ST) 137 (clonal complex [CC] 45) human isolate kindly provided by Lisa Williams 
(University of Bristol) (Chaloner et al., 2014). This ST is commonly represented within UK retail 
poultry and has been used within our laboratories for similar in vivo methodologies 
(Humphrey et al., 2014). 
 
C. jejuni stock was maintained at - 80 °C on Microbank™ beads (ProLab Diagnostics, Cheshire, 
UK) until use. Stored C. jejuni strains were subsequently cultured using a 5 µl sterile disposable 
loop as previously described by (Chaloner et al., 2014). Briefly, bacteria were grown on 
Columbia blood agar (CAB) (Lab M Ltd., Heywood, Lancashire, UK) supplemented with 5% 
defibrinated horse blood (Oxoid, Basingstoke, Hampshire, UK at 41.5 °C for 48 hours under 
microaerobic conditions (80 % N2, 12 % CO2, 5 % O2 and 3 % H2).  
 
A single colony from the grown bacterial culture was selected and used to inoculate 10 ml of 
Mueller Hinton broth (MHB) (Lab M Ltd, Heywood, Lancashire, UK) in a sterile 30 ml universal 
tube. Isolation of a single colony from the initial growth minimised the possibility of genetic 
variation within the resulting C. jejuni working solution. The 10 ml working liquid culture was 
grown for 24 hours under microaerobic conditions at 41.5°C with a loosely capped lid. After 
overnight incubation, liquid culture was mixed using a vortex mixer and 2 ml of culture tested 
for Optical Density (OD) value using a spectrophotometer (Cecil CE2040, Cambridge, UK). 
Measured OD of the liquid culture was adjusted to 0.1 - 0.13 at OD600, corresponding to a 
count of 1 x 108 CFU/ml. To obtain the desired 1 x 106 CFU/ml for subsequent infection, a 
1:200 (v/v) dilution of 100 µl liquid culture into 20 ml MHB was made. Serial 10-fold dilutions 
of the final liquid culture in 1 x Maximal Recovery Diluent (MRD) (Lab M Ltd, Bury, UK) were 
made to 10-8 for viable colony enumeration via the Miles & Misra method (Miles & Misra, 
1938). Briefly, two agar plates were visibly divided into 8 equal sectors (four sectors per plate) 
and thoroughly dried. In each sector, 3 x 20 µl of the appropriate sample dilution was pipetted 




before incubation. Each sector was then observed for colony growth. Colonies were 
enumerated in the highest dilution series that contained three replicates of full-size, discrete 




Experimental infection trials were carried out at the University of Liverpool poultry unit 
(Liverpool, UK) in accordance with United Kingdom legislation governing experimental 
animals. All work was conducted under project licences PPL 40/3652 (Experiment 1) and 
P999B8C93 (Experiment 2) and was approved by the University of Liverpool ethical review 
process prior to the award of the licence. All animals held at the site were checked a minimum 
of twice daily to ensure individual and flock animal health and welfare. All in vivo experiments 
used day-old broiler chicks (Ross 308) of mixed sex, obtained from a local commercial 
hatchery. Ross 308 remains the most commonly reared broiler breed within the UK, justifying 
its use within these experimental models. All chicks were transported directly from the 
hatchery environment to the experimental unit and observed for any potential indications of 
ill health.  
 
Chicks were maintained according to treatment group in separate experimental rooms within 
floor pens at a stocking density in accordance with Home Office Code of practice 
recommendations. All rooms were supplied with filtered air supply, while groups intended for 
experimental infection protocols were housed in rooms with lobbied entry and additional 
dedicated protective clothing and boots. All animals were housed in conditions previously 
described by Humphrey et al. (2014). Birds were given ad libitum access to water and a 
pelleted vegetable protein-based diet (SDS, Witham, Essex, UK). Feeders and drinkers were 
provided at a level of 1 per 15 birds. Room temperature was kept at 30oC before being reduced 
to 20oC when the birds were three weeks of age. To limit welfare problems associated with 
wet litter and to limit within-group retransmission, litter was changed, and pens were cleaned 
once every four days.  
 
At 14 d.p.h (days post hatch), Campylobacter negative status was confirmed for all birds prior 
to experimental infection through cloacal swabbing, with full description of swabbing 
procedures listed in Chapter 3. Swabs were subsequently streaked onto Campylobacter-
selective blood-free agar, (modified charcoal-cefoperazone-deoxycholate agar [mCCDA]) 




Merseyside, UK), covering the entire agar surface before incubating at 41.5°C for 48-hours in 
microaerobic conditions. 
 
At 21 d.p.h, all birds within the challenge group of each experimental trial were orally 
challenged with 0.2 ml 106 CFU/ml C. jejuni M1 in MHB, prepared as previously described. All 
birds within the control group were administered 0.2 ml of sterile MHB. Challenge at 21 d.p.h 
has previously been shown as a robust model of infection that mimics field infection within 
the UK, where birds typically become infected around three weeks of age (Sahin et al., 2003). 
Inoculation material was administered through oral gavage using a sterile 1 ml syringe (Fisher 
Scientific, Loughborough, UK) and a custom produced sterile gavage needle. The bird’s neck 
was gently stretched upward and the beak held open. The gavage needle was placed gently 
into the oesophagus and the plunger depressed to dispense 0.2 ml of either sterile MHB or C. 
jejuni inoculation material. All birds were observed closely for 2 hours post infection. 
 
EXPERIMENTAL TRIAL DESIGNS  
 
This study is comprised of two separate experimental trials completed in accordance with 
protocols ZIPP 41 and ZIPP 56. Figure 2 & 3 provide a visual explanation of key experimental 
features and timelines for experiment 1 and experiment 2.  
 
Experimental design – Experiment 1  
 
Age-matched, 1 d.p.h mixed sex Ross 308 chicks (n = 90) were introduced to the University of 
Liverpool high-biosecurity poultry unit under housing conditions described previously. On 
point of entry, the chicks were randomly assigned to one of two groups; Group 1 (n=57) or 
Group 2 (n = 30). 
 
Prior to infection, at 14 d.p.h, all animals were confirmed to have Campylobacter negative 
status as previously described. At 21 d.p.h, all birds within the C. jejuni Group 1 were orally 
infected with 0.2 ml 106 CFU/ml C. jejuni in MHB via oral gavage. All birds in Group 2 were 
given 0.2 ml sterile MHB via oral gavage. Preparation of inoculum and infection protocols were 
conducted as described previously. From this point, experimental groups 1 and 2 were named 





At 23 (2 days post infection [d.p.i]), 28 (7 d.p.i), 35 (14 d.p.i), 42 (21 d.p.i) and 49 (28 d.p.i) 
days post hatch, randomly selected birds were culled via cervical dislocation from the C. jejuni 
infected group (see Figure 2) and non-infected trial group (n = 6). Blood samples were 
collected via cardiac puncture immediately post-cull, before samples of splenic & liver tissues 
and caecal & ileal content were aseptically collected. An additional ileal tissue section was 
collected, and ileal content removed for subsequent gut wash processing. 
 
Experimental design – Experiment 2  
 
Age-matched, 1 d.p.h mixed sex Ross 308 chicks (n = 55) were introduced to the University of 
Liverpool high-biosecurity poultry unit under housing conditions described previously. On 
point of entry, the chicks were randomly assigned to one of two groups; Group 1 (n=26) or 
Group 2 (n = 27). 
 
Prior to infection, at 14 d.p.h, all animals were confirmed to have Campylobacter negative 
status as previously described. At 21 d.p.h, all birds within the C. jejuni Group 1 were orally 
infected with 0.2 ml 106 CFU/ml C. jejuni in MHB via oral gavage. All birds in Group 2 were 
given 0.2 ml sterile MHB via oral gavage. Preparation of inoculum and infection protocols were 
conducted as described previously. From this point, experimental groups 1 and 2 were named 
C. jejuni infected and non-infected control groups respectively.  
 
At 23 (2 days post infection [d.p.i]), 28 (7 d.p.i), 35 (14 d.p.i) and 42 (21 d.p.i) days post hatch, 
a pre-defined number of randomly selected birds from each group were culled via cervical 
dislocation (Figure 3). Blood samples were collected via cardiac puncture immediately post-
























Chicks received into unit and 
assigned to treatment group 
Day 21 
All birds orally infected with 106 
C. jejuni M1  
Day 23 
10 birds culled from infected 
group and 6 from control group 
Day 28 
11 birds culled from infected 
group and 6 from control group 
Day 35 
12 birds culled from infected 
group and 6 from control group 
Day 42 
12 birds culled from infected 
group and 6 from control group 
 (n = 90)  
Infected 
(n = 47)  
Infected 
(n = 36)  
Control    
(n = 24)  
Control    
(n = 18)  
Control    
(n = 12)  
Infected  
(n = 24)  
Control    
(n = 6)  
Infected  
(n = 12)  
Group 1 
(n = 57)  
Group 2 
(n = 30)  
Day 49 
All remaining birds from each 
treatment group culled 
 
Day 1 
Chicks received into unit 
and assigned to treatment 
group 
Day 21 
All birds orally infected with 
106 C. jejuni M1  
Day 23 
6 birds culled from infected 
group and 6 from control 
group 
Day 28 
7 birds culled from infected 
group and 7 from control 
group 
Day 35 
7 birds culled from infected 
group and 7 from control 
group 
Day 42 
6 birds culled from infected 
group and 7 from control 
group 
 (n = 53)  
Infected 
(n = 20)  
Infected 
(n = 13)  
Control    
(n = 21)  
Control    
(n = 14)  
Control    
(n = 7)  
Infected  
(n = 6)  
Group 1 
(n = 26)  Group 2 (n = 27)  




POST-MORTEM SAMPLING  
 
Birds were culled according to a pre-determined protocol specific to each experiment. All 
tubes pertaining to samples for bacteriological analysis were weighed ante-mortem. Control 
groups always underwent post-mortem sampling prior to infected groups to avoid cross 
contamination. Dissection kits (forceps and scissors) were sanitised by returning to a 100 % 
EtOH bath following each use and new kits were used between different experimental groups.  
Birds were euthanized by cervical dislocation before being surface sterilised with 70 % EtOH. 
Sterile latex gloves were used and changed for each bird, and then again after initial bird skin 
removal. All consumables used during post-mortem analysis can be seen in Table 3 below. 
Post-mortem sampling was conducted according to the following order of process: 
 
1.  Using sterile forces and scissors, the skin and muscle covering the chest cavity was 
removed and the heart and liver exposed.  
2. A cardiac puncture was performed using a sterile 23G gauge needle and a sterile 2 ml 
syringe to obtain ~ 0.5 ml – 1 ml of whole blood.  
3. A 1-3 gram sample of liver was isolated for bacteriological analysis.  
4. The bird was turned onto one side and the spleen located and removed. Half of the 
spleen was collected for bacteriological analysis.  
5. The large intestine was cut at the junction immediately above the cloaca and the small 
intestine cut immediately below the duodenum to free the section of the gastrointestinal 
tract from the body cavity. The intestines were retained, and the carcass disposed of. 
The following samples were obtained; 
5.1.   A small section of the ileum was cut, and the contents collected for 
microbiota analysis.  
5.2.  A second small (~ 20 cm) section of ileal tissue (content removed) was 
collected and place in a sterile Falcon tube for ELISA analysis.  
5.3.  One caecal tonsil, a visible nodule of lymphoid tissue located at the 
proximal end of the blind ended caeca, was removed and placed in 1 ml 
RNA later (Sigma, Poole, Dorset, UK).  
5.4. Caecal contents were then collected for bacteriological analysis.  
5.5.  A small section of caecal tissue (contents removed), ~0.5 cm in length, 





All blood samples collected during post-mortem analysis were centrifuged at 13000 xg for 
5 minutes. The serum was removed and stored in a sterile 2 ml Eppendorf at -20°C for 
subsequent ELISA analysis.  
 






At post-mortem, samples of spleen, liver, caecal and ileal content were taken for 
bacteriological analysis. Samples outside of the GIT were collected first to avoid 
contamination from intestinal contents. All samples were aseptically collected and placed into 
separate, pre-weighed 30 ml universal tubes, which were then re-weighed following sample 
addition.  
 
To spleen and liver samples, a 1 x MRD (Lab M Ltd., Heywood, Lancashire, UK) in 1:5 dilution 
was added. Diluted tissue samples were subsequently homogenised in a MicroStomacher 80 
(Seward, UK) for 1 minute. Following 15 seconds of vortexing, 100 µl of sample homogenate 
was plated onto mCCDA agar, ensure sample was spread to cover the entirety of the agar 
surface using Fisherbrand™ L-shaped cell spreaders (Fisher Scientific, Loughborough, UK). The 
plates were incubated at 41.5°C for 48 hours in microaerobic conditions. A further 200 µl of 
homogenised sample was used to inoculate 2 ml of Exeter selective enrichment broth 
(1100 ml nutrient broth, 55 ml lysed defibrinated horse blood, Campylobacter enrichment 
Consumable Sample 
1 x 2 ml Eppendorf / sample  
Blood sample 1 x 23 g Needle / sample 
1 x 2 ml Syringe / sample 
1 x 30 ml Universal / sample (weighed)  Bacteriology (caecal content, ileal 
content, liver tissue, spleen 
tissue) 
1 x 2 ml Eppendorf / sample containing 1ml RNA later RNA extraction (caecal and caecal 
tonsil tissue) 










supplement SV59 [containing trimethoprim (10 mg/L) and amphotericin B (2mg/L); Mast 
Group Ltd, Bootle, UK] and Campylobacter growth supplement SV61 [containing sodium 
pyruvate (250mg/L), sodium metabisulphate (250 mg/L) and ferrous sulphate (250mg/L); 
Mast Group Ltd]) and incubated at 41.5°C for 48 hours in microaerobic conditions. Following 
enrichment, samples were vortexed and plated onto mCCDA using a 3 µl loop. All plates were 
incubated at 41.5°C for 48 hours in microaerobic conditions before being assessed for C. jejuni 
growth.  
 
To caecal and ileal content, a 1 x MRD in 1:10 dilution was added. Diluted contents were 
subsequently vortexed for 1 minute at maximal speed to ensure full sample dispersal within 
diluent. Each sample was serially diluted in 1 x MRD to 10-8 and plated onto mCCDA agar using 
Miles and Misra methodologies as previously described (Miles & Misra, 1938). All plates were 
incubated at 41.5°C for 48 hours in microaerobic conditions before being enumerated.   
 
STATISTICAL ANALYSIS  
 
Statistical analysis was performed using GraphPad Prism version 7.00 for Mac OS X (GraphPad 
Software Inc., San Diego, USA). Prior to further statistical analysis, all data was first assessed 
for distribution normality using D’Agostino-Pearson omnibus normality testing. Pairwise 
treatment group comparisons of normally distributed data sets (p > 0.05) were conducted 
using an Unpaired t-test and described using data mean and standard deviation values (SD). 
Pairwise treatment group comparisons of non-normally distributed data sets (p < 0.05) were 
conducted using a Mann Whitney-U test and described using data median and interquartile 
range (IQR). Statistical significance was determined using a p < 0.05 threshold. For statistical 
comparisons assessing more than two distinct groups, Kruskal-Wallis testing was used with a 
p < 0.05 threshold.  
 
ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
Production of C. jejuni whole cell lysate antigen  
 
Frozen stocks of C. jejuni M1 stored at – 80 °C were grown on CBA at 41.5°C for 48 hours under 
microaerobic conditions. A single colony from the grown bacterial culture was selected and 




three times to create four CAB plates before incubation at 41.5°C for a further 48 hours under 
microaerobic conditions.  
 
Following incubation, the agar surface of each plate was flushed with approximately 1.5 ml 
sterile 1 x PBS (Lab M Ltd, Heywood, Lancashire, UK), using a sterile disposable 5 µl loop to 
manually disrupt bacteria from the agar surface. This bacterial suspension was collected and 
centrifuged at 4000 x g for 20 minutes. The supernatant was aseptically removed using a 
pipette and the remaining bacterial pellet re-suspended in 1.5 ml sterile 1 x PBS. Bacterial 
suspensions were incubated in a water bath at 65 °C for 5 hours. Bacterial suspensions were 
subsequently sonicated 5 freeze thaw cycles in liquid nitrogen, ensuring complete thaw of 
bacterial suspensions between each cycle. Bacterial suspensions were centrifuged at 4000 x g 
for 20 minutes at 4°C before all supernatant was removed aseptically using a pipette and 
pooled in a sterile ultracentrifuge tube. The supernatant was then ultra-centrifuged at 30000 
x g for 20 minutes at 4 °C before the supernatant was aseptically removed using a pipette, 
placed into sterile 2 ml Eppendorf tubes and stored at – 20 °C until further processing.  
 
Protein concentration was subsequently quantified using a Pierce ™ Modified Lowry Protein 
Assay kit (Product number #23240; ThermoFisher Scientific, Loughborough, UK), according to 
manufacturer’s instructions. Briefly, 0.2 ml of Bovine Serum Albumin (BSA) (Sigma, Poole, 
Dorset, UK) standards of known concentration (ranging from 1 µg/ml – 1500 µg/ml) were 
prepared according to manufacturer’s instruction. At 15 – second intervals, 1 mL of Modified 
Lowry Reagent (provided) was added to each standard alongside three replicates of our 
sample antigen of unknown concentration. All samples were vortexed and incubated for 
10 minutes at room temperature (RT). Immediately following incubation, 100 µl of prepared 
1 x Folin-Ciocalteu Reagent (provided) was added to each sample, vortexed and incubated for 
a further 30 minutes. Standard and sample optical density at 750 nm (OD750) was measured 
using a spectrophotometer and a standard curve plotted to interpolate the protein 
concentration of our unknown antigen samples.  
 
 
Serum IgY and IgM  
 
Chicken serum Immunoglobulin M (IgM) and IgY were determined for blood samples collected 
at post-mortem using ELISA’s, according to protocols previously described by Lacharme-Lora 




Poole, Dorset, UK) were coated with 100 µl per well of C. jejuni whole cell lysate antigen, 
diluted in carbonate-bicarbonate buffer (pH 9.6) (Sigma, Poole, Dorset, UK) to a concentration 
of 10 µg/ml and incubated overnight at 4°C. Following incubation, plates were washed three 
times with PBS Tween-20 (0.05 %), (Sigma, Poole, Dorset, UK) before incubation with 100 µl 
per well blocking buffer for 1 hour at 37°C (0.05 % Tween-20 in PBS and 3 % skimmed milk 
powder). Plates were then washed once with PBS Tween-20 (0.05 %). Collected serum 
samples were diluted in blocking buffer for the detection of IgY and IgM. Plates were 
incubated with 100 µl per well (in duplicate) of the diluted serum samples for 1 hour at 37°C 
and washed three times in PBS Tween-20 (0.05 %). Specific anti-Campylobacter antibodies 
were detected by the addition of 100 µl per well alkaline phosphatase conjugated to either 
goat anti-chicken IgY (1:1000) or IgM (1:1000) (Serotec, Oxford, UK) diluted in blocking buffer, 
for 1 hour at 37°C. Plates were washed once further with PBS Tween-20 (0.05 %) and 
incubated with 100 µl per well of p-nitrophenyl phosphate (Sigma, Poole, Dorset, UK) in the 
dark for 30 minutes at RT. The reaction was stopped with the addition of 100 µl per well of 3N 
sodium hydroxide (Fisher Scientific, Loughborough, UK) before absorbance was determined 
using a microplate reader at 405 nm. A full experimental protocol is provided in Appendix 1.  
 
All assays were conducted alongside duplicate ‘blank’ wells containing dH2O in replacement 
of query sample. Resulting absorbances for all wells were first corrected for background 
absorbance by subtracting the mean ‘blank’ absorbance reading for each assay from all 
sample absorbance readings. Positive and Negative controls were included, in duplicate, for 
every assay plate. Control serum samples were sourced from the study described by  
Lacharme-Lora et al. (2017). The positive control sample confirmed correct technical 
implementation of the ELISA assay, being a blood serum sample from a C. jejuni infected 
experimental Ross 308 chicken with known absorbance values at OD405. Blood serum used as 
a negative control was obtained from an experimental Ross 308 chicken successfully 
bursectomised by daily intramuscular injection of 3mg cyclophosphamide during four days 
post-hatch. The limit for positivity was determined at the level of such negative control. 
 
Secretory IgA  
 
As a means of determining secretory IgA levels within the ileum, a section of ileal tissue 
(without ileal content) was aseptically collected at post-mortem. Ileal sections were flushed 




and centrifuged for 10 minutes at 500 x g before aseptic collection of the supernatant with a 
pipette. All processed samples were stored at – 20 °C until further processing.  
 
Quantification of secretory IgA within the processed samples was then conducted using an 
IgA Chicken ELISA Kit according to manufacturer’s instructions (ab15, Abcam®, Cambridge, 
UK). Briefly, 100 µl of pre-prepared standard solutions (concentrations ranging from 
12.5 – 400 ng/ml) including blank control (consisting only of provided diluent solution) were 
added in duplicate into pre-designated wells of a provided 96-well plate. Gut wash samples 
were diluted 1:5000 in 1 x diluent solution provided and added to wells of the provided 96-
well plate in duplicate. Plates were incubated for 20 minutes at RT before being washed 4 
times with 1 x wash buffer (provided). 100 µl of 1 x enzyme-antibody conjugate (provided) 
was added to each well and incubated for 20 minutes at RT in the dark. Plates were washed 4 
times with 1 x wash buffer (provided) and 100 µl of TMB substrate solution (provided) was 
added to each well before incubation in the dark at RT for 10 minutes. Absorbance was 
determined using a microplate reader at 405 nm and a standard curve plotted to interpolate 
total secretory IgA concentrations in ng/ml  
 
RNA EXTRACTION  
 
Tissue samples of spleen, caeca, caecal tonsil and ileum were collected from all infected and 
control birds of experiment 1 and stored in 1 ml RNAlater™ at -20°C until further processing 
(Sigma, Poole, Dorset, UK). Total RNA was extracted from 20 – 30 mg of all tissue samples 
using an RNeasy minikit (Qiagen, West Sussex, United Kingdom) according to manufactures 
instructions. Prior to extraction protocols, Buffer RLT solution (provided) was first 
supplemented with 10 µl of β- mercaptoethanol (Sigma, Poole, Dorset, UK) per 1 ml Buffer 
RLT. All tissues were disrupted using a TissueLyser (Qiagen, West Sussex, UK) at a frequency 
of 10,000/S for 10 minutes, with the addition of one stainless steel metal bead per sample. 
Isolated RNA was eluted into 50 µl of RNase-free water and stored at - 80 °C until processing. 
Total RNA yield per sample was determined using a Nanodrop (ND-1000) spectrophotometer, 









IMMUNE GENE EXPRESSION BY QUANTITATIVE REAL-TIME PCR 
 
Cytokine and chemokine 2-ΔΔCt RT-qPCR 
 
mRNA expressional changes for the cytokines interleukin-1β (IL-1β), IL-4, IL-6, IL-10, IL-17A, 
Transforming growth factor ß4 (TGFβ4) and the chemokine ligand CXCLi2 were measured in 
these tissue samples by real-time quantitative reverse-transcription PCR (RT-qPCR) using a 
Rotor-Gene Q version 2.3.1.49 (Qiagen, West Sussex, UK) as previously described by 
(Humphrey et al., 2014). All primer and probe sequences for these genes have previously been 
described by (Shini & Kaiser, 2009) and are listed in Table 4 alongside threshold values used. 
Selection of cytokine, chemokine and growth factor genes for analysis was based upon 
demonstration of potential modulation within the chicken following C. jejuni infection. Reid 
et al. (2016) highlights particular importance of IL-1β and IL-6 in the upregulation of IL-17A, a 
pathway of suggested to have a protective response against C. jejuni. With Th17 cells known 
to have protective effects at mucosal barriers through their role as sentinels, CXCLi2 was 
considered as an important mediator to this pathway (Connerton et al., 2018). Connerton et 
al. (2018) goes on to state greatly increased IL-17A response following C. jejuni infection 
however no observed increase in caecal IL-10. This is in contrast to the work by Humphrey et 
al. (2014) who present differential expression of IL-10 within broiler chicken breeds following 
infection, emphasising its importance in the outcome of infection. Maintenance of gut 
homeostasis by IL-10 is often considered to be supplemented by the effects of TGFβ. While 
this represents on a subset of the cytokine repertoire that have been described as effectors 
following C. jejuni infection of the chicken, primer and probe sequences for these particular 
genes were readily available and demonstrated reaction profiles conducive to our tissue 
samples. For all reactions, 28S rRNA was used as the housekeeping gene to normalise mRNA 
levels between samples. All RNA samples were first diluted 1:10 using RNase-free water to 
obtain desired concentration per sample.  
 
One-step RT-qPCR was performed using the RotorGene Probe RT-PCR kit (Qiagen, West 
Sussex, UK) to a final reaction volume of 20 µl. All reactions contained 1 µl of total RNA (at a 
concentration of 20 ng/µl), 10 µl of RotorGene Probe RT-PCR master mix, 0.2 µl of RotorGene 
reverse transcriptase enzyme mix, 1.6 µl forward primer (at 10 µM), 1.6 µl reverse primer (at 
10 µM), 0.8 µl of probe (at 5 µM) and 4.8 µl of RNase-free water (Humphrey et al., 2014). Each 




water in place of total RNA, being used for each run. All reactions were conducted according 
to the following reaction profile listed in Table 4. 
 










Mucin2 2-ΔΔCt RT-qPCR 
 
mRNA expressional changes in the glycoprotein Mucin2 (MUC2) was measured in caecal tissue 
biopsy samples by RT-qPCR using a Rotor-gene Q version 2.3.1.49 (Qiagen, West Sussex, UK) 
as described previously (Humphrey et al., 2014). MUC2 is one of the most prominent mucin 
gel-forming mucin in the small and large intestine (Jiang et al., 2013). While MUC5AC and 
MUC6 are also widely utilised within published research as mucin’s associated with prevention 
of pathogenic enteric disease in humans, primer sequences selected for these genes showed 
abnormal reaction profiles when assessed using our samples and so were not considered for 
this study. Primer sequences used are listed in Table 6 alongside the respective threshold 
value. For each reaction, β-actin rRNA (ACTB) was used as the reference gene to normalise 
mRNA levels between samples. Threshold values for each gene transcript were determined at 
10 % of the curve plateau of known Campylobacter-positive control samples. All RNA samples 
were first diluted 1:10 using RNase-free water to obtain desired concentration per sample. 
Selection of the correct reference gene was based on comparison of stability and expression 
according to our experimental protocols and sample-set, assessed against a selection of 
reference candidates using a geNorm Kit (PrimerDesign Camberley, UK).  
 
 One-step RT-PCR was performed using the Precision®PLUS OneStep RT-qPCR Master Mix 
premixed with SYBRgreen (PrimerDesign, Camberley, UK) to a final reaction volume of 20 µl 
according to manufacturers’ instructions. All reactions contained 2 µl of total RNA (at a total 
concentration of 25 ng), 10 µl of the Precision®PLUS OneStep RT-qPCR Master Mix premixed 
with SYBRgreen, 0.6 µl forward primer (at 6pmols), 0.6 µl reverse primer (at 6pmols), and 6.8 
µl of RNase-free water. Each sample was assessed in triplicate, with no-template control 
 
 
Step Time Temperature 
Reverse Transcription 10 minutes 50°C 
Enzyme Activation 5 minutes 95°C 
Cycling X 40 Denaturation 5 seconds 95°C 




samples, containing RNase-free water in place of total RNA, being used for each run. All 
reactions were conducted according to the following reaction profile listed in Table 5. 
 



































 Step Time Temperature 
Reverse Transcription 10 minutes 55°C 
Enzyme Activation 2 minutes 95°C 
 
CYCLING X 40 
Denaturation 10 seconds 95°C 
Data Collection 60 seconds 60°C 
















Target Primer sequence (5' - 3')  Probe sequence (5' - 3') Source Ct 
Threshold 
Acc. No. 


















R: GACGACCGATTTGCACGTC  



















R: CCCCGGGTTGTGTTGGT  




R: TGTCGATGTCCCGCATGA  
IL-4 F: AACATGCGTCAGCTCCTGAAT P: (FAM)-
AGCAGCACCTCCCTCAAGGCACC-(TAMRA) 
0.008 AJ621249 
R: TCTGCTAGGAACTTCTCCATTGAA  




R: GGTAGGTCTGAAAGGCGAACAG  
IL-10 F: CATGCTGCTGGGCCTGAA P: (FAM)-CGACGATTCGGCGCTGTCACC-
(TAMRA) 
0.0115 AJ621614 
R: CGTCTCCTTGATCTGCTTGATG  






R: GCGGCACTGGGCATCA  





R: CCTGCTTGCTGATCCACCTGA  
MUC2 F: ATGCGATGTTAACACAGGACTC   (Forder 
et al., 
2012) 
0.03 JX284122  
 





Analysis of 2-ΔΔ Ct RT-qPCR 
 
For each expression triplicate per sample, an average Ct value was calculated based on 
threshold value used per gene of interest. All expression values for target genes were 
determined using 2-ΔΔCt methodologies. Firstly, gene of interest (GOI) Ct was determined 
relative to that of the housekeeping 28S rRNA (ΔCt). ΔCt values given for samples from C. jejuni 
infected birds were then normalised against those of uninfected control animals to give final 
readings as relative fold changes (2-ΔΔCt).  To determine statistical significance of variations in 
transcript expression between control and infected samples, pairwise comparisons of 40 - ΔCt 
was performed using Mann Whitney-U analysis, with statistical significance set at p < 0.05. 
RESULTS 
 
CAECAL COLONISATION  
 
Caecal content was aseptically collected from all infected and control birds in both 
experimental trials 1 and 2 between 2 d.p.i – 28 d.p.i and 2 d.p.i – 21 d.p.i respectively (Figure 
4). All birds within the non-infected control group were negative for C. jejuni caecal 
colonisation at all time-points in both experimental trials and will not be discussed in further 
detail. For all samples with detectable C. jejuni colonisation, counts of morphologically distinct 
bacterial colonies were taken at each post-mortem time-point. To account for any variation 
in sample weight, all values were subsequently corrected to 1 g total sample weight, with data 
presented as Colony Forming Units (CFU)/g. Caecal enumeration data sets for both 
Experiment 1 and Experiment 2 were non-normally distributed and, as such, will be discussed 
in regard to median and IQR values.  
 
Caecal colonisation of C. jejuni was present from as early as 2 d.p.i in both experiment 1 (Figure 
4a) and experiment 2 (Figure 4b) sample populations, found in 2/10 (20 %) and 4/6 (67 %) 
respectively.  By 7 d.p.i, 9/11 (82 %) of the experiment 1 sample group had detectable C. jejuni 
within the caeca, with median bacterial loads of 6.92 Log10CFU/g (IQR 4.72), with this being 
significantly higher than the C. jejuni burden of birds culled at 2 d.p.i (p = 0.0128). While 
colonisation load continued to rise between 7 and 14 d.p.i to 8.50 Log10CFU/g (IQR 1.89), this 
was not found to be significantly higher than C. jejuni colonisation at 7 d.p.i (p = 0.0671). 




burden within the caeca remained high, ranging from 5.52 – 10.03 Log10CFU/g between 21 to 
28 d.p.i, there was no statistically significant increase between 14 d.p.i – 28 d.p.i (p = 0.6891). 
 
Similar to experiment 1, C. jejuni burden at 7 d.p.i within experiment 2 was significantly higher 
than that seen for birds culled at 2 d.p.i within the sample experimental trial (p = 0.0216). This 
increase in C. jejuni burden between sampling time-points continued, with bacterial loads at 
14 d.p.i being significantly higher than those seen at 7 d.p.i (p = 0.0006). As seen in experiment 
1, 14 d.p.i was the time-point whereby maximal caecal C. jejuni colonisation was recorded, 
being 7.98 Log10CFU/g (IQR 0.75). There was no significant increase in C. jejuni colonisation of 
the caeca between sample groups of 14 d.p.i and 21 d.p.i (p = 0.5338). Significance values for 















































Figure 4. Levels of C. jejuni M1 in the caeca of C. jejuni infected broiler chickens under experimental 
conditions based on the protocols listed for experiments 1 (a) and 2 (b). Each symbol represents caecal C. 
jejuni load for an individual animal, with bars representing median values and their respective IQR. 
Comparable representation of caecal load between both experimental trials is shown in figure (c). 
Statistical significance was determined using Mann Whitney-U analysis, with ‘*’ denoting time-points 
where C.  jejuni load was statistically different from that of the immediately previous time-point (p < 
0.05). Experient 1; 2 d.p.i n=10, 7 d.p.i n=11, 14, 21 and 28 d.p.i n=12. Experiment 2; 2 d.p.i n=6, 7 & 14 







Table 7. Statistical parameters and specific sampling time-point comparison significance values determined for Log10CFU/g C. jejuni caecal colonisation 
 
   
  Experiment 1 Experiment 2 
  C. jejuni Load (Log10CFU/g) 
Data normality Group comparison p value  
C. jejuni Load (Log10CFU/g) 





  Q1 Q2 Q1 Q2 
  
2 0 0 1.88 0.021 
7 0.0128 
3.94 0 5.01 
7 0.0216 
  14 0.0002 14 0.0012 
  21 0.0006 21 0.0022 
  28 0.0002 N/A N/A 
  
7 6.92 4.32 9.04 0.29 
14 0.0671 
5.71 5.15 6.9 
14 0.0006 
  21 0.2292 21 0.0082 
Caeca 28 0.1301 N/A N/A 
  
14 8.5 7.54 9.43 0.79 
21 0.3777 
7.98 7.45 8.2 
21 0.5338 
  28 0.8428 N/A N/A 
  21 8.1 7.31 8.96 0.747 28 0.6707 
7.6 6.82 8.18 N/A N/A 








ILEAL COLONISATION  
 
Ileal content was aseptically collected from all infected and non-infected control birds in both 
experimental trials 1 and 2 between 2 d.p.i – 28 d.p.i and 2 d.p.i – 21 d.p.i respectively (Figure 
5a). In accordance with the information attained for caecal colonisation, all birds within the 
non-infected control groups of both experiment 1 and experiment 2 showed no detectable 
C. jejuni colonisation within the ileum and will not be discussed in further detail. Processing of 
ileal samples was conducted in the same manner as for caecal samples with presentation of 
data as Log10CFU/g. Ileal enumeration data sets for both experiment 1 and experiment 2 
were non-normally distributed and as such, will be discussed in regard to median and IQR 
values.   
 
C. jejuni colonisation within the ileum was notably less prominent compared to that of the 
caecum. In both experiment 1 and experiment 2, detection of C. jejuni was first observed at 7 
d.p.i in 1/11 (9 %) and 2/7 (29 %) samples respectively. While colonisation of the ileum within 
experiment 1 showed highest frequency in samples collected 14 d.p.i (7/12 [58 %]), 
persistence of C. jejuni colonisation within the ileum was markedly reduced compared to that 
of the caecum, with colonisation detected in only 1/12 (8 %) and 3/12 (25 %) samples 21 and 
28 d.p.i respectively (Figure 5b). In addition to lesser colonisation frequency compared to the 
caecum, C. jejuni load within the ileum was considerably lower, with a range of 3.57 – 7.74 
Log10CFU/g across all sampled time-points within experiment 1.  
 
As with experiment 1, ileal colonisation within experiment 2 was considerably less frequent 
compared to that of caecal samples obtained from the same experimental birds. Maximal ileal 
colonisation within experiment 2 was observed at 21 d.p.i with 3/6 (50 %) samples showing 
C. jejuni colonisation at a load ranging from 4.45 – 5.16 Log10CFU/g. Frequency of C. jejuni 
detection within sampled ileal content at each time point of experiment 1 and experiment 2 




























EXTRA-INTESTINAL SPREAD OF C. JEJUNI  
 
Tissue samples from both the spleen and liver were collected from all birds at post-mortem in 
both experimental trials 1 and 2 between 2 d.p.i – 28 d.p.i and 2 d.p.i – 21 d.p.i respectively 
to assess the ability of C. jejuni M1 to establish beyond the GIT. All birds in the non-infected 
control groups of both experiment 1 and experiment 2 showed no detectable C. jejuni 
colonisation of either tissue and will not be discussed in any further detail.  
 















































Figure 5. Levels of C. jejuni M1 in the ileum of broiler chickens under experimental conditions based on 
the protocols listed for experiments 1 (a) and 2 (b). Each symbol represents caecal C. jejuni load for an 
individual animal, with bars representing median values and their respective IQR. Percentage frequency 
of ileal C. jejuni colonisation out of total sample population per time-point for both experimental 
protocols is provided in figure (c). Experient 1; 2 d.p.i n=10, 7 d.p.i n=11, 14, 21 and 28 d.p.i n=12. 






C. jejuni was identified as early as 2 d.p.i within the splenic tissue of sampled birds from 
experiment 1 (Figure 6). While detection remained at a relatively low frequency, detection of 
C. jejuni within at least one spleen sample occurred at all sampling time-points within this 
experimental trial. Maximal colonisation frequencies occurred later after infection, with 2/12 
(16 %) spleen samples at both 21 d.p.i and 28 d.p.i detected as C. jejuni positive. Detection of 
C. jejuni within the spleen was detected slightly later, at 7 d.p.i within experiment 2. Frequency 
of C. jejuni detection within the spleen was highest at 21 d.p.i with 2/6 (33 %) samples positive 
for the bacteria. 
 
C. jejuni invasion of the hepatic tissues was observed later than that seen for splenic tissues 
in both experiment 1 and experiment 2 (Figure 5). First detection of C. jejuni was observed 7 
d.p.i in 1/11 (9 %) birds sampled within experiment 1. As with invasion of splenic tissues, 
C. jejuni was detected more frequently in samples taken at later time-points, with 4/12 (33 %) 
samples positive for C. jejuni at 28 d.p.i within experiment 1. Detection of C. jejuni within the 
liver tissue was first observed 14 d.p.i within experiment 2 and showed maximal incidence 











Figure 6. Detection of C. jejuni M1 within spleen tissue of broiler chickens under experimental conditions based on the protocols listed for experiment 1 and 
experiment 2. Red squares depict C. jejuni detection within a single sample, whereby 'D' indicates results are from direct plating of tissue homogenate and ‘E’ 
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Figure 7. Detection of C. jejuni M1 within liver tissue of broiler chickens under experimental conditions based on the protocols listed for experiment 1 and 
experiment 2. Red squares depict C. jejuni detection within a single sample, whereby 'D' indicates results are from direct plating of tissue homogenate and ‘E’ 





To assess whether high caecal C. jejuni colonisation was a predictor for systemic bacterial 
spread, splenic and hepatic tissue C. jejuni positivity was related back to caecal C. jejuni load, 
with this being shown in Figure 8. There appears to be no visible association between extra-











Serum IgY and IgM 
 
Samples of 2 ml whole blood were collected from each bird in both infected and non-infected 
groups of experiment 1 and experiment 2 via cardiac puncture at post-mortem. Serum 
samples were prepared and measured for specific IgY and IgM against C. jejuni. Following 
antigen preparation protocols, whole cell C. jejuni lysate antigen was prepared at a 
concentration of 257.35 µg/ml following interpolation from the plotted standard curve 
provided in Figure 9. 
Figure 8. Extra-intestinal detection of C. jejuni mapped against C. jejuni caecal load for broiler chickens under 
experimental conditions based on experimental protocols 1 (a) & 2(b). Each symbol represents results from an 
individual animal with caecal load given as Log10CFU/g of caecal content. Green shapes indicate birds with C. 
jejuni detected in splenic tissue, blue shapes show detection in liver tissue and red shapes represent animals with 
C. jejuni detected in both splenic and liver tissues. Experient 1; 2 d.p.i n=10, 7 d.p.i n=11, 14, 21 and 28 d.p.i 




















Within both experiments, the level of serum IgY was similar at 2 d.p.i between C. jejuni 
infected and non-infected birds (Experiment 1 p = 0.8639; Experiment 2 p = 0.9372) (Figure 
10). Within experiment 1, IgY levels for non-infected control birds remained relatively low 
across all time-points, with an OD405 absorbance range of 0.24 – 0.82. From 7 d.p.i onward, 
C. jejuni infected birds showed significantly higher serum IgY compared to non-infected birds 
sampled at the same time-point (p < 0.05). Serum IgY was highest within this experiment at 
21 d.p.i, with median OD405 of 1.60 (IQR 0.55). A similar IgY response was observed for 
experiment 2, with peak OD405 of 0.90 (IQR 0.64) at 21 d.p.i and persistently low serum IgY of 
non-infected control birds ranging from 0.017 – 0.23. Details of statistical parameters and 







Figure 9. Standard curve representing OD750 against protein 

























As with serum IgY, serum IgM levels remained similar between C. jejuni infected and non-
infected birds early after infection (2 d.p.i) (p < 0.05) (Figure 11).However, by 14 d.p.i in 
experiment 1, serum IgM in infected birds was significantly higher than that of non-infected 
control birds (p = 0.0001). Peak serum IgM within infected birds was observed at 21 d.p.i, with 
median levels of OD405 2.23 (IQR 1.28), with this being significantly above that of non-infected 
controls at the same-time point (p = 0.0008). Interestingly, although IgM was still increased 
within infected chickens compared to non-infected at 28 d.p.i (p = 0.0069), levels were lower 
than that of infected birds at 21 d.p.h.  
Figure 10. Normalised serum IgY response according to C. jejuni M1 infection status at samples time-
points post-challenge according to experimental protocols for experiment 1 (a) and experiment 2 (b). 
Statistical analysis is based on median values with associated IQR. Statistical significance was determined 
using Mann Whitney-U analysis with levels of significance given as *p < 0.05, **p < 0.01, ***p < 0.001. 
The dotted line of both plots indicates the average absorbance for plate negative control samples. 
Experient 1; 2 d.p.i n=10, 7 d.p.i n=11, 14, 21 and 28 d.p.i n=12. Experiment 2; 2 d.p.i n=6, 7 & 14 d.p.i 
n=7, 21 d.p.i n=6. 
(a) 
(b) 

































As with experiment 1, increases in serum IgM levels of C. jejuni infected birds were first 
identified at 14 d.p.i (p = 0.0043). This continued at 21 d.p.i, whereby median levels reached 
1.01 (IQR 0.95) within C. jejuni infected birds, considerably higher than that of non-infected 
birds’ samples at that time (p = 0.014).  Details of statistical parameters and pairwise group 



















Figure 11. Normalised serum IgM response according to C. jejuni M1 infection status at samples 
time-points post-challenge according to experimental protocols for experiment 1 (a) and 
experiment 2 (b). Statistical analysis is based on median values with associated IQR. Statistical 
significance was determined using Mann Whitney-U analysis with levels of significance given as *p 
< 0.05, **p < 0.01, ***p < 0.001. The dotted line of both plots indicates the average absorbance for 
plate negative control samples. Infected 2 d.p.i n=10, 7 d.p.i n=11, 14, 21 and 28 d.p.i n=12; Control  









































Table 8. Statistical parameters and pairwise comparison significance values determined for C. jejuni specific serum IgY and IgM (OD405). All p values are 
 provided on infected against non-infected control comparison at each given time point.  
 
Immunoglobulin  d.p.i Challenge 
status 
Experiment 1 Experiment 2 
OD405 p-value OD405 p-value 
Median Quartiles Median Quartiles 







2 Infected  0.6049 0.4283 0.7759 0.8639 0.1205 0.08973 0.1934 0.9372 
Control 0.4714 0.274 0.6769 0.1223 0.07599 0.1745 
7 Infected  0.5029 0.4027 0.8856 0.0312 0.1234 0.0901 0.1391 0.9015 
Control 0.3336 0.3143 0.5262 0.1124 0.0811 0.2121 
14 Infected  1.195 0.3984 1.945 0.0668 0.5856 0.1241 0.7753 0.0022 
Control 0.3708 0.274 0.4915 0.08408 0.05389 0.1044 
21 Infected  1.601 1.356 1.906 0.0013 0.9033 0.357 0.9965 0.0012 
Control 0.4739 0.3777 0.6874 0.1623 0.07665 0.1751 
28 Infected  1.113 1.026 1.522 0.0013 
 
      
Control 0.3065 0.2545 0.4245 
 







2 Infected  0.4032 0.3847 0.4796 0.0663 0.1886 0.136 0.2759 0.9372 
Control 0.3483 0.308 0.4263 0.1892 0.1581 0.2906 
7 Infected  0.3471 0.3264 0.4016 0.9578 0.2922 0.2182 0.3329 0.3829 
Control 0.3555 0.2825 0.6236 0.2481 0.194 0.2931 
14 Infected  1.017 0.8307 1.803 0.0001 0.5493 0.3448 0.5962 0.0043 
Control 0.4221 0.3567 0.4894 0.1172 0.03683 0.2034 
21 Infected  2.228 1.567 2.845 0.0008 1.014 0.3379 1.283 0.014 
Control 0.8756 0.44 1.265 0.2463 0.14 0.2614 
28 Infected  1.278 0.8114 1.758 0.0069         






Sections of ileal tissue were collected from all C. jejuni infected and non-infected control birds 
of Experiment 1 at post-mortem to determine the levels of total secretory IgA (Figure 12). 
Total secretory IgA within non-infected control chickens showed considerably higher variation 
at early time-points compared to that of C. jejuni infected birds, with concentrations ranging 
from 1.13 – 54.49 ng/ml and 0.39 – 21.71 ng/ml respectively at 2 d.p.i. Total secretory IgA was 
similar in C. jejuni infected and uninfected birds at 7 and 14 d.p.i (p = 0.5908; p = > 0.9999 
respectively). While total IgA appeared to show gradual decline within uninfected control 
birds from 14 d.p.i, the opposite was true for C. jejuni infected birds, with significantly higher 
IgA at both 21 d.p.i (p = 0.0240) and 28 d.p.i (p = 0.004). Details of statistical parameters and 









































Figure 12. Total secretory IgA response within ileal tissue according to C. jejuni M1 infection 
status at sampled time-points post-challenge according to experimental protocols for 
experiment 1 (a) and experiment 2 (b). Statistical analysis is based on median values with 
associated IQR. Statistical significance was determined using Mann Whitney-U analysis with 
levels of significance given as *p < 0.05, **p < 0.01. Experient 1; 2 d.p.i n=10, 7 d.p.i n=11, 14, 




Table 9. Statistical parameters and pairwise comparison significance values determined for total 
secretory IgA. All p values are provided on infected against non-infected control comparison at 
each given time point. 
 




To assess the presence of inflammatory response to Campylobacter challenge, specific 
cytokine, chemokine and glycoprotein expression within the caecal and caecal tonsil tissue of 
all birds from experiment 1 was quantified relative to non-infected control birds (Figure 13, 
Table 10, Table 11). Campylobacter jejuni challenge was determined to elicit time-dependent 
alterations in immune response and regulation over the duration of the experiment. Here 
expression levels of the cytokine gene transcripts IL-1β, IL-4, IL-6, IL-10, IL-17A and TGFβ4 
alongside the chemokine CXCLi2 were targeted as inducers or mediators of major immune 
pathways. While IL-1β, IL-6, IL-17A, and CXCLi2 are all strongly associated with a pro-
inflammatory Th17 pathway response, IL-4 is associated with a Th2 response and IL-10 an anti-
inflammatory regulatory T cell (Treg response) (Connerton et al., 2018; Reid et al., 2016). 
TGFβ4 is often implicated in a Th17 role however strongly influences multiple Treg functions. 
At 2 d.p.i, an innate upregulation of IL-1β, IL-6 and CXCLi2 was seen within the caecal tissue (p 
< 0.01) (Figure 13). All are known inducers of pro-inflammatory immune responses and potent 
initiators of further Th17 pathways. In contract, IL-1β and IL-17A were downregulated within 
the caecal tonsil by 0.27 (IQR 0.27) and 0.27 (IQR 0.19) -fold respectively (p < 0.05) at the same 
time-point. Infection status did not influence the gene expression of any other gene transcript 
in either tissue type (p > 0.05). It may be of importance to note that at the 2 d.p.i time-point, 
Immunoglobulin d.p.i Challenge 
status  
IgA (ng/ml) p-value 







2 Infected  6.306 2.662 11.73 0.0663 
Control 24.67 7.337 36.7 
7 Infected  14.05 5.292 19.08 0.5908 
Control 15.32 6.493 33.33 
14 Infected  17.69 7.599 27.57 >0.9999 
Control 14.77 9.936 34.12 
21 Infected  9.116 6.736 14.88 0.024 
Control 4.573 2.676 6.936 
28 Infected  17.69 7.599 27.57 0.004 
























Figure 13. Relative expression (i) and 40 - ΔCt (ii) of assessed cytokine, chemokine and AMP transcripts within caecal tissue (a) and caecal tonsil tissue (b) of 
experimental chickens according to C. jejuni challenge status at 2 d.p.i (23 d.p.h). Error bars represent IQR of the median value and statistical significance has been 
assessed according to 40 - ΔCt. Statistical significance was determined using Mann Whitney-U analysis with levels of significance given as **p < 0.01, ***p < 0.001. 
Infected 2 d.p.i n=10, 7 d.p.i n=11, 14, 21 and 28 d.p.i n=12; control 2, 7, 14, 21 & 28 d.p.i n=6. 
 (i)  (ii) a
















































































































































































































































































































































































































































































































By 7 d.p.i, most cytokines associated with the Th17 response were upregulated within the 
caecal tissue in accordance with the increase in caecal colonisation seen within the 
bacteriological results for this time-point. (p < 0.05) (Figure 14). In conjunction with the pro-
inflammatory cytokines mentioned previously, TGFβ4 showed significant upregulation by 
7 d.p.i (p < 0.01) of 4.57 (IQR 3.60) fold. With primary influence in initiation of the Treg 
pathways, this was accompanied by an increase of 3.57 (IQR 4.78) fold in IL-10 within the 
caeca, although such change was not of statistical significance (p < 0.05). An increase in IL-4 
transcripts provides evidence pertaining to the activation of the Th2 pathways by this time-
point and may have been stimulated by the early innate production of IL-6 within the caecal 
tissues (p < 0.05) (Reid et al., 2016). Unseen at 2 d.p.i, transcription of the gel-forming mucin 
MUC2 was significantly downregulated in C. jejuni infected chickens compared to non-
infected controls (p < 0.001). While mucins form a major component of the physical mucus 
barrier protecting the avian intestinal tract they have been denoted as an environmental 
trigger for the production of several pathogenicity and colonisation factors from C. jejuni 
found within the caecal intestinal mucus (Tu et al., 2008).  
 
Caecal tonsil tissues had markedly different cytokine expression profiles relative to non-
infected control birds compared to that at 2 d.p.i. A continued up-regulation of IL-1β by 3.46 
(IQR 2.40) -fold supplemented by upregulation of IL-6 and IL-17A perpetuates the pro-
inflammatory response seen within the caecal tissue (p < 0.05) (Figure 14). As seen within the 
caecal tissue, increases in TGFβ4 expression were evident by 7 d.p.i within the caecal tonsil 
(p < 0.01). This 2.84 (IQR 1.92) fold TGFβ4 up-regulation may play an instrumental role in 
activation of the same Treg pathway associated with the accompanying IL-10 upregulation 
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CXCLi2 IL-1β IL-10 MUC2IL-6IL-4 TGFβ4IL-17A
** ****** ** * *** (ii) a (i) 
 (ii) b (i) 
Figure 14. Relative expression (i) and 40 - ΔCt (ii) of assessed cytokine, chemokine and AMP transcripts within caecal tissue (a) and caecal tonsil tissue (b) of 
experimental chickens according to C. jejuni challenge status at 7 d.p.i (23 d.p.h). Error bars represent IQR of the median value and statistical significance has been 
assessed according to 40 - ΔCt. Statistical significance was determined using Mann Whitney-U analysis with levels of significance given as * p < 0.05, **p < 0.01, ***p < 




14 d.p.i  
 
By 14 d.p.i, there appears to be a marked shift in the characteristics of immune response to 
C. jejuni challenge within both the caecal and caecal tonsil tissues. The upregulation of the 
innate pro-inflammatory cytokines IL-1β and IL-6 has diminished but may have in turn 
stimulated an increase in IL-17A expression (p < 0.01). Caecal TGFβ4 upregulation is evident 
by 2.16 (IQR 2.82)-fold, continuing from that seen at 7 d.p.i. (p <0.05). Expression of IL-4 
continues to be elevated within the caecal tissues (p < 0.05) alongside the caecal tonsil 
(p < 0.01) at 14 d.p.i. The anti-inflammatory nature of IL-10 foresees its upregulation at 14 
d.p.i and is likely positively correlated with both the array of pro-inflammatory transcript 
expression seen at 7 d.p.i and continued TGFβ4 upregulation.  
 
21 d.p.i & 28 d.p.i 
 
During the later time-points post-infection, relative expression of all analyzed transcripts 
remained similar to those of non-infected control birds. Within the caeca, both IL-6 and CXCLi2 
showed further up-regulation by 2.68 (IQR 3.76) fold and 5.25 (IQR 2.17) fold respectively, 
however this pro-inflammatory response was likely countered by parallel increases in IL-10 
and TGFβ4 (Figure 16, Figure 17). This increase in regulatory pathways continues into 28 d.p.i 
within the caeca whereby IL-10 shows 12.83 (IQR 11.30) fold upregulation (Figure 17). This 
regulatory response is largely mirrored within the caecal tonsil across both 21 and 28 d.p.i, 
with upregulation of IL-10 (Figure 16, Figure 17). However an additional Th2 response 
continues from 14 d.p.i across both 21 and 28 d.p.i, with further IL-4 upregulation by 2.15 
































































































































































































































































































































































































CXCLi2 IL-4IL-1β IL-10 IL-17AIL-6 TGFβ4
*** *
 (ii) a (i) 
Figure 15. Relative expression (i) and 40 - ΔCt (ii) of assessed cytokine, chemokine and AMP transcripts within caecal tissue (a) and caecal tonsil 
tissue (b) of experimental chickens according to C. jejuni challenge status at 14 d.p.i (23 d.p.h). Error bars represent IQR of the median value and 
statistical significance has been assessed according to 40 - ΔCt. Statistical significance was determined using Mann Whitney-U analysis with levels 
of significance given as * p < 0.05, **p < 0.01. Infected 2 d.p.i n=10, 7 d.p.i n=11, 14, 21 and 28 d.p.i n=12; control 2, 7, 14, 21 & 28 d.p.i n=6. 




















Figure 16. Relative expression (i) and 40 - ΔCt (ii) of assessed cytokine, chemokine and AMP transcripts within caecal tissue (a) and caecal tonsil tissue (b) of 
experimental chickens according to C. jejuni challenge status at 21 d.p.i (23 d.p.h). Error bars represent IQR of the median value and statistical significance has been 
assessed according to 40 - ΔCt. Statistical significance was determined using Mann Whitney-U analysis with levels of significance given as * p < 0.05, ***p < 0.001. 
Infected 2 d.p.i n=10, 7 d.p.i n=11, 14, 21 and 28 d.p.i n=12; control 2, 7, 14, 21 & 28 d.p.i n=6. 
 (ii) a (i) 




































































































































































































































































































































































































































































































































































































































































CXCLi2 IL-4IL-1β IL-10 IL-17AIL-6 TGFβ4
Figure 17. Relative expression (i) and 40 - ΔCt (ii) of assessed cytokine, chemokine and AMP transcripts within caecal tissue (a) and caecal tonsil 
tissue (b) of experimental chickens according to C. jejuni challenge status at 28 d.p.i (23 d.p.h). Error bars represent IQR of the median value and 
statistical significance has been assessed according to 40 - ΔCt. Statistical significance was determined using Mann Whitney-U analysis with levels of 
significance given as * p < 0.05, ***p < 0.001. Infected 2 d.p.i n=10, 7 d.p.i n=11, 14, 21 and 28 d.p.i n=12; control 2, 7, 14, 21 & 28 d.p.i n=6. 
 (ii) b (i) 




Table 10. Statistical parameters for relative fold change and 40-Ct values for all analysed genes in control and C. jejuni infected caecal tissues of chickens at various 
time-points post infection. All statistical significance values are given for 40-Ct values of gene expression in infected tissues relative to that of control tissues.  
 Days post infection  
Challenge 
status 
 2 7 14 21 28 
Gene 









































CXCLi2 21.57 (1.41) 0.0002 15.85 (13.23) 21.08 (1.03) 0.002 12.00 (5.63) 19.03 (0.87) 0.0823 
2.91 
(1.51) 18.56 (0.61) 0.0496 5.25 (2.17) 17.51 (1.89) 1.89 1.08 (1.54) 
IL-1B 20.34 (0.57) 0.0002 6.30(2.56) 20.06 (1.64) 0.001 4.48 (3.05) 18.81 (0.79) 0.6993 2.50 (1.20) 18.55 (1.37) 0.1469 1.89 (1.95) 18.60 (2.19) 2.19 1.45 (1.71) 
IL-4 16.70 (0.41) 0.5135 0.77 (0.25) 18.98 (1.52) 0.0002 5.38 (5.03) 17.32 (1.13) 0.0127 2.66 (1.98) 16.65 (1.83) 0.6993 1.52 (1.81) 16.07 (2.82) 2.82 2.29 (1.96) 
IL-6 20.30 (0.21) 0.0002 5.43 (2.60) 17.56 (1.31) 0.0029 3.40 (2.75) 16.75 (1.11) 0.0637 1.96 (1.27) 17.97 (1.88) 0.0312 2.68 (3.76) 17.61 (1.48) 1.48 0.99 (2.55) 
IL-10 15.11 (2.94) 0.2853 0.88 (1.31) 17.57 (2.34) 0.0503 3.57 (4.78) 15.23 (1.46) 0.2212 1.59 (1.77) 15.98 (1.70) 0.042 8.20 (6.41) 21.01 (2.11) 2.11 
12.83 
(11.30) 
IL-17A 16.97 (0.84) 0.0513 1.99 (1.25) 17.87 (1.05) 0.0619 3.20 (2.53) 19.95 (1.30) 0.0018 4.79 (5.40) 20.19 (1.50) 0.0559 5.04 (5.91) 20.39 (1.74) 1.74 7.24 (8.58) 
TGFb4 20.84 (0.80) 0.6354 0.95 (0.47) 20.28 (1.51) 0.028 4.57 (3.60) 17.81 (1.42) 0.0193 2.16 (2.82) 18.81 (1.15) 0.0023 1.95 (2.03) 17.16 (1.52) 1.52 0.78 (1.38) 
MUC2 18.85 (2.35) 0.1419 2.26 (2.99) 15.97 (4.31) 0.0007 0.14 (0.15) 17.95 (3.99) 0.1079 0.59 (0.87) 21.13 (1.36) 0.1419 0.64 (0.61) 22.25 (2.62) 0.1812 1.62 (2.04) 
Control 
CXCLi2 18.04 (2.16)     17.10 (2.17)     17.37 (0.95)     16.58 (1.39)     17.64 (0.71)     
IL-1B 17.86 (0.49)     17.26 (0.39)     18.52 (0.45)     17.60 (0.22)     18.25 (0.99)     
IL-4 16.44 (1.03)     16.69 (0.33)     15.82 (0.39)     16.88 (1.23)     16.95 (0.80)     
IL-6 17.74 (1.52)     16.02 (1.07)     15.46 (0.99)      16.13 (1.42)     16.14 (0.09)     
IL-10 15.85 (2.85)     15.56 (1.19)     14.12 (0.76)     12.90 (1.64)     15.54 (1.21)     
IL-17A 15.22 (0.66)     16.82 (0.26)     17.99 (0.80)     17.83 (1.48)     17.49 (0.40)     
TGFb4 20.92 (0.75)     17.76 (0.58)     17.01 (1.20)     17.00 (1.34)     16.31 (0.44)     






Table 11. Statistical parameters for relative fold change and 40-Ct values for all analysed genes in control and C. jejuni infected caecal tonsil tissues of chickens at 
various time-points post infection. All statistical significance values are given for 40-Ct values of gene expression in infected tissues relative to that of control tissues. 
  Days post infection 
  Gene 
2 7 14 21 28 











































CXCLi2 19.46 (1.06) 0.8887 1.23 (0.87) 18.79 (1.02) 0.1914 2.46 (1.45) 17.18 (1.39) 0.829 0.92 (0.65) 18.56 (0.61) 0.002 2.41 (3.48) 17.44 (2.44) >0.9999 0.67 (0.75) 
IL-1B 18.44 (1.71) 0.007 0.27 (0.27) 20.00 (0.91) 0.0006 3.46 (2.40) 12.51 (2.16) 0.6835 1.83 (3.22) 17.81 (1.13) 0.2397 1.77 (1.50) 19.25 (1.68) 0.682 1.27 (1.15) 
IL-4 17.77 (2.42) 0.0559 0.41 (0.54) 17.22 (0.58) >0.9999 1.52 (0.57) 18.27 (0.98) 0.0032 2.24 (2.36) 17.37 (0.84) 0.0182 2.15 (1.56) 18.43 (1.33) 0.5249 3.59 (3.35) 
IL-6 19.02 (2.18) 0.4559 1.20 (2.98) 19.07 (1.40) 0.0005 10.23 (10.86) 16.55 (0.83) 0.9636 0.94 (0.66) 14.83 (1.72) 0.8591 0.75 (1.31) 17.72 (2.36) 0.3011 1.96 (2.64) 
IL-10 19.93 (1.45) 0.3277 1.88 (1.29) 17.37 (0.44) 0.0007 2.46 (0.78) 18.01 (1.75) 0.0031 4.17 (3.44) 17.74 (0.46) 0.028 10.85 (4.75) 18.23 (2.59) 0.0135 2.73 (6.67) 
IL-17A 19.25 (1.06) 0.0017 0.27 (0.19 20.84 (0.75) 0.016 6.59 (5.88) 19.18 (1.34) 0.8916 1.46 (1.01) 17.23 (1.69) 0.3011 2.14 (3.26) 19.63 (1.25) 0.6165 1.39 (1.16) 
TGFb4 22.29 (1.51) 0.0553 2.24 (2.37) 22.77 (0.85) 0.0048 2.84 (1.92) 23.23 (0.70) 0.0144 2.06 (1.34) 21.54 (1.00) 0.6165 0.97 (1.12) 22.81 (1.24) 0.7669 1.14 (0.91) 
Control 
CXCLi2 19.33 (1.22)     18.09 (2.19)     17.37 (0.95)     16.58 (1.39)     17.64 (0.71)     
IL-1B 20.15 (1.98)     17.87 (1.42)     11.81 (1.55)     17.14 (0.30)     19.41 (1.50)     
IL-4 19.64 (1.98)     17.43 (0.87)     17.50 (1.40)     15.06 (0.59)     16.93 (1.08)     
IL-6 18.88 (0.72)     15.73 (0.49)     16.69 (0.58)     15.75 (1.57)     16.90 (1.21)     
IL-10 19.52 (1.23)     15.86 (0.88)     15.88 (0.53)     14.62 (3.05)     16.68 (1.04)     
IL-17A 21.04 (0.63)     18.65 (1.53)     18.77 (1.64)     17.10 (2.75)     19.19 (1.28)     

































































Figure 18 highlights potential correlation between caecal C. jejuni load and serum IgY 
and IgM production, as described previously. There appears to be no apparent 








Figure 18. Comparison of IgY and IgM absorbance values following ELISA 
testing alongside CFU/g of C. jejuni within the caecal content of each 






Both experimental infection protocols used within this study highlight the ability of C. jejuni 
to colonise the avian intestinal tract rapidly following ingestion. Although colonisation was 
apparent in both experimental trials at 2 d.p.i, there was slight disparity between colonisation 
rate between experiment 1 and experiment 2, being 20 % and 67 % respectively at this time 
point. Differences between experiments were less apparent by 7 d.p.i, with infected groups 
from both experimental trials showing between 80 - 90% colonisation. All birds given infection 
inoculum were positive for C. jejuni within the caeca by 14 d.p.i, irrespective of experimental 
trial. Using similar infective doses of two C. jejuni strains (S3B and 21190) to those within our 
study, Sahin et al. (2003) saw a dramatic increase in percentage of birds shedding C. jejuni 
between 2 d.p.i and 8 d.p.i. By 14 d.p.i, all birds within the work of Sahin et al. (2003) were 
shedding C. jejuni and continued to do so until 28 d.p.i, a characteristic presented within 
caecal positivity of our study. Caecal colonisation of birds positive for C. jejuni across each trial 
ranged from 5.52 to 10.68 Log10 CFU/g in experiment 1 and 5.12 to 8.9 Log10 CFU/g in 
experiment 2. These results are in accordance with the levels of caecal colonisation observed 
in previous literature, stating a general range of colonisation from 106 CFU/g to loads in excess 
of 109 CFU/g (Hermans et al., 2014; Humphrey et al., 2014). This increase in bacterial numbers 
over time has also been evident in other studies (Hansson et al., 2010) and linked to the 
increase in flock risk of colonisation with flock age (Bouwknegt et al., 2004). Increases in C. 
jejuni colonisation such as those described here will almost certainly increase the risk of 
human campylobacteriosis from the broiler chicken reservoir as high proportions of C. jejuni 
positive caecal samples or high bacterial numbers within these contents increase the numbers 
of Campylobacter on chicken carcasses (Hansson et al., 2010). It is important to consider that 
while routinely described as highly motile, no confirmation of motility was performed during 
this research. With flagellar-mediated motility central to C. jejuni colonisation, future work 
should incorporate such methodologies as standard practice prior to infection.  Work by de 
Vries et al (2015) highlights the importance of such methodologies and defines how this can 
be conducted through inoculation of solid growth medium with the bacterium and 
subsequently recording the diameter of the ring of bacterial growth following incubation.  
 
Although obvious trends in dynamics of colonisation existed across both trials, variation in 
both positivity status and subsequent C. jejuni load existed within experimental animals at 
specific time points of each experimental trial. This variation was particularly evident at earlier 




infectious dose of C. jejuni at the same time point, differences in infection dynamic between 
individuals reflects how homogenous infection dynamics are rarely associated with C. jejuni 
infection and that individuals within the same flock can exhibit largely dissimilar susceptibility 
to infection (Hansson et al., 2010).  
 
In conjunction with caecal colonisation, C. jejuni colonisation was often detected within the 
ileal tissues of birds from both experimental trials. While it is generally accepted that the 
predominant site for C. jejuni colonisation of the chicken is within the caecal crypts, as with 
this work, reports of its colonisation throughout the intestinal tract are prevalent (Hermans 
et al., 2014; Humphrey et al., 2014; Lin, 2009). When directly comparing caecal C. jejuni 
burden with that of the ileum, this temporal variation in colonisation was of similar magnitude 
between experiments 1 & 2, with caecal colonisation being 2.74 and 2.59 fold higher 
respectively. Work by Beery et al. (1988) supports this finding that C. jejuni primarily colonizes 
distal regions of the GIT, principally the caecum. The blind ended caeca represent a region of 
the GIT with a relatively low flow rate and as such, high retention time of ingested material 
(Savage, 1977). In contrast, the ileum is a straight section of intestinal canal with a much 
higher rate of flow and more dynamic environment (Johansen et al, 2006). This stable 
environment within the caecal crypts denotes a site easily colonised by C. jejuni, and 
subsequently a site that makes colonisation difficult to clear. Further to this, Johansen et al. 
(2006) has demonstrated how infection with C. jejuni potentially alters the microbial 
communities within the caeca, a function not found following infection within the ileum. 
Consequently, it may be that the anatomical structure of the intestinal site provides primary 
influence on the ability of C. jejuni to establish colonisation, while persistence within these 
niches once established might be the results of a combination of both anatomical structure 
and alterations in the host microbiome resulting from this first pathogenic colonisation. 
 
Extending from the established colonisation of sites throughout the GIT, this study further 
confirms the ability of C. jejuni to colonise systemic sites, far beyond that of the GIT. 
Colonisation of splenic tissue occurred as early as 2 d.p.i within experiment 1 and shortly after 
at 7 d.p.i in experiment 2. Within both experimental trials, splenic infection always preceded 
hepatic infection. There appeared to be no apparent correlation between the frequency of 
extra-intestinal C. jejuni identification and C. jejuni burden within the GIT. While of relatively 
recent discovery, this dissemination of C. jejuni to systemic tissues has previously been 




blood and liver tissues of broiler breeds, with this being subsequently linked to intrinsic 
invasive abilities of specific Campylobacter strains, alongside disparities in the susceptibility 
of chicken lines to such invasion. While further corroborated in the work of others (Chaloner 
et al., 2014; Humphrey et al., 2014), the means by which Campylobacter is able to navigate 
the intestinal barrier is still undefined. Knudsen et al. (2006) suggests that the very 
colonisation characteristics of Campylobacter species, whereby they interact heavily with the 
intestinal microbiota allow for a close interface with the intestinal epithelial surface and, as 
such, an increased prospect for invasion and spread to distant tissues. Arguments of this 
nature provide further weight to the notion that C. jejuni infection within the broiler chicken 
may not be solely commensal as once suggested, but instead able to induce immune 
responses outside that of a tolerogenic nature. Our study shows maximal frequency of 
colonisation of extra-intestinal tissues occurred from 21 d.p.i onward, the common slaughter 
age of most commercial broiler chickens. While current C. jejuni control strategies within 
poultry systems are generally focused on reducing caecal C. jejuni load, this work suggests 
concomitant importance of other tissues, such as the liver and spleen, in providing a source 
of carcass contamination post-slaughter (Reich et al., 2008). C. jejuni contamination of poultry 
liver tissues offers not only a means of contamination for outer carcass tissue, but also acts as 
a direct source for human campylobacteriosis. As identified by Whyte et al. (2006), poultry 
liver tissues are commonly consumed by people worldwide. Internal and external 
contamination of liver tissues with C. jejuni is often identified, which, considering the common 
cooking method of leaving such liver tissues ‘pink in the middle’, makes chicken liver tissue an 
important risk factor in itself for human exposure (Whyte et al., 2006). Despite showing high 
C. jejuni colonisation at post-mortem, no obvious clinical signs of disease were present in 
either experimental study.  This lack of clinical disease has been reported widely in current 
literature, however Humphrey et al. (2014) has stated evidence of diarrhoea within fast 
growing poultry breeds following bacterial infection. The ubiquitous nature of C. jejuni within 
the poultry industry alongside its lack of recognizable signs of infection make bacterial control 
within poultry farming ever more arduous.  
 
This study further confirmed the induction of inflammatory responses within the caecal 
tissues of a commercial broiler chicken line following exposure to C. jejuni infection, with this 
showing strong time-dependent succession.  While median expression values have been used 
to represent specific transcript expression per-time point according to challenge status, 




Reflecting the lack of conformity in C. jejuni colonisation patterns in vivo, this variable immune 
response supports such understanding that both pathogen infection dynamics alongside host 
immunological responses are not unilateral. Changes in the chemokine ligand CXCLi2 
alongside IL-1β and IL-6 associated with C. jejuni infection were found in the caecal tissue as 
early as 2 d.p.i. IL-1β and IL-6 are known pro-inflammatory cytokines with IL-1β acting as part 
of an innate immune response able to potently induce the upregulation of both IL-6 and 
CXCLi2 (Reid et al., 2016). Together IL-1β and IL-6 are vital in early stimulation of Th17 
responses, a pathway previously highlighted as being a predominant cytokine response to 
C. jejuni infection within the broiler chicken (Reid et al., 2016). This may be supplementing 
this with an early influx of heterophils likely induced from pro-inflammatory CXCLi2 
upregulation, being a highly homologous ligand to human IL-8 (Kogut et al., 2005). While 
caecal tonsil tissues also showed tendency toward an early pro-inflammatory response with 
an early surge in IL-1β expression, this was instead accompanied by IL-17A upregulation. Reid 
et al. (2016) has previously linked increases in IL-1β expression with subsequent IL-17A 
upregulation as a mechanism of protection against experimental C. jejuni challenge. At 7 d.p.i, 
all analysed cytokine and chemokine gene transcripts following C. jejuni infection showed 
some magnitude of upregulation in both caecal and caecal tonsil tissues compared to tissues 
of non-infected animals. While the pro-inflammatory response, initiated early post-infection 
continued to dominate, IL-4 upregulation became apparent within the caeca. It could be 
postulated that an early increase in IL-6 expression induced an increase IL-4 response whereby 
a Th2 mediated response could be initiated (Avery et al., 2004). Interestingly, although many 
cytokine transcripts appear upregulated within the caecal tonsil 7 d.p.i, it is those associated 
with anti-inflammatory regulatory responses (IL-10 & TGFβ4) that appear most dissimilar to 
samples from non-infected birds, with such a response continuing through to 28 d.p.i. This 
sequential decline in pro-inflammatory inducers has been previously associated with 
subsequent increase in anti-inflammatory response within Salmonella infection as a means of 
preventing exaggerated inflammatory responses within the intestinal tissue to infecting 
bacterium (Salisbury, 2012). It is also of interest that expression of the innate immune 
glycoprotein Mucin2 showed strong downregulation within the caecal tissue of infected birds 
at this time-point. While true in vivo response of secreted and surface mucins to C. jejuni 
challenge remains uncharacterized, use of RT-qPCR techniques in work by (Tu et al., 2008) has 
shown how Mucin2 may in fact act as an environmental prompt for C. jejuni to modulate 





Production of specific IgY, IgM and total secretory IgA in response to C. jejuni infection varied 
according to the level of prolonged persistence. For both serum IgY and IgM, peak titres were 
reached at 21 d.p.i, although this was not correlated with any significant reduction in C. jejuni 
colonisation within the caeca. The rise in Campylobacter specific IgY and IgM has previously 
been understood to begin approximately 2-3 weeks post experimental infection, and so our 
results are not thought to be dissimilar to previous conjecture (de Zoete et al., 2007). IgM are 
associated with low-affinity binding with high avidity to an array of self and non-self antigens. 
With a range of activities, including the regulation of immune response and induction of 
further antibody mediated activity against bacterial and viral infection, the induction observed 
here is likely indicative of primary immune response to the experimental C. jejuni infection. 
While IgY is able to utilize complement and Fc mediated macrophage uptake as a means of 
direct bacterial clearance, sIgA instead acts primarily through receptor blockade and immune 
exclusion mechanisms (Mantis et al., 2011). Generally, little is known regarding exact immune 
exclusion mechanisms attributed to sIgA, but consensus largely refers to agglutination, mucus 
entrapment and mechanistic clearance preventing pathogenic interaction with the intestinal 
epithelium (Mantis et al., 2011). Our data shows significant increases in sIgA of C. jejuni 
challenged birds above that of non-challenged from 21 d.p.i, with this trend accompanied by 
a general upregulation of Treg association cytokine subsets, being IL-10 and TGFβ4 within 
caecal tonsil tissues. IL-10 and TGFβ4 have been suggested as important inducers of class 
switching processes modifying B cell production from IgM to IgA production within chickens   
(de Vries et al., 2014). Although Campylobacter-specific sIgA has previously been association 
with protection against disease in humans (Janssen et al., 2008), the increases in total sIgA 
shown within this study indicate that this may only become apparent toward commercial 
slaughter age, making their influence on general poultry C. jejuni burden negligible, as 
indicated in work by Lacharme-Lora et al. (2017) . Such findings, notably those regarding sIgA, 
would benefit from further corroboration principally due to the variation observed within the 
titres recorded for birds acting as controls. This variation between individuals of the same 
group may limit the biological relevance of the findings described since these largely rely on 
comparison to control individuals.  
 
The results from this study have provided a foundation of understanding in the colonisation 
dynamics and host immune response to Campylobacter that can be built upon throughout the 
remaining work demonstrated within this thesis. We have exhibited how the infection biology 




literature (Awad et al., 2018; Lin, 2009; Newell, 2002). This involves rapid colonisation of the 
intestinal tract, with high levels of bacterial load within the caecal contents at a level which 
remains sustained until at least commercial slaughter age (Hermans et al., 2014). Bacterial 
load was lower within other sites of the intestinal tract outside of the caecal crypts. Isolation 
of C. jejuni from two systemic sites provides evidence of the bacteria being able to diffuse 
outside of the GIT, and into systemic tissues (Awad et al., 2018; Chaloner et al., 2014; 
Humphrey et al., 2014). This dissemination into sites distant from the intestine appears to 
increase alongside general C. jejuni infection persistence. We have generated data sets 
providing supporting theory that C. jejuni infection within the chicken is not simply commensal 
as previously described and is capable of generating an array of inflammatory immune 
pathways largely centralized around Th17 responses. Colonisation of multiple tissues such as 
the liver will more than likely make it increasingly difficult to prevent carcass C. jejuni 
contamination and also limit bacterial entry into the human food chain. There were no 
indications of obvious disease within any animals included within either study, in direct 
disparity to that seen in human campylobacteriosis (Newell, 2002). Oral infection 
methodologies used here provide a relatively accurate infection model due to the fecal-oral 























































Campylobacter infection remains the most common cause of global bacterial foodborne 
gastroenteritis (de Zoete et al., 2007). The acute gastroenteritis resulting from the majority of 
human Campylobacter infections is self-limiting, although can infrequently manifest into 
sequelae indications including arthritis and Guillain-Barré syndrome (GBS) (Acheson & Allos, 
2001; Pasquali et al, 2011).  As previously highlighted, both campylobacteriosis and any 
subsequent indication presents an economic burden to both the worlds most developed and 
deprived countries.  A consequence of low infectious dose requirements for human infection, 
prevalence of Campylobacter in more than 80 % of UK retail poultry carcasses and carcass 
contamination often in excess of several thousand bacteria per cm2 skin, has made poultry 
meat a reservoir of infection with huge public health implication (Corry & Atabay, 2001).  
 
To implement effective infection control strategies, identifying the high-risk phases of the 
overall ‘farm-to-table’ production system within the poultry industry is essential (Hayama et 
al., 2011). Some focus has been placed on the impact of carcass processing at slaughter houses 
on the entry of Campylobacter into the human food chain (Hayama et al., 2011). Although 
much emphasis is placed on carcass contamination from bird feathers and introduction of 
intestinal content  (Berrang et al., 2004), results from Chapter 2 highlight the ability of a 
multitude of tissues, both within the alimentary canal and more distant, to harbour 
Campylobacter. Cross contamination of C. jejuni bacteria to previously non-positive broiler 
carcasses during poultry processing post-slaughter has been reported at over 75% within 
slaughterhouses across Europe (Meunier et al., 2016) and will have influence on whole 
production flocks processed on a single line (Hayama et al., 2011). Hayama et al. (2011) show 
how it is not only initial flock prevalence of Campylobacter that can be a problem at this stage 
of production, but also the total Campylobacter load of each contaminated carcass. 
Interventions, in place to limit the frequency of carcass contamination during processing post 
slaughter, are often constrained by this factor. To illustrate this understanding, when mean 
carcass Campylobacter load was identified as 2.7 Log10 CFU/carcass, the frequency of 
Campylobacter carcass contamination across that flock post processing was lower than that 
prior to processing (Hayama et al., 2011). However, with a higher initial carcass contamination 
of 6.7 Log10 CFU/carcass, flock Campylobacter cross-contamination was considerably higher, 
resulting in a significant increase in prevalence post-processing (Hayama et al., 2011). As such, 
both Campylobacter prevalence and total colonisation load are of significant importance in 




risk of human exposure, implementing control strategies to reduce both load and prevalence 
of Campylobacter in the primary, on-farm production stage are seen as the most effective 
measures (Meunier et al., 2016).  
 
Multiple on-farm control strategies have been considered as a means of controlling C. jejuni 
levels in poultry production (Ghunaim, 2009). Refinements in biosecurity processes has been 
heralded as one of the most effective methods of C. jejuni control that can be implemented 
at farm level and throughout this phase of production. In theory, a reduction in the initial 
exposure of poultry to Campylobacter through comprehensive biosecurity practices should be 
an effective means of intervention (Lin, 2009). However, intervention strategies employing 
varying levels of biosecurity practices have reported mixed success (Pasquali et al., 2011). It is 
suggested by Wagenaar et al. (2006), that for improvements in biosecurity to truly have any 
further impact on Campylobacter levels within poultry flocks, the current understanding of 
both infection sources, and the risk factors mitigating these must first be refined. While 
considerable effort has been afforded to deriving an effective vaccination strategy to reduce 
Campylobacter infection of the chicken, results have been largely contradictory, with no 
reputable model developed (de Zoete et al. 2006; Meunier et al. 2017; Kobierecka et al. 2016; 
Hermans et al. 2014). With understanding of the avian immune response to Campylobacter 
still in its infancy, developing an effective vaccination strategy to the point of commercial 
realisation requires the navigation of multiple obstacles (Pasquali et al., 2011). One 
particularly problematic challenge is the short life span of commercial broiler chickens (~ 6 
weeks of age) and the initial presence of maternally derived antibodies (until ~ 2-3 weeks of 
age) (Lin, 2009). Together, these factors result in a relatively short phase in the broiler lifecycle 
within which a strong antibody response to Campylobacter infection must be mounted (Lin, 
2009). It should also be considered that, depending on the vaccination strategies utilized, this 
short timespan must also encompass any withdrawal period necessary.   
 
Therapeutic administration of bacteriophages or bacteriocins to chickens already showing 
C. jejuni colonisation has been demonstrated as a potential replacement for widespread 
antimicrobial use (Lin, 2009). Working in accordance with the intestinal mucosal barrier, 
bacteriophages and bacteriocins show a range of antibacterial properties and prove 
particularly promising modulators of the intestinal environment in both humans and animals 
(Lopetuso et al., 2019). However, links to Campylobacter resistance to both therapies have 





Since the chicken gut microbiome acts as an immediate biological barrier against C. jejuni, it’s 
manipulation through pre- and probiotics has been thought to play an essential role in 
Campylobacter reduction and control in commercial poultry production. Therapeutic 
manipulation of the microbiota in production of livestock has an extensive history (Borody,  et 
al., 2013). Animal husbandry practices including transfaunation, the transfer of rumen content 
in cattle are well established therapies for common indications. Incorporation of the use of 
dietary products, particularly probiotics alongside other microbial interventions, to 
manipulate or modify poultry intestinal microbiomes are becoming increasingly popular 
within the commercial poultry industry (Gupta et al., 2016). The food and agriculture 
organisation of the united nations (FAO) adopted definition of a probiotic formulation is “live 
microorganisms which when administered in adequate amounts confer a health benefit to the 
host”, with these often being administered via a digestive route (FAO/WHO, 2001). Early work 
using avian intestinal flora to reduce Salmonella colonisation in chicks by (Rantala & Nurmi, 
1973) was the forerunner of many subsequent studies on probiotics. However, the basis of 
how any manipulation of the microbiota is effective in reducing pathogen load within the 
chicken remains unclear. Forming the basis of current literature, common theory would 
indicate that there are two broad hypotheses; firstly, any microflora preparation may have a 
competitive exclusion (CE) effect, originally an ecological term, based around competition for 
a niche and resources. We also now understand that intestinal tract bacteria such as 
Firmicutes produce metabolites, such as butyrates, that can inhibit the growth of 
Proteobacteria (Eeckhaut et al., 2011). Secondly, probiotics and microflora preparations may 
drive immune development and immunity in the gut, helping limit pathogen colonisation and 
as such, decrease host disease susceptibility (Stanley et al., 2014). While somewhat promising 
data exists on the efficacy of probiotics against specific gastrointestinal tract (GIT) illness in 
veterinary species, attempts at reproducing and refining this for use against C. jejuni 
colonisation of the modern broiler chicken has been largely empirical in nature, with little 
evidence of a practical industrial role (Oakley et al. 2014; Stanley et al. 2014). Recommended 
doses of oral probiotics will often deliver a relatively low magnitude of viable microorganisms 
compared to that found within the native microbiota (Borody & Khoruts, 2012). In addition, 
although often initially derived from the avian intestinal tract, many probiotic bacterial strains 
have undergone extensive environmental adaptation during ex vivo culture, potentially 
limiting its ability to establish within the complex intestinal niche of the broiler chicken 




only transient influence on the intestinal microbiota and will generally require repeat 
administration  (Borody & Khoruts, 2012).            
 
Often, a probiotic preparation is of relatively trivial bacterial taxonomic complexity when 
compared to that of the developed chicken caecal microbiome. As such, it may be 
conceptually more pertinent to consider the gut as an entire system, with multiple interwoven 
facets as oppose to the distinct sum of individual bacterial entities. The introduction of a 
complete, stable gut microbiota from a healthy donor into a recipient through a Faecal 
Microbiota Transplant (FMT) has recently been incorporated into the therapeutic treatment 
of an array of known and idiopathic conditions (Borody & Khoruts, 2012). Perhaps the best 
described and most effective clinical use of FMT in human medicine is to treat recalcitrant 
Clostridium difficile infection (CDI), a result of dysbiosis stemming from antibiotic use, is one 
of the most notable examples of current therapeutic applications. A study by Aas et al. (2003) 
presented a FMT treatment success rate exceeding 90% within trial evaluable patients, such 
findings being reproducible throughout considerable further research (Agrawal et al., 2016; 
Kelly et al., 2016). Although the scientific rationale behind its efficacy remains somewhat 
elusive, the undoubtable success of FMT in the treatment of CDI warrants further indication 
of multiple applications beyond current practice. While use of FMT is becoming progressively 
disseminated throughout human clinical practice, FMT in a modern sense has not yet been 
adopted into livestock.  
 
In contrast to many animal species, the large intestine of the poultry GIT comprises a pair of 
blind ended caecal sacks, a unique feature strongly developed within the domesticated 
chicken. Comparable to other regions of the poultry GIT, the caecal microbiome has long been 
correlated with poultry health and productivity. Feeding on from the ileum, the ceca is the 
main site of fermentation for undigested foodstuffs, being emptied only once every 12 - 24 
hours (Clavijo & Flórez, 2018). Potentially interlinked with this extended food retention time, 
the caeca are often described as having the most taxonomically diverse and abundant 
microbiota across all chicken GIT sites (Clavijo & Flórez, 2018). Additionally, with the caecum 
being the primary site of Campylobacter species colonisation, transplantation of caecal 
microbiota in replacement of the more commonly utilised faecal microbiota may offer unique 





Here we transfer a caecal microbiota from healthy, Campylobacter-free control donor 
chickens directly to newly hatched chicks.  The aims of all in vivo challenge models used here 
were to assess the effect of CMT on host susceptibility to subsequent C. jejuni infection and 
its transmission within an experimental flock. From this we were looking to devise practice 
guidelines of donor selection, Caecal Microbiota Transplant (CMT) material selection and 
preparation and route of administration.  
 
MATERIALS AND METHODS 
 
BACTERIAL ISOLATES AND GROWTH CONDITIONS  
 
Strain Campylobacter jejuni M1 was used as the infecting inoculum, prepared as previously 
described in Chapter 2. Serial 10 - fold dilutions of the final Mueller Hinton Broth (MHB [Lab 
M Ltd., Heywood, Lancashire, UK]) liquid culture were made in 1 x Maximum Recovery Diluent 
(MRD [Lab M Ltd, Bury, UK]) to 10-8 for viable colony enumeration via Miles & Misra (1938) 
and plated onto Colombia Blood Agar (CAB [Lab M Ltd., Heywood, Lancashire, UK]) 
supplemented with 5 % defibrinated horse blood (Oxoid, Basingstoke, Hampshire, UK) as 
described in Chapter 2 before incubation for 48 hours at 41.5°C.  
 
CAECAL MICROBIOTA TRANSPLANT (CMT) PREPARATION  
 
Since CMT has not been widely tested, a lack of standard practice guidelines exists for the 
preparation of caecal material for transplantation (Borody & Khoruts, 2012). All trials listed 
within this work were conducted using CMT material prepared as described here. Samples of 
10 g caecal content were aseptically collected at point-of-cull from five uninfected control 
animals used within experiment 1 (Chapter 2) and pooled to create a sample of 50 g. Caecal 
content was immediately snap frozen at collection using liquid nitrogen to prevent the 
deterioration of transplantation material and prolonged aerobic exposure. This pooled CMT 
material was stored at - 80°C until further processing.  
 
Stored CMT material was subsequently thawed in a warm water bath set at 37°C before being 
diluted 1:20 (w/v) in sterile  1 x Phosphate Buffered Saline (PBS [Lab M Ltd, Heywood, 
Lancashire, UK]) and filtered through a coarse 25 µM Whatman® (Sigma, Poole, Dorset, UK) 
filter to achieve desired CMT consistency. Diluted CMT was vortexed for 1 minute to ensure 




2 mL aliquots of CMT (1:20) were warmed in a water bath at 37°C until fully thawed. Thawed 
CMT material was vortexted for 1 minute before being delivered to recipient chicks within 1 - 
hour of thawing. Treatment was delivered to all chicks using a 1 mL sterile syringe (Fisher 
Scientific, Loughborough, UK) through a sterile oral gavage (Sigma, Poole, Dorset, UK). 
 
 MALDI-TOF MS BIOTYPER SAMPLE PREPARATION  
 
A Sterilin sterile cotton swab (ThermoFisher Scientific, Loughborough, UK) containing 
prepared CMT inoculum was spread onto CAB agar ensuring to cover the entire agar surface, 
replicating this process a total of nine times. Of these replicates, three were incubated in 
either aerobic, microaerobic or anaerobic conditions for a period of 48 hours. 
 
Following incubation, plates were observed for morphologically distinct colony growth, with 
each differentially identified colony being sub-cultured on CAB agar and incubated for a 
further 48 hours in their respective growth conditions. Each identified colony was smeared as 
a thin film directly onto a spot on a stainless steel MALDI target plate (Bruker Daltonic, 
Billerica, MA, USA). Samples were then overlain with 1 µl of 70 % formic acid and allowed to 
air dry at room temperature. Immediately, 1 µl of α-cyano-4-hydroxycinnamic acid matrix 
(HCCA), prepared according to manufacturers’ instruction, was overlain and allowed to air dry 
at room temperature. All further processing was conducted by the Veterinary Diagnostic 
Microbiology Service, University of Liverpool, using standard operating procedures for Matrix-
assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) 
biotyper analysis.  
 
EXPERIMENTAL ANIMALS  
 
All work was conducted in accordance with United Kingdom legislation governing 
experimental animals under project license PPL 40/3652 and was approved by the University 
of Liverpool ethical review process prior to the award of this license. All animals held at this 
site were checked a minimum of twice daily to ensure individual animal health and welfare. 
Description of experimental housing condition, feed and unit biosecurity measures can be 





For all experimental trial groups requiring chicks to be hatched within our experimental unit, 
embryonated Ross 308 hens’ eggs were obtained from a commercial hatchery and 
transported directly to the University of Liverpool high biosecurity experimental unit. All eggs 
were inspected for shell quality and those with catastrophic damage were discarded from the 
experiment. All eggs were dipped for 2 - 3 minutes in a 1 % (1:100 dilution) solution of 
Ambicide™ (PatrickPinker, Latteridge, Bristol, UK) maintained at 38 – 41 °C. Eggs were 
subsequently air dried and wiped with 1 % peracetic acid (Sigma, Poole, Dorset, UK) before 
transfer to a sterile incubator. Eggs were incubated for 21 days at 37.7 °C in an automatic roll 
incubator (Brinsea, Milton Keynes, UK) and candled 7 days after setting to ascertain viability. 
Only viable eggs were retained for the remainder of the trial. Relative humidity was 
maintained at 45 - 55 % until day 18 of incubation where the humidity increased to 60 - 70 % 
until hatching.   
 
OVERVIEW OF INDIVIDUAL EXPERIMENTAL TRIAL DESIGNS 
 
The key aims underpinning each trial within this study are described below in addition to being 
detailed in Table 12. For full detail on all experimental animal housing, protocols for inoculum 
preparation and administration, and post-mortem processing, see Chapter 2.   
 
Table 12. Key experimental protocol time points for experimental challenge models 3 – 6 
 
 
Experimental design – Experiment 3  
 
A total of 22 chicks were successfully hatched following 21 days of incubation, with these 
receiving 0.1 – 0.2 ml prepared CMT inoculum within 4-hour post-hatch as previously 
described. At point of hatch, a further 24 age-matched day-old Ross 308 chicks were obtained 
from the same commercial hatchery and received 0.1 – 0.2 ml sterile 1 x PBS within 4 hours 
 Experiment 3 Experiment 4 Experiment 5 Experiment 6 
CMT Inoculation Immediate Immediate 7 d.p.h Immediate 
C. jejuni challenge 
model 
Seeder Seeder Seeder Direct 
C. jejuni challenge 
dose 
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of arrival. Treatment groups were housed in separate rooms with lobbied entry and additional 
dedicated protective clothing and boots. At 14 days post-hatch (d.p.h) all animals were 
confirmed to have Campylobacter negative status. At 21 d.p.h, two randomly selected birds 
from each group were orally infected with 0.2 mL 106 CFU/mL C. jejuni in MHB via oral gavage.  
 
Cloacal swabs were collected from all birds at multiple time-points post infection to assess 
within-group C. jejuni shedding. Swabs were collected from all birds at 23 (2 d.p.i), 26 (5 d.p.i), 
29 (8 d.p.i) and 33 (12 d.p.i) days post-hatch. At 35 d.p.i (14 d.p.i) all birds were culled via 
cervical dislocation. Aseptic collection of splenic & liver tissues and caecal & ileal content was 
conducted as described in Chapter 2. Figure 19 provides a visual explanation of key 
experimental time-points.  
 
Experimental design – Experiment 4 
 
This experiment was designed to act as a repeat experimental study of Experiment 3 with the 
aim of validating the initial results obtained.  
 
A total of 8 chicks were successfully hatched following 21 days of incubation, with these 
receiving 0.1 – 0.2 ml prepared CMT inoculum within 4 hours post hatch as previously 
described. At point of hatch, a further 12 age-matched day-old Ross 308 chicks were obtained 
from the same commercial hatchery and received 0.1 – 0.2 ml sterile 1 x PBS within 4 hours 
of arrival. Treatment groups were housed in separate rooms with lobbied entry and additional 
dedicated protective clothing and boots. At 14 d.p.h, all animals were confirmed to have 
Campylobacter negative status. At 21 d.p.h, two randomly selected birds from each group 
were orally infected with 0.2 ml 106 CFU/ml C. jejuni in MHB via oral gavage.  
 
Cloacal swabs were collected from all birds at multiple time-points post infection to assess 
within-group C. jejuni shedding. Swabs were collected from all birds at 24 (3 d.p.i), 26 (5 d.p.i), 
28 (7 d.p.i) and 31 (10 d.p.i) days post hatch. At 33 d.p.i (12 d.p.i) all birds were culled via 
cervical dislocation. Blood samples were collected via cardiac puncture immediately post-cull 
before aseptic collection of splenic & liver tissues and caecal & ileal content was conducted as 

























Figure 20. Key time-points associated with experimental trial 4 
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Experiment 3 - Effect of CMT on seeder C. jejuni infection; Experiment 4 – Effect of CMT on seeder C. jejuni infection (Repeat); 




Experimental design – Experiment 5 
 
The aim of this trial was to understand how time of CMT administration will impact its efficacy 
by delaying CMT delivery to 7 d.p.h. Age matched, 1 day-old mixed sex chicks (n=32) of Ross 
308 broiler chickens were obtained from the same commercial hatchery as in used in all 
previous experimental trials and transported directly to the University of Liverpool high-
biosecurity experimental poultry unit. At 7 d.p.h, birds were divided into two treatment 
groups, with one being inoculated with 0.1 – 0.2 ml prepared CMT (n=15) and the other sterile 
1 x PBS (n=17). From this point on, treatment groups were housed within separate rooms with 
lobbied entry and additional dedicated protective clothing and boots. At 14 d.p.h, all animals 
were confirmed to have Campylobacter negative status. At 21 d.p.h, two randomly selected 
birds from each group were orally infected with 0.2 mL 106 CFU/ml C. jejuni in MHB via oral 
gavage. Cloacal swabs were collected from all birds at multiple time points post infection to 
assess within-group C. jejuni shedding. Swabs were collected from all birds at 24 (3 d.p.i), 26 
(5 d.p.i) and 28 (7 d.p.i) and 31 (10 d.p.i) days post hatch. At 33 d.p.i (12 d.p.i) all birds were 
culled via cervical dislocation. Aseptic collection of splenic & liver tissues and caecal & ileal 
content was conducted as described in Chapter 2. Figure 21 provides a visual explanation of 
key experimental time-points.  
 
Experimental design – Experiment 6 
 
The aim of this trial was to understand CMT efficacy against direct doses of C. jejuni, where 
level of infection is not determined by within-flock transmission. 20 chicks were hatched 
following 21 days of incubation, with these receiving 0.1 – 0.2 ml prepared CMT inoculum 
within 4 hours post-hatch as previously described. At point-of-hatch, a further 24 age-
matched day-old Ross 308 chicks were obtained from the same commercial hatchery and 
received 0.1 – 0.2 ml sterile 1 x PBS within 4-hours of arrival. At 14 d.p.h, all animals were 
confirmed to have Campylobacter negative status. At 21 d.p.h, all birds from each group were 
orally infected with 0.2 mL 104 CFU/ml C. jejuni in MHB via oral gavage. On day 25 (4 d.p.i), 22 
birds were culled via cervical dislocation for post-mortem analysis (CMT n = 10; Ext. Control n 
= 12). Cloacal swabs were collected from all remaining birds at 28 (7 d.p.i) and 31 (10 d.p.i) 
days post hatch to assess within-group C. jejuni shedding. At 31 d.p.h (10 d.p.i) all remaining 
birds were culled via cervical dislocation. For all post-mortem analyses, samples of splenic and 
liver tissues & caecal and ileal content were collected aseptically as described in Chapter 2. 
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Figure 19. Key time-points associated with experimental trial 5 
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Figure 20. Key time-points associated with experimental trial 6 






Cloacal swabs were collected in all described trials as a means of assessing within-group 
C. jejuni shedding. Table 1 provides further detail on swabbing time-points according to each 
experimental protocol. Swabs were streaked onto selective blood-free agar (mCCDA 
[modified charcoal-cefoperazone-deoxycholate agar supplemented with Campylobacter 
enrichment supplement SV59]) (Mast Group Ltd, Bootle, Merseyside, UK) in a way to cover 
the entire agar surface before incubating at 41.5°C for 48 hours in microaerobic conditions. 
The cotton tip of each swab was subsequently used to inoculate 2 mL of Exeter enrichment 
broth (1100 mL nutrient broth, 55 mL lysed defibrinated horse blood, Campylobacter 
enrichment supplement SV59 [containing trimethoprim (10mg/L) and amphotericin B 
(2mg/L); Mast Group Ltd, Bootle, UK] and Campylobacter growth supplement SV61 
[containing sodium pyruvate (250mg/L), sodium metabisulphate (250mg/L) and ferrous 
sulphate (250mg/L); Mast Group Ltd])  and incubated at 41.5°C for 48 hours in microaerobic 
conditions. Following enrichment, samples were vortexed and plated onto mCCDA using a 3 µl 
loop. All plates were incubated at 41.5°C for 48 hours in microaerobic conditions before being 
assessed for C. jejuni positivity. Cloacal swabs were processed within 2 hours of sample 
collection. 
 
STATISTICAL ANALYSIS  
 
Statistical analysis was performed using GraphPad Prism version 7.00 for Mac OS X (GraphPad 
Software Inc., San Diego, USA). Prior to further statistical analysis, all bacterial enumeration 
data was first assessed for normality using a D’Agostino-Pearson omnibus normality test. Data 
sets showing non-normal distribution (p < 0.05) were further assessed for significance using 
non-parametric Mann Whitney-U testing to compare ranks, with significance set at p < 0.05. 
For those data sets showing normal Gaussian distribution, parametric unpaired t-tests were 
used with significance set at p < 0.05.   
 
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
 
Post-mortem blood samples were aseptically collected via cardiac puncture from all birds 
within experiment 3 at 35 days post-hatch (14 d.p.i). All blood samples were centrifuged at 




analysis. All samples were assessed for Campylobacter specific serum immunoglobulin-G (IgY) 




MALDI-TOF MS BIOTYPER IDENTIFICATION 
 
Culture of CMT inoculum onto CAB agar yielded a total of 34 morphologically distinct colonies 
when assessed visually. Using MALDI-TOF MS biotyping, taxonomic assignments were able to 
classify 28 of these into 15 taxonomic species. Species identification was assigned a unique 
score classification generated by comparing the peak profile (or peptide mass fingerprint) of 
each tested strain against known database entries, quantifying similarity on a logarithmic 
score between 0 and 3 (Richter et al., 2012). Only species identifications with a score value of 
≥ 1.7 were included in analysis as being highly probable (Richter et al., 2012). Full MALDI 
Biotyper identification results and associated logarithmic score values are provided in 
Appendix 2 with only unique taxonomies by growth condition shown in Table 13. 
 
Table 13. Culture conditions and bacterial taxonomic identification following MALDI TOF   
biotyper analysis. All presented species were identified with a representative score value of ≥ 1.7 
Culture media Culture 
conditions 










































EXPERIMENTAL TRIALS 3 & 4 
Cloacal shedding 
 
Between 2 d.p.i and 12 d.p.i, cloacal swabs were used to determine the dynamics of C. jejuni 
infection within each population of birds. Looking first at experimental seeder models used in 
experiment 3 and 4, transmission of C. jejuni was considerably delayed within the CMT group 
of both experiments compared to that of respective External hatchery treatment groups 












By 2 d.p.i, 2/19 birds (94 %) within the External control group of experiment 3 were shedding 
C. jejuni, with 19/19 birds (100 %) being C. jejuni positive by 8 d.p.i. In contrast, no cloacal 
shedding of C. jejuni was detectable within the CMT group of experiment 3 until 12 d.p.i, 
whereby only 4/19 birds (21 %) were C. jejuni positive. The transmission dynamics within 
experiment 3 were similar to that of experiment 4, however CMT treated birds of experiment 
4 showed no detectable C. jejuni shedding during the course of the trial. Shedding was 
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Figure 21. C. jejuni M1 transmission within treatment groups of experimental broiler chickens. 
Cloacal shedding was determined through cloacal swabbing at pre-defined time points according to 
experimental protocol. Red shapes depict birds detected as shedding C. jejuni while blue shapes show 
groups with no detected bacterial shedding. Experiment 3: CMT (n=19), External control (n=19); 




%) were C. jejuni positive. Results are provided in Figure 22 and Figure 23 detailing C. jejuni 
detection pre- and post- enrichment of cloacal swabs for all experimental birds of experiment 


























Group Bird ID 
Cloacal swab C. jejuni detection (d.p.i) 
Pre 2 5 8 12 
D E D E D E D E D E 
CMT 
Treated 
949           
950           
951*           
954           
955           
956           
958           
959           
961           
963           
966*           
969           
970           
971           
972           
973           
974           
975           
925           
External 
Control 
1551           
1552           
1553           
1554           
1555           
1556           
1557           
1559           
1560*           
1561           
1562           
1563*           
1566           
1567           
1569           
1570           
1571           
1572           
1575           
Figure 22. Detection of C. jejuni via cloacal swabbing at time points stipulated in experiment 3 
protocols. Red squares depict C. jejuni detection within a single swab sample, whereby 'D' 
indicates results are from direct plating of swab and 'E' depicts results are from enriched 
samples. All birds showing ‘*’ were directly infected as seeder birds as part of experimental 




















Caecal content was aseptically collected from all birds in experiment 3 and experiment 4 at 
35 d.p.h (14 d.p.i) and 33 d.p.h (12 d.p.i) respectively. Early caecal microbiota transplantation 
significantly reduced C. jejuni M1 load within caecal content compared to non-treated 
External control birds using seeder bird infection models (Figure 24). Enumeration data 
collected detailing C. jejuni load within caecal content of birds from both experiment 3 and 
experiment 4 showed non-normal distribution (p < 0.05) and as such, will be discussed and 











Cloacal swab C. jejuni detection (d.p.i) 
Pre 3 5 7 10 
D E D E D E D E D E 
CMT 
Treated 
1801           
1802           
1803           
1804*           
1805*           
1806           
1808           
1809           
External 
Control 
3751*           
3752           
3753           
3754           
3755*           
3756           
3757           
3758           
3759           
3760           
3761           
3762           
Figure 23. Detection of C. jejuni via cloacal swabbing at time points stipulated in experiment 4 
protocols. Red squares depict C. jejuni detection within a single swab sample, whereby 'D' 
indicates results are from direct plating of swab and 'E' depicts results are from enriched 
samples. All birds showing ‘*’ were directly infected as seeder birds as part of experimental 




















All birds within the External control groups of both experiment 3 and experiment 4 showed 
caecal C. jejuni colonisation at point-of-cull, with median Log10CFU/g values of 11.23 (IQR 0.3) 
and 8.58 (IQR 1.25) respectively. C. jejuni was detected in the caecal content of all but one 
(18/19; 95 %) CMT treated birds within Experiment 3 with median detected load of 4.78 (IQR 
4.18) Log10CFU/gram, although this was significantly lower than that detected for External 
control birds (p < 0.0001). Similarly, experiment 4 showed significant protective ability of CMT 
treatment against C. jejuni colonisation compared to External control birds (p < 0.0001), with 




Samples of ileal content were collected at post-mortem from each bird of both experiment 3 
and experiment 4 at 35 d.p.h (14 d.p.i) and 33 d.p.h (12 d.p.i) respectively. As with caecal 
colonisation, early CMT reduced ileal colonisation within both experimental trials 3 & 4 
Figure 24. Levels of C. jejuni M1 in the caeca of broiler chickens under experimental 
conditions based on protocols listed for experiment 3 (CMT n=19; Ext. control n=19) 
and experiment 4 (CMT n=8; Ext. control n=12). Each symbol represents caecal 
C.  jejuni load for an individual animal. Statistical analysis per treatment group are 
given as median values with associated IQR with significance determined using Mann 
Whitney-U analysis. Levels of significance are given as ****p<0.0001. All birds 
detected as shedding are given reported using a hollow triangle symbol, while all birds 



































compared to non-treated External control birds using seeder bird infection models (Figure 25). 
Enumeration values collected for C. jejuni load within ileal content of birds from both 
experiment 3 and experiment 4 showed non-normal conformation (p < 0.05) and as such, 
these results will be discussed and presented as medians, including their respective 
interquartile range. 
 
Within both trials described, ileal colonisation occurred at both a lower frequency and, when 
found, to a lower burden than that found within the caeca. In both experiment 3 and 
experiment 4, no ileal C. jejuni colonisation was detected in any bird treated with CMT. The 
External control group of experiment 3 showed 15/19 (79 %) birds to be colonized with 
C. jejuni within the ileum, with group median colonisation of 3.6 Log10CFU/gram (IQR 1.47). 
Ileal colonisation of the External control group of experiment 4 showed 5/12 birds (42 %) 
were C. jejuni positive, although median colonisation remained at 0.00 Log10 CFU/g (IQR 















Figure 25. Levels of C. jejuni M1 in the ileum of broiler chickens under experimental conditions based on 
protocols listed for experiment 3 (CMT n=19; Ext. control n=19) and experiment 4 CMT n=8; Ext. 
control n=12). Each symbol represents ileal C. jejuni load for an individual animal. Statistical analysis 
per treatment group are given as median values with associated IQR with significance determined using 
Mann Whitney-U analysis. Levels of significance are given as ****p<0.0001. All birds detected as 
shedding are given reported using a hollow triangle symbol, while all birds not detected as shedding C. 


































Extra-intestinal spread of C. jejuni  
 
At post-mortem examination, extra intestinal C. jejuni colonisation was present in both 
experimental replicates 3 and 4. Experiment 3 showed C. jejuni within the liver tissue of 2/19 
(11 %) External control birds and 1/19 (5 %) CMT birds. This result was similar in experiment 
4, with C. jejuni present in 2/12 (17 %) liver and 1/12 (8 %) spleen samples from External 
control birds while no C. jejuni colonisation was seen within the CMT population of this 
experimental model. Figure 26 shows spleen and liver C. jejuni detection per bird for 
experiment 3 and 4 respectively according to their unique identification number pre and post 




















































Figure 26. Detection of C. jejuni M1 within liver and splenic tissues of broiler chickens under 
experimental conditions based on protocols listed for (a) experiment 3 (CMT n=19; Ext. control 
n=19) and (b) experiment 4 (CMT n=8; Ext. control n=12). Red squares depict C. jejuni detection 
within a single sample, whereby ‘D’ indicates results are from direct plating of tissue homogenate 




Group Bird ID 
C. jejuni positivity  
Spleen  Liver   
D E D E 
CMT Treated 
949         
950         
951*         
954         
955         
956         
958         
959         
961         
963         
966*         
969         
970         
971         
972         
973         
974         
975         
925         
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control  
1551         
1552         
1553         
1554         
1555         
1556         
1557         
1559         
1560*         
1561         
1562         
1563*         
1566         
1567         
1569         
1570         
1571         
1572         
1575         
Treatment 
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D E D E 
CMT Treated 
1801         
1802         
1803         
1804*         
1805*         
1806         
1808         
1809         
External 
Control  
3751*         
3752         
3753         
3754         
3755*         
3756         
3757         
3758         
3759         
3760         
3761         




EXPERIMENTAL TRIAL 5 
Cloacal shedding 
 
To assess the impact of 7 d.p.h CMT administration on efficacy against C. jejuni transmission, 
swabs taken between 24 d.p.h (3 d.p.i) and 31 d.p.h (10 d.p.i) during experimental model 5. 
Here, we saw a slight delay in transmission of C. jejuni within the CMT population compared 
to that of the External control group, however protection against colonisation was not 










At 3 d.p.i 1/15 birds (7 %) was shedding C. jejuni within the group of birds given the CMT while 
this number was 3/17 (18 %) within the External control group. By 5 d.p.i, the difference in 
frequency of shedding between the two groups was negligible, with this relationship 
continuing until swabbing at 10 d.p.i whereby all birds in both groups were shedding C. jejuni 
in almost all individuals; 14/15 birds (93 %) from the CMT treatment group and 17/17 (100 %) 
from the External control group. Swab results for experiment 5 are provided in Figure 28, 
















Figure 27. C. jejuni M1 transmission within treatment groups of experimental broiler chickens. Cloacal 
shedding was determined through cloacal swabbing at pre-defined time-points according to experimental 
protocols. Red shapes depict birds detected as shedding C. jejuni while blue shapes show groups with no 
detected bacterial shedding. CMT n=15; Ext. control n=17. 






 Bird ID 
Cloacal swab C. jejuni detection (d.p.i) 
Pre 3 5 7 10 
D E D E D E D E D E 
CMT Treated 
2251                     
2252                     
2253                     
2254                     
2255*                     
2256                     
2257                     
2258                     
2259                     
2260                     
2261                     
2262*                     
2263                     
2264                     
2265                     
External Control 
1776                     
1777                     
1778                     
1779                     
1780                     
1781                     
1782                     
1783                     
1784                     
1785                     
1786                     
1787                     
1788*                     
1789                     
1790                     
1791                     
1792*                     
 
Figure 28. Detection of C. jejuni via cloacal swabbing at time points stipulated in experiment 5 
protocols (CMT n=15; Ext. control n=17). Red squares depict C. jejuni detection within a single 
swab sample, whereby 'D' indicates results are from direct plating of swab and 'E' depicts results 
are from enriched samples. All birds showing ‘*’ were directly infected as seeder birds as part of 
experimental protocols listed.   
 
Caecal colonisation  
 
Caecal content was collected 33 d.p.h (12 d.p.i) from all birds of experiment 5, with all birds 
in both treatment groups showing caecal positivity for C. jejuni (Figure 29). Enumeration 
values collected for caecal C. jejuni load showed normal conformation following Log10 
transformation (p > 0.05) and as such, these results will be discussed and presented as mean 
values, including their respective standard deviation values. Sample processing errors 
occurred during post-mortem affecting one experimental animal of the External control 




post-mortem samples for this experimental animal. Treatment group sizes were modified to 
n= 15; CMT administration 7 d.p.h and n=16; External control for all tissue sample data sets 




























All birds in both the External control treatment group and the treatment group receiving 7-
day CMT administration had detectable C. jejuni colonisation of the caeca, with mean 
Log10CFU/gram values of 8.00 (± 1.06) and 8.60 (±1.01) respectively. CMT administration 
delayed until 7 days of age, as applied within this protocol, resulted in no significant difference 
in final caecal C. jejuni colonisation between treatment groups (p = 0.1041).  
 
Ileal colonisation  
 
Ileal colonisation with C. jejuni was both less frequent and less pronounced as that seen with 
caecal colonisation and previous experiments. Unlike trends described with early delivery of 
CMT inoculum, 7 d.p.h CMT administration had no effect on frequency of ileal C. jejuni 
Figure 29. Levels of C. jejuni M1 in the caeca of broiler chickens under 
experimental conditions based on protocols listed for experiment 5 (CMT n=15; 
Ext. control n=16). Each symbol represents caecal C. jejuni load for an individual 
animal. Statistical analysis treatment group are given as median values with 
associated IQR with significance determined using Mann Whitney-U analysis. All 
birds detected as shedding are given reported using a hollow triangle symbol, 



























colonisation or final ileal C. jejuni burden (Figure 30). Enumeration values collected for C. jejuni  
load within ileal content of birds from Experiment 5 showed non-normal conformation 
(p < 0.05) and as such, these results with be discussed and presented as medians, including 
their respective interquartile range. 
 
Of the birds given CMT 7 d.p.h, 6/15 birds (40 %) had C. jejuni present within the ileum at 
point of cull, with this being 6/16 (38 %) of the External control group. No significant variation 
was seen between treatment groups in ileal burden of C. jejuni (p = 0.8402). Appendix 2 details 














Extra-intestinal spread of C. jejuni  
 
C. jejuni was detected in both liver and splenic tissue samples of both treatment groups of 
experiment 5 at point of cull. Of the 15 birds within the CMT treatment group, 5 birds (33 %) 
had detectable C. jejuni within the spleen, with 7 birds (47 %) C. jejuni positive within hepatic 
tissues. Of the 16 External control birds, a total of 3 birds (19 %) were C. jejuni positive within 
splenic tissues, with 7 birds (44 %) positive within hepatic tissues. A representation of C. jejuni 
detection within both tissue samples for all birds of experiment 5 pre- and post-enrichment is 
presented in Figure 31.  
Figure 30. Levels of C. jejuni M1 in the ileum of broiler chickens under experimental 
conditions based on protocols listed for experiment 5 (CMT n=15; Ext. control n=16). 
Each symbol represents ileal C. jejuni load for an individual animal. Statistical analysis 
per treatment group are given as median values with associated IQR with significance 
determined using Mann Whitney-U analysis. All birds detected as shedding are given 
reported using a hollow triangle symbol, while all birds not detected as shedding C. 























































Figure 31. Detection of C. jejuni M1 within liver and splenic tissues of broiler chickens under 
experimental conditions based on protocols listed for experiment 5 (CMT n=15; Ext. control 
n=16). Red squares depict C. jejuni detection within a single sample, whereby ‘D’ indicates 





EXPERIMENTAL TRIAL 6 
Cloacal shedding 
 
Direct challenge of all experimental animals with C. jejuni, as seen in experiment 6, resulted 
in an initial reduction in flock bacterial shedding compared to hatchery External control birds 
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Of the External control birds 8/12 (67 %) were shedding C. jejuni at 7 d.p.i compared to just 
3/10 (30 %) within the CMT treated group. However, by 10 d.p.i there was no apparent 
difference between the two treatment groups with 11/12 (92 %) External control birds 
shedding C. jejuni compared to 8/10 (80 %) CMT treated birds. A representation of C. jejuni 




















Figure 32. C.jejuni M1 transmission within treatment groups of experimental broiler chickens. 
Cloacal shedding was determined through cloacal swabbing at pre-defined time-points according 
to experimental protocols. Red shapes depict birds detected as shedding C. jejuni while blue shapes 



















Caecal samples were collected from birds of both CMT and External control treatment groups 
at two cull points during Experiment 6; 25 d.p.h (4 d.p.i) and  31 d.p.h (10 d.p.i) (Figure 34). 
Normality of distribution was not observed for the C. jejuni enumeration data sets of some 
treatment groups (p < 0.05) and as such, all results will be discussed and presented as group 
median values, including their respective interquartile range. 
Treatment Group Bird ID 
Cloacal swab C. jejuni 
detection 
Pre 7 10 
D E D E D E 
CMT Treated 
1907             
1908             
1909             
1910             
1911             
1912             
1913             
1917             
1920             
1921             
External Control 
2161             
2162             
2163             
2165             
2166             
2167             
2170             
2172             
2178             
2180             
2182             
2193             
Figure 33. Detection of C. jejuni via cloacal swabbing at time points stipulated in experiment 6 
protocols. Red squares depict C. jejuni detection within a single swab sample, whereby 'D' 
indicates results are from direct plating of swab and 'E' depicts results are from enriched 





Caecal colonisation of experimental birds culled 4 d.p.i was found to be less frequent and of 
lower burden than that seen for birds culled 10 d.p.i. Of the 12 External control birds culled 4 
d.p.i, 3 had detectable levels of C. jejuni within the caeca (25 %). Median C. jejuni colonisation 
of 4 d.p.i External control birds was 0.00 (IQR 2.72), with CMT treated birds showing no 
detectable C. jejuni colonisation at this time point (p = 0.2208). By 10 d.p.i, caecal colonisation 
was present within 11/12 (92 %) External control birds, with median colonisation of 8.21 (IQR 
2.02). Caecal colonisation was lower in frequency within the CMT treated population, in 8/10 
(80 %) of birds from this treatment group, with median colonisation of 7.88 (IQR 4.52). As with 
4 d.p.i, CMT treated birds showed lower caecal C. jejuni burden, although this relationship was 
not statistically significant (p = 0.7219).  
 
Ileal colonisation  
 
As with caecal sample collected, samples of ileal content were collected from groups of birds 
of each treatment group at 25 d.p.h (4 d.p.i) and 31 d.p.h (10 d.p.i). Enumeration values 
collected for C. jejuni load within ileal content of birds from experiment 6 showed non-normal 





























4 d.p.i 10 d.p.i
Figure 34. Levels of C. jejuni M1 in the caeca of broiler chickens under experimental 
conditions based on protocols listed for experiment 6. Each symbol represents caecal 
C.  jejuni load for an individual animal. Statistical analysis treatment group are given as 
median values with associated IQR with significance determined using Mann Whitney-U 





medians, including their respective interquartile range. Ileal colonisation with C. jejuni 
occurred within both treatment groups of experiment 6, although colonisation was first 
detected at a later time-point post infection compared to that of External control birds (Figure 
35). 
 
While no birds treated with CMT were positive for C. jejuni within the ileal samples collected 
at 4 d.p.i, colonisation was evident in 2/12 External control birds (17%), although median 
Log10CFU/g values remained at 0.00 (IQR 3.82) for this group (p = 0.4805). Interestingly, by 
10 d.p.i, 7/8 CMT treated birds (88 %) were colonized by C. jejuni within the ileal tract, with 
this being 9/12 (75 %) for the External control group at the same time point. In accordance 
with this, CMT treated birds had a median C. jejuni burden of 5.13 Log10CFU/g (IQR 1.68) while 
median External control C. jejuni burden was 3.91 Log10CFU/g (IQR 3.80) (p = 0.0712). 



































4 d.p.i 10 d.p.i
Figure 35. Levels of C. jejuni M1 in the ileum of broiler chickens under experimental 
conditions based on protocols listed for experiment 6. Each symbol represents ileal C. 
jejuni load for an individual animal. Statistical analysis per treatment group are given as 
median values with associated IQR with significance determined using Mann Whitney-U 





Extra intestinal spread of C. jejuni  
 
At post-mortem examination, no extra-intestinal spread of C. jejuni to either the splenic or 
hepatic tissues was observed for birds culled 4 d.p.i in either treatment group. By 10 d.p.i 4/12 
(25 %) External control birds had C. jejuni colonisation of the liver tissue and 5/12 birds (42 %) 
of the splenic tissue. Birds treated with CMT showed no liver colonisation of C. jejuni at 10 
d.p.i but 3/8 (38 %) had detectable C. jejuni within the splenic tissue. A representation of 
C. jejuni detection within both tissue samples for all birds of Experiment 6 pre- and post-
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Figure 36. Detection of C. jejuni M1 within liver and splenic tissues of broiler chickens under 
experimental conditions based on protocols listed for experiment 6 at 10 d.p.i. Red squares depict 
C. jejuni detection within a single sample, whereby ‘D’ indicates results are from direct plating of 









During post-mortem, serum samples were collected via cardiac puncture from all birds in 
experiment 4 to determine the degree of humoral response produced by the chickens to 
primary infection with C. jejuni following CMT treatment (Figure 37). Optical density readings 
for all data sets showed normal data distribution (p > 0.05) and so statistical analysis was 
conducted using unpaired t-tests. Birds within the External control treatment group showed 
highest variation in serum IgY titres compared to that of CMT treated birds. While mean serum 
IgY titres were highest within birds of the External control treatment group, this increase was 
not of statistical significance when compared against CMT treated animals (p = 0.0983). 
Conversely to that observed for serum IgY, serum IgM titres were significantly higher within 
birds treated with CMT at-hatch, compared to untreated birds within the External control 






































































Figure 37. Campylobacter specific serum IgY (a) and IgM (b) responses in experimental chickens 
given as OD405 readings following ELISA protocols. All results are based on blood samples 






The results of this study show that the transplantation of a microflora preparation, derived 
from whole ‘adult’ broiler chicken microbiota directly to chicks’ post-hatch, might be effective 
in reducing susceptibility of recipient birds to subsequent Campylobacter infection. In all 
experimental models where administration of CMT was given immediately post-hatch, 
subsequent within-flock transmission of C. jejuni was disrupted compared to chickens not 
given treatment. This influence was particularly evident when using a seeder model of 
infection whereby experiment 3 showed 19/19 hatchery External control chickens actively 
shedding C. jejuni compared to just 4/19 CMT chickens at 33 days post-hatch. Since bacterial 
shedding is not necessarily indicative of level of C. jejuni colonisation within individual birds, 
caecal and ileal content were collected post-mortem for bacterial enumeration. As seen with 
bacterial shedding, GIT colonisation of C. jejuni within chicks given immediate CMT post-hatch 
was significantly lower at both sites in comparison to that of non-treated hatchery chickens 
using seeder infection methodologies. CMT delivered in this way was able to prevent 
detectable colonisation of the ileal tract within both experiment 3 and experiment 4. Of more 
importance was the impact of CMT treatment on level of C. jejuni caecal colonisation, being 
its primary niche within the avian host (Humphrey et al., 2014). Impact of CMT on such 
colonisation was demonstrated in both experiment 3, where hatchery chicken caecal C. jejuni 
load was 6-fold higher than that of CMT chickens, and experiment 4, where CMT seemed to 
completely prevent detectable caecal colonisation of the CMT treatment group compared to 
mean colonisation of 9.06 Log10CFU/g in hatchery control chickens. Comparisons can be made 
between these findings and those of the pioneering research from Rantala & Nurmi (1973), 
who demonstrated how microbiota from healthy donor chickens was able to reduce 
colonisation of chickens with Salmonella following experimental infection.  
 
Poultry act as a particular novelty within farmed animal production, in that young generally 
receive no maternal contact post-hatch (Stanley et al., 2014). Commercial hatcheries employ 
strict hygiene processing protocols, with eggs being washed and fumigated following 
collection, a process that will erase most traces of maternal and environmental bacteria 
(Stanley et al., 2014). Since the development of broiler microbiome begins immediately post-
hatch, it is the hatchery environment that will form the first bacterial inoculum and likely have 
most bearing on a chickens’ microbial profile over time (Stanley et al., 2014). As such, a 
potentially ‘humanised’ chick microbiome with restricted bacterial diversity and distribution 




infection and subsequent disease (Volf et al., 2016). Experimental demonstration of this 
understanding can be seen in work from Dicksved and colleagues (2014) using a mouse model. 
Although inherently resistant to C. jejuni infection, when artificially colonised with a 
humanized intestinal microbiota, experimental mice exhibited signs of intestinal inflammation 
commonly associated with human campylobacteriosis (Dicksved et al, 2014). Early inoculation 
of chicks with microbiota could offer a promising means of curtailing the detrimental effects 
of poultry production systems on the microbiota of broiler chickens and reduce their 
susceptibility to infection (Volf et al., 2016). Disease prevention through the improvement of 
avian gut health in this manner presents an effective method of disease prevention and 
control in a climate where alternatives to antibiotic use in farm animal practice are required.  
 
Although the fundamental rationale behind FMT is similar to that of dietary supplements such 
as probiotics; restoration and restructuring of the intestinal microbiota to confer health 
benefit, the pathophysiological understanding behind probiotic therapies are considerably 
more developed compared to those of FMT and similarly derived Competitive Exclusion (CE) 
products (Chaitman et al., 2016). Unlike the temporary colonisation of the gut lumen by 
modern probiotic therapies, FMT infusion is more effective at the bacterial engraftment of 
donor microbiota, establishing both an enhanced and more durable alteration to the 
recipients’ microbiota (Cammarota et al., 2014). It may be likely to assume that not only may 
the mechanisms of action described for probiotic therapies be applied for FMT treatment, 
these may also be exaggerated in effect (Cammarota et al., 2014).  
 
As with probiotic therapies, one of the most postulated principles behind FMT success is its 
ability to competitively occupy the niche of indigenous gut microbiota. FMT action may also 
be characterised by promotion of host immunological defense mechanisms, mediating 
immune responses through pro and anti – inflammatory cytokine modulation (Isolauri et al.,  
2001). It is of interest that CMT treated birds had higher serum Campylobacter specific IgM 
compared to that of untreated control birds within experiment 4. Work by Haghighi et al 
(2005) developed this notion of immunomodulation through use of probiotic formulations, 
with multiple host-microbiota mechanisms potentially underpinning important functionality 
of CMT against C. jejuni infection within our infection model.  
 
Although FMT should be considered a true organ transplantation as oppose to simply an 




immunological match is necessary between donor and recipient (Cammarota et al., 2014). 
When considering human FMT use, multiple donor screening criteria must first be satisfied 
before continuation of the procedure, although optimal donor characteristics are yet to be 
standardized and published guidance remains limited (Chaitman et al., 2016). Of greatest 
importance across both human and veterinary clinical application remains the necessity to 
avoid transfer of disease from host to recipient. It may also be important to note that 
application of chicken CMT practices in countries still utilizing antimicrobials at therapeutic 
and sub therapeutic levels in chicken feed may have additional selection criteria to eliminate 
the transfer of resistance determinants between bacterial species from donor to host. Here, 
all control birds acting as donors of caecal material were confirmed as having C. jejuni negative 
status and were otherwise healthy at point of post-mortem.  
 
Limitations of this work can be drawn from the preservation and preparation methods used 
in regard to CMT material. Within human clinical FMT use, little evidence exists for best 
practice to ensure preservation of donor microbiota viability, with the same being said for 
veterinary application. Although FMT in humans is becoming an ever-established treatment 
regime for infections such as C. difficile, processing of donor stool for transplantation is often 
found to vary between trials, including freezing, freeze drying and preparation across any 
degree of aerobic to anaerobic conditions (Papanicolas et al., 2019).  Research by Papanicolas 
et al (2019) into specific viability implications of several preparation methods on the bacterial 
communities within FMT material provides insight into how the freeze-thaw preparation used 
in this work could influence the bacterial composition transferred by transplantation. Such 
work suggests that although overall transplant material viability was significantly reduced 4-
fold, microbial composition of this viable microbiota was unaffected compared to 
anaerobically processed fresh transplantation material (Papanicolas et al., 2019). Additionally, 
while glycerol is commonly used as a preservative media in clinical FMT use (Cammarota et 
al., 2014), Dan et al (1989) postulates that this technique offers no significant benefit in faecal 
material quality when stored at very low temperature (- 70°C). With this being said, it 
continues to be a priority to ensure only short lag times are employed between transplant 
material collection and utilization alongside only moderate use of freeze-thaw cycles (Chu et 
al., 2017).  
 
Similar to techniques employed in most clinical FMT trials communicated in American, British 




material was conducted aerobically, although conscious effort was placed on minimizing the 
extent of this aerobic exposure. Work by Chu et al., (2017) confirms general conjecture across 
published literature that oxygen exposure during aerobic preparation of transplantation 
material will somewhat compromise viable microbiota composition within the transplanted 
material, although it continues to be unclear as to how these alterations may impact the 
potential therapeutic benefit. It may be assumed that this oxidative stress will 
disproportionately impair strictly anaerobic microbial families, however Chu et al., (2017) goes 
on to discuss particular oxygen tolerance of the strictly anaerobic Bacteroides genus and how 
this may denote insufficiency of using information on bacterial growth conditions as a 
predictor for the response of specific bacterial taxa to stressors within a complex community. 
Applying this concept to the findings from this study, it should be considered that although 
processed aerobically, culture of multiple strictly anaerobic bacterial taxa were confirmed 
through MALDI-TOF MS biotyping. As such, a definite viable community of anaerobic bacterial 
taxa exists within our CMT material following processing, suggesting potential for re-
expansion of these taxonomic groups in the gut of transplant recipients. It should also be 
considered, that host immunostimulatory effects can also be induced through transfer of non-
viable bacterial cells and bacterial DNA, as discussed in work by Bojanova & Bordenstein 
(2016). The undoubted success of CMT within our work at reducing C. jejuni flock transmission 
and subsequent colonisation provides reasoning that the transplantation methodologies 
employed are unlikely to negate much of the therapeutic benefit offered. Conversely, the 
negative influence of oxygen exposure to transplantation material is justifiably deliberated in 
published literature and may be an important mediator on the efficacy of CMT within our 
study. It would be beneficial for future work to assess the impact of oxygen exposure to CMT 
material during processing on subsequent efficacy against C. jejuni infection and 
implementing viability assays to ensure transplantation of a broad range of viable bacterial 
communities.  
 
It is also yet to be determined how long post-administration the influence of CMT treatment 
might extend, and whether a protective effect against C. jejuni is observable at time-points 
more indicative of a later commercial slaughter age. Second to this, it might also be of 
importance to ascertain whether this effective period can be manipulated by repeated CMT 
dosing. Our results indicate that, although directly infected with C. jejuni, seeder birds were 
regularly not identified as shedding the bacterium until considerably after infection. To truly 




future work could potentially gain more useful insight by determining the exact limit of 
detection for C. jejuni using the protocols described here, while also increasing the frequency 
at which each individual was cloacally swabbed.  
 
In conclusion, the novel application of CMT used here demonstrates efficacy against C. jejuni 
transmission and GIT colonisation of the broiler chicken. There remain many unanswered 
questions regarding clinical use of microbiota transplantation in therapeutic treatment in both 
human and veterinary medicine, but these data provide an interesting theory on how 
modification of the avian microflora at point of hatch may provide promising prophylactic 





















Chapter Four: A comparison of two microflora preparations: 




























The poultry industry produces much of the global meat supply, with preference for chicken 
meat continuing to overshadow that seen for almost all other protein sources (FAO 2019). 
Poultry production is the fastest growing meat sector, contributing to over a 35% share of 
global meat production in 2016 (FAO, 2019). Selection pressures placed on the broiler chicken 
over decades of domestication have refined flock growth performance, a phenotypic trait of 
upmost concern for producers (Clavijo & Flórez, 2018). Although flock efficiency can be 
assessed using multiple parameters, the most universal measure remains the measure of food 
conversion ratio (FCR); a measure of growth efficiency with respect to nutrient provision 
(Stanley et al., 2013). Current estimates of broiler chicken FCR stand at 1.5 – 2.0, with 
continued industrial drive for refinement. 
 
Crucially, FCR is dependent on the effective extraction of energy and nutrient resources from 
ingested feed within the gastrointestinal tract (GIT). It is this interface that presents the 
chicken intestinal microbiota as having potentially the most fundamental influence on broiler 
productivity, health and susceptibility to opportunistic disease (Clavijo & Flórez, 2018). With 
the economic benefit offered to industries such as the poultry industry, improvement in our 
understanding of the gastrointestinal (GI) microbiota, and more importantly how it can be 
manipulated, has been driven to the forefront of scientific research more than ever before. 
Where antibiotic alternatives to disease treatment and prevention have previously been 
available, global campaigns in reduction of such practices have meant that use of the natural 
microbial ecosystems to protect against production animal disease may no longer be just a 
viable alternative, but more one of the only tools available (Callaway et al., 2008; Mountzouris 
et al., 2010). Aside from directly benefiting production animal health and productivity, 
potential reduction in economic and labour costs further demonstrate value (Callaway et al., 
2008). However, manipulation of the microbial ecosystem in this way within the poultry 
industry remains a relatively novel concept with limited substantiated research into how and 
when this microbial treatment should occur (Kabir, 2009). Although many different strategies 
of microbiota manipulation within the poultry industry have been suggested, it is only a 
selection of these that have dominated much of the ensuing research, namely probiotics and 
Competitive Exclusion (CE) products (Callaway et al., 2008).  
 
As previously detailed in Chapter three, probiotics consist of a general category of dietary 




disease (Callaway et al., 2008). Although probiotic use has been widely correlated with 
reductions in infections such as Salmonella enteritidis and Clostridium perfringens within the 
poultry industry (Kizerwetter-Swida & Binek, 2005), the complexity of microbial composition 
offered within CE products appear to offer greater protective success against Campylobacter 
infection compared to that of more defined, simple microbial probiotic preparations (Callaway 
et al., 2008). Unlike CE products, probiotics used within animal production comprise of 
individual/mixtures of bacteria, yeasts and metabolic end products that are not species 
specific or even originally derived from animal origin and may not be delivered 
instantaneously post-hatch (Callaway et al., 2008).  
 
Competitive exclusion products used within the poultry industry consist of a variety of 
anaerobic bacterial cultures usually derived from adult intestinal microbiota, applied to chicks’ 
post-hatch, to establish early colonisation of a ‘normal’ protective enteric microbiota 
(Wagner, 2006).  Such cultures can be of two forms, CE cultures with defined microbial isolates 
(defined CE cultures) or those whereby the microbial composition has not been completely 
characterised (undefined CE cultures) (Zhang et al., 2007), with both primarily intended for 
prophylactic use. The complexity of both host-microbe and microbe-microbe interactions 
occurring within the avian gut has continued to obscure the precise mechanisms by which CE 
microorganisms exert a protective effect (Mead, 2000). One of the most probable factors is 
likely to include the competition for adherence sites within the gut, a physical process 
evidentiarily supported by the protection of chicks from Salmonella infection only 1 hour post-
treatment with a CE product (Mead, 2000; Seuna & Nurmi, 1979). It is however, unlikely that 
any single factor could explain the effects seen from CE treatment, and so further conceivable 
factors include the production of Short Chain Fatty Acids (SCFAs) (including butyric, propionic 
and acetic acid) by the introduced microbial groups in addition to direct competition for scarce 
intestinal nutrients (Zhang et al., 2007). Since first introduced, the concept of CE culture in the 
protection against gastroenteric disease, continued research interest has formed the basis for 
the manufacture of a selection of commercial CE products (Zhang et al., 2007).  
 
Developed in Finland, BROILACT® (Orion Corporation, Espoo, Finland) was the first 
commercial CE product marketed for use in poultry targeting Salmonella infection (Nakamura 
et al., 2002). With use across Finland being previously reported at over 90% of newly hatched 
chicks in production (Nuotio et al., 2013), BROILACT® has since been used across Europe. 




developed and retailed, including Avifree™ and Aviguard®, MSC and Preempt™ (Nakamura et 
al., 2002). Developed as a CE treatment with extended shelf life compared to that of 
previously marketed commercial products, Aviguard® has experienced considerable 
commercial popularity since its launch in 1993 (Nakamura et al., 2002). Aviguard® is defined 
as “a natural, live intestinal microflora derived from specific-pathogen-free chickens and 
manufactured by fermentation” (MSD, 2009), having partially characterized microbial 
composition. Aviguard® has well characterised success for its capability of protecting newly 
hatched chicks from Salmonella colonisation throughout published literature (Al-Zenki et al., 
2009; Ferreira et al., 2003; Nakamura et al., 2002) however little research has been performed 
to evaluate such protective ability against Campylobacter spp. Thanks to the pioneering work 
by Rantala & Nurmi (1973) into the fundamental concepts of CE, much of the ensuing research 
into CE within animals has been directed primarily toward poultry disease. However, many 
probiotic and CE studies within poultry systems have lacked consistency in fundamental 
understanding of the microbial ecology of the avian GI system and, as such, further 
confirmation of the effectiveness of such commercial products may be necessary with few 
long-term Campylobacter colonisation studies available (Callaway., et al., 2008; Schneitz & 
Hakkinen, 2016).  
 
As discussed previously, FMT involves the transplantation of intestinal microbiota from 
healthy donor to recipient to introduce or restore a ‘balanced’ intestinal microecology 
(Niederwerder et al., 2018). Although more commonly discussed in reference to human 
clinical medicine and the treatment of CDI, interest has grown rapidly over recent years 
regarding veterinary application of FMT (Niederwerder et al., 2018). Peer-reviewed 
publications exploring therapeutic use of FMT within production animals show primary focus 
on swine and poultry, although much of this research is centered around clinical response to 
FMT treatment and less-so its potential mechanistic action (Niederwerder et al., 2018). 
Consequently, there are many fundamental concepts of the therapeutic action of FMT within 
veterinary species that are yet to be defined. Two general mechanistic principles exist for FMT, 
although each is largely though to be complementary to the other. One of the most commonly 
described is the restoration or repopulation of the intestinal microbiota improving the ability 
of such a microbial community to outcompete opportunistic GI pathogens for adhesion sites 
and metabolisable resources, similar in manner to that discussed for CE products (Mead, 
2000). Supplementary to this, it is also plausible that FMT may act as an immunotherapeutic 




Presley et al. (2010) reinforces such theory with research highlighting how a ‘normal’ gut 
microbiome within experimental mice was associated with a more cellular and responsive 
immune function compared to that of germ-free, pathogen-free mice.  
 
Although conceptually similar to CMT, commercial poultry CE products could be limited in 
their protective efficacy against bacterial species with colonisation ecologies such as those 
exhibited by C. jejuni. C. jejuni is well recognized for its ability to successfully colonise poultry 
caecal crypts establishing a largely non-invasive persistent presence of high burden 
(Hermans et al., 2014). The continued latent presence of C. jejuni within the poultry GI tract 
necessitates the need for a persistently ‘healthy’ avian host microbiome able to prevent the 
opportunistic adherence and colonisation of C. jejuni to the enteric epithelium. As previously 
identified by (Khoruts, 2018), commercial bacterial formulations such as probiotics will often 
offer only transient modification to host microbiota compared to the long-lasting, durable 
alteration identified following the administration of a complete fecal microflora preparation. 
Although derived from chickens, production methods utilised during Aviguard® culture and 
fermentation are highly selective toward cultivable bacteria under specific conditions (Shang 
et al., 2018). A result of this may be a tendency toward reduced taxonomic richness and 
diversity within commercial CE products (Shang et al., 2018). Furthermore, with published 
research highlighting the strong influence of genetic background on intestinal microbiota 
composition, the use of Specific Pathogen Free (SPF) ‘layer-type’ chickens as a source of 
Aviguard® microbial flora to be used in commercial broiler production may fundamentally 
undermine such physiological differences between microbiota compositions (Kers et al., 
2018). Maki et al. (2019) states that the vastly different production practices used between 
layer and broiler chicken industries makes drawing inference on any difference in breed 
microbiota innately complex. Although the broiler microbiome was viewed as having an 
increased ‘simplicity’ compared to that of layer type chickens, it should not be 
underestimated how the increased longevity of these layer chickens could influence this 
finding (Maki et al., 2019).  
 
Shortcomings such as these discussed may culminate in a CE product less efficacious in 
establishing robust colonisation of the broiler GI tract undermining the central biological 






MATERIALS AND METHODS  
 
BACTERIAL ISOLATES AND GROWTH CONDITIONS  
 
Strain Campylobacter jejuni M1 was used as the infecting inoculum, prepared as previously 
described in Chapter 2. Serial 10 - fold dilutions of the final Mueller Hinton Broth (MHB [Lab 
M Ltd., Heywood, Lancashire, UK]) liquid culture were made in 1 x Maximum Recovery Diluent 
(MRD [Lab M Ltd, Bury, UK]) to 10-8 for viable colony enumeration via Miles & Misra methods 
(Miles & Misra 1938) and plated onto Colombia Blood Agar (CAB [Lab M Ltd., Heywood, 
Lancashire, UK]) supplemented with 5% defibrinated horse blood (Oxoid, Basingstoke, 
Hampshire, UK) as described in Chapter 2 before incubation for 48 hours at 41.5°C. 
 
AVIGUARD® AND CMT INOCULATE PREPARATION  
 
Aviguard® (Batch number: 1517) (Lallemand, Worcestershire, UK) was prepared as directed 
by manufacturers instruction for drinking water application. The entire contents of one 
Aviguard® packet (stated treatment sufficiency of 2000 birds) was dissolved in 1 L of deionized 
water, free of chlorine or disinfectant contamination. The bottle of ready-to-use Aviguard® 
solution was inverted routinely over 5 minutes to ensure compete dispersal of sachet 
contents. Once fully dissolved, the Aviguard® solution was dispersed into 2 ml aliquots and 
stored at - 80°C. 
 
At point-of-use, stored 2 ml aliquots of CMT prepared to 1:20 (w/v) or Aviguard® inoculum or 
were warmed in a water bath at 37°C until fully thawed. Thawed aliquots of inoculum were 
vortexed for 1 minute to ensure thorough dispersion of contents before being delivered to 
recipient chicks within 1 hour of thawing. Treatment was delivered to all chicks using a 1 ml 
sterile syringe (Fisher Scientific, Loughborough, UK) through a sterile oral gavage (Sigma, 
Poole, Dorset, UK). Complete description of CMT preparation prior to aliquot dispensing and 




Work was conducted in accordance with United Kingdom legislation governing experimental 
animals under project license P999B8C93 and was approved by the University of Liverpool 
ethical review process prior to the award of this license. All animals held on-site were checked 




experimental animal housing conditions, feed and unit biosecurity measures can be found in 
Chapter 2, also described by Humphrey et al 2014. 
 
EXPERIMENTAL TRIAL DESIGN  
 
Embryonated Ross 308 hens’ eggs were obtained from a commercial hatchery and 
transported directly to the University of Liverpool high biosecurity experimental unit. As 
previously described in Chapter 3, all eggs were inspected for shell quality and subsequently 
sterilized using a 1% (1:100 dilution) solution of Ambicide™ (PatrickPinker, Latteridge, Bristol, 
UK) and 1% Peracetic acid (Sigma, Poole, Dorset, UK) before transfer to a sterile incubator. All 
eggs were incubated for 21 days at 37.7 °C in an automatic roll incubator (Brinsea, Milton 
Keynes, UK). All eggs were candled at 7 days after setting to ascertain viability, with only viable 
eggs being retained for the remainder of the incubation period. Relative humidity was 
maintained at 45 – 55 % until day 18 of incubation where the humidity increased to 60 - 70 % 
until hatching.  
 
A total of 87 chicks were successfully hatched following 21 days of incubation, with these 
being divided into three separate treatment groups;  
 
- CMT treated (n = 29); received 0.1 - 0.2 ml prepared CMT inoculum within 4 hours 
post-hatch  
- Aviguard® treated (n=29); received 0.1 – 0.2 ml prepared Aviguard® inoculum 
within 4 hours post-hatch 
- Internal control (n=29); received 0.1 – 0.2 ml sterile 1 x Phosphate Buffered Saline 
(PBS [Lab M Ltd, Heywood, Lancashire, UK]) within 4 hours post-hatch  
 
At point-of-hatch, a further 36 age matched day-old Ross 308 chicks were obtained from the 
same commercial hatchery, with these being divided into two groups;  
- External control (n = 29); received 0.1 – 0.2 ml sterile 1 x PBS within 4 hours of 
arrival 
- Trial control (n = 7); received no treatment 
 
All five treatment groups were housed in separate rooms with lobbied entry and additional 
dedicated protective clothing and boots. For details of animal housing throughout study 





On day three (3 days post-hatch [d.p.h]), six birds from each group excluding the trial control 
group were culled via cervical dislocation. A sample of 1 – 2 g of caecal content was aseptically 
collected from each experimental chick by pooling entire contents of both caecal crypts. 
Previous work by Stanley et al (2015) has identified no statistical difference in bacterial 
abundance or taxonomic composition between left and right caecal crypts of the same 
individual. Samples were immediately snap frozen post-collection in liquid nitrogen before 
storage at – 80 °C and subsequent 16S rRNA gene analysis. Similarly, at 7 d.p.h a further 10 
birds from each treatment group excluding the trial control group were culled and caecal 
samples collected in the same manner for 16S rRNA gene analysis. Further clarification on post 
mortem methodologies are provided in Chapter 2 and all information pertaining to the 
described 16S rRNA sequencing is detailed in Chapter 5.  
 
At 14 d.p.h, all remaining birds were confirmed to have campylobacter negative status via 
cloacal swabbing as described in Chapter 3. At 21 d.p.h, two randomly selected birds from 
each group, excluding the Trial control group were orally infected with 0.2 mL 106 Colony 
Forming units/ml (CFU/ml) C. jejuni M1 in MHB via oral gavage. Preparation of inoculum and 
infection protocols were conducted according to those described in Chapter 2.  
 
Cloacal swabs were collected from all birds at multiple time-points post infection to assess 
within-group C. jejuni shedding. Swabs were collected from all birds at 23 (2 d.p.i), 26 (5 d.p.i), 
29 (8 d.p.i), 31 (10 d.p.i), 33 (12 d.p.i) and 35 (14 d.p.i) days post-hatch. Full protocols of swab 
bacteriological processing are provided in Chapter 3. At 35 d.p.h (14 d.p.i) all birds were culled 
via cervical dislocation and whole carcass weight recorded. Blood samples were collected via 
cardiac puncture immediately post-cull, before samples of splenic & liver tissues and caecal & 
ileal content were aseptically collected. Full detail on post-mortem aseptic sample collection 
alongside sample processing post-collection are provided in Chapter 2. Figure 38 provides a 




















































CMT     
(n = 23)  
Aviguard 
(n = 23) 
Int. Control 
(n = 23) 
Ext. Control   
(n = 23) 
CMT     
(n = 29)  
Aviguard 
(n = 29) 
Int. Control 
(n = 29) 
Ext. Control   
(n = 29) 
Trial Control     
(n = 7) 
Hatchery  
CMT     
(n = 13)  
Aviguard 
(n = 13) 
Int. Control 
(n = 13) 
Ext. Control   
(n = 13) 
Eggs received into unit 
Day 1 
Hatched chicks receive 
inoculum; day old chicks 
received 
Day 3 
6 birds culled/group* 
Day 7 
10 birds culled/group* 
Day 21 
2 birds/group orally infected with 
106 C. jejuni M1  
Day 23, 26, 29, 31, 33, 35 
All birds cloacally swabbed  
Day 35 
All birds culled for post 
mortem analysis 
Figure 38. Key time-points associated with experimental trial 7. ‘*’ denotes sample collected 







Statistical analysis was performed using GraphPad Prism 7.00 for Mac OS X (GraphPad 
Software Inc., San Diego, USA). Prior to further statistical analysis, all data sets were assessed 
for normality of distribution using D’Agostino & Pearson normality testing. Data sets showing 
non-normal distribution (p < 0.05) were further assessed for statistical significance using an 
Unpaired t-test and described using data mean and standard deviation, with significance set 
as p < 0.05. Pairwise treatment group comparisons of non-normally distributed data sets were 
conducted using a Mann Whitney-U test and described using data median and interquartile 
range (IQR) with statistical significance set at p < 0.05.   
 
ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)  
 
Post-mortem blood samples were aseptically collected via cardiac puncture from all birds at 
35 d.p.h (14 d.p.i). All blood samples were centrifuged at 13000 x g for 5 minutes before serum 
collection and storage at - 20°C for subsequent ELISA analysis. All samples were assessed for 
Campylobacter specific serum immunoglobulin-G (IgY) and IgM levels through ELISA protocols 
described in Chapter 2. Using the same protocols, specific serum IgA immunoglobulin levels 




All cell culture protocols were performed under a laminar flow hood using appropriate aseptic 
tissue culture techniques. 8E11 cells were used in all experiments, with this cell line being 
derived from chicken small intestinal epithelial cells. The cell line was maintained as continual 
laboratory cell stock. Through pre-exposure of this avian intestinal epithelial cell line to 
different treatment conditions, we were able to ascertain whether treatment could induce 
cell specific changes that protect against bacterial invasion.  
 
Revival of 8E11 cells  
 
Seed stock of 8E11 cells were cryopreserved in sterile cryogenic storage vials (STARLAB, Milton 
Keynes, UK) in liquid nitrogen until use. Storage of cells was in complete medium in the 
presence of the cryoprotective agent dimethylsulfoxide (DMSO) (Sigma, Poole, Dorset, UK).  
The adherent 8E11 cell line was cultured in Gibco® Dulbecco’s Modified Eagles Medium: 




supplemented with 10 % (v/v) fetal bovine serum (Sigma-Aldrich, Poole, UK), 2 % 
Penicillin/Streptomycin solution (Sigma-Aldrich, Poole, UK) and 2 % L-glutamine solution 
(Sigma-Aldrich, Poole, UK). Upon revival, 8E11 cells were thawed for one minute in a water-
bath set to 37°C, gently agitating the vial during this period. Once completely thawed, the vial 
contents were transferred directly to 15 ml of complete culture medium, pre-warmed to 37°C, 
in a T75 tissue culture flask (STARLAB, Milton Keynes, UK) before incubation at 37°C, 5 % CO2 
for 24 hours. After this initial incubation, cells were checked for flask adherence, signs of 
contamination and general cell layer dispersion before the conditioned growth media was 
aspirated and replaced with 20 ml of fresh complete growth medium. Cells were routinely 
sub-cultured every 3 – 4 days to preserve cell viability.  
 
Cell subculture  
 
All media was pre-warmed before use in a water bath set at 37°C. Conditioned culture media 
was first aspirated and disposed of in a 1 % Virkon® solution. The adhered cells were rinsed 2 
times using a wash of 5 – 10 ml of 1 x PBS followed by a rinse using 2 ml 1 x PBS-EDTA-Trypsin 
(Sigma-Aldrich, Poole, UK) solution. Another 2 ml 1 x PBS-EDTA-Trypsin was added before 
incubation at 37°C, 5 % CO2 for 5 – 10 minutes or until the cells visibly detach from the flask 
surface. During this time, flasks were routinely agitated to aid in cell detachment. When 
completely detached, 18 ml of complete growth medium was added to inhibit Trypsin action 
and pipetted gently to prevent cell clumping. Three sterile T75 tissue culture flasks were 
seeded with 4 ml of cell solution, with the original flask now containing 6 ml of cell solution. 
All four flasks were diluted to a final volume of 20 ml by the addition of pre-warmed complete 




Three days after cell seeding, as described above, the three culture flasks seeded with 4 mL of 
culture solution were assessed under a microscope for visible confluency (ideally between 
70 – 90 %). These flasks were subsequently trypsinised as described above, before 8 mL of 
complete media added to inhibit the trypsin and gently pipetted to prevent cell clumping. Cell 
solution from these three flasks was pooled into a separate sterile T75 flask, with this flask 
being gently swirled to ensure all cells were evenly distributed, before 50 µl aliquoted into a 
1.5 ml microcentrifuge tube containing 50 µl Trypan Blue Stain (ThermoFisher Scientific, 




pipetted onto a haemocytometer in both chambers underneath the glass coverslip, allowing 
the cell suspension to be drawn over the haemocytometer by capillary action.  
 
Haemocytometers are a quick and commonly used tool in the measurement of cell viability 
and number within a given sample. The number of cells suspended in a given area on the 
haemocytometer matrix, observed under magnification are counted to give an estimate on 
total cell count. Using a 10 X objective, a microscope was used to focus on the 
haemocytometer grid (Figure 39) allowing all viable cells to be counted. All cells stained blue 
(those taking up Trypan Blue) are non-viable and were excluded from any count, while 
colorless cells represent live, viable cells that can be included in the cell count. When counting, 
cells were only counted if they were set within a central grid square or on the right-hand or 
bottom boundary of the highlighted corner square shown in Figure 39. The same process was 
continued for the remaining three large corner grid squares. 
 
Once counted, an estimate of total cell count within the pooled cell solution can be calculated 








The cell concentration was then multiplied by the original pooled cell solution volume to get 
the total number of cells estimated within our total sample volume. This cell solution was then 
diluted to 1 x 105/ml with pre-warmed complete medium and seeded into 24-well tissue 
culture plates (STARLAB, Milton Keynes, UK) at a volume of 1 ml per well. Cell plates were 
incubated at 37°C, 5 % CO2 for 2 - 3 days or until fully confluent.  
 
Once fully confluent, conditioned cell medium was aspirated from each well. 1 ml of 1 x PBS 
was added to each well and subsequently aspirated, with this forming 1 rinse of each well. A 
further 2 rinses were complete for all wells before the addition of 1 ml antibiotic-free medium 
(Nutrient Mixture F-12 (DMEM/F-12) (ThermoFisher Scientific, Loughborough, UK) 




glutamine solution (Sigma-Aldrich, Poole, UK) to each well. Plates were incubated for 24 hours 










BACTERIAL ISOLATES AND GROWTH CONDITIONS  
 
Two C. jejuni isolates (C. jejuni M1 and C. jejuni 13126) and one S. Typhimurium isolate 
(Salmonella enterica subsp. enterica serovar Typhimurium str. 4/74) were included in 
gentamicin protection assay protocols. C. jejuni M1 was the bacterial isolate used in all in vivo 
infection models throughout this work and representing a commonly isolated field strain. 
C. jejuni 13126 also represents a commonly isolated field strain, but more importantly has 
been reported by Humphrey et al. (2014) as being a rapidly invasive phenotype in both human 
epithelial cell lines (Caco-2) and Galleria insect models compared to other C. jejuni isolates. 
With such differences in C. jejuni infection biology between exhibited between strains, 
assessing the protective capacity of CMT and Aviguard® against these different invasive 
capabilities may have important implications in utilizing these products as control strategies.  
 
For C. jejuni culture, stock strains stored at - 80°C were grown on CAB agar supplemented with 
5% defibrinated horse blood (Oxoid, Basingstoke, Hampshire, UK) at 41.5°C for 48 hours under 
microaerobic conditions (80 % N2, 12 % CO2, 5 % O2 and 3 % H2). A single colony from the 
grown bacterial culture was selected and used to inoculate 10 ml of MHB in a sterile 30 ml 
universal tube. The 10 ml working liquid culture was grown for 24 hours under microaerobic 
conditions at 41.5°C with a loosely capped lid. After overnight incubation, the liquid culture 
was vortexed and 2 ml transferred to a sterile cuvette. Optical density (OD) was measured 
using a spectrophotometer (Cecil CE2040, Cambridge, UK) and adjusted using MHB to an 
OD600 of 0.1 – 0.3, corresponding to 1 x 108 CFU/ml of the specific C. jejuni strain. A further 
dilution of 1:200 (v/v) of the adjusted liquid culture into 20 ml MHB was made. Serial 10 - fold 




dilutions of the final liquid culture were made in 1 x MRD to 10-8 and plated onto CAB (Lab M 
Ltd., Heywood, Lancashire, UK) supplemented with 5% defibrinated horse blood (Oxoid, 
Basingstoke, Hampshire, UK) via the previously described Miles & Misra method to allow for 
enumeration (Miles & Misra, 1938).   
 
In addition to the described C. jejuni bacterial challenge strains selected, Salmonella 
Typhimurium 4/74 was also used as a challenge organism. Strain 4/74 was originally isolated 
from a calf suffering salmonellosis and has well documented virulence in cattle, pigs, chicken 
and mice (Chaudhuri et al., 2013). S. Typhimurium ST4/74 was similarly grown from - 80°C 
stored stock strains onto CAB agar (Lab M Ltd., Heywood, Lancashire, UK) supplemented with 
5% defibrinated horse blood (Oxoid, Basingstoke, Hampshire, UK) before incubation for 24 
hours at 37°C. A single bacterial culture was selected and used to inoculate 10 ml of Luria-
Bertani (LB) broth (Lab M Ltd., Heywood, Lancashire, UK) in a sterile 30 ml universal tube with 
loosely capped lid. The 10 ml working liquid culture was grown for 24 hours at 37°C in an 
orbital shaking incubator at 150 rpm. After overnight incubation, the liquid culture was 
vortexed, and 2 ml placed in a cuvette for OD analysis as previously described for C. jejuni 
strains. A further dilution of 1:200 (v/v) of the adjusted liquid culture into 20 ml LB broth was 
made. Serial dilutions of the final liquid culture were made in 1 x PBS to 10-8 and plated onto 
LB agar (Lab M Ltd., Heywood, Lancashire, UK) via the previously described Miles & Misra 
method to allow for enumeration (Miles & Misra, 1938). Non-infected control cells were 
inoculated with sterile broth in accordance with that used for all other cells, i.e. MH Broth for 
Campylobacter protocols or LB Broth for Salmonella protocols. Such methodologies allowed 
us to minimise the potential impact of culture media on cell response.  
 
AVIGUARD® AND CMT INOCULATE PREPARATION 
 
CMT (1:20 [w/v]) material were obtained as described previously in Chapter 3. Aviguard® 
material was dispersed in 1L of deionized water as previously described in Chapter 3 before 
being incubated at 37°C in a sealed container for 24-hours. To prepare the filtrate material for 
each inoculum, 10 ml of each individual inoculum was passed through a sterile 0.22 µm Millex-
GP syringe filter (Sigma-Aldrich, Poole, UK) to remove bacteria suspended in either solution. 





GENTAMICIN PROTECTION ASSAY (GPA) 
 
To assess the protective ability of CMT and Aviguard® filtrate in reducing the invasiveness of 
C. jejuni and S. Typhimurium into epithelial cells, a gentamicin protection assay was 
performed. This widely used enumeration protocol was used as an assessment of the Colony 
Forming Units (CFU) of bacteria infecting cultured avian intestinal epithelial cells after killing 
extracellular, non-invading bacteria with gentamicin treatment. Following the overnight 
incubation of 8E11 cells in antibiotic free medium, cells were inoculated with 100 µl/well of 
either control inoculum, CMT filtrate or Aviguard® filtrate. Control inoculum consisted of 
syringe filtered 1 x PBS. All plates were incubated for 2 hours at 37°C, 5 % CO2. Immediately 
following incubation, cells were infected with 100 µl/well of adjusted C. jejuni or S. 
Typhimurium culture, leaving two wells per treatment group, per infection strain, non-
infected. The infection was allowed to proceed for 4 hours at 37°C, 5 % CO2.  
 
After 4 hours of infection, the host-pathogen mixture was washed three times with 1 x PBS to 
remove excess extracellular bacteria alongside any non-adherent 8E11 cells. Wells were 
overlain with 1 ml/well DMEM F12 media supplemented with 100 µg/ml of Gentamicin 
sulphate (Sigma-Aldrich, Poole, UK) and incubated for 1 hour at 37 °C, 5 % CO2 to kill the 
remaining extracellular bacteria that did not invade the adhered tissue cells. Cells were 
washed twice with 1 x PBS to remove any killed extracellular bacteria. 8E11 cells were lysed 
by the addition of 1 ml/well of 1 x PBS containing 0.5 % Triton-X100 (Sigma-Aldrich, Poole, UK) 
before incubation for 5 - 10 minutes at room temperature, with cell suspension being pipetted 
up and down vigorously to ensure maximal lysis. For C. jejuni, serial dilutions of cell 
supernatant to 10-8 were made in MRD and plated onto CAB agar (Lab M Ltd., Heywood, 
Lancashire, UK) supplemented with 5% defibrinated horse blood (Oxoid, Basingstoke, 
Hampshire, UK) according to methods previously described by Miles & Misra (Miles & Misra, 
1938) and incubated for 48 hours at 41.5°C in microaerophilic conditions (80 % N2, 12 % CO2, 
5 % O2 and 3 % H2). All agar plates were subsequently enumerated for internalised C. jejuni. 
For S. Typhimurium ST4/74, serial dilutions of cell supernatant to 10-8 were made in PBS and 
plated onto LB agar according to methods previously described by Miles & Misra (Miles & 
Misra, 1938) before being incubated for 24 hours at 37°C to allow for enumeration of 
internalized S. Typhimurium. A visual representation showing the key stages of the adapted 
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STATISTICAL ANALYSIS  
 
The average CFU of internalized bacteria (bacteria surviving the GPA) for the most appropriate 
dilution series was enumerated for each replicate (each well). The percentage of internalized 
bacteria for each replicate was determined by dividing the CFU/ml recovered from that well 
by the CFU/ml of inoculum used to infect cells during GPA protocols.  
 
Statistical analysis was performed using GraphPad Prism 7.00 for Mac OS X (GraphPad 
Software Inc., San Diego, USA). Prior to further statistical analysis, all data sets were assessed 
for normality of distribution using D’Agostino & Pearson normality testing. Pairwise treatment 
group comparisons of normally distributed data sets were conducted using an Unpaired t-test 
and described using data mean and standard deviation. Pairwise treatment group 
comparisons of non-normally distributed data sets were conducted using a Mann Whitney-U 
test and described using data median and IQR. All test statistics whereby p < 0.05 were 
considered as statistically significant.  
 
NITRIC OXIDE PRODUCTION ASSAY  
 
Intestinal epithelial cells are known to produce Nitric Oxide (NO) from their apical surface as 
a form of host defense from foreign pathogen. Nitrite is a stable metabolite of NO and is 
commonly measured within samples using the Griess Assay (Bryan & Grisham, 2007). Here, 
8E11 cells were cultivated as previously described and seeded into 24 - well plates (STARLAB, 
Milton Keynes, UK) at a cell concentration of 1 x 105 cells per well. Once fully confluent, 
conditioned cell medium was aspirated from each well. 1 ml of 1 x PBS was added to each well 
and subsequently aspirated, with this forming 1 rinse of each well. A further 2 rinses were 
complete for all wells before the addition of 1 ml antibiotic-free medium containing no phenol 
red (Nutrient Mixture F-12 (DMEM/F-12, no phenol red) (ThermoFisher Scientific, 
Loughborough, UK) supplemented with 10 % (v/v) fetal bovine serum (Sigma-Aldrich, Poole, 
UK) and 2 % L-glutamine solution (Sigma-Aldrich, Poole, UK) to each well. Plates were 
incubated for 24 hours at 37°C in a 5 % CO2 incubator.  
 
Following the overnight incubation of 8E11 cells in antibiotic free medium, cells were 
inoculated with 100 µl/well of either control inoculum, CMT filtrate or Aviguard® filtrate. 
Control inoculum consisted of syringe filtered 1 x PBS. All plates were incubated for 2 - hours 
at 37°C, 5 % CO2. Immediately following incubation, cells were infected with 100 µl/well of 




treatment, per infecting strain leaving a further 5 replicate wells without treatment or 
infection. Two time points were of investigation and so the infection was allowed to proceed 
for either 4 hours or 24 - hours at 37°C, 5 % CO2. Immediately post-incubation, 150 µl of 
culture supernatant from each well was transferred to the wells of a sterile flat-bottomed 90 
- well plate in duplicate (STARLAB, Milton Keynes, UK) and mixed with 130 µl of deionized 
water.  
 
A sufficient volume of Griess reagent was prepared by mixing equal volumes of N-(1-naphthyl) 
ethylenediamine and sulfanilic acid (ThermoFisher Scientific, Loughborough, UK) before 20 µl 
of the prepared reagent was added to each well. After 30 minutes of incubation, absorbance 
was measured relative to nitrite standard solutions of known concentration in a 
spectrophotometric microplate reader at 550 nm. A well containing only cell culture media, 
deionized water and Griess reagent in the quantities previously stated was used as a 
reference. When analysing results, the OD550 absorbance reading for the reference well was 
deducted from all other well absorbance readings. A standard curve was created of nitrate 
concentration (x-axis) against absorbance (y-axis) using the absorbance readings from the 
nitrite standard solutions prepared and sample nitrite concentrations interpolated.  
 
RNA EXTRACTION AND RT-qPCR 
 
Quantitative reverse transcription PCR (RT-qPCR) was performed to assess the expression of 
central mediators produced by our cultured cell line during the artificial ‘host’-pathogen 
interaction orchestrated during the GPA. As shown in Figure 40, RNA was harvested from cells 
designated for RT-qPCR at the GPA stage immediately post 1-hour incubation with 
DMEM/Gentamicin. The gentamicin containing media was aspirated from each well, and all 
wells washed twice with 1 x PBS as described previously. 200 µl of 1 x PBS-EDTA-Trypsin was 
added to each well and incubated at 37°C for 2 minutes, or until cells have visibly detached. 
An overlay of 500 µl of non-supplemented DMEM/F12 cell media was added to each well to 
quench the trypsin before the well contents was aspirated and dispensed into individually 
labelled 2 ml sterile eppendorf tubes. Samples were centrifuged at 300 x g for 5 minutes until 
cells formed a visible pellet at the base of the eppendorf tube. The supernatant was aspirated 
and the pellet containing total sample RNA dispersed in 20 µl RNase free water before storage 





Total RNA was isolated from cell pellets using a Qiagen RNeasy Mini Kit (Qiagen, Hilden, 
Germany) as described by the manufacturer according to ‘Purification of Total RNA from 
Animal Cells using Spin Technology’ protocols. Briefly, an appropriate volume of buffer RLT 
supplemented with 1% (v/v) b - mercaptoethanol (Sigma-Aldrich, Poole, UK) was added the 
cell pellet to disrupt the cells. The disrupted cell lysate was vortexed for 1 minute at full speed 
before being passed through a blunt 20-gauge needle using a sterile RNase free syringe. One 
volume of 70 % ethanol was added to the homogenized cell lysate and mixed by pipetting 
before transferring 700 µl of sample to a supplied RNeasy spin column. Samples were 
centrifuged for 15 seconds at > 8000 x g, flow through discarded and collection tube replaced. 
700 µl of Buffer RW1 was added to the RNeasy spin column and centrifuged for 15 seconds at 
> 8000 x g before flow through was discarded and collection tube replaced. 500 µl of Buffer 
RPE (diluted 1:4 from concentrate using 100 % Ethanol to obtain working solution) was added 
to the RNeasy spin column and centrifuged as above for 15 seconds before discarding 
throughflow and replacing collection tube. This step was repeated once, using an extended 
centrifugation of 2 minutes. The RNeasy spin column was placed in a new collection tube and 
centrifuged at 18,000 x g for 1 minute. The RNeasy spin column was placed into a sterile 1.5 
mL eppendorf and 30 µl of RNase-free water added directly to the spin column membrane. 
The sample was centrifuged at 9,000 x g for 1 minute to elute RNA. RNA samples were stored 
at – 80°C for no longer than 2 weeks.  
 
All extracted samples were assessed for RNA quality and concentration using a Nanodrop (ND-
1000) spectrophotometer before being diluted 1:4 (v/v) to attain a final concentration of 
20 ng/µl using RNase-free water supplied. All RT-qPCR analysis was conducted according to 
protocols discussed in Chapter 2. Reference and target gene primer and probe (if applicable) 
sequences are provide in Chapter 2. Expression analysis was conducted for the following 
target genes - IL-1β, IL-6, IL-10, TGFβ4, CXCLi1, CXCLi2, MUC2. SYBR Green RT-qPCR techniques 
were also used for assessment of the antimicrobial peptide (AMP) sequence for avian beta-
defensin 9 (AvBD9) using the cycling conditions listed in Chapter 2 and the following primer 
sequences; F: ACCGTCAGGCATCTTCACAG R: CCATTTGCAGCATTTCAGC (Hong et al., 2012). 
AvBD9 has been identified as having bactericidal properties against a number of bacteria 
associated with commercial poultry, including Salmonella (Sunkara et al., 2011).Both AvBD1 
and AvBD6 have also previously been associated with upregulation in broiler ileal and caecal 




proved ineffective for our tissue samples and so have not been included in the results (Garcia 
et al., 2018). 
 
RESULTS 




Between 23 d.p.h (2 d.p.i) and 35 d.p.h (14 d.p.i), cloacal swabs were used to determine the 
dynamics of C. jejuni infection within each experimental flock. Birds were shedding C. jejuni as 
early as 2 d.p.i in Aviguard®, External and Internal control groups, with these positive birds all 
being seeder birds directly infected with C. jejuni M1.  By 10 d.p.i all birds in both the 
Aviguard® treated and Internal control groups tested positive for C. jejuni shedding, compared 
to 6/13 (46%) for External control birds and 0/13 (0%) for CMT treated birds. The percentage 
of birds shedding C. jejuni in the External control group reached maximum at 12 d.p.i with 
10/13 (77 %) detected as C. jejuni positive. At 14 d.p.i, detected birds shedding C. jejuni was 
1/13 (8 %) for CMT treated, 13/13 (100%) for Aviguard® treated, 9/13 (69%) for External 
control and 13/13 (100%) for Internal control experimental birds. All birds in the non-infected 
trial control group showed no shedding of C. jejuni throughout the course of the experimental 
trial phase. A representation of C. jejuni shedding positivity per group is provided in Figure 41, 













Figure 41. C. jejuni M1 transmission within groups of experimental broiler chickens. Cloacal shedding was 
determined through cloacal swabbing at pre-defined time-points according to experimental protocols. Red shapes 
depict birds detected as shedding C. jejuni while blue shapes show groups with no detected bacterial shedding. 





Figure 42. Detection of C. jejuni via cloacal swabbing at time-points stipulated in experiment 7 
protocols. Red squares depict C. jejuni detection within a single swab sample, whereby ‘D’ 
indicates results are from direct plating of swabs and ‘E’ depicts results are from enriched swab 






Treatment Group Bird ID Pre Day 2 Day 5 Day 8 Day 10 Day 12 Day 14 D E D E D E D E D E D E D E 
CMT Treated  
1703                             
1704                             
1705                             
1706                             
1707                             
1710                             
1712                             
1713                             
1714                             
1715                             
1717                             
1718*                             
1719*                             
Aviguard® Treated  
3651                             
3652*                             
3653                             
3654*                             
3655                             
3657                             
3659                             
3660                             
3661                             
3662                             
3663                             
3664                             
3665                             
Internal Control  
226                             
227                             
228                             
229                             
230                             
231*                             
232                             
233*                             
234                             
236                             
237                             
238                             
239                             
External Control  
802*                             
803                             
804                             
805                             
806                             
807                             
809                             
810                             
811                             
812                             
813                             
814*                             





CAECAL COLONISATION  
 
Caecal content was taken from each bird at post-mortem (35 d.p.h) 14 d.p.i. All birds in the 
non-infected trial control group were negative for C. jejuni colonisation and will not be 
discussed further in any detail. Caecal C. jejuni colonisation was present in all experimental 
birds of both the Aviguard® treated and the Internal control experimental groups. Of the birds 
acting as External controls, 12/13 (92%) showed C. jejuni colonisation of the caecal content, 
with this being only 1/13 (8 %) in the CMT treated group. All birds shown to be shedding 
C. jejuni through cloacal swabbing analysis were positive for C. jejuni within the caecal 
content. A graphical representation of Log10 CFU/gram C. jejuni within the caecal content of 




















Enumeration data collected on C. jejuni colonisation of the caeca was not normally distributed 
for all treated groups and so the results are being discussed and presented as medians, 
Figure 43. Levels of C. jejuni in the caeca of broiler chickens under experimental 
conditions based on the protocol listed for experiment 7. Each symbol represents caecal 
C. jejuni load for an individual animal. Statistical analysis per treatment group are given 
as median values with associated IQR. Significance was determined using Mann 
Whitney-U analysis with levels of significance given as **p < 0.01, ****p < 0.0001. All 
birds detected as shedding are given reported using a hollow triangle symbol, while all 










































including their respective interquartile range, given as lower (Q1) and upper (Q3) quartile 
values. Caecal C. jejuni colonisation showed the Internal control experimental population 
having the bacterial load, with a median log10 CFU/gram value of 8.94; compared to that of 
Aviguard® (8.10), External (8.07) and CMT (0.00) treatment groups. C. jejuni colonisation was 
significantly lower in the caecal content of both Aviguard® (p = 0.0051) and External control 
(p = 0.0051) groups compared to that of the Internal control group. There was no significant 
difference in levels of C. jejuni colonisation of the caeca between birds given Aviguard® 
treatment and those acting as External controls (p = 0.6139). CMT treated birds had 
significantly lower caecal C. jejuni load compared to all three other treatment populations 
(p < 0.0001). Details of statistical parameters and group comparison significance values are 
provided in Table 14. 
 
Table 14. Statistical parameters and treatment group comparison significance values determined 




ILEAL COLONISATION  
 
As described for caecal content, samples of ileal content were collected from each bird at post 
mortem 14 d.p.i. All birds in the non-infected trial control group were negative for C. jejuni 
colonisation and will not be discussed further in any detail. In all treatment groups, detectable 
presence of C. jejuni was less frequently observed within ileal content compared to that of the 
caeca. Of the 13 experimental birds in the CMT treatment group, all showed no detectable 
C. jejuni colonisation of the ileum. In all other treatment groups C. jejuni was detected in ileal 
content, with 10/13 (77%) Aviguard® treated, 9/13 (69%) Internal control and 8/13 (62%) 





C. Jejuni Load 
(Log10 CFU/g)  
 
Data 










p-value Median Quartiles 
Q1 Q3 
CMT  0.00 0.00 0.00 <0.0001 Mann Whitney-U  Aviguard® <0.0001 
 Internal Control <0.0001 
 External Control <0.0001 
Aviguard® 8.10 7.43 8.54 0.1833 Mann Whitney-U Internal Control 0.0051 
 External Control 0.6139 
Internal 
control 
8.94 8.28 9.63 0.8589 Mann Whitney-U External Control 0.0051 
External 
control  






















As with data collected on caecal samples, the data collected on C. jejuni colonisation of the 
ileum was not normally distributed for all treatment groups and so the results are being 
discussed and presented as medians, including their respective interquartile range, given as 
lower (Q1) and Upper (Q3) quartile values. In accordance with the values collected for caecal 
content, the Internal control population had highest median log10 CFU/gram C. jejuni load 
values of 4.35, compared to 4.30 for Aviguard®, 3.85 for External control and 0.00 for CMT 
treatment groups. There was no significant variation between the load of C. jejuni found in 
the ileal content of Aviguard®, Internal and External control populations (p > 0.05). Since no 
birds that had been given CMT treatment showed ileal C. jejuni positivity, the CMT population 
had significantly lower C. jejuni colonisation of this part of the GIT compared to Aviguard® 
treated (p = 0.0001), Internal control (p = 0.0005) and External control (p = 0.0016) groups. 
Details of statistical parameters and group comparison significance values are provided in 
Table 15, with enumeration data for all individually identified experimental animals listed in 
Appendix 3.  
 
Figure 44. Levels of C. jejuni in the ileum of broiler chickens under experimental 
conditions based on the protocol listed for experiment 7. Each symbol represents 
ileal C. jejuni load for an individual animal. Statistical analysis per treatment 
group are given as median values with associated IQR. Significance was 
determined using Mann Whitney-U analysis with levels of significance given as 
**p < 0.01, ***p < 0.001. All birds detected as shedding are given reported using a 
hollow triangle symbol, while all birds not detected as shedding C. jejuni are 







































Table 15. Statistical parameters and treatment group comparison significance values determined 
for Log10CFU/g C. jejuni ileal colonisation 
 
 
EXTRA-INTESTINAL SPREAD OF C. JEJUNI  
 
A tissue samples from both the spleen and liver were collected from all birds at post-mortem 
35 d.p.h (14 d.p.i). As with previous samples, all birds in the non-infected trial control groups 
were negative for C. jejuni colonisation and will not be discussed further in any detail. No birds 
having received CMT treatment were positive for C. jejuni in either spleen or liver tissue 
samples collected.  
 
Aviguard® and External control groups showed highest frequency of splenic tissue C. jejuni 
infiltration with presence in 5/13 (38 %) of each population. Of the Internal control population, 
3/13 (21 %) were positive for C. jejuni in the splenic tissue. Hepatic colonisation of Aviguard® 
treated birds was higher than seen for splenic tissue of this group, with 6/13 (46 %) positive 
for C. jejuni in liver tissue. Both Internal and External control groups showed lower liver 
C. jejuni colonisation than seen for splenic colonisation, with hepatic colonisation in 1/13 (8 
%) and 4/13 (31 %) birds in respective groups. Figure 45 shows spleen and liver positivity per 



































Internal Control 0.0005 













Internal Control 0.8385 
External Control 0.0547 
Internal 
control 
4.35 0.00 6.11 0.5171 Mann Whitney-U External Control 0.2123 
External 
control 
































Treatment Group Bird ID Spleen tissue Liver tissue  







CMT Treated  
1703         
1704         
1705         
1706         
1707         
1710         
1712         
1713         
1714         
1715         
1717         
1718*         







Aviguard Treated  
3651         
3652*         
3653         
3654*         
3655         
3657         
3659         
3660         
3661         
3662         
3663         
3664         







Internal Control  
226         
227         
228         
229         
230         
231*         
232         
233*         
234         
236         
237         
238         







External Control  
802*         
803         
804         
805         
806         
807         
809         
810         
811         
812         
813         
814*         
815         
Figure 45 Detection of C. jejuni within liver and splenic tissues of broiler chickens under 
experimental conditions based on the protocol listed for experiment 7. Red squares depict 
C. jejuni detection within a single sample, whereby ‘D’ indicates results are from direct plating of 
tissue homogenate and ‘E’ depicts results are from enriched samples. All birds showing ‘*’ were 




To assess whether high caecal C. jejuni colonisation was a predictor for systemic bacterial 
spread, splenic and hepatic tissue C. jejuni positivity was related back to caecal C. jejuni load, 
with this being provided in Figure 46. As shown, there is no visibly clear relationship between 
caecal C. jejuni colonisation and the likelihood of systemic bacterial spread within this 




















Immediately post-cull, whole carcasses of all birds were individually weighed to assess the 
impact of CMT or Aviguard® treatment on broiler weight gain. Data on bird weight was not 
normally distributed for all treatment groups and so results are discussed and presented as 
median values with their respective interquartile ranges (Figure 47). External control birds not 
hatched within our experimental unit showed highest overall group body weight, with a group 
median of 1020 g while birds hatched within our experimental unit and treated with CMT 

































Figure 46. Extra-intestinal detection of C. jejuni mapped against C. jejuni caecal load for broiler 
chickens under experimental conditions based on experimental protocol 7. Each symbol 
represents results from an individual animal with caecal load given as Log10CFU/g of caecal 
content. Green shapes indicate birds with C. jejuni detected in splenic tissue, blue shapes show 
detection in liver tissue and red shapes represent animals with C. jejuni detected in both splenic 
















Aviguard® treated birds had significantly higher body weight than both CMT treated (p = 
0.005) and Internal control (p = 0.044) birds, with all groups hatched within out experimental 
unit. CMT treated birds had significantly lower body weight compared to the External control 
group. External control birds had significantly higher overall body weight compared to that of 
the Internal control group, with hatchery environment being the only variation in treatment 
between these two groups. Statistical significance following group comparison is provided in 
Table 16. 
 
Table 16. Statistical parameters and treatment group comparison significance values for 
bodyweight (g) 




























Internal Control 0.6405 
External Control 0.0124 













Internal Control 0.044 
External Control 0.544 
Trial Control 0.1181 
Internal control 855 733 1005 0.3331 Mann 
Whitney-U 
External Control 0.0455 
Trial Control 0.9385 
External control 1020 910 1138 0.2757 Mann 
Whitney-U 
Trial Control 0.1517 









































Figure 47. Whole body weight of broiler chickens based on the protocol listed for Experiment 7. Each symbol 
represents the body weight immediately post-cull for an individual animal. Statistical analysis is based on 
median values with associated IQR. Statistical significance was determined using Mann Whitney-U analysis with 
levels of significance given as *p < 0.05, **p < 0.01. For CMT, Aviguard, Int. control and Ext. control n=13, for 






Samples of 2 mL whole blood were collected from each bird via cardiac puncture at post-
mortem 35 d.p.h (14 d.p.i). Serum samples were prepared and measured for specific IgM, IgA 
and IgY against C. jejuni using ELISA protocols detailed in Chapter 2. Data sets for all 
immunoglobulins tested were not normally distributed and so are discussed from this point 
onward in regard to median values and their respective IQR.  
 
Across all treatment groups, median IgY levels were highest in the External control treatment 
group with an optical density at 405nm (OD405) of 0.2185 (Figure 48a). The non-C. jejuni 
infected trial control group had the lowest median IgY, with a median OD405 of 0.1227, with 
this being significantly lower than that overserved in External control chickens (p = 0.0002). 
Median OD405 readings across the remaining three treatment groups (Internal control, CMT 
treated and Aviguard® treated) showed similar serum IgY levels, with median OD405 readings 
ranging from 0.155 – 0.1427. Serum IgY recorded for the External control treatment group 
were significantly higher than those of CMT treated (p = 0.0083), Aviguard® treated (p = 
0.0083) and Internal control (p = 0.0242) experimental birds.  
 
C. jejuni specific serum IgM was more strongly represented in each experimental group 
compared to IgY (Figure 48b). Serum IgM was significantly higher in all infected treatment 
groups compared to that found for non-infected trial control chickens (p < 0.0001). CMT 
treated birds had highest recoverable serum IgM titres, with median OD405 values of 0.2534, 
with this significantly higher than values observed for internal control birds (p < 0.05). Serum 
IgA titres were highest within samples of CMT treated birds, with median OD405 readings for 
this group being significantly higher than for all other treatment groups (p < 0.05) (Figure 48c). 

























































 Figure 48. Serum (a) IgY (b) IgM and (c) IgA response to C. jejuni challenge and 
treatment group. Statistical analysis is based on median values with associated IQR. 
Statistical significance was determined using Mann Whitney-U analysis with levels of 
significance given as *p < 0.05, **p < 0.01, ***p < 0.001. For CMT, Aviguard, Int. control 















































































Table 17. Statistical parameters and treatment group comparison significance values determined 














value  Median Quartiles 
Q1 Q3 




Int. Control 0.5512 
Ext. Control 0.0083 
Trial Control 0.2908 
Aviguard® 0.094 0.0749 0.134 <0.0001 Mann 
Whitney-
U 
Int. Control 0.5137 
Ext. Control 0.0083 
Trial Control 0.1505 
Int. Control 0.104 0.0794 0.153 0.4008 Mann 
Whitney-
U 
Ext. Control 0.0242 
Trial Control 0.0529 
Ext. Control 0.152 0.123 0.227 0.0029 Mann 
Whitney-
U 
Trial Control 0.0002 
Trial Control 0.0839 0.0539 0.0898 N/A N/A N/A N/A 




Int. Control 0.0233 
Ext. Control 0.6994 
Trial Control 0.0005 
Aviguard® 0.168 0.126 0.229 <0.0001 Mann 
Whitney-
U 
Int. Control 0.9487 
Ext. Control 0.0557 
Trial Control 0.0009 
Int. Control 0.169 0.128 0.216 0.1793 Mann 
Whitney-
U 
Ext. Control 0.0652 
Trial Control 0.0005 
Ext. Control 0.214 0.173 0.255 0.077 Mann 
Whitney-
U 
Trial Control 0.0005 
Trial Control 0.059 0.036 0.0862 N/A N/A N/A N/A 




Int. Control 0.0004 
Ext. Control 0.0145 
Trial Control 0.0039 
Aviguard® 0.123 0.0915 0.343 0.0061 Mann 
Whitney-
U 
Int. Control 0.1135 
Ext. Control 0.9323 
Trial Control 0.0637 
Int. Control 0.0935 0.0893 0.104 0.0514 Mann 
Whitney-
U 
Ext. Control 0.0173 
Trial Control 0.3827 
Ext. Control 0.108 0.102 0.168 <0.0001 Mann 
Whitney-
U 
Trial Control 0.0637 











Pre-exposure of avian intestinal epithelial cells to CMT or Aviguard® filtrate was assessed for 
its protective ability against invasion from two C. jejuni isolates (C. jejuni M1 and C. jejuni 
13126) and one S. Typhimurium isolate (Salmonella enterica subsp. enterica serovar 
Typhimurium str. 4/74). Multiple repeat gentamicin invasion assays were completed for each 
bacterial strain, 3 for C. jejuni M1; 2 for C. jejuni 13126 and 2 for S. Typhimurium 4/74, with 
Figure 49 showing the average Log10 CFU/ml and percentage invasion for each group per 
challenge bacterial strain across all repeats. Appendix 3 details all enumeration data for each 

















GENTAMICIN PROTECTION ASSAY (GPA) 
 
Bacteria internalized – C. jejuni M1 
 
C. jejuni M1 invasion capacity was assessed in-vitro using three repeat gentamicin protection 
assays with an average infecting inoculum of 1.22 x 107 CFU/ml. Table 18 provides colony 
counts and levels of bacterial invasion of cultured 8E11 cells, with a complete assay 
Figure 49. Invasion rate (%) and total internalised bacteria (Log10CFU/ml) of all challenge strain 
following in-vitro GPA protocols. Results are shown as an average of all replicates for each GPA 

















CMT Control Aviguard CMT Control Aviguard CMT Control Aviguard



























representing a ‘Repeat’ and each individual plate well seeded with 1 x 105 8E11 cells 
representing a ‘Replicate’ 
 
 We can first assess the recovered Log10 CFU/ml C. jejuni M1 for each of the three standalone 
assay repeats (Figure 50). Highest bacterial recovery was observed for all groups in Repeat 2 
with Log10 CFU/ml ranging from 4.82 to 6.34 across treatment groups, reflecting the higher 






Cells pre-exposed to CMT filtrate prior to C. jejuni M1 infection showed significantly lower 
recoverable bacteria compared to MHB treated cells across all three assay repeats (Repeat 1 
p = 0.0041, Repeat 2 p = 0.0238, Repeat 3 p = 0.0093). Cells pre-exposed to Aviguard® filtrate 
prior to C. jejuni M1 infection also showed significantly lower recoverable bacteria compared 
to MHB treated cells in assay repeat 1 (p = 0.0195), however this protection was non-
reproducible in repeat 2 and 3 (p = 0.4567; p = 0.2239 respectively). Although recovered C. 
jejuni M1 was lower in cells pre-treated with CMT compared to those pre-treated with 
Aviguard® in all three assay repeats, this relationship was not found to be statistically 
Figure 50. Recovered Log10CFU/ml C. jejuni M1 following GPA protocols on 8E11 
cells. Data is shown for each of 3 repeat assays with each point representing a single 
well replicate. Data is represented as median values with their associated IQR. 
Statistical significance was determined using Mann Whitney-U analysis with levels of 
significance given as *p < 0.05, **p < 0.01. Repeat 1; Control (n=12), CMT and 
Aviguard (n=10). Repeat 2; n=6 for all treatment groups; Repeat 3; n=10 for all 



























































significant (Repeat 1 p = 0.27; Repeat 2 p = 0.8268; Repeat 3 p = 0.0928). Data-set normality 
and treatment group significance values are provided in Table 18.  
 
 
Table 18. Statistical parameters and treatment group comparison significance values determined 





















Recovered C. jejuni 
(log10CFU/ml) 
Data 

































Control v CMT 0.0041 
CMT        
(n= 10) 




(n= 10 ) 






Control    
(n= 6) 





Control v CMT 0.0238 
CMT     
(n=6) 


















Control v CMT 0.0093 
CMT 
(n=10) 









Bacteria internalized – C. jejuni 13126 
 
C. jejuni 13126 invasion capacity was assessed in vitro using two repeat gentamicin protection 
assays with an average infecting inoculum of 4.17 x 106 CFU/ml (Figure 51). Assessing 
Log10CFU/ml C. jejuni 13126 for each assay repeat, highest recovery for all treatment groups 
was in assay repeat 1, with an overall Log10 CFU/ml ranging from 5.07 to 6.03. As with C. jejuni 
M1, this could represent the higher infecting C. jejuni 13126 inoculum used in assay repeat 1 






















Cells pre-treated with CMT filtrate had the lowest level of recoverable C. jejuni 13126 in both 
assay repeat 1 (5.305 Log10CFU/ml) and assay repeat 2 (4.75 Log10CFU/ml). Treatment group 
showed no significant effect on C. jejuni 13126 internalization in assay repeat 1 (p > 0.05), 
while in repeat 2, prophylactic CMT filtrate treated reduced challenge strain internalization 
compared to prophylactic Aviguard® treatment (p= 0.0054).  Interestingly in assay repeat 2, 
cells pre-treated with Aviguard® filtrate showed higher C. jejuni 13126 recovery following lysis 
Figure 51. Recovered Log10CFU/mL C. jejuni 13126 following GPA protocols on 8E11 cells. 
Data is shown for each of 2 repeat assays with each point representing a single well replicate. 
Data is represented as mean values with their associated SD. Statistical significance was 
determined using Unpaired t-test analysis with levels of significance given as  **p < 0.01. 













































compared to non-treated cells, however this was not statistically significant (p = 0.3472). Data 
set normality and treatment group significance values are provided in Table 19. 
 
Table 19. Statistical parameters and treatment group comparison significance values determined 
for Log10CFU/ml C. jejuni 13126 invasion of 8E11 cells using GPA protocols 
 
 
Bacterial internalized - S. Typhimurium 4/74  
 
S. Typhimurium 4/74 invasion capacity was assessed in vitro using two repeat gentamicin 
protection assays with an average infecting inoculum of 6.58 x 108 CFU/ml. Between assay 
repeat variation was less defined for S. Typhimurium assays compared to those of C. jejuni, 
with treatment groups from both assay repeats showing similarly recoverable levels of S. 
Typhimurium. Overall Log10 CFU/ml ranged from 6.52 to 7.91 in assay repeat 1 and 7.07 to 
8.18 in assay repeat 2. The high bacterial recovery rate obtained in both S. Typhimurium 
assays was likely due to the higher bacterial CFU/ml in the inoculating infection material, 







































CMT (n=10) 5.31 ± 
0.10 




















CMT (n=10) 4.75 ± 
0.24 




















Cells pre-treated with CMT filtrate had significantly lower recoverable S. Typhimurium 4/74 
levels compared to LB-treated control cells in both assay repeat 1 (p = 0.0296) and assay 
repeat 2 (p = 0.0056). Similarly, this relationship was also evident for cells pre-treated with 
Aviguard® filtrate, showing significantly reduced S. Typhimurium levels in both assays 
compared to untreated control cells (Repeat 1 p = 0.0196; Repeat 2 p = 0.0356). Although cells 
pre-treated with CMT showed lower recoverable S. Typhimurium compared to pre-treated 
Aviguard® cells, this was not statistically significant for either assay repeat 1 (p = 0.374) or 
repeat 2 (p = 0.1017) (Figure 52). Data set normality and treatment group significance values 





Figure 52. Recovered Log10CFU/mL S. Typhimurium 4/74 following GPA 
protocols on 8E11 cells. Data is shown for each of 2 repeat assays with each point 
representing a single well replicate. Data is represented as mean values with their 
associated SD. Statistical significance was determined using Unpaired t-test 
analysis with levels of significance given as *p < 0.05, **p < 0.01. Repeat 1; CMT 














































Table 20. Statistical parameters and treatment group comparison significance values determined 





Percentage invasion was calculated for each challenge strain to show the number of invading 
bacteria (CFU/ml) as a percentage of the number of bacterium (CFU/ml) in the infecting 
inoculum, with percentage invasion values per replicate provided in Appendix 3. Standardizing 
the data in this way allowed for the merging of percentage invasion data from each assay 
repeat to form one individual data set. Prior to pairwise comparison analysis, datasets were 
assessed for normality using a D’Agostino & Pearson normality test. Since non-normal 
distribution was not confirmed for all datasets, description will be given according to median 
values and respective IQR.    
 
The range of C. jejuni M1 percentage invasion across well replicates was appreciably higher in 
Control cells (47.48%) compared to both Aviguard® (17.91%) and CMT (6.66 %) treated cells. 
Average cell invasion of C. jejuni M1 was significantly lower in cells pre-treated with CMT 
(1.93%) compared to non-treated control cells (5.01%) (p = 0.00177). Although average cell 
invasion percentage was lower in cells pre-treated with CMT compared to those pre-treated 
with Aviguard® filtrate (3.60%), this was not of statistical significance (p = 0.0952). There was 
no significant reduction in C. jejuni M1 invasion of Aviguard® filtrate treated cells compared 
to non-treated control cells (p = 0.1947)(Figure 53). Median invasion percentage and 
































































































Although less drastic, as with C. jejuni M1 the range of C. jejuni 13126 percentage invasion 
across well replicates was higher in Control cells (17.94%) compared to both Aviguard® filtrate 
(10.38%) and CMT filtrate (4.21%) treated cells. Neither cells treated with CMT filtrate nor 
Aviguard® filtrate showed significant reduction in invasion percentage of C. jejuni 13126 (p = 
0.1184; p = 0.9605 respectively). CMT filtrate pre-treatment offered significantly better 
protection from C. jejuni 13126 invasion compared to pre-treatment of cells with Aviguard® 
filtrate (p = 0.0309)(Figure 53). Median invasion percentage and significance values per 
treatment group are provided in Table 21. 
 
Unlike both Campylobacter challenge strains, replicates with high levels of S. Typhimurium 
invasion were seen across all treatment groups with invasion percentage ranges of 19.51 % 
for Control cells, 16.95 % CMT treated cells and 14.02 % for Aviguard® treated cells. Pre-
treatment of cells with both Aviguard® and CMT material significantly reduced the ability of 
S. Typhimurium to invade 8E11 cells compared to LB treated control cells (p = 0.0177; p = 
0.0038 respectively). Median invasion percentage and significance values per treatment group 





































































C. jejuni M1 C. jejuni 13126 S. typhimurium 4/74
* ** **
Figure 53. Invasion percentage of challenge bacterial strains on 8E11 cells according to treatment 
group. Data is represented as median values with their associated IQR. Statistical significance was 




Table 21. Statistical parameters and treatment group comparison significance values determined 





Invasion ability of challenge bacterial strains  
 
Identification of strain variation in in-vitro avian intestinal cell invasion ability was 
demonstrated through comparison of percentage bacterial invasion of untreated control cells 
between each inoculated bacterial strain. We were then able to infer how the protective 
ability of CMT and Aviguard® filtrate may be impacted by infecting bacterial invasive capability 
in-vitro. Figure 54 shows percentage cell invasion of un-treated control replicates for each 























































CMT       
(n= 26) 










































































Table 22. Statistical parameters and challenge strain comparison significance values determined 





Looking at percentage cell invasion to take into account for between assay variation in 
infection inoculum bacterial load, S. Typhimurium was found to be the most invasive bacterial 
strain tested on our 8E11 cultured cells. Invasion capability of S. Typhimurium was significantly 
higher than both C. jejuni M1 (p < 0.0001) and C. jejuni 13126 (p = 0.0047). There was no 
significant variation in the invasion ability between the tested C. jejuni strains (p = 0.14) on 



























Invasion (%)  
Data 









Median Q1 Q3 
C. jejuni M1 3.18 0.955 6.09 <0.0001 Mann 
Whitney-
U 
C. jejuni 13126 0.14 
S. Typhimurium 4/74 <0.0001 
C. jejuni 
13126 













































Figure 54. Invasion percentage of challenge bacterial strains on 8E11 cells. Data is 
represented as median values with their associated IQR. Statistical significance was 
determined using Mann Whitney-U analysis with levels of significance given as **p < 0.01, 





NITRIC OXIDE PRODUCTION ASSAY  
 
C. jejuni M1 
 
Griess reagent was used to assess nitrite production from cells following 4 - or 24-hour 
infection with C. jejuni M1 or S. Typhimurium 4/74. Minimal concentrations of Nitrite were 
recovered from cells following 4-hour incubation with C jejuni, with median values ranging 
from 2.16 – 2.51 (IQR 1.54) across all infected cell groups. Incubation with C. jejuni over a 24 
hour period increased the maximal recoverable nitrite concentrations within all infected cell 
groups, with median recovery of 12.74 – 15.28 (IQR 5.93) (Figure 55a). Nitrite release from 
non-infected cells at 24 hours incubation showed no significant increase compared to that of 
4-hour incubation, indicating no underlying trend of increasing Nitrite release from cells over 
time.  
 
Assessing Nitrite release from cells in respect to specific treatment groups showed, at 4 hours 
post infection, Aviguard® treated and infected control cells had significantly higher release of 
Nitrite compared to cells not infected with C. jejuni (Figure 55b). However, median Nitrite 
release from both groups remained comparably low being 2.44 (IQR 1.11) and 2.51 (IQR 0.31) 
respectively. Cells treated with CMT filtrate showed no significant increase in Nitrite release 
compared to non-infected cells (p = 0.1797). A longer, 24 hour incubation period significantly 
increased recoverable nitrite in all C. jejuni infected groups compared to non-infected cells (p 
< 0.05) (Figure 55c). Cells prophylactically treated with Aviguard® filtrate had highest median 
Nitrite release (15.28; IQR 3.66) compared to those treated with CMT filtrate (12.77; IQR 3.75) 
and infected control cells (12.74; IQR 2.09) (p = 0.021; p = 0.0019) Figure 55c.  Data set 
































































































































































































































Figure 55. Effects of treatment on the concentration of nitrites in 8E11 cell supernatant after challenge with 
C. jejuni M1. Data is represented as median values with their associated IQR. Pairwise comparisons have 
been made for (a) challenge duration (b) effect of treatment group after 4-hour challenge (c) effect of 
treatment group after 24-hour challenge. Statistical significance was determined using Mann Whitney-U 
analysis with levels of significance given as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. For CMT, 




S. Typhimurium 4/74 
 
Nitrite recovery from cell supernatant followed similar trends for all treatment groups when 
using infection strain S. Typhimurium as with C. jejuni. Low median nitrite concentrations were 
recovered from all infected groups at 4 hours post infection, ranging from 3.17 - 4.072 (IQR 
2.37), with significantly higher nitrite at 24 hours post infection, ranging from 34.23 – 44.54 
(IQR 18.67) (p < 0.05) (Figure 56a). Nitrite release from non-infected cells at 24 hours 
incubation showed no significant increase compared to that of 4 hour incubation (p = 0.0823), 
indicating no underlying trend of increasing Nitrite release from cells over time.  
 
Assessing effects of specific treatment group against nitrite release at 4 hours post infected, 
all infected treatment groups released significantly more nitrite than cells that were not 
infected with S. Typhimurium (Figure 56b). Infected control cells released significantly higher 
nitrite compared to CMT treated cells (p = 0.0205). Incubation with S. Typhimurium over 24 
hours significantly increased recoverable nitrite in infected cell groups compared to non-
infected cells (p < 0.05) (Figure 56c). Cells pre-treated with Aviguard® had highest median 
nitrite release (44.54; IQR 13.94), with this being significantly higher than that of CMT 
treated cells (p = 0.0242). Data set normality and comparison significance values are 





























































































































































































































Figure 56. Effects of treatment on the concentration of nitrites in 8E11 cell supernatant after challenge 
with S. Typhimurium 4/74. Data is represented as median values with their associated IQR. Pairwise 
comparisons have been made for (a) challenge duration (b) effect of treatment group after 4-hour challenge 
(c) effect of treatment group after 24-hour challenge. Statistical significance was determined using Mann 
Whitney-U analysis with levels of significance given as *p<0.05, ***p<0.001, ****p<0.0001. For CMT, 







Table 23. Statistical parameters and treatment group comparison significance values determined 


















































CMT 2.16 1.81 2.44 Aviguard® 0.078 
Non-infected 0.1797 
Aviguard® 2.44 2.25 3.35 Non-infected 0.0097 















CMT 3.17 2.51 3.74 Aviguard® 0.2657 
Non-infected 0.0008 
Aviguard® 3.83 2.74 4.88 Non-infected 0.0008 





















CMT 12.77 10.84 14.59 Aviguard® 0.0121 
Non-infected 0.0003 
Aviguard® 15.28 13.11 16.77 Non-infected 0.0003 















CMT 34.23 31.96 42.79 Aviguard® 0.0242 
Non-infected 0.0003 
Aviguard® 44.54 36.69 50.63 Non-infected 0.0003 




NO production by challenge strain  
 
By comparing release of nitrite from infected control cells of both C. jejuni M1 and S. 
Typhimurium 4/74 infection models, we can assess the differential ability of each bacterial 
strain to induce nitrite response. After both 4- and 24 hours of incubation with each challenge 
strain. S. Typhimurium showed significantly higher nitrite response compared to C. jejuni, with 





















































































































Figure 57. Effects of challenge strain on the concentration of nitrites in 8E11 cell supernatant. Data is 
represented as median values with their associated IQR. Pairwise comparisons have been made for (a) 
challenge duration (b) effect of treatment group after 4-hour challenge (c) effect of treatment group 
after 24-hour challenge. Statistical significance was determined using Mann Whitney-U analysis with 
levels of significance given as *p<0.05, ***p<0.001, ****p<0.0001. For each challenge strain CMT, 





GENE EXPRESSION BY 2-ΔΔCT RT-qPCR: 4 HOUR CHALLENGE 
 
Pre-treatment of cultured avian 8E11 epithelial cells with CMT or Aviguard® treatment was 
investigated for its ability to influence inducible immune gene expression. Expression of IL-1ß, 
IL-6, IL-10, TGFß4, CXCLi1, CXCLi2, Mucin2 and AvBD9 mRNA was measured following RNA 
extraction from treated 8E11 cell lines (Figure 40) at 4 hours post infection with either C. jejuni 
or S. Typhimurium. For both invasion models, I was unable to attain reliable qRT-PCR reaction 
data using IL-1ß and IL-10 primers and as such, the data presented within this chapter will 
excluded both IL-1ß and IL-10 cytokine expression values. All data presented was first assessed 
for normality of distribution using D’Agostino & Pearson analysis. Since all data did not adhere 
to a normal distribution (p < 0.05), description will be based upon median values and their 
respective IQR according to Mann Whitney-U comparison-based analysis with a significance 
threshold of p < 0.05. Each cell culture well was designated as a single replicate, with 10 
replicates per treatment group, per immune gene. Non-infected control groups were 
represented by six replicates.   
 
C. jejuni M1  
 
IL-6 expression significantly increased within all infected groups compared to that of the non-
infected control cells, with CMT treated cells showing highest up-regulation of 5.08 – fold 
(Figure 59 & Figure 60). The chemokine ligand CXCLi1 showed lesser tendency toward 
upregulation following C. jejuni infection compared to that of IL-6 with fold change ranging 
from 0.17 - 1.81 across all treatment groups compared to non-infected cells. Treatment group 
had no effect on CXCLi1 expression (p > 0.05). A secondary chemokine ligand, CXCLi2 showed 
tendency toward downregulation within both Infected control and Aviguard® treated cell 
groups compared to non-infected cells, while CMT treated cells showed upregulation of 2.19 
- fold. Expression of CXCLi2 was significantly higher in CMT treated cells compared to 
Aviguard® treated (p = 0.0012) and infected control cells (p = 0.0047). C. jejuni infected control 
cells showed minimal change in TGFß4 expression compared to that of non-infected cells, with 
an overall 1.04 - fold change observed. Expression of TGFß4 was significantly upregulated in 
CMT treated cell populations compared to all other treatment groups (p < 0.01), while 
Aviguard® treated cells showed significant upregulation compared to only those cells not 





Expression of Mucin 2 (MUC2) was largely consistent across cells of all treatment groups 4 
hours post C. jejuni infection, with only CMT treated cells showing any marked variability. 
Expression of MUC2 in CMT treated cells was significantly upregulated compared to C. jejuni 
infected control cells (p = 0.0070). Conversely, avian beta-defensin 9 (AvBD9) expression 
showed apparent modulation according to specific treatment group. All groups infected with 
C. jejuni had increased transcription of AvBD9 compared to non-infected cell replicates. 
Greatest upregulation of AvBD9 was recorded within the CMT group compared to all other 
cell treatment groups (p < 0.05) with a 4.81-fold increase compared to non-infected cells. 
Statistical analysis parameters and p - values for all treatment group comparisons are provided 













































































































































IL6 CXCLi2CXCLi1 TGFβ4 Muc2 AvBD9
Figure 58. Log2 relative expression of IL-6, CXCLi1, CXCLi2, TGFß4, MUC2 and AvBD9 following RNA extraction 
from 8E11 cells challenged with C. jejuni M1 over 4-hours compared to non-challenged cells. Data is represented as 




Figure 59. Expression of (a) IL-6, (b) CXCLi1, (c) CXCLi2, (d) TGFb4, (e) MUC2 and (f) AvBD9 
genes given as 40 – Ct values following qRT-PCR analysis of RNA extracts from 8E11 cells 
challenged with C. jejuni M1 over 4 hours. Data is represented as median and respective IQR values. 
Statistical significance was determined using Mann Whitney-U analysis with levels of significance 





































































































































































































































Salmonella Typhimurium 4/74 
 
For cell invasion protocols modelling 4-hour infection with S. Typhimurium 4/74, as 
described for IL-1ß and IL-10, I was unable to attain reliable RT-qPCR reaction data 
using the chemokine ligand CXCLi2 with this data not being presented here (Figure 62 
& Figure 63). Data regarding IL-6, TGFß4 and CXCLi2 transcription all followed a similar 
trend in upregulation of expression compared to cells not challenged with 
S. Typhimurium (p < 0.05).  Little variation in the degree of upregulation of the IL-6 
and TGFß4 cytokines between challenged treatment groups, however CMT cell 
treatment significantly reduced the upregulation of the chemokine CXCLi1 compared 
to both Aviguard® and infected control cells (p < 0.05).  
 
MUC2 expression was significantly increased in all infected treatment groups 
compared to non-S. Typhimurium challenged cells (p < 0.05), with Aviguard® treated 
cells showing highest upregulation of 1.69 - fold. Interestingly, although infection had 
limited influence on AvBD9 expression for control and Aviguard® treated cell groups, 
a downregulation trend was observed for CMT treated cells of 0.06-fold compared to 
non-infected cells (p = 0.0646). Statistical analysis parameters and p - values for all 





















































































































IL6 CXCLi1 TGFβ4 Muc2 AvBD9
Figure 60. Log2 relative expression of IL-6, CXCLi1, TGFß4, MUC2 and AvBD9 following RNA extraction from 8E11 
cells challenged with S. Typhimurium 4/74 over 4 hours compared to non-challenged cells. Data is represented as median 















































































































































































Figure 61. Expression of (a) IL-6, (b) CXCLi1, (c) TGFß4, (d) MUC2 and (e) AvBD9 genes 
given as 40 – Ct values following qRT-PCR analysis of RNA extracts from 8E11 cells 
challenged with S. Typhimurium 4/74 over 4 hours. Data is represented as median and 
respective IQR values. Statistical significance was determined using Mann Whitney-U analysis 
with levels of significance given as *p<0.05, **p<0.01, ***p<0.001. For all treatment groups, 







Table 24. Statistical significance values given for genes of interest following modified GPA protocols using 8E11 cell lines. Results depict incubation of 4-hours with 







































Aviguard® 0.007 0.8785 0.0012 0.0002 0.3823 0.003 
Infected Control 0.0019 0.4418 0.0047 0.0002 0.007 0.0019 
NI Control 0.0016 0.0932 0.1709 0.0016 0.0932 0.0016 
Aviguard® 
Infected Control 0.7209 0.6454 0.7209 0.0379 0.069 0.0881 
NI Control 0.0451 0.1826 0.1274 0.9433 0.1709 0.0016 











Aviguard® 0.3423 0.0011 n/a 0.5737 0.9329 0.3671 
Infected Control 0.2455 0.2345 n/a 0.0006 0.1049 0.0611 
NI Control 0.004 0.004 n/a 0.0283 0.004 0.0646 
Aviguard® 
Infected Control 0.026 0.7984 n/a 0.3823 0.0463 0.2345 
NI Control 0.004 0.0162 n/a 0.004 0.004 0.2828 




GENE EXPRESSION BY 2-ΔΔCT RT-qPCR: 24-HOUR CHALLENGE 
 
As described for 4-hour challenge models already described, influence of CMT or Aviguard 
treatment was investigated for ability to influence inducible immune gene expression. 
Expression of IL-1β, IL-6, IL-10, TGFβ4, CXCLi1, CXCLi2, MUC2 and AvBD9 mRNA was measured 
following RNA extraction from 8E11 cell lines at 24 hours post infection with either C. jejuni 
or S. Typhimurium (Figure 40). For both invasion models of this challenge duration, I was 
unable to attain reliable RT-qPCR reaction data using IL-1β, IL-10 and CXCLi1 primers and as 
such, the data presented within this chapter will exclude expression values for these data sets. 
All data presented was first assessed for normality of distribution using D’Agostino & Pearson 
analysis. Since all data did not adhere to a normal distribution (p < 0.05), description will be 
based upon median values and their respective IQR according to Mann-Whitney-U 
comparison-based analysis with a significance threshold of p < 0.05.  
 
C. jejuni M1  
 
For both cytokine transcripts showing reliable expression patterns (IL-6 and TGFβ4), 
expression was significantly upregulated in all C. jejuni challenged groups compared to non-
infected cell replicates (p < 0.05). For both IL-6 and TGFβ4 gene transcripts, cells treated with 
Aviguard® filtrate showed highest expression of all C. jejuni challenged treatment groups (p < 
0.05), with respective 4.98 - fold and 6.00 - fold increases compared to non-infected cells 
(Figure 63 & 64).  
 
Expression of the chemokine ligand CXCLi2 was downregulated in all cell replicates challenged 
with C. jejuni compared to non-challenged cell replicates. Treatment of cells with CMT filtrate 
was correlated with strongest downregulation of CXCLi2 compared to non- C. jejuni 
challenged cells (p = 0.0019), with expression also significantly lower than both other C. jejuni 
challenged treatment groups (p < 0.05). Expression of MUC2 was not influenced by either C. 
jejuni challenge or specific treatment group within the 24-hour infection model used 
(p > 0.05). Conversely, AvBD9 was significantly upregulated in all cells challenged with C. jejuni 
compared to non-challenged cells (p < 0.05). Pre-treatment of cells with CMT resulted in a 
lower expression of AvBD9 transcripts compared to C. jejuni infected control and Aviguard® 
treated cell groups (p < 0.05). Statistical analysis parameters and p - values for all treatment 



























































































































IL6 CXCLi2 TGFβ4 MUC2 AvBD9
Figure 62. Log2 relative expression of IL-6, CXCLi2, TGFß4, MUC2 and AvBD9 following RNA extraction 
from 8E11 cells challenged with C. jejuni M1 over 24 hours compared to non-challenged cells. Data is 
represented as median values with respective IQR. For all treatment groups, n=10; for non-infected 


































Figure 63. Expression of (a) IL-6, (b) CXCLi2, (c) TGFß4, (d) MUC2 and (e) AvBD9 genes given as 40 – Ct 
values following qRT-PCR analysis of RNA extracts from 8E11 cells challenged with S. Typhimurium 4/74 
over 4 hours. Data is represented as median and respective IQR values. Statistical significance was determined 
using Mann Whitney-U analysis with levels of significance given as *p<0.05, **p<0.01, ***p<0.001. For all 

















































































































































































S. Typhimurium 4/74  
Expression of IL-6 and CXCLi2 transcripts in all cells challenged with S. Typhimurium 4/74 was 
upregulated across all treatment groups compared to that of non-challenged cell replicates 
(p < 0.05), with CMT treated cells showing greatest increase at 12.94 - fold and 9.83 - fold 
respectively (Figure 65 & 66). While TGFß4 expression was upregulated in infected control cell 
replicates (p < 0.05) but downregulated in both Aviguard® treated and CMT treated cell groups 
(p < 0.05).  
S. Typhimurium challenge over 24 - hours resulted in downregulation of MUC2 expression for 
all cell replicates compared to non-infected cells. Pre-treatment of cells with CMT filtrate 
resulted in significantly lower expression of MUC2 transcripts compared to both other S. 
Typhimurium challenged treatment groups (p < 0.05). Little observable change in expression 
was observed for AvBD9 mRNa transcripts for both Aviguard® and CMT treated cells 
compared cells not challenged with S. Typhimurium with changes of 1.58 - fold and 1.39 - fold 
respectively. Untreated infected control cells showed significantly higher AvBD9 expression 
compared to unchallenged alongside CMT and Aviguard® treated cells (p < 0.05). Statistical 












































































































IL6 TGFβ4 MUC2 AvBD9CXCLi2
Figure 64. Log2 relative expression of IL-6, CXCLi2, TGFß4, MUC2 and AvBD9 following RNA extraction from 
8E11 cells challenged with S. Typhimurium 4/74 over 24-hours compared to non-challenged cells. Data is 







   
 
Figure 65. Expression of (a) IL-6, (b) CXCLi2, (c) TGFß4, (d) MUC2 and (e) AvBD9 genes given as 40 – Ct 
values following qRT-PCR analysis of RNA extracts from 8E11 cells challenged with S. typhimurium 4/74 over 
24-hours. Data is represented as median and respective IQR values. Statistical significance was determined 
using Mann Whitney-U analysis with levels of significance given as *p<0.05, **p<0.01, ***p<0.001. For all 



















































































































































































Table 25. Statistical significance values given for genes of interest following modified GPA protocols using 8E11 cell lines. Results depict incubation of 24 hours 




















































Aviguard® 0.0095 0.0499 0.0499 0.8575 0.0104 
Infected Control 0.9383 0.0281 0.2345 0.8177 0.0042 
NI Control 0.0002 0.0019 0.0379 0.7776 0.007 
Aviguard® Infected Control 0.0162 0.8785 0.2786 0.8553 0.2238 
NI Control 0.0002 0.065 0.0002 0.4586 0.0002 
Infected Control NI Control 0.0002 0.0148 0.0003 0.4244 0.0003 
 
 






Aviguard® 0.003 0.0379 0.083 0.0002 0.0301 
Infected Control 0.083 0.0148 0.0003 0.0002 0.0002 
NI Control 0.0002 0.0002 0.0002 0.0002 0.2786 
Aviguard® Infected Control 0.0876 0.1949 0.0003 0.8785 0.0002 
NI Control 0.0006 0.0002 0.003 0.0002 0.5737 






The modern broiler chicken offers one of the most efficient production systems available 
within food animal systems, being able to convert 6.37 kg of feed into a 3.48 kg weight gain 
in only 49 days (Oakley et al., 2014). While this phenomenon must be attributed to a multitude 
of concomitant factors, largely encompassing genetic background, the importance of the 
gastrointestinal microbiota is being increasingly recognised. It is through previous work, 
discussed in Chapter 3, that we have begun to highlight the efficacious potential of CMT 
administration in reducing broiler susceptibility to Campylobacter jejuni infection. Using 
similar approaches to those before, this study investigated CMT and a commonly used avian 
CE product for their antimicrobial activity against C. jejuni.  Similar to trends previously 
described, prophylactic CMT administration was associated with significant disruption of C. 
jejuni colonisation as seen in both Internal and External control groups. Conversely, treatment 
of chicks with a commercial CE product, Aviguard®, had no observable influence on C. jejuni 
flock transmission and only a 1.05 - fold decrease in final caecal C. jejuni burden compared to 
infected control treatment groups. Such results provide additional evidence that CMT 
treatment possibly acts an effective prophylactic therapy to reduce C. jejuni colonisation of 
the commercial broiler chicken. It is, however, important to note the significant reduction in 
body weight potentially associated with such treatment compared to those treated with 
Aviguard® preparation. With unrelenting drive to attain high broiler body weights within the 
poultry industry, secondary impacts such as those associated with body weight might 
significantly influence the feasibility of such a product commercially. Increased weight gain 
and improvements in feed conversion efficiency have both been reported following probiotic 
and/or prebiotic supplementation of broiler chickens feed or water (Utami and Wahyono, 
2018). Increased digestive enzyme production often associated high populations of bacteria 
such as Lactobacillus spp.  alongside potential alterations to intestinal morphology that 
increase intestinal villi length, increasing surface area for absorption could provide reasoning 
for this. It remains unclear form this work why such differences in body weight were observed 
between Aviguard® and CMT treated birds, however it is imperative that future work explores 
this correlation. Such work would perhaps gain more useful insight by utilizing ‘weight gain’ 
measurements as oppose to sole use of a final weight measurement as used here.  
 
At a point in time where more is understood about the mechanistic actions of many of our 
therapeutic interventions, microbial intervention strategies such as CE products and FMT 




claimed to be a ‘healthy’ or ‘balanced’ gut flora into newly hatched broiler chicks with 
commercial CE products has been well documented over recent years (Khoruts, 2018). Since 
the early work of Nurmi and Rantala in 1973, modulation of the microbiota with CE products 
has become an established research area within published literature. Generally, much of the 
therapeutic potential described for CE cultures within poultry is centered on limitation of 
Salmonella infection, being confirmed across multiple studies (Zhang et al., 2007). This being 
said, extension of this research to incorporate C. jejuni control within the broiler chicken has 
been explored, with both defined and undefined cultures showing limited success (Chen & 
Stern 2001; Stern et al. 2001; Mead 2000). Although published reports of the effectiveness of 
Aviguard® in particular are scarce and relatively inconsistent, Nakamura et al. (2002) has gone 
some way in emphasizing its ability to provide prophylactic control over subsequent 
Salmonella spp. colonisation.  
 
Minimal research is currently available detailing the efficacy of therapeutic administration of 
CMT to avian species to reduce susceptibility of disease. Of particular note, is research 
presented by Hofacre et al. (2000) comparing the efficacy of Aviguard® or fresh turkey caecal 
material in reducing Salmonella colonisation in turkeys. Reminiscent of the trends in 
colonisation seen within our own trial, administration of fresh caecal material (CMT) was 
significantly more protective compared to Aviguard® administration (Hofacre et al., 2000).  
 
While the competitive exclusion mechanisms likely to be a fundamental factor associated with 
both Aviguard® and CMT products will be discussed in Chapter 5, here we assess their 
modulation of the immune system.  Through our study, we tested the ability of Aviguard® or 
CMT to either modulate or inhibit the invasion of Campylobacter or Salmonella into of avian 
intestinal cells. Bacterial challenge strains were incubated with an avian intestinal monolayer 
alongside each therapeutic treatment (CMT or Aviguard®) and the invasion of challenge strain 
assessed.  
 
Bacterial challenge status and prophylactic treatment group resulted in differential expression 
of both cytokine and chemokine parameters examined. While the data presented for both 4- 
and 24-hour represents a relatively small dataset, it provides a valuable basis for how CMT or 
Aviguard® therapies may demonstrate up- or downregulation of cytokines and chemokines 
post-challenge. From the results attained, it was observed that the pro-inflammatory cytokine 




IL-6 is a cytokine usually indicative of acute phase protein synthesis and is critical in 
modulating the transition from innate to acquired immunity (Kaiser et al., 2000). Expression 
of CXCLi1 and CXCLi2 homologues following Salmonella infection exhibited trends toward 
early and sustained upregulation. However, with these chemokines assessed at only one time-
point each – 4 hours and 24 hours post-infection respectively, biologically reliable conclusions 
cannot be formed. This tentative tendency toward upregulation following Salmonella 
infection has previously been described by Salisbury et al (2014) in tissues of the chicken 
gastrointestinal system following infection with Salmonella Virchow. Similar trends CXCLi2 
response were not observed for C. jejuni challenge models. Treatment of 8E11 cells with CMT 
filtrate stimulated an upregulation of CXCLi2 expression 4 hours post C. jejuni challenge, being 
downregulated in both Aviguard® treated and infected control cells. At 24 hours post C. jejuni 
challenge, CMT treated cells conversely showed significant CXCLi2 downregulation compared 
to all other treatment groups. While the full complement of roles played by CXCLi2 in the 
chicken immune response to bacterial infection is yet to be elucidated, known chemotactic 
influence for monocytes and lymphocytes have been highlighted (Larson et al., 2008). The 
initial CXCLi2 upregulation seen within CMT treated enterocytes, alongside gradual 
upregulation of IL-6 appears indicative of rapid initiation of an inflammatory response 
particularly associated with CMT treatment. Work by Larson et al. 2009 has provided previous 
link between infection of chicken cell lines in vitro with C. jejuni and increasing chemokine 
ligand (CXCLi1 and CXCLi2) expression. John et al., (2017) provides extension to this by not 
only confirming the importance in CXCLi1 and CXCLi2 in early inflammatory response to a 
number of C. jejuni strains within a chicken epithelial cell line but highlighting how the 
response of homologue CXCLi2 may be significantly higher than that of CXCLi1 in this infection 
model.  
 
Interestingly, the rapid induction of CXCLi chemokines during early (4 hours post-infection) S. 
Typhimurium infection was accompanied by an upregulated TGFβ4, anti-inflammatory 
response. By 24-hours post infection, control cells sustained such upregulation, while both 
Aviguard® and CMT treated cells showed significant TGFβ4 downregulation. TGFβ4, 
upregulation was only observed for CMT treated cells within the 4-hour post-infection C. jejuni 
model.  By 24-hours post C. jejuni challenge, this TGFβ4 upregulation was present across all 
challenged treatment groups. It could be speculated that the initial surge in pro-inflammatory 
IL-6, but more importantly, CXCLi2 in CMT treated cell groups stimulated the transcription of 




inflammatory regulation. This expression profile proposed for TGFβ4 has previously been 
described by Brisbin et al. (2010) who described TGFβ4 expression and its involvement in 
maintaining intestinal homeostasis in the chicken reducing production of proinflammatory 
cytokines.  
 
Using AvBD9 and MUC2 as markers of endogenous antimicrobial peptide (AMP) and 
glycoprotein response respectively following both microflora filtrate treatment and/or 
bacterial challenge provided further insight into how these therapies may influence innate 
immune response. Therapeutic treatment or challenge status showed little significant 
influence on MUC2 expression from enteric cells following C. jejuni challenge at both tested 
time-points. Conversely, AvBD9 was significantly upregulated in all treatment groups, most 
notably CMT treated, compared to non-challenged cells at 4-hours post infection. 
Transcriptional profiles of various β-defensins have been associated with bactericidal activity 
against multiple enteric pathogens, including Salmonella Typhimurium both in vivo and in-
vitro (Garcia et al., 2018; Hong et al., 2012). More recently, Garcia et al., (2018) assessed the 
expression of multiple AvBD genes (AvBD1, AvBD6, AvBD8, 1 AvBD10, AvBD11, AvBD12 and 
AvBD13) in the ileal and caecal tissues of broiler chickens experimentally infected with doses 
of C. jejuni, with all being significantly upregulated following challenge at 106 cfu. This 
relationship was observed to be dose dependent, with higher doses showing no such 
expression (Garcia et al., 2018). This role in innate host defense against food borne pathogens 
and an apparent upregulation in expression within CMT treated cells may provide a basis of 
understanding the reduced bacterial invasion recorded here using gentamicin protection 
assay techniques. With potent induction of AvBD9 provided by pro-inflammatory cytokines 
such as IL-6, such AMP’s may be being promoted and utilised as effector molecules in the very 
early stages post challenge (Hong et al., 2012). Such response could perpetuate further pro-
inflammatory cytokine expression and reduced C. jejuni systemic invasion. Supplementary to 
this, while negligible following only 4-hour challenge strain incubation, both C. jejuni and S. 
Typhimurium were able to induce significant increases in cell nitric oxide release by 24 hours 
post-infection. Produced by a wide variety of cells, nitric oxide acts plays a crucial role in host 
defense against infection through the gastrointestinal system (Singh et al., 2012). 
Contradictory to initial expectation, C. jejuni challenge showed little impact on MUC2 
expression using avian cell models. Interaction of C. jejuni with the avian intestinal mucosal 
liming is thought to be crucial to its infection biology due to its lack of invasive ability (Smith 




implies that alterations in MUC2 expression was not underlying the variation in invasiveness 
of C. jejuni according to specific treatment group within this intestinal cell line. Salmonella 
infection appeared to induce different MUC2 expression characteristics, exhibiting early 
upregulation 4 hours post infection compared followed by significant downregulation, with 
this being particularly associated with CMT treatment. While this work provides notable 
insight into broiler chicken intestinal immune response to bacterial challenge and how this 
might be manipulated through administration of probiotic filtrate, there exist a number of 
limitations. An important limitation of the in vitro models described here are that they are 
monolayer cellular tissues that harbor minimal biological complexity or immunological 
potential offered within the natural in vivo system. Additionally, while known as an intestinal 
epithelial cell line, the 8E11 cells used within this experimental work show little in the way of 
published experimental use and as such, understanding of cellular limits in transcriptional 
response following challenge is limited. Assessing the expression profiles associated biological 
tissue samples collected from in vivo tissue samples may provide more biologically relevant 
answers to gaps in our current knowledge. The high variation in control cell technical replicate 
may also call the biological relevance of these findings into question. While the importance of 
such a limitation cannot be underestimated, and may prevent reliable intergroup 
comparisons, the results presented may pose interesting theoretical understanding that can 
underly further experimental analysis.  
 
Work by Sahin et al. (2003) has previously shown a weak IgM and IgA response to 
Campylobacter infection within the chicken during the first two weeks of infection. While this 
appears to be the case regarding IgY response within our study, all study treatment groups 
experimentally infected showed significant increases in serum IgM titres by 14 d.p.i. Sahin et 
al (2003) goes on to state that IgY response is often significantly preceded by that of IgA and 
IgM, occurring much later in C. jejuni infection, potentially even that of systemic biology. This 
may provide explanation as to why some chickens underwent systemic C. jejuni infection but 
lacked corresponding IgY response. IgM is usually associated with primary antibody response 
to infection, being the initial immunoglobulin isotype secreted during infection (Schroeder & 
Cavacini, 2010). CMT treatment showed significant influence on increases Campylobacter-
specific serum IgA by this time point, with a lack of IgA response observed across all other 
study treatment groups. As such, CMT treatment may influence early stimulation of the avian 
immune response, leading to rapid induction of IgM secretion and subsequently, an earlier 




using bursectomy techniques in the broiler chicken illustrates how although present, increases 
in antibody titre during these early stages of life do not correlate with decreases in C. jejuni 
colonisation of the caeca. The presence of Immunoglobulin levels of all classes in non-infected 
chickens also confirms that observed measure of absorbance cannot be fully indicative of 
response to an active C. jejuni infection, or in fact, CMT treatment.   
 
While much of the influence of CE cultures and CMT are thought to be derived from direct 
microbe interactions once established within the intestinal tract, here we show that this 
understanding can be developed. Using only sterile filtrate transfer of both Aviguard® and 
CMT we were able to alter the pathogenic potential of both Campylobacter and Salmonella 
challenge strains using an in-vitro model. Such an effect provides further indication that 
additional elements of both Aviguard® and CMT, such as microbial metabolites can also be 
effective. Multiple published findings have established a strong understanding of particular 
bacterial metabolites, particularly SCFAs such as acetate, propionate, and butyrate are crucial 
control mechanisms through which microbial components of the gut can modulate the host 
immune system (Hong et al., 2019). Nagpal et al. (2018) have made further indication that an 
increase in taxonomic diversity within the microbiome will result in increased production of 
SCFAs, with a diverse range of microbial communities all able to produce such metabolites, 
including Bacteroides, Ruminococcaceae, Lachnospiraceae. Such work further states how 
potential microbe-microbe ‘cross-feeding’ behaviors may underlie this relationship (Nagpal et 
al., 2018). With FMT-, and similarly CMT- derived samples known to possess increased 
composition of bacterial commensals including SCFA-producing taxa such as 
Ruminococcaceae compared to more modified probiotic cultures, it may be sensible to infer 
that the CMT material used within this work derives potential for more SCFA production 




























Chapter Five: Effects of Caecal Microbiota Transplantation on 
























The microbiome encompasses the entire collection of genetic compliment from a microbial 
community representing commensal, pathogenic, and symbiotic organisms co-existing within 
a specific host (Cisek & Binek, 2014). Although comprising a diverse taxonomic range of 
organisms including bacteria, fungi, archaea, protozoa and viruses, this interrelated microbial 
community should not simply be considered on the basis of a sum of its individual 
components, but more an interactive organ in its own right (Borody et al., 2013).  
 
From the moment of hatch, the chicken microbiome begins to be established. It is this first 
exposure to microorganisms from the egg shell, hatchery environment and, over subsequent 
days, litter, water and feed within farm sheds that will ultimately determine the intestinal 
microbiota that develops in the first weeks of life (Schokker et al., 2014). Successive 
colonisation of the gastrointestinal tract (GIT) of chicks commonly undergoes two successional 
stages during the first week of life, developing from a community dominated by 
Enterobacteriaceae during days 1 – 3 post-hatch, to one dominated by Firmicutes from 7 days 
post-hatch (d.p.h) onward (Connerton et al., 2018). Adding complexity, the broiler GIT will 
undergo divisional temporal changes in microbiota development whereby intestinal segments 
differentiate in their microbial community ecology (Jurburg et al., 2019). Due to the nature of 
the commercial broiler industry, all individuals within a commercial broiler flock will invariably 
share consistent environmental influences and so will exhibit a somewhat common 
microbiome community at each point of development. For the purposes of this research, our 
focus will be solely on the caecal microbial community since this is the most intestinal section 
most densely populated with bacteria and is the microbial community most likely to 
encounter extended contact with C. jejuni following experimental infection (Newell & 
Fearnley, 2003).  
 
Notably, Juburg et al (2019) has emphasised how caecal microbiota taxonomic diversity 
increases most during the first 7 days of life, further highlighting how bacterial succession 
during this period could be crucial in the development and stability of microbiomes in adult 
broiler chickens. It is during this time that bacterial succession of the microbiome is most 
extreme, exhibiting radial shifts in composition on a daily basis (Jurburg et al., 2019; Richards 
et al., 2019). Microbial function is intrinsically determined by the presence of specific taxa and 




microbial communities. Potentially undesirable shifts in microbial communities stemming 
from this may have substantial influence on host health and performance (Cisek & Binek, 
2014). With the GIT presenting an interface whereby the avian microbiota is in direct contact 
with the host epithelial surface, these host-microbe interactions are heavily linked to 
intestinal development and maturation, immunomodulation, maintenance of intestinal 
homeostasis and contribution to host nutrition (Shang et al., 2018). Shang et al (2018) 
described how an imbalance in the normal microbial ecology of the GIT, or dysbiosis, can lead 
to sequential deterioration in function of the intestinal epithelium, poor nutrient digestibility, 
increased risk of bacterial translocation and subsequent inflammatory responses. 
 
With poultry meat consumption showing no significant decrease worldwide, a continued drive 
for efficiency of production within the poultry industry exists (FAO 2019). While it remains 
undeniable that the microbial communities inhabiting the intestinal tract of all animals will 
have profound impact on the nutritional state of the host, the intensive nature of the poultry 
production makes this facet imperative (Ramakrishna, 2013). Consistently production of 
broiler chickens with a ‘healthy’ and stable microbiome will increase the production of host-
utilisable elements within distal regions of the gut such as SCFAs and amino acids that all 
represent an energy source readily available for the bird (Oakley et al., 2014; Shang et al., 
2018; Van Der Wielen et al., 2000). Dibner & Richards (2005) also highlight additional function 
of SCFAs in the stimulation of intestinal epithelial cells to rapidly proliferate, resulting in 
increased villi surface area for absorption (Oakley et al., 2014). Natural, endogenous 
production of multiple dietary vitamins by the healthy intestinal microbiota could also aid the 
common practice of dietary vitamin supplementation seen in broiler chicken production 
(Oakley et al., 2014). 
 
Of perceivably greater importance, is the relationship between the development of a healthy 
chicken microbiome in the caecum and the reduced susceptibility of chicks to various enteric 
pathogens (Pan & Yu, 2014). Colonisation resistance, as described in work by Pickard et al. 
(2017) shows commensal gut symbionts forming an established microbial community that in 
turn, resists the invasion of non-native bacteria through a combination of potentially 
bactericidal and bacteriostatic mechanisms. Cisek & Binek (2014) have corroborated this 
theory in poultry, showing, in the absence of a normal caecal microbiota, chicks were 
appreciably more susceptible to opportunistic infection. In spite of the fact that a definitive 




processes are widely heralded as the driving force, described in early work by Nurmi & Rantala 
(1973) in the protection of broiler chickens against Salmonella infection. As explained 
previously, ecologically, CE negates the ability of two species competing for the same limiting 
resource to coexist as a stable community (Mead, 2000; Schneitz, 2005). This competition 
within a particular niche may be in the form of physical competition for space, resources or 
direct confrontation between native and invading colonisers (Clavijo & Flórez, 2018). A 
microbiota undergoing dysbiosis represents a less stable community which, in turn, will be 
less able to compete with invading pathogens. In addition, although variation exists in exact 
microbiome composition between individual adult chickens, the acquired microbiome will 
work to develop the immune system, pertaining particularly to the mucus layer, epithelial 
monolayer and intestinal immune cells (Shang et al., 2018). Shifts in the microbiota 
community constitution can both beneficially optimise immune capability but, in the same 
respect, hamper its function (Broom & Kogut, 2018). It is undeniably clear that the intestinal 
epithelium and adjacent microbiota are crucial in understanding how gut health can be 
maintained and consequently, how any impairment may increase host susceptibility to 
disease (Awad et al., 2018).  
 
Although a comprehensive understanding of avian microbiome structure and respective 
functionality is important in many aspects of commercial production, until recently, our 
ability to define this structure has been reliant on culture based microbial techniques 
(Arnold et al., 2016; Oakley et al. 2014). Recovery of an accurate representation of the avian 
gut microbiome through microbiological cultivation is inefficient and vastly inaccurate, and 
so the advances in next generation sequencing over recent years has opened new 
opportunity to assess the previously unculturable communities (Stanley et al., 2014). Early 
studies often utilised 16S rRNA sequencing techniques for such purposes (Zhu et al., 2002; 
Lu et al., 2003). Supported by both culture-based and 16S sequencing techniques is the 
understanding that the caecal microbiome is predominated by anaerobes, with fewer 
facilitative representatives (Lu et al., 2003). Shaping of the caecal microbiota during early 
successional development is thought to be particularly dependent upon environmental 
exposure and so compositional observations vary somewhat between experimental study 
(Richards et al., 2019). However, it is largely corroborated that the caecum is dominated by 
Clostridiaceae, Bacteroidaceae, Lactobacillacea and Lachnospiraceae families, alongside an 





As highlighted in previous chapters, C. jejuni infection within the commercial broiler chicken 
is subject to a strong age-based delay, the lag-phase, with colonisation occurring 
predominantly at around 3 weeks of age (Newell, 2002). At this point of infection, C. jejuni 
colonisation is rapid and efficient, with the frequency of colonisation within a flock increasing 
from 5 to 95 % within as little as 6 days (Connerton et al., 2018). Work by Haag et al. (2012) 
has gone some way in demonstrating how the ability of C. jejuni to colonise within a mouse 
model is heavily dependent on the microbiome of the individual host, and after inducing 
significant microbial shifts, the mouse microbiome is heavily reliant on presence of C. jejuni 
infection. Sofka et al. (2015) noted that, although not statistically significant, C. jejuni infection 
of the chicken was associated with higher Proteobacteria and Bacteroidetes taxons as oppose 
to higher Firmicutes taxons in C. jejuni negative samples. Subsequent work by Sakaridis et al. 
(2018) into the association between the broiler microbiome and Campylobacter burden 
showed a somewhat contrary outcome, with higher Firmicutes composition concomitant with 
higher Campylobacter counts. Perhaps of most interest, is the evidential link between 
Enterobacteriaceae presence within chicken microbiome and the C. jejuni burden of the host 
(Bereswill et al., 2011; Sakaridis et al., 2018; Sofka et al., 2015). It remains largely 
undetermined how the colonisation of the broiler chicken with C. jejuni will ultimately impact 
the microbiota and which, if any, microbial communities may be important in reducing or 
prohibiting initial infection.  
 
Here we aim to elucidate how the early (up to 7 d.p.h) microbiome of the broiler chicken can 
be manipulated through point-of-hatch inoculation with a commercial microflora preparation 
or a Caecal Microbiota Transplantation (CMT), and how this might influence subsequent C. 














MATERIALS AND METHODS 
  
SAMPLE COLLECTION  
 
Caecal samples used for DNA extraction and subsequent 16S rRNA sequencing were obtained 
from the experimental trial conducted in accordance with the complete experimental 
protocol ZIPP 54 and discussed in Chapter 4.  
 
A total of 13 caecal samples (CMT n = 4; Aviguard® n = 3; Internal control n = 3; External control 
n=3) were aseptically collected from chicks 3 d.p.h and a further 40 caecal samples (10 
samples per treatment group) were collected 7 d.p.h. Caecal samples were collected from 
both caecal sacs to create one pooled sample per bird. All samples were immediately snap-
frozen post-collection in liquid nitrogen before storage at – 80°C for no longer than 2 weeks.  
 
DNA EXTRACTION AND PREPARATION  
 
Microbial community DNA was extracted from the collected caecal samples using the Qiagen 
QIAampâ Fast DNA Stool Mini Kit (Qiagen, Hilden, Germany) following the protocol for the 
‘Isolation of DNA from Stool for Pathogen Detection’. Since stool samples were frozen prior 
to extraction, a scalpel and spatula were used to scrape caecal material into a 2 ml sterile 
centrifuge tube on ice to a final sample weight of 180 – 220 mg. DNA extraction protocols 
were combined with an initial bead-beating step to improve microbial DNA yield. All samples 
were eluted into 200 µl DNase-free water (Qiagen, Hilden, Germany) as oppose to the stated 
Buffer ATE as required for further downstream analysis. Low DNA concentrations (of < 10 
ng/µl) were obtained for some samples and so elutant was passed through the column filter 
twice as part of the final centrifugation step (Step 14). Samples were stored at – 20 °C until 
further processing. Opsonisation of DNA extraction according to our samples was performed 
by comparing three separate extraction kits for microbial DNA yield. Inclusion of InhibitEX 
ensured effective removal of PCR inhibitors from extracted samples. To account for the effects 
of contamination introduced through DNA extraction reagents and disposables, negative 
controls consisting of only nuclease-free water, with no sample added, were processed 
alongside our samples of interest. These were included on all agarose gel processing, being 





Subsequent to extraction, 1 µl of each DNA sample were comprehensively assessed for yield 
and quality using NanoDrop (ND-1000) Optical Density (OD) 260/230 and 260/280 ratios. Both 
ratios interpret DNA extract quality in relation to contamination and potential problems with 
the DNA extraction procedure used to obtain the sample.  An OD 260/280 ratio of ~ 1.8 and 
an OD 260/230 ratio of ~ 2.0 – 2.2 were accepted as being optimal for good quality extracted 
DNA. To improve the yield and reduce contaminants for some extraction samples, DNA was 
precipitated in ethanol. For samples that required precipitation, 10 µl of 3M Sodium 
hydroxide (NaOH) (Sigma-Aldrich, Poole, UK) was added before a further addition of 275 µl of 
cold 100 % Ethanol. Samples were vortexed at maximum speed for 3 seconds before being 
incubated at – 80 °C for at least 1 hour. Following incubation, samples were thawed at room 
temperature (RT) and centrifuged at 12,000 x g for 30 minutes at room temperature. The DNA 
pellet was identified visibly, and any supernatant discarded. The DNA pellet was rinsed with 
1 ml of 70 % Ethanol before being centrifuged at 12,000 x g for 15 minutes. The pellet was 
visibly identified, and the supernatant discarded. The remaining purified DNA pellet was air 
dried to remove remaining Ethanol before being rehydrated in 100 µl DNase free water. 
Samples were stored at – 20°C until further quality analysis.  
 
After extraction and purification methods, DNA samples were assessed for quality and 
integrity. DNA were visualised using agarose gel electrophoresis using a 2 % (w/v) gel. The 
agarose gel was prepared by dissolving 1 g high pure low EEO agarose powder (Alpha 
Laboratories, Eastleigh, UK) in 100 mL 1 X Tris-acetate-EDTA (TAE) buffer (Promega, 
Southampton, UK). The agarose solution was heated until molten and all agarose powder was 
fully dissolved. After cooling of the molten agarose to below 55 °C, 5 µl of peqGREEN (2 x 10-5 
µl/ml; Peqlab, Fareham,UK) was added and incorporated fully into the solution by swirling. 
The agarose was poured directly into a gel cassette before being allowed to set for 1 hour. 
DNA samples were prepared for loading by mixing 5 µl extracted sample DNA and 1 µl dye. 
Lambda hindIII ladder (ThermoFisher Scientific, Loughborough, UK) was loaded into a pre-
designated lane. 12 µl of Prepared DNA/loading buffer pertaining to individual samples were 
loaded into subsequent lanes. The loaded gel cassette was placed into an electrophoresis tank 
containing TAE buffer. The electrophoresis was run at 120 V for 30 minutes before DNA bands 
were visualised under ultraviolet transillumination using Uvitec software. Level of degradation 





Purified DNA samples were also amplified using Polymerase Chain Reaction techniques using 
primers specific for the 16S rRNA gene (spanning the V4 region) (F: 5’- 
TGCCAGCMGCCGCGGTAA-3’, R: 5’-GGACTACHVGGGTWTCTAAT-3’) to confirm the production 
of visible gel bands of the expected size. PCR reactions were conducted using an Applied 
Biosystems 2720 thermo cycler (Thermofisher Scientific, Cheshire, UK) in 0.2 µl PCR tubes. 
PCR reactions contained 17 µl water, 5 µl 5x FIREPol® master mix ready to load with 7.5 mM 
MgCl2 (Solis-Biodyne, Tartu, Estonia), 1 µl each of the forward and reverse primers, and 1 µl 
of genomic DNA. PCR was performed according to the following conditions: 95 °C for 5 
minutes and 30 cycles of denaturing at 95 °C for 30 seconds, annealing at 55 °C for 45 seconds 
and elongation at 72 °C for 40 seconds, with a final extension of 72 °C for 5 minutes (Caporaso 
et al., 2012). Samples were subsequently run on a 2 % agarose gel as described above. 
 
DNA was quantified with Qubit fluorometic analysis using a dsDNA High Sensitivity Assay 
(Invitrogen, Thermofisher Scientific, Loughborough, UK) was used, with a quantification range 
of 0.2 - 100 ng. DNA samples were submitted for V3/V4 hypervariable 16S rRNA gene 
amplification and Illumina MiSeq platform processing.  
 
16S rRNA GENE SEQUENCING 
Extracted DNA was sent for Illumina MiSeq sequencing of the V3/V4 hypervariable 16S rRNA 
gene at the Centre for Genomic Research (University of Liverpool). Briefly, primers used by 
Caporaso et al. (2010) were used to amplify the V4 region of 16S through a two-stage nested 
PCR;  
 
F: 5'ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGCCAGCGCCGCGGTAA3'  
R: 5'GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGGACTACGGGTTCTAAT3' 
 
This first round PCR reactions contained 5 µl of DNA with PCR conditions of 10 cycles set at 
95°C for 20 seconds, 65°C for 15 seconds. 70°C for 30 seconds. This was then followed by a 
72°C extension step for 5 minutes.  
 
Primers were designed through incorporation of a recognition sequence to allow a secondary 
nested PCR process after purification with AMPure SPRI beads (Beckman Coulter, Indianapolis, 
US). This secondary PCR is performed largely for the incorporation of Illumina adapter 




barcode sequences used for sample identification. The sequences used for forward and 
reverse priming of this PCR are illustrated below with the 8 base-pair (bp) barcode sequence 
being underlined.  
 
N501F:5'AATGATACGGCGACCACCGAGATCTACACTAGATCGCACACTCTTTCCCTACACGACGCTC3' 
N701 R : 5'CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTGACTGGAGTTCAGACGTGTGCTC3' 
 
Creating an additional 15 cycles using the same conditions as previously described, a total of 
35 cycles were performed. Samples were again purified using AMPure SPRO beads (Beckman 
Coulter, Indianapolis, US) before being quantified using Qubit fluorometic analysis with 
successful libraries proceeding to further processing.  
 
Based on data from the Qubit and fragment analyser, and according to a Pippin Prep (Sage 
Science, Beverly, MA, US) size range of 300 – 600 bps, final libraries were pooled in equimolar 
quantities for Bioanalyser assessment. Using Illumina® Library quantification kits (KAPA, 
Wilmington, MA, US), qPCR was performed on a Roche Light Cycler® LC48011. All 20 µl qPCR 
reactions were performed in triplicate for each pooled library and prepared using 12 µl SYBR 
Green I Master Mix and 4 µl of the diluted pooled DNA. Thermal cycling conditions were set 
at 5 minutes at 95°C for denaturing, 35 cycles of 30 minutes of 95°C (denaturing) and 60°C for 
45 seconds for annealing and extension followed by melt curve analysis reaching 95°C and 
subsequent cooling at 37°C.Diluted 0.1M NaOH was used to denture the final pool for 5 
minutes before reaction termination by the addition of HT1 hybridization buffer with a final 
loading concentration of 11pM.  All libraries were subsequently sequenced on an Illumina 
MiSeq platform with version 2 chemistry using sequencing by synthesis (SBS) technologies to 
generate 2 x 250 bp paired-end reads. CASAVA v1.8.2 was used to demultiplex all synthesised 
reads while Cutadapt v 1.2.1 (Martin, 2011) was used to remove any Illumina adapter 
sequences.  
 
MICROBIOTA ANALYSIS  
 
16S rRNA sequencing data processing was performed using the next-generation 
bioinformatics platform QIIME 2™ (2019.1) [Quantitative Insights Into Microbial Ecology v.2] 
(Bolyen et al., 2019). Microbial diversity within a treatment group was determined using alpha 
diversity parameters and diversity between treatment groups was determined using beta 




brief overview provided in Figure 66. Forward and reverse Fastq raw sequencing data were 
imported into QIIME 2™ through creation of a manifest file. Created as a CSV (comma-
separated text-file), the manifest file served to map sample identities with sequence data by 
providing absolute file-paths, sample IDs and read direction.  
 
DATA PROCESSING: DADA2 
 
The Diverse Amplicon Denoising Algorithm 2 (DADA2) plugin was used to provide sequence 
quality control and feature table construction (Callahan et al., 2016). Low quality sequence 
reads were removed through trimming and truncating processes, whereby the forward reads 
were trimmed 7 nucleotides from the left and truncated 250 nucleotides from the right. The 
reverse reads were timed 21 nucleotides from the left and truncated 250 nucleotides from 
the right. DADA2 also acts as a filter, to remove chimeric sequences that may act as a 
‘contaminant’ when assessing sample biodiversity. Chimeric sequences are artefacts 
generated following incomplete amplicon extension during PCR amplification (Haas et al., 
2011). The premature amplicon generated can then act as a primer in subsequent PCR cycles 
and form a chimeric sequence (Haas et al., 2011). Following further amplification of this 
sequence, a chimeric artefact will falsely represent novel organisms in the sample dataset 
(Haas et al., 2011). Consensus chimera filtering was applied to detect chimeric sequences in 
individual samples and remove those chimeras representing a sufficient fraction of that 
sample.  
 
The non-chimeric amplicon sequence variants (ASV) table generated from the DADA2 pipeline 
displays the observation frequency of each ASV relative to individual samples. Use of ASV 
sequences has recently superseded previous construction of Operational Taxonomic Unit 
(OTUs) tables (Callahan et al., 2017). An ASV, previously referred to as an OTU, is a cluster of 
sequence reads that differ from each other by less than a fixed dissimilarity threshold, most 
commonly 3 % (Callahan et al., 2017). A higher resolution picture of ecological patterns within 
samples is thought to be demonstrated with ASV methods compared to OTU based methods. 
The de novo-based process of ASV inference employed by the DADA2 pipeline occurs prior to 
introduction of amplification and sequencing errors and is able to discriminate between 
sequence variants at even single nucleotide level (Callahan et al., 2017). The mafft pipeline 
from the q2-phylogeny plugin was used to perform multiple sequence alignment of the 




then masked to remove highly variable sequences and a midpoint rooted phylogenetic tree 
generated for use in further downstream analysis.  
 
DATA ANALYSIS: ALPHA AND BETA DIVERSITY 
 
The rooted phylogenetic tree generated was used to assess microbial community diversity 
both within and between samples. The QIIME2™ q2-diverity plugin was used to perform alpha 
and beta diversity analysis to a depth of 44, 841. The sampling depth used was determined 
based on the minimum frequency of sequences per sample, allowing for maximal retention of 
sequences per sample (Navas-Molina et al., 2013).  
 
Alpha diversity analysis represents a commonly used tool for the composite measure of the 
number of species in relation to that species abundance within a given sample, with this being 
described as species richness and evenness.  Alpha, or within-sample, diversity was analysed 
using the following core-metric parameters: 
 
• Pielou’s Evenness index – A measure of microbial community evenness. (Qiime2, 
2019) 
• Observed ASV index – A qualitative measure of community richness (Qiime2, 2019) 
• Shannons diversity index – A quantitative measure of community richness using 
natural logarithm and accounting for both abundance and evenness of the taxa 
present. (Qiime2, 2019) 
 
Statistical relevance of identified alpha diversity metrics and sample metadata groups was 
validated through pairwise ANOVA Kruskal-Wallis testing. Application of Kruskal-Wallis for this 
dataset was favourable since it makes no assumption of data distribution normality (non-
parametric) and shows limited sensitivity regarding asymmetrical sample size (McCrum-
Gardner, 2008). To account for multiple-testing, p - values were adjusted using the Benjamini-
Hochberg correction, with these provided as q - values.  
 
Often used in accordance with alpha diversity, beta diversity is a useful measure of taxonomic 
diversity between different samples. To compare patterns of beta diversity (diversity in 




Fraction) distance matrices were calculated whereby greater values indicate greater sample 
dissimilarity (Anderson et al., 2011).  
 
• Unweighted UniFrac – A qualitative measure of community dissimilarity considering 
only ASV presence or absence (community membership) (Qiime2, 2019).  
• Weighted UniFrac – A quantitative measure of community dissimilarity considering 
ASV presence, absence and relative abundance (community structure) (Qiime2, 
2019). 
 
The incorporation of phylogenetic information within these UniFrac metrics allows for 
interpretation of the degree of divergence between sequences and improves model power 
(Lozupone & Knight, 2005). Utilising both weighted and unweighted UniFrac measures 
minimises the likelihood that individual taxonomic abundance would mask the identification 
of trends in community differences between the samples. Together, these UniFrac metrics are 
able to provide a comprehensive picture of sample taxonomic composition and microbial 
community shifts.  
 
After UniFrac beta diversity statistics were determined, the Permutational Multivariate 
Analysis of Variance (PERMANOVA) was applied to each UniFrac metric to assess statistical 
significance against individual covariates of interest. No assumption of data normality is 
required in the application of PERMANOVA analysis, allowing this distance-based method to 
be widely used in the estimation of microbial community dissimilarity. Metrics were 
determined in comparison of different treatment groups. Microbial communities showing 
strong similarity had a Unifrac score tending toward 0 while microbial communities of higher 
divergence will have Unifrac scores tending toward 1.  
 
The UniFrac dissimilarity statistics generated were presented using Principle Coordinates 
Analysis (PCoA), a distance-based plot assigning individual samples a specific location in three-
dimensional space (Halko et al., 2011; legendre & legendre, 2012). PCoA plots are often used 
as a means of identifying overall similarity/dissimilarity between populations of samples 
according to covariates of interest. Samples with more similar population compositions will 
cluster closer together, while samples showing more compositional dissimilarity will be 
positioned farther apart in PCoA space. For determining differential abundance of specific taxa 





DATA ANALYSIS: TAXONOMIC COMPOSITION 
 
ASVs were assigned taxonomy using the QIIME2™ q2-feature-classifier plugin with the pre-
trained Naïve Bayes Greengenes 13_8 99% classifier (16S rRNA) (Pedregosa et al., 2011). A 
QIIME2™ taxa bar-plot was generated to view the assigned taxonomic composition of 
individual samples according to sample metadata variates of interest. A venn diagram was 
created using MetaCoMETs jvenn programme (Bardou et al., 2014) to compare the 
microbiome data from each treatment group. The core microbiome can be represented within 
the shared overlapping regions.   
 
Linear Discriminant Analysis (LDA) effect size (LEfSe) methods were used to identify 
differentially abundant features across sample groups (Segata et al., 2011). LEfSe utilises the 
two-tailed nonparametric Kruskal-Wallis test to first evaluate the differential between 
treatment groups, with all features not agreeing with the null hypothesis undergoing pairwise 
Wilcoxon testing. Finally, an LDA model was constructed, from which the relative difference 
of this feature among different groups was used as a rank. Microbial features were considered 
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DNA was extracted from all samples collected using protocols previously described, resulting 
in a submission sample size of 56 samples for 16S rRNA Illumina MiSeq processing. All samples 
were checked for DNA isolation and integrity using agarose gel electrophoresis before being 
quantified using Qubit dye-based methodologies. Results from DNA quantification and are 
provided in Appendix 5.  
 
MICROBIOTA DIVERSITY ANALYSIS 
 
The 56 samples processed via 16S rRNA techniques gave an average of 287,108 raw data reads 
per sample. Downstream application of denoising and chimera removal QIIME2™ pipelines 
refined these raw data reads, deriving a total of 4,893,551 sequences across all samples, with 
an average of 87,385 sequences per sample. Sequence frequency per sample had a range of 
79,148 sequences with minimum and maximum counts per sample being 44,841 and 123,989 
respectively. Detail on specific sequence counts attained per sample is provided in Appendix 
XX. The 4,893,551 sequences presented 724 differential features or ASVs. Of the 724 ASV 
clusters, 11 (2 %) were assigned to Kingdom, 29 (4 %) Order, 110 (15 %) Family, 41 (6 %) Genus 
and 533 (73 %) to Species.  
 
ALPHA DIVERSITY ANALYSIS 
 
Alpha rarefaction was used to ascertain the correct sampling depth for downstream analysis, 
by visualisation of the number of samples that are retained within the analysable dataset at 
varying rarefaction sampling depths (Figure 67). A sampling depth of 44,841 was used, 
retaining all samples and 51.31% (2,511,096) of the total sequences in the analysis when 









Observed ASV metric 
 
Observed ASV alpha diversity metrics were assessed as an initial primary assessment of 
individual sample microbial community richness (Figure 68a). Analysis was first directed at 
identifying significant differences in the number of unique observed ASVs between the 3 d.p.h 
microbiota from each treatment group, with these groups being defined from this point 
forward as; 3 d.p.h CMT, 3 d.p.h Aviguard®, 3 d.p.h Internal Control and 3 d.p.h 
External Control. Unique ASV frequencies derived for each 3 d.p.h treatment group ranged 
from 29 – 139 ASVs, with Internal (29 ASVs) and External (34 ASVs) control groups showing 
the lowest ASV frequencies and the CMT treated group (139 ASVs) showing the greatest. 
Microbiota from Aviguard® treated birds returned a total of 58 unique sequence variants. 
Treatment group did not significantly alter observed ASV using pairwise Kruskal-Wallis 
analysis (corrected for FDR) (q > 0.05), likely due to the small sample size used.  
 
The second focus was towards microbiota samples from 7 d.p.h birds of each treatment group. 
From this point forward defined as; 7 d.p.h CMT, 7 d.p.h Aviguard®, 7 d.p.h Internal Control, 
7 d.p.h External Control. Alpha diversity analysis of observed ASVs showed an ASV count 
ranging from 83 – 328 per treatment group. As with 3 d.p.h samples, lowest unique ASV 
frequencies were found in Internal control (119 ASVs) and External control (83 ASVs) 
Figure 67. The number of individual samples retained per treatment group following alpha 
rarefaction at specified sequencing depths. At 3 d.p.h (Aviguard n=3; Ext. control n=3; Int. 
control n=3; CMT n=4) and 7 d.p.h (7day) (all treatment groups n=10) 
3day_Int.Control  
CMT Treated  
Aviguard® Treated  
Ext. Control  





CMT Inoculum  




treatment group samples, with 7 d.p.h Aviguard® (144 ASVs) and 7 d.p.h CMT (328 ASVs) 
microbiota having substantially more. Pairwise Kruskal-Wallis testing between each of the 7 
d.p.h treatment groups showed 7 d.p.h Aviguard® microbiota had significantly more observed 
ASVs compared to 7 d.p.h Internal control (H = 9.15; q = 0.02) and 7 d.p.h Ext. control (H = 
14.31; q = 0.00) microbiota ( 
Table 26). Similarly, 7 d.p.h CMT microbiota was significantly distinct according to this 
diversity metric to both 7 d.p.h Int. control (H = 14.30; q = 0.00) and 7 d.p.h Ext. control (H = 
14.31; q = 0.00) microbiota. Pairwise comparison of 7 d.p.h Aviguard® and 7 d.p.h CMT sample 
groups identified CMT samples as having significantly higher frequency of observed ASVs (H = 
14.28; q = 0.00). Individual ASV counts per sample are provided in Appendix 5.   
 
Inoculum material given to Aviguard® and CMT treatment groups were assessed for sample 
microbial composition and diversity and from this point forward will be defined as CMT 
Inoculum and Aviguard® Inoculum. Alpha diversity parameters were not applied to the same 
depth as for 3 d.p.h and 7 d.p.h treatment group samples due to small inoculum sample 
populations. The observed ASV alpha diversity metric was applied to inoculum samples and 
returned 392 observed ASVs for CMT inoculum and 92 ASVs for Aviguard® inoculum, although 
this variation was not statistically significant by pairwise significance testing (H = 1.25; 
q = 0.24).  
 
Shannon’s diversity metric 
 
Shannon alpha diversity metrics were calculated to derive a more comprehensive 
understanding of the abundance of each of the Observed ASV’s within individual samples. 
Shannon values ranged from 1.44 – 4.33 for 3 d.p.h treatment group samples and 1.62 – 5.78 
for 7 d.p.h treatment group samples (Appendix 5). After FDR adjustment of p - values, 
treatment group resulted in no significant divergence through pairwise comparison of 3 d.p.h 
data (q > 0.05) (Figure 68b) ( 
Table 26).  
 
Shannon diversity was significantly higher in 7 d.p.h Aviguard® treatment samples compared 
to that of the 7 d.p.h Internal control (H = 10.08; q = 0.01) and 7 d.p.h External control (H = 
8.69; q =0.01) groups (Table 2). At 7 d.p.h, the CMT microbiome had higher average Shannon 




0.00) groups. CMT treatment did not significantly alter Shannon diversity of samples 
compared to that of Aviguard® samples at 7 d.p.h (H = 7.00; q = 0.05). 
 
Pielou’s evenness metric 
 
Pielou’s Eveness metric works to incorporate both differential ASV number with individual 
ASV abundance to create a metric of the evenness of ASV distribution within a sample. 
Measured on a scale of 0 to 1, the closer an evenness value is to 1, the more evenly spread 
abundancy is within that sample. Derived evenness values ranged from 0.36 - 0.70 for 3 d.p.h 
treatment groups, with no statistically significant difference in group evenness following 
pairwise Kruskal-Wallis analysis of all 3 d.p.h treatment groups (q > 0.05) (Figure 68c) ( 
Table 26). Treatment groups of 7 d.p.h microbiota had Pielou evenness scores ranging from 
0.38 – 0.77, showing little variation in microbiota community evenness between different 
treatment groups. 7 d.p.h CMT treated birds showed significantly more evenly distributed 
microbial communities compared to Internal control (H = 10.08; q = 0.03) and External control 






















Table 26. Summary statistics of alpha diversity analysis according to sample treatment group. 
Pairwise comparisons of alpha diversity metrics were calculated through ANOVA Kruskal-wallis 
testing. All p-values were adjusted using Benjamini-Hochberg correction, with these provided as 
q-values.  
 
Cull  Group comparisons Pairwise kruskal-wallis 
Observed ASV Shannon Pielou’s Evenness 







CMT  1.13 0.31 0.00 1.00 1.13 0.37 
Ext. Control 3.86 0.09 3.86 0.09 3.86 0.14 
Int. Control   3.86 0.09 3.86 0.09 3.86 0.14 
CMT  Ext. Control  4.50 0.07 4.50 0.07 4.50 0.12 
Int. Control   4.50 0.07 4.50 0.07 0.50 0.58 




Aviguard® CMT  14.28 0.00 7.00 0.05 0.14 0.74 
Ext. Control  14.31 0.00 8.69 0.04 7.00 0.06 
Int. Control  9.15 0.02 10.08 0.02 7.00 0.06 
CMT  Ext. Control 14.31 0.00 14.29 0.00 10.57 0.03 
Int. Control  14.30 0.00 14.29 0.00 10.08 0.03 
Ext. Control  Int. Control  4.66 0.07 5.49 0.06 0.14 0.74 





























Figure 68. Box and whisker plot of alpha diversity metrics showing (a) observed ASV metric (b) shannon diversity metric (c) pielou's evenness metric 
according to specific treatment group. 3 d.p.h (Aviguard n=3; Ext. control n=3; Int. control n=3; CMT n=4) and 7 d.p.h (7day) (all treatment groups n=10) 




























































BETA DIVERSITY ANALYSIS 
 
Beta diversity metrics were calculated with the purpose of determining differences and 
similarities between the microbiota community membership and the community structure of 
different treatment groups. Analysis of both weighted and unweighted Unifrac measurements 
was essential to appropriately explore microbial diversity, with statistical significance of 
pairwise comparisons provided in Table 27. 
 
Unweighted Unifrac beta diversity  
 
Pairwise PERMANOVA comparisons of taxa presence or absence within 3 d.p.h treatment 
groups (unweighted Unifrac) revealed no significant divergence between any treatment group 
(q > 0.05), with significance values for each comparison provided in Table 27. Performing such 
pairwise comparisons on 7 d.p.h microbiota samples shows dissimilarity of statistical 
significance (q = 0.01) when comparing both the 7 d.p.h Aviguard® and 7 d.p.h CMT 
microbiome with 7 d.p.h Internal and External control microbiota samples. Pairwise 
PERMANOVA comparison of Aviguard® and CMT Inoculum material yielded no level of 
significant dissimilarity between the two microbial communities (Pseudo-F =  61.90; q = 0.34).  
 
Using a PCoA transformation of unweighted Unifrac matrices showed distinct spatial 
clustering of both Aviguard® treated and External control samples at 3 d.p.h compared to the 
higher dispersal seen of 3 d.p.h CMT and Internal control samples. By 7 d.p.h it is External 
control and CMT treated samples that show visibly greater spatial clustering. CMT inoculum 
appears to form stronger clustering with samples from CMT treated birds than the 
relationship seen for Aviguard® inoculum and samples from Aviguard® treated birds (Figure 
69).  
 
Weighted Unifrac beta diversity  
 
Relative ASV abundance was incorporated to weight the UniFrac measurement (weighted 
UniFrac) and minimise the influence of low abundance ASV’s. Pairwise PERMANOVA 
comparisons of weighted Unifrac metrics for 3 d.p.h treatment group samples revealed no 
significant effect of specific treatment on sample beta diversity (q > 0.05), with significance 




Pairwise comparisons of 7 d.p.h treatment groups showed both CMT and Aviguard® treated 
birds had significantly distinct caecal microbial communities compared to both Internal and 
External control groups (q = 0.01). Comparison of microbiota from 7 d.p.h CMT and 7 d.p.h 
Aviguard® treated birds showed significant effects of treatment on beta diversity using this 
metric (Pseudo-F =  9.72; q = 0.01). No such impact was observed between the beta diversity 
of 7 d.p.h Internal and 7 d.p.h External control groups when directly compared (Pseudo-F =  
2.37; q = 0.14). 
 
Pairwise PERMANOVA comparison of Aviguard® and CMT Inoculum material yielded no level 
of significant dissimilarity between the two microbial communities via weighted UniFrac 
analysis (Pseudo-F = 794.23; q = 0.35). All UniFrac distances were plotted using PCoA 
transformation. While no obvious clustering could be identified for 3 d.p.h samples, both 7 
d.p.h internal and external control groups appear to show less dispersal compared to CMT 
and Aviguard® samples. As with unweighted Unifrac measures, CMT inoculum shows stronger 
clustering with samples from CMT treated birds compared to Aviguard® inoculum with 
samples from Aviguard® treated birds (Figure 70). 
 
Table 27. Summary statistics of beta diversity analysis according to sample treatment group. P-
values show pairwise PERMANOVA comparisons of Unweighted and Weighted Unifrac 
measures. All p-values were adjusted using Benjamini-Hochberg correction, with these provided 




Unweighted Unifrac Weighted Unifrac 
Group 1 Group 2 Pseudo-F q-value Pseudo-F q-value 
  
Aviguard®  
CMT  3.04 0.07 1.67 0.23 
3 d.p.h Ext. Control  7.83 0.12 8.77 0.14 
  Int. Control  2.46 0.12 6.41 0.13 
CMT  
Ext. Control  3.21 0.11 6.15 0.09 
Int. Control  1.77 0.1 5.19 0.1 
Ext. Control  Int. Control  1.95 0.12 0.93 0.43 
  
Aviguard® 
CMT  11.99 0.01 9.72 0.01 
  Ext. Control  9.26 0.01 15.72 0.01 
  Int. Control  4.22 0.01 14.71 0.01 
7 d.p.h 
CMT  
Ext. Control 24.69 0.01 36.70 0.01 
  Int. Control  13.07 0.01 34.58 0.01 
  Ext. Control  Int. Control  5.48 0.01 2.37 0.14 
 Inoculum 
CMT Inoculum  
Aviguard® 
Inoculum 
























Figure 69. Principal coordinate analysis (PCoA) plots based on Unweighted Unifrac distances for all samples 
collected at 3 d.p.h (Aviguard n=3; Ext. control n=3; Int. control n=3; CMT n=4) and 7 d.p.h (7day) (all 


























Figure 70. Principal coordinate analysis (PCoA) plots based on Weighted Unifrac distances for all samples 
collected at 3 d.p.h (Aviguard n=3; Ext. control n=3; Int. control n=3; CMT n=4) and 7 d.p.h (7day) (all treatment 


















CAECAL COMMUNITY TAXONOMIC COMPOSITION 
 
Taxonomic classification applied to all samples revealed a small group of identified sequences 
that could not be classified to any Kingdom, making up 0.0003% of the total relative 
abundance. A further sequence group were classified to the taxonomic kingdom level Bacteria 
but were unable to be further classified, with this bacterial group comprising 0.0012% of the 
total relative abundance. Classification of assigned taxonomies at Class level identified 25 
bacterial Classes, with each being present in at least one sample. Accounting for all samples, 
the relative abundance of two taxonomic classes predominated, with these being Clostridia 
(52.27 %) and Gammaproteobacteria (42.10 %).  
 
Further taxonomic classification to family level identified 68 different family taxons. An 
additional two groups were unable to be assigned taxonomic classification further than Order, 
with these comprising 0.01 % and 1.36 % of the overall relative abundance taking in to account 
all samples. Three taxonomic families comprised the majority of the total relative abundance 
for all samples, being Enterobacteriaceae (42.10 %), Lachnospiraceae (28.20 %) and 
Ruminococcaceae (16.13 %). Figures detailing relative abundance of taxonomic classifications 




















































































































































































































































































































































































1 of 1 14/05/2019, 13:17
Figure 71. Taxa plot showing the relative abund nc  at bacterial Class taxonomic level within the chicken caecal microbiota. Samples are given 
according to treatment group as 3 d.p.h (3day) (Aviguard n=3; Ext. control n=3; Int. control n=3; CMT n=4) and 7 d.p.h (7day) (all treatment 










































































































































































































































































































































































































1 of 1 14/05/2019, 13:21
Figure 72. Taxa plot showing the relative abundance at bacterial Family taxonomic level within the chicken caecal microbiota. Samples are given 
according to treatment group as 3 d.p.h (Aviguard n=3; Ext. control n=3; Int. control n=3; CMT n=4) and 7 d.p.h (7day) (all treatment groups 




Taxonomic level: Class 
 
Considering only taxa with > 2 % relative abundance averaged over treatment group, 3 d.p.h 
microbial communities belonged to 3 taxonomic classes and 7 d.p.h communities to 5. Looking 
first at samples from 3 d.p.h treatment groups, Clostridia and Gammaproteobacteria 
predominated, with an average relative abundance of 44.18 % and 51.32 % across all 3 d.p.h 
samples, respectively. Clostridia was the predominant taxonomic class in both 3 d.p.h 
Aviguard® (70.02 ± 25.73 %) and 3 d.p.h CMT (57.90 ± 22.92 %), treatment groups, while 
Gammaproteobacteria predominated in both 3 d.p.h Internal (65.20 ± 11.64 %) and 3 d.p.h 
External (77.07 ± 11.11 %) control microbiota. Similarly for 7 d.p.h samples, Aviguard® and 
CMT treated birds showed microbiota with communities rich in Clostridia (60.03 ± 16.92 %; 
85.03 ± 12.87 %, respectively). 7 d.p.h Internal and External control microbiota was instead 
more dominantly composed of Gammaproteobacteria (58.91 ± 14.95 %; 62.21 ± 11.18 % 
respectively.  
 
Clostridia taxons represented a large proportion of the CMT inoculum samples (83.73 ± 1.67 
%) with Gammaproteobacteria comprising 9 ± 0.25 % and Bacilli 6.05 ± 1.17 %. Aviguard® 
inoculum showed a more diverse composition, being largely composed of five different 
taxonomic classes; Clostridia (45.06 %), Bacteroidia (29.42 %), Betaproteobacteria (9.69 %), 
Fusobacteriia (9.12 %) and Bacilli (5.56 %). Three bacterial taxonomic Classes (Bacteroidia, 
Fusobacteriia and Betaproteobacteria) collectively comprised 48.20 % of the Aviguard® 
inoculum material, however showed 0.00 % relative abundance within the microbiota 
samples collected from Aviguard® treated birds at 7 d.p.h. Representation of each taxonomic 
class (with relative abundance of > 2% in at least one treatment group) within treatment 
groups at 3 d.p.h and 7 d.p.h are provided in Table 28 accompanied by visible representation 
in Figure 75. 
 
Taxonomic level: Family 
 
Further in-depth assessment of family taxonomic classifications, again considering only taxa 
with > 2 % relative abundance averaged over treatment group, showed 3 d.p.h microbial 
communities belonged to 6 family taxons, while 7 d.p.h communities belonged to 9. Of the 
Gammaproteobacteria that dominated Internal and External control samples at Class 
taxonomic level, classification to Family taxonomic level found this to be almost exclusively 




samples, but particularly dominant in Aviguard® and CMT treated birds, Family level 
classification divided this class into Lachnospiraceae and Ruminococcaceae families.  
Microbiota of 3 d.p.h samples comprised primarily of three Family taxons; being 
Enterobacteriaceae (51.32 ± 21.20 %), Lachnospiraceae (23.61 ± 15.43 %) and Clostridiaceae 
(11.72 ± 9.03 %). Enterobacteriaceae constituted a larger proportion of 3 d.p.h control group 
samples, being 65.19 (± 11.62) % of Internal control communities and 77.07 (± 11.11) % of 
External control communities. The relative abundance of Enterobacteriaceae was 
considerably lower in microbial communities of 3 d.p.h CMT treated samples (40.37 ± 21.49 
%) and 3 d.p.h Aviguard® treated samples (22.65 ± 18.07 %). The opposite was true for both 
Lachnospiraceae and Clostridiaceae taxons. Lachnospiraceae comprised 36.12 (± 18.98) % of 
3 d.p.h Aviguard®, 37.39 (± 9.01) % of 3 d.p.h CMT, 7.06 ± 8.28 % of 3 d.p.h Internal control 
and 13.89 (± 12.07) % of 3 d.p.h External control microbiota while Clostridiaceae comprised 
17.62 ± 15.27 % of 3 d.p.h Aviguard®, 1.53 ± 1.92 % of 3 d.p.h CMT, 20.8 (± 16.04) % of 3 d.p.h 
Internal control and 6.89 (± 9.43) % of 3 d.p.h External control microbiota. Ruminococcaceae 
taxons were relatively highly represented in both 3 d.p.h Aviguard® (16.22 ± 7.65 %) and 3 
d.p.h CMT (8.79 ± 7.48 %) microbial communities, whilst showing little contribution to both 3 
d.p.h Internal control (0.03 ± 0.04 %) and 3 d.p.h External control (0.06 ± 0.06) microbial 
communities.  
 
Enterobacteriaceae and Lachnospiraceae were the predominant families in 7 d.p.h microbial 
communities sampled, comprising an average relative abundance of 39.65 ± 24.68 % and 
30.14 ± 7.70 % across all 7 d.p.h treatment groups respectively. Ruminococcaceae taxons 
contributed an average of 19.65 ± 20.30 % across all 7 d.p.h treatment groups. Comparing 7 
d.p.h microbial community composition according to specific treatment group, 
Lachnospiraceae showed relatively even representation across treatment groups (ranging 
from 21.00 ± 8.50 % - 39.03 ± 14.50 %). Clostridia Ruminococcaceae showed higher relative 
abundance in both 7 d.p.h Aviguard® (25.54 ± 17.03 %) and 7 d.p.h CMT (45.59 ± 15.03 %) 
compared to 7 d.p.h Internal control (0.38 ± 0.33 %) and External control (7.11 ± 6.55 %) 
groups. An inverse relationship was observed for Enterobacteriaceae within 7 d.p.h microbial 
communities, with Internal control (58.91 ± 14.95 %) and External control (62.21 ± 11.18 %) 
microbiota having higher relative abundance when compared to microbial communities from 





Aviguard® inoculum was comprised of 9 taxonomic families with a treatment group averaged 
relative abundance of > 2 %, with CMT inoculum represented by 6. While Lachnospiraceae 
was fairly evenly represented in the microbiota of different treatment groups, it was 
considerably lower in relative abundance within Aviguard® inoculum compared to CMT 
inoculum (6.16 and 27.29 ± 1.31 % respectively). Although present in both inoculum material, 
Ruminococcaceae was considerably more represented in CMT inoculum (41.85 ± 0.82 %) 
compared to that of Aviguard® inoculum (19.05 %). Family taxon representation averaged by 
treatment group (for taxons with group representation > 2 %) is provided in Table 29 and a 
































Figure 73. Average relative abundance of assigned bacterial Classes according to treatment group at (a) 3 d.p.h (Aviguard n=3; Ext. control n=3; Int. control n=3; 
CMT n=4) and (b) 7 d.p.h (all treatment groups n=10) alongside (c) Aviguard® (AviguardInoc; n=1) and CMT inoculum (CMT Inoc; n=2) material. Only Classes 
with > 2 % relative abundance in at least one treatment group are shown. 
CMT Treated Aviguard Treated CMT Treated Aviguard Treated 
Int. Control Ext. Control Int. Control Ext. Control 







Table 28. Relative abundance with associated SD of bacterial Classes within specific treatment groups of caecal or inoculate material collected at 3 d.p.h and 7 
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Kingdom Phylum Class 3d.p.h 7d.p.h 3d.p.h 7d.p.h 3d.p.h 7d.p.h 3d.p.h 7d.p.h Aviguard® CMT 
Bacteria Actinobacter Actinobacteria 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 7.33 ± 6.35 0.00 ± 0.00 0.01 ± 0.01 0.00 ±0.00 0.00 ± 0.00 0.00  0.00 ± 0.00 
Bacteria Actinobacteria Coriobacteriia 0.00 ± 0.00 0.00 ± 0.00 1.81 ± 1.30 2.89 ± 2.77 0.00 ± 0.00 0.00 ±0.00 0.00 ± 0.00 0.00 ± 0.00 0.16 0.00 ± 0.00 
Bacteria Bacteroidetes Bacteroidia 0.00 ± 0.00 0.00 ± 0.00  0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.04 ± 0.12 0.00 ± 0.00 0.00 ± 0.00 29.42 0.00 ± 0.00 
Bacteria Firmicutes Bacilli 0.18 ±0.22 1.47 ± 2.20 4.93 ± 7.28 4.87 ± 2.99 6.87 ± 10.60 0.93 ± 0.62 1.92 ± 0.72 2.70 ± 3.39 5.56 6.05 ± 1.17 
Bacteria Firmicutes Clostridia 57.90 ± 22.92 85.03 ± 12.87 70.02 ± 25.73 60.03 ± 16.92 27.92 ± 22.12 39.88 ± 14.77 20.86 ± 11.58 35.04 ±11.04 45.06 83.73 ± 1.67 
Bacteria Fusobacteria Fusobacteriia 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 9.12 0.00 ± 0.00 
Bacteria Proteobacteria Betaproteobacteria 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ±0.00 0.00 ± 0.00 9.69 0.00 ± 0.00 
Bacteria Proteobacteria Gamma 
proteobacteria 




























Figure 74. Average relative abundance of assigned bacterial Families according to treatment group at (a) 3 d.p.h (Aviguard n=3; Ext. control n=3; Int. control n=3; 
CMT n=4) and (b) 7 d.p.h (all treatment groups n=10) alongside (c) Aviguard® (AviguardInoc; n=1) and CMT inoculum (CMT Inoc; n=2) material. Only Classes 
with > 2 % relative abundance in at least one treatment group are shown. 
CMT Treated Aviguard Treated CMT Treated Aviguard Treated 
Aviguard Inoc. CMT Inoc. 






Table 29. Relative abundance with associated SD of bacterial Families within specific treatment groups of caecal or inoculate material collected at 3 d.p.h and 7 
d.p.h. Only classes with > 2 % relative abundance in at least one treatment group are shown. 
 
Taxonomic group 
Relative abundance (%)  ± SD 

































1.81 ± 1.30 0.00 ± 0.00 0.00 ± 0.00 2.89 ± 2.77 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.16  0.00 ± 0.00 
Bacteroidia Bacteroidales Bacteroidaceae 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 28.90  0.00 ± 0.00 
Bacilli Lactobacillales Enterococcaceae 4.47 ± 6.63 0.16 ± 0.14 0.18 ± 0.22 1.57 ± 2.17 6.87 ± 10.60 0.68 ± 0.58 1.92 ± 0.72 2.55 ± 3.36 3.23  0.21 ± 0.03 





0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.06 0.00  5.10 ± 1.01 
Clostridia Clostridiales Unclassified 0.00 ± 0.00 2.97 ± 3.40 9.83 ± 10.06 0.00 ± 0.00 0.01 ± 0.01 0.00 ± 0.00 0.02 ± 0.02 0.00 ± 0.00 0.33 2.82 ± 0.23 
Clostridia Clostridiales o__Clostridiales; 
f_ 
0.00 ± 0.00 14.03 ± 11.82 0.35 ± 0.38 0.73 ± 0.88 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.09 ± 0.17 0.00  9.55 ± 0.44 
Clostridia Clostridiales Clostridiaceae 17.62 ± 15.27 1.28 ± 2.05 1.53 ± 1.92 0.35 ± 0.76 20.81 ± 
16.04 
0.45 ± 0.90 6.89 ± 9.43 0.22 ± 0.22 9.22  0.26 ± 0.05 




27.5 ± 6.86 6.16  27.39 ± 1.31 
Clostridia Clostridiales Ruminococcacea
e 
16.22 ± 7.65 45.59 ± 15.03 8.79 ± 7.48 25.54 ± 17.03 0.03 ± 0.04 0.38 ± 0.33 0.06 ± 0.06 7.11 ± 6.55 19.05  41.85 ± 0.82 





0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ±0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 9.12  0.00 ± 0.00 
Betaproteob
acteria 






















MetaCOMET ANALYSIS  
 
For each time point (3 d.p.h and 7 d.p.h), the microbiota taxa assigned per treatment group 
were compared in order to reveal a core microbiome, and potentially highlight those features 
that could be correlated with a phenotype of reduced sensitivity to Campylobacter jejuni 
infection (Figure 75).  
 
3 days post-hatch  
 
Initially, taxonomic composition of 3 d.p.h treatment group samples were compared, both 
with each other and with CMT and Aviguard® inoculum materials (Figure 76). Looking first at 
the ASVs shared only between inoculum and each treatment group (not being present in any 
other microbiota group), CMT and Aviguard® inoculum shared most common features with 
their respective treatment group (Figure 76a and b). CMT inoculum shared 100 ASVs with 3 
d.p.h CMT, 1 ASV with 3 d.p.h Aviguard®, 3 ASVs with 3 d.p.h Internal control and 0 ASVs with 
3 d.p.h External control microbiota. Aviguard® inoculum shared 0 ASVs with 3 d.p.h CMT, 27 
ASVs with 3 d.p.h Aviguard®, 1 ASV with 3 d.p.h internal control and 2 ASVs with 3 d.p.h 
external control microbiota. As such, 25.51 % of the ASVs found in CMT inoculum were found 
only in 3 d.p.h CMT microbiota and 29.35 % of the ASVs found in Aviguard® inoculum was 
found only in 3 d.p.h Aviguard® microbiota. The bacterial communities of each of the four 3 
d.p.h treatment groups were compared in order to reveal a core microbiome of 6 common 
ASVs shared between all treatment groups, with taxonomic classification of these ASVs being 
provided in Table 30. 
 
Table 30. Conserved ASV sequences found within the caecal content of birds from all four 
treatment groups at 3 d.p.h. 
Taxonomy 
Kingdom Phylum Class Order Family Genus Species 
Bacteria Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae Shigella  
Bacteria Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae   
Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae Enterococcus  
Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae [Ruminococcus] _ 
Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae   





Figure 75. Venn diagram showing ASV sequences (a) shared between specific treatment groups (b) 
specific to each treatment group from samples collected 3 d.p.h (Aviguard n=3; Ext. control n=3; Int. 
control n=3; CMT n=4). CMTInoc (n=2) denotes CMT inoculum samples while AGInoc (n=1) denotes 









Figure 76. Venn diagrams with highlighted sections showing the number of ASVs shared 
solely between the corresponding groups. 3 d.p.h treatment groups (a) CMT treated (n=4), 
(b) Ext. Control (n=3), (c) Int. Control (n=3) and (d) Aviguard® (n=3) directly compared 





















Figure 77. Venn diagrams with highlighted sections showing the number of ASVs shared 
solely between the corresponding groups. 3 d.p.h treatment groups (a) CMT treated (n=4), 
(b) Ext. Control (n=3), (c) Int. Control (n=3) and (d) Aviguard® (n=3) directly compared 








7 days post-hatch  
 
Similar to that of 3 d.p.h microbiota, 7 d.p.h treatment group microbiota community structure 
was compared between treatment group and to that of the CMT and Aviguard® inoculum 
(Figure 78). Looking first at the ASVs shared only between inoculum and each treatment 
group (not being present in any other microbiota group), as with 3 d.p.h microbiota, CMT and 
Aviguard® inoculum shared most common features with their respective treatment group 
(Figure 79; Figure 80). CMT inoculum shared 203 ASVs with 7 d.p.h CMT, 2 ASVs with 7 d.p.h 
Aviguard®, 0 ASVs with 7 d.p.h Internal control and 5 ASVs with 7 d.p.h External control 
microbiota. Aviguard® inoculum shared 2 ASVs with 7 d.p.h CMT, 23 ASVs with 7 d.p.h 
Aviguard®, 0 ASV with 7 d.p.h Internal control and 0 ASVs with 7 d.p.h External control 
microbiota. As such, 51.78 % of the ASVs found in CMT inoculum were found only in 7 d.p.h 
CMT microbiota and 25.00 % of the ASVs found in Aviguard® inoculum was found only in 7 
d.p.h Aviguard® microbiota. The bacterial communities of each of the four 7 d.p.h treatment 
groups were compared in order to reveal a core microbiome of 15 ASVs shared between all 


















Table 31. Conserved ASV sequences found within the caecal content of birds from all four 
treatment groups at 7 d.p.h 
 
Taxonomy 
Kingdom Phylum Class Order Family Genus Species 
Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae Clostridium  
Bacteria Firmicutes Bacilli Lactobacillales Lactobacillaceae Pediococcus  
Bacteria Cyanobacteria Chloroplast Streptophyta _ _ _ 
Bacteria Proteobacteria Alphaproteobacteria Rickettsiales mitochondria   
Bacteria Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium celatum 
Bacteria Firmicutes Clostridia Clostridiales _ _  
Bacteria Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae   
Bacteria Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae Shigella  
Bacteria Firmicutes Bacilli Lactobacillales Enterococcaceae   
Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillospira _ 
Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae _ _ 
Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae [Ruminococcus] _ 
Bacteria Firmicutes Clostridia Clostridiales Lachnospiraceae Clostridium  
Bacteria Firmicutes Clostridia Clostridiales Peptostreptococcaceae _ _ 
Bacteria Firmicutes Clostridia Clostridiales Ruminococcaceae   







Figure 78. Venn diagram showing ASV sequences (a) shared between specific treatment groups (b) 
specific to each treatment group (all treatment groups n=10) from samples collected 7 d.p.h. CMTInoc 








Figure 79. Venn diagrams with highlighted sections showing the number of ASVs shared solely 
between the corresponding groups. 7 d.p.h treatment groups (a) CMT treated, (b) Ext. Control, (c) Int. 







Figure 80. Venn diagrams with highlighted sections showing the number of ASVs shared solely 
between the corresponding groups. 7 d.p.h treatment groups (a) CMT treated, (b) Ext. Control, 
(c) Int. Control and (d) Aviguard® treated (all treatment groups n=10) were directly compared 



















To identify which of the ASVs identified may have been differentially represented between 
our sample treatment groups, LEfse differential abundance analysis was applied. Samples of 
CMT and Aviguard® inoculum were not included in this analysis because we expected a lot of 
ASV changes between inoculum material and treatment group samples. LEfse was applied 
separately to 3 d.p.i and 7 d.p.i treatment group microbiota at family taxonomic level. While 
no differentially represented taxa were identified in 3 d.p.h treatment group microbiota, 7 
d.p.h microbiota analysis returned one bacterial family as being a discriminative biomarker - 
Ruminococcaceae (p < 0.05) (Figure 81). Ruminococcaceae was significantly more abundant 
























Figure 81. LEfSe results for 7 d.p.h chicken caecal samples (a) histogram of LDA score (log10) derived for 
biomarkers differentially expressed between treatment groups, (b) Relative abundance data for the detected 






Having exhibited in Chapters 3 and 4 that CMT inoculation has the potential to hinder C. jejuni 
infection of experimental broiler chickens, it was important to develop a mechanistic 
understanding of the biological rationales underlying this. Bacterial competitive exclusion 
within the GIT presents an effective approach in limiting pathogenic infection of live poultry 
in an array of published literature (Nakamura et al. 2002; Al-Zenki et al. 2009; Nurmi & Rantala 
1973), examining the microbial communities of our experimental chickens posed an 
interesting line of scientific enquiry. Caecal samples were selected for all downstream analysis 
as oppose to other commonly used faecal and ileal samples. Microbial analysis of faecal 
material has been reported to give less accurate GIT representation compared to caecal 
microbiota, with the caeca also being the primary site for C. jejuni colonisation and harbouring 
the highest microbial cell density of the chicken GIT (Oakley et al., 2014). High representation 
of caecal sampling within avian microbiome studies allows this research to be timely and 
comparable to much of that publicly available (Seargent et al., 2004; Zhu &joergen, 2002).  
 
When considering bacterial communities of the chicken microbiota, age is one of the most 
influential factors in the shifting community composition over time (Richards et al., 2019; 
Shang et al., 2018). Although 3-day old chicks treated with CMT inoculum showed generally 
higher ASV counts, there was no significant difference in microbial richness between the 
caecal microbiota according to treatment group communities at this early age. While chicken 
microbial communities are established as early as one day of age, GIT microbial richness is 
widely shown to increase during the first weeks of life (Kers et al., 2018; Oakley et al., 2014). 
The increased ASV count for 3-day old Aviguard®, but more strikingly CMT, treated groups 
may be relatively insignificant in phenotype within the transient 3-day early microbiome but 
could be essential in driving successional microbiota composition changes establishing a 
prematurely stable microbiota.  
 
By 7 days of age, Aviguard® and CMT treatment had significantly altered the microbial 
taxonomic composition of the chick microbiota compared to that of their Internal and External 
control counterparts. This shift from an intestinal microbiome of low diversity to a more 
complex and diverse microbiome in the first week post hatch has previously been identified 
by Ballou et al. (2016) when identifying how early exposures of a chick can later influence 
development of the chick microbiome. Although microbial community diversity increased for 




and Aviguard® treated birds compared to all other groups. While also showing significant 
increase in microbial diversity, these taxons were most evenly distributed within the samples 
of 7 d.p.h CMT treated chicks.  
 
Having already identified an increase in bacterial diversity following introduction of complex 
microflora preparations, be it Aviguard® or CMT, it was important to identify the taxonomic 
groups underlying this shift in caecal microbial community. A wide source of literature 
presents early chick microbiota as being primarily Proteobacteria Phyla (encompassing 
Betaproteobacteria and Gammaproteobacteria at Class level), with the lesser addition of 
Bacteroidetes (Class Bacteroidia) and Firmicutes (Class Clostridia and Bacilli) (Ballou et al., 
2016; Shang et al., 2018). The function of this early compositional characteristic is still 
undefined. Successional changes in the gut microbiome of a chick as it ages shows an increase 
in Firmicutes (Kers et al., 2018; Ocejo et al., 2019; Richards et al., 2019), namely of Clostridia 
taxons, with this being appreciably larger in adult chickens. Bacteroides and Preoteobacteria 
decrease in the relative composition of adult caecal microbiota while Actinobacteria taxons 
show steady incline (Oakley et al., 2014). Microbiota from both 7 d.p.h CMT and Aviguard® 
treated chicks principally consisted of Firmicutes taxons, compared to that of 7 d.p.h non-
treated Internal and External control groups. Increased Firmicutes representation, particularly 
evident in CMT treated birds, could further indicate how the introduction of a complex 
microbiota has potentially induced ecological primary succession to for a stable, less naïve 
microbial community in these groups.  
 
Collected from the caeca of 7-week old chickens, the CMT inoculum material was almost 
exclusively composed of Firmicutes taxons. Comparing CMT inoculum with that of 7 d.p.h CMT 
treated chick microbiota, composition of bacterial taxonomic classes was somewhat 
comparable between the two communities. In their work on broiler chicken commensal 
microbial communities, Lan et al. (2005) state how microbial communities are often fully 
established from 6 - 7 weeks of age within the growing broiler chicken, and so the CMT 
microbial communities transplanted from these adult chickens to newly hatched chicks 
represented what should be a relatively stable ‘adult’ chicken microbiome. Moreover, 
Kubasova et al. (2019) showed, while investigating the effects of contact between newly 
hatched chicks and adult hens that chicks raised in the presence of adult birds quickly 
developed a caecal microbial community similar to that of the adult hens within a week of 




the microbiota from both 7 d.p.h Internal and External control groups. With neither having 
received microbial stimulation from a more complex external microbial inoculum, both 
control groups showed caecal microbial compositions of large Proteobacteria abundance.  
 
Although similarly being comprised predominantly of Firmicutes, the microbiota from birds 
treated with Aviguard® inoculum shows comparably lower Firmicutes abundance than that of 
CMT treated chicks, a shift associated concomitantly with an increase in Actinobacteria and 
Proteobacteria. Work from Kubasova et al. (2019) reports analogous enrichment of 
Actinobacteria, with the addition of Bacteroidetes in Aviguard® treated chicks. Although 
Aviguard® represents a complex community of bacteria, it presents little in the way of ‘natural’ 
complexity compared to that of primary CMT inoculum material. Compositionally, Firmicutes 
are represented to an extent almost half of that in CMT inoculum, with Bacteroidetes and 
Proteobacteria comprising a significant proportion of the remaining inoculum material. With 
these bacterial classes largely associated with a more ‘naÏve’ chicken microbiota, potential 
notion could be applied that Aviguard® treated microbiota encompasses a richness and 
diversity more developed than that of the both control groups but less sophisticated than that 
of birds receiving CMT inoculum. It can also be postulated that, since Aviguard® inoculum 
shared only 25.00 % of its taxonomic composition solely with its respective treatment group, 
compared to 51.78 % for that of CMT inoculum, a large proportion of the Aviguard® inoculum 
may not be able to form an established and preserved microbial community when transferred 
directly to a live chicken. As such, the potential environmental adaptation during ex-vivo 
fermentation may alter the expressed phenotype within the avian gut environment and 
potentially limit the beneficial impact of Aviguard®, and similarly derived competitive 
exclusion formulations. 
 
 Recalling the dissimilarities observed in the microbiota of chicks receiving prophylactic CMT 
and untreated control chicks, the potential implication of this microbial shift could be related 
back to the susceptibility of our experimental treatment groups to subsequent C. jejuni 
infection as described in previous chapters. With reduced susceptibility to C. jejuni 
colonisation and transmission observed in CMT treated birds within this project, it is plausible 
to infer that the change in microbiome resulting from at-hatch CMT inoculation could be one 
explanatory factor for this reduction in infection and subsequent transmission. While still 
poorly understood, the influence of CE is widely heralded as one explanation of CMT action 




ecological phenomenon of colonisation resistance is a well-known CE mechanism and could 
be applied to the disrupted colonisation dynamics of C. jejuni in birds treated with CMT. 
Pickard et al. (2017) describes how formation of a stable gut microbiota may inhibit the 
subsequent invasion and expansion of potentially pathogenic bacterial taxa. With this work 
going on to connect an immature, infantile bacterial community with reduced protective 
ability, associations can be made between the naïve microbiome of our experiment control, 
and to a certain extent Aviguard®, chicks and their increased susceptibility to C. jejuni infection 
compared to chicks receiving CMT (Pickard et al., 2017). This may also prove to exemplify how 
it is critical for CMT intervention strategies to be applied immediately post hatch to ensure 
establishment of the desired microbial community. Due to the vast complexity of interactions 
within the GIT microbiome alongside host-microbiome interactions, unearthing the exact 
rationale behind this protective effect is still to be achieved, however, direct competition for 
the occupation of both physical and nutritional niches has been postulated (Pickard et al., 
2017). Persistent Campylobacter infection of the avian intestinal tract is heavily reliant on 
interaction with the avian intestinal mucosa (Hermans et al., 2014). Administration and 
subsequent establishment of a complex bacterial community to a newly hatched chick offers 
commensal adherent bacteria a distinct advantage in colonisation of the gut mucosal surface, 
forming a microflora that already occupies the adhering niches essential during later C. jejuni 
infection (Lan et al., 2005). This competition for adhesion site is often described in conjunction 
with competition from nutrient and physical space within the microbiota, all being likely 
confounding factors that can be applied here (Lan et al., 2005).  
 
Upon entry to the CMT enriched GIT, invading C. jejuni will not only have to encounter 
increased adhesion site competition from an established, native, microbial community but 
also potentially inhibitory metabolites produced by the bacterial taxa of such a community. 
From the bacterial community that comprises the broiler chicken microbiota, one of the most 
notable terminal metabolites produced is butyrate (Onrust et al., 2015). Butyrate is a SCFA 
produced in the GIT during bacterial digestion of carbohydrates and dietary fibre (Guilmeau 
et al., 2013). Having been identified for beneficially affecting chicken growth and intestinal 
integrity following dietary supplementation, intestinal butyrate has long since been linked 
with the control of important avian pathogens including Salmonella Enteritidis (Onrust et al., 
2015) and enhancement of anti-inflammatory properties. Increasing in caecal dominance with 
increasing bird age, Firmicutes commonly comprise over 80% of the adult caecal microbiota 




Lachnospiraceae and Ruminococcaceae are known efficient butyrate producers (Onrust et al., 
2015). When present in a sufficiently high concentration, Van Deun et al., (2008) has shown 
butyrate to have a strong bactericidal effect on C. jejuni in-vitro. Coupled with the benefit to 
intestinal epithelial structure and anti-inflammatory influence, a similar inhibition of butyrate 
on C. jejuni may be observed as that long described for Salmonella (Nurmi & Rantala 1973). 
Analysis of the microbiota of our experimental chickens following CMT treatment shows 
significantly increased presence of the butyrate producing Ruminococcaceae family taxons to 
levels of that seen in CMT inoculum from adult chickens. This leads to the inference that CMT 
inoculation develops the intestinal microbiota, creating a caecal environment highly rich in 
butyrate and, as a result, considerably less hospitable for the invading C. jejuni.  
 
In the absence of experimental microbial transfer at hatch, Proteobacteria taxons continued 
to dominate the microbial communities of 7-day old chicks. Of the Proteobacterial Phyla, 
Enterobacteriaceae was almost the sole bacterial Class in our treatment group microbiota. 
Interestingly, Winter et al., (2014) has explored the impact of Enterobacteriaceae on the 
human GIT, relating an expansion in taxa abundance of this facultative anaerobe to intestinal 
dysbiosis. Additionally, a bloom of Enterobacteriaceae is commonly a sequential event 
evolving from enteric pathogenic infection in mice. In relation to the broiler chicken, the FSA 
has postulated that the Enterobacteriaceae may be used as a crude indicator of broiler carcass 
Campylobacter contamination, with levels of intestinal contamination of both bacterial taxa 
being analogous (Corry et al., 2017). Corroborated by Sakaridis et al., (2018), there is an 
undeniable correlation between high Campylobacter colonisation and an increased relative 
abundance of Enterobacteriaceae in the avian caeca. This same research raised an important 
theory on the temporality of causation, in that Enterobacteriaceae may create an intestinal 
environment beneficial for Campylobacter, or vice versa. With our microbiota samples 
showing a clear indication that higher Enterobacteriaceae abundance, shown here in both 
Internal and External control treatment groups, might be associated with subsequent 
susceptibility to Campylobacter infection, this research may go some-way in elucidating a 
resolution (Sakaridis et al., 2018).  
 
It is undeniably clear from this research that the intestinal ecosystem of the broiler caecum 
contains a vast and diverse bacterial community, with each taxon performing different 
functions to influence host growth, performance and susceptibility to infection. The dynamic 




susceptibility proves that manipulation of the caecal microbiome is an essential facet in any 
C. jejuni control strategies. Not only may a CMT rapidly and prematurely develop the avian 
microbiome, it may also outcompete currently available competitive exclusion products 
through the introduction of an ‘adult’, complex microbiome not achievable through their ex-
vivo culture.  Future research might place interest in the intriguing portion of unclassified 
bacterial taxa observed primarily within both CMT inoculum and the microbiota of CMT 
treated chicks at 7 d.p.h. A complex community of remarkable bacterial abundance 
elucidating the complete catalogue of components inhabiting the chicken microbiota remains 
elusive. As such, a large portion of unknown bacterial taxa, often referred to as ‘microbial dark 
matter’ continues to form the backbone of microbiome research in both human and 
veterinary models. A current limitation in the use of reference-based analysis of next 
generation sequencing output is the fundamental lack of ‘completeness’ in even the most 
comprehensive of reference catalogues. As such, these techniques are largely constrained by 
the databases available at the time of data analysis which may result in the oversight of 
taxonomic groups with crucial biological importance.  Such a limitation is acknowledged 
within the research presented here. Further to this, 16S rRNA gene sequencing techniques 
have long been hampered by introduction of biases from PCR artefacts such as, formation of 
chimeras and preferential amplification of specific bacterial taxa over other (Sze & schloss, 
2019). While little can be done to limit such factors, implementation of whole genome 
sequencing as a progression of this work would go some way in minimising the effect on our 
data set. We would also gain vital functional insight into these bacterial groups, alongside 
profiling of archaeal, viral, protozoan and fungal communities not assessed here.  
 
In addition to the bead-beating techniques and specific selection of DNA extraction kit used 
here, all future work should incorporate the use of a well-defined microbial standard 
community. These mock communities of gram-negative and gram-positive bacterial 
communities allow for more precise optimisation and validation of cell lysis processes during 














































GENERAL DISCUSSION  
 
Absence of obvious pathological clinical indication makes C. jejuni infection within commercial 
poultry of limited animal welfare concern (Alpigiani et al., 2017). However, its continued 
establishment as a causative agent for global human campylobacteriosis has made C. jejuni a 
persistent risk to public health (Rushton et al., 2019). This project aimed to build on the 
current understanding of Campylobacter infection within the broiler chicken to gain further 
insight into the infection biology of Campylobacter alongside the long-term Immune reaction 
to infection within the commercial broiler chicken. Using this understanding we aimed to 
assess the efficacy of the otherwise unexplored concept of caecal transplantation within the 
broiler chicken in reducing Campylobacter infection at flock level.  
 
Since the immune response to Campylobacter infection within the broiler chicken is yet to be 
fully defined, a multifaceted approach to its study throughout Chapter 2 was employed, 
utilising both bacteriological and immunological techniques. From point-of-inoculation at 3 
weeks post-hatch, colonisation of the intestinal tract with C. jejuni was that of rapid and 
sustained establishment until common point-of-slaughter, largely reflecting that described in 
work by (Humphrey et al., 2014; Smith et al., 2008). This work provides support to the 
generally accepted notion of C. jejuni colonisation showing greatest burden within the caecal 
crypts, but sporadic presence elsewhere within the GIT (Hermans et al., 2011). Median 
bacterial loads at point of slaughter exceeding 7.6 log CFU per g caecal content in both studies 
of Chapter 2, and as such, would represent a significant source of contaminating 
Campylobacter cells to both the individual and associated flock broiler carcasses during 
slaughter and processing (Berrang et al., 2004). While no chickens associated with this study 
showed any signs of malaise, recovery of C. jejuni from systemic tissues of the chicken within 
both experimental studies of Chapter 2 strongly support earlier indication that C. jejuni is able 
to traverse the intestinal mucosal barrier and cause systemic infection. This systemic C. jejuni 
propagation into tissues distant from the intestinal tract, including blood, lung, spleen, liver 
and heart has been reported throughout available literature sources (Knudsen et al., 2006; 
Cox et al., 2006; Young et al., 1999). While this area of research has an underlying dogma 
associated with a lack of definitive description of C. jejuni translocation across the intestinal 
epithelial barrier, a number of theories are continually identified in published literature. The 
majority of scientific reports centre upon C. jejuni-induced intestinal epithelial barrier 
disruption – particularly due to alterations of in the proteins forming tight-junction barriers 




has been described for later stages of infection, similar to findings seen here. Epithelial barrier 
permeability could be further exaggerated by findings of Connell et al (2013), who 
demonstrated cadherin cleavage alteration to adherin cellular junctions. Transcytosis through 
specialised M cells is a well-known mechanism for passage across the intestinal epithelial 
barrier for other enteric pathogens, and as such has been linked as a potential mechanism for 
C. jejuni systemic invasion of the chicken (Backert et al 2013). However, reports of such 
interaction for C. jejuni in the chicken are scarce and so the lack of consensus understanding 
in this field of research remains. This is of particular concern with chicken liver representing a 
common protein source globally, acting as a poorly described vehicle for human ingestion of 
C. jejuni (Lanier et al., 2018).  
 
Since the understanding that C. jejuni is not simply a commensal within the broiler chicken 
has become ever-more accepted, increasing bodies of research now exist that focus on the 
immune response of the chicken to infection. However, such work is often restricted to early 
time points post infection. Using post-mortem samples of caecal and caecal tonsil tissues 
collected throughout the four-week period post-infection, Chapter 2 illustrates the induction 
of an innate immune response within both tissues. Two days following initial exposure of birds 
to C. jejuni, both tissues exhibited the induction of IL-1β, IL-6, IL-17A and CXCLi2, all known 
pro-inflammatory signals. Early upregulation of such transcripts is also illustrated in the 
findings of Humphrey et al., 2014 and Smith et al., 2008. Elevation of these innate pro-
inflammatory regulators remains until 14 days post infection within caecal tissues, however, 
this is accompanied by upregulation of signals associated with regulatory (TGFβ4) and Th2 (IL-
4) responses from as early as 7 days post challenge. By 7 days post challenge, caecal tonsil 
tissues showed upregulation of only mediators, with the addition of IL-10. While IL-10 and 
TGFβ4 play central roles in regulating the inflammatory response to infection through T 
regulatory lymphocyte (Treg) stimulation, IL-4 is a potent mediator in humoral immunity 
(Humphrey et al., 2014). As such, it might be postulated that the immunoglobulin stimulation 
seen within serum IgY and IgM of our experimental studies might be driven by this IL-4 
expression. These immunological findings alongside associated in vivo infection phenotype, 
provide a valuable understanding on how the avian immune system responds to 
Campylobacter infection, and forms a framework supplementing other research from which 





Common to all in vivo studies within this project, inoculation of experimental animals was 
conducted at 21 days post-hatch. Employment of such design was largely on the basis of 
understanding that prevalence of Campylobacter infection within the commercial broiler flock 
incurs an age-dependent lag phase of 14 – 21 days post-hatch (Stern et al., 2001; Conlan et 
al., 2007; Conlan et al., 2011). Use of this administration time-point minimised the potential 
influence of these lag-phase determinants on the infection biology characteristics observed 
and is a protocol previously described in literature (Humphrey et al., 2014; Chaloner et al., 
2014). In itself, this ecological characteristic of Campylobacter infection within the chicken has 
been hailed as a ‘window of opportunity’ for the implementation of intervention strategies 
aimed at reducing or eliminating C. jejuni burden within the commercial poultry flock.  
 
While countless control strategies have been postulated to mitigate Campylobacter infection 
within the commercial broiler chicken, there remains no effective method of intervention in 
place (Lin., 2009). Conceivably the most important factor associated with the limitation of 
human exposure to Campylobacter infection would be to minimise broiler carcass 
contamination, with Meunier et al., 2016 highlighting colonisation at primary production as 
crucial to this. This production stage can be further distinguished into two successional points 
at which intervention strategies could be applied, those acting as preventative measures 
which aim to reduce likelihood of initial colonisation and those acting as colonisation 
reduction methods that aim to reduce or eliminate an already established infection (Ghareeb 
et al., 2012). Derived from this understanding, multiple approaches to Campylobacter control 
on the commercial broiler farm have been suggested and assessed, with the rationale and 
efficacy of each being described in Chapter 1. While increases in on-farm biosecurity practises 
has long been heralded as an effective control of Campylobacter within the poultry industry, 
recent understanding is that this intervention may have reached saturation point in regard to 
efficacy without further understanding of risk factors associated with infection (Lin., 2009). 
Although of a different nature, vaccination strategies are accompanied by their own 
associated limitations, with the restricted window of functional application within the 
commercial broiler chicken largely hampering commercial realisation (Pasquali et al., 2011).  
 
As our understanding of the importance of the intestinal microbiota on the health and welfare 
of its host, increasing interest is being placed onto the use of prophylactic microflora cultures 
as an antibiotic-free medium in preventing or reducing the frequency of Campylobacter 




complexity, such as probiotic preparations have been developed in abundance, however their 
effectiveness within the poultry industry remains controversial (Clavijo & Flórez, 2018). With 
relatively little in the way of taxonomic diversity, these products show tendency toward only 
transient modification of the host microbiota only in the periods after consumption (Ciorba., 
2012). Of conceivably more benefit are complex microflora products, with these being either 
Competitive Exclusion (CE) products, or the introduction of entire donor microbiota through 
Faecal Microbiota Transplantation (FMT) procedures. While CE products such as Aviguard® 
have long been used in poultry production, with mixed success, FMT has largely been confined 
to human based application in the treatment of Clostridium difficile infection (Aas et al., 2003; 
Agrawal et al., 2016).While the entirety of the avian gastrointestinal tract comprises an array 
of microbial taxonomies and communities, it is the caecal crypts that contribute greatest to 
this bacterial abundance, while also being the primary site of C. jejuni colonisation. As such, 
for this project, Caecal Microbiota Transplantation (CMT) procedures replaced those of the 
more commonly known FMT, based on the understanding the both concept and function is 
will be largely transferable.  
 
 
Until recently, FMT use in both human and veterinary medicine was not subject to widespread 
application, and consequently, continues to lack formal guidelines for standard practice of 
donor and recipient selection, screening of microbiota preparation and administration 
(Borody & Khoruts, 2012). This is particularly true for use of CMT within poultry, whereby this 
novel application has previously been overlooked. Using consistent methodologies regarding 
CMT preparation and administration, this project has been able to produce reproducible 
protection of broiler chickens against experimental C. jejuni infection. Protocols defined here 
could aid the development of standardised guidelines for the application of CMT within the 
chicken.  
 
With experimental study replicates of Chapter 3 and Chapter 4 largely confirming potential 
efficacy of CMT practices in the prevention of C. jejuni colonisation and establishment at flock 
level, we were subsequently able to consider both the comparable level and mechanism of 
this protection against a commercial CE product in both Chapter 4 and Chapter 5. 
Phenotypically, prophylactic administration of Aviguard® preparation showed limited efficacy 
in improving host susceptibility to C. jejuni infection, with no obvious reduction in infection 




protective success of Aviguard® has been described throughout research, this is primarily 
described for Salmonella based infection models and as such, limited data exists on the 
efficacy of such product against C. jejuni within the broiler chicken (Hofacre et al., 2000; 
Ferreira et al., 2003). With this research, we can begin to unearth how Aviguard® preparations 
might influence the unique infection biology characteristics of C. jejuni within the broiler 
chicken.  
 
Both FMT and CE preparations are, theoretically, used on the basis of introducing a complex 
microbial environment to the recipient, with the aim of establishing the early colonisation of 
a ‘normal’ protective microbiota (Wagner et al., 2006). This is particularly pertinent within the 
poultry industry, whereby a lack of parental contact post-hatch and general environmental 
sterility might dampen the development of the early pioneering microbiota (Videnska et al., 
2014). Beginning immediately post-hatch, the early development of the chicken microbiome 
is a dynamic process of rapid successional changes, with bacterial taxonomic composition 
shifting at an almost daily rate (Gilbert et al., 2010; Juburg et al., 2019). It is during this period 
post-hatch that the intestinal microbial community is thought to be most susceptible to 
modulatory interventions (Juburg et al., 2019). In vivo data presented in Chapter 3 supports 
this understanding, with birds receiving CMT administration at 7 days post-hatch showing 
marked reduced susceptibility to C. jejuni infection compared to similar studies whereby CMT 
had been delivered early post-hatch. With widespread indication that these bacterial 
colonisation characteristics are primarily the effects of direct or indirect competition, or 
competitive exclusion, between resident and colonising taxa, Chapter five used 16S ribosomal 
RNA (rRNA) sequencing tools as a means of uncovering the influence of such theory on the in 
vivo results already attained. With the upsurge in use of Next Generation Sequencing (NGS) 
tools such as 16S rRNA gene sequencing over the previous decade, an increase in 
understanding of the compositional dynamics of the chicken microbiome has become evident 
throughout literature (Richards et al., 2019; Schokker et al 2014; Connerton et al., 2018).  
 
Findings within Chapter 5 for caecal samples obtained 3 days post hatch (3 d.p.h) are 
supportive of conclusions made in the work of Richards et al., (2019) and Ballou et al., (2016), 
whereby the early microbiome of the commercial broiler chicken is characterised by a low 
taxonomic diversity and predominated by Enterobacteriaceae (phylum Proteobacteria). 
Considering next the birds of this age treated with either CMT or Aviguard® preparation, both 




and predomination of Clostridiales (phylum Firmicutes). Successional development of the 
caecal bacterial communities by 7 d.p.h of our study had increased Lachnospiraceae 
abundance within the untreated chicken microbiota, with associated decline in 
Enterobacteriaceae. This developmental trait of the avian intestinal microbiome is well 
characterised within available literature and is thought to continue at similar trend until 
approximately 14 days post-hatch whereby Firmicutes taxons will predominate at over 90 % 
(Ocejo & Hurtado, 2019; Videnska et al, 2014). While the exact function of this early 
Enterobacteriaceae dominated microbiota remains unclear, Richards et al., (2019) confirms 
its relatively short-lived occurrence, with peak relative abundance between only 0 – 3 days 
post-hatch. Treatment of chicks with either of the studied microflora preparations (CMT or 
Aviguard®) appeared to rapidly accelerate this progression away from Enterobacteriaceae 
toward Firmicutes taxons, with this being particularly apparent for CMT treated birds. By 7 
d.p.h, Ruminococcaceae was the predominant taxa within the caecal microbiota of CMT 
treated birds. With taxonomic establishment of Firmicutes to such high relative abundance 
usually occurring appreciably later in stages of development within the broiler chicken 
microbiome, it could be perceived that CMT administration is causing premature maturation 
of the broiler microbiota to that of an adult chicken. Composition of the caecal content of 
CMT treated birds was largely emulated in that of the CMT inoculum, a facet not achieved for 
Aviguard®. This might give further support to the understanding that microflora preparations 
not achieving the same taxonomic complexities as seen within whole caecal samples may 
provide only transient microbial modulation.  
 
While much of the protection derived from many microflora preparations is attributed to this 
competitive exclusion principle, stimulation of the host immune system has also been widely 
theorised as a supplementary mechanism (Ajuwon, 2015). In-vitro models have commonly 
been utilised as a means of assessing the interactions between pathogen and host (Barrila et 
al., 2018).  While somewhat reductionist in approach, these in-vitro models can draw 
attention to underlying mechanisms that could be conceptually applied as a basis for further 
in vivo experimental design. Contrary to the adhesion and invasion characteristics identified 
for Campylobacter infection in vivo, Chapter 4 states how both S. Typhimurium and C. jejuni 
were effectively about to invade avian intestinal epithelial cell monolayers in-vitro. This 
disparity in invasive capabilities of C. jejuni to invade avian intestinal cells between in vivo and 
in-vitro systems has previously been described Byrne et al., 2007. While pre-treatment of cell 




invasion, pre-treatment with Aviguard® filtrate showed only protection against S. 
Typhimurium invasion. While the exact mechanisms behind this effect are not fully 
understood, the sterile filtration of this inoculation material to remove bacterial molecules 
would suggest that secreted metabolites, such as short chain fatty acids, from 
Lachnospiraceae and Ruminococcaceae show influence on avian epithelial cells and invading 
pathogenic organisms to prevent infection. Such an influence may be dictated by induction of 
early pro-inflammatory host responses that, in turn, induce premature immunomodulation 
through regulatory cytokine cascades. Particular genus of Rumminococcaceae, including 
multiple Faecalibacterium prausnitzii strains, experienced limited scientific exploration 
largely due to difficulty in culture of this oxygen-sensitive species. More recently, 
human medicine and in turn, veterinary medicine, have dedicated a wealth of 
investment in understanding Faecalibacterium prausnitzii due to its observed anti-
inflammatory effects against human colitis (Sokol et al., 2018). Qiu et al (2013) 
observed that both cellular and supernatant components of F. prausnitzii suspensions 
were are to provide a positive environment for T-reg and IgA production, likely 
through stimulation of cytokines including TGF-ß1 and IL-10.  
 
While the results seen throughout chapters 3-5 indicate that the at-hatch delivery of an adult 
chicken microbiome to chick has potential reducing susceptibility to C. jejuni infection 
spanning the life-span of the commercial broiler, consideration must be applied to the safety 
aspects associated with its application. While this research goes some way in outlining how 
CMT therapies can be applied to the commercial broiler chicken, and indeed how this might 
induce stimulatory immune responses and modifications to the intestinal microbiota, there is 
need for continued refinement before confident large-scale application aimed at reducing 
susceptibility to Campylobacter infection. It should also be noted that, although apparently 
beneficial in protection against C. jejuni colonisation, CMT administration was also correlated 
with a negative impact on final bird body weight. This finding has not been highlighted in 
previous probiotic research for the chicken and so may be specifically associated with CMT 










Table 32. Table of key project findings 
Conclusion Reasoning Location of 
findings 
 
C. jejuni is able to form a rapid and 
prolonged colonisation of the broiler 
chicken GIT 
C. Jejuni was present within the caecal content 




Once colonised, high C. jejuni load persisted until 
point of slaughter at 28 d.p.i (49 d.p.h) 
Identification of C. jejuni within ileal regions Chapters 2, 3 & 4 
 
C. jejuni is able to colonise beyond 
the chicken GIT 
Detection of C. jejuni within liver and spleen tissue 
samples from infected chickens 
Chapters 2, 3 & 4 
Invasive ability of C. jejuni strains using in-vitro 
avian intestinal cell models 
Chapter 4 
GIT tissues exhibit early pro-
inflammatory and Th-17 responses 
to C. jejuni infection  
Early upregulation of IL-1β, IL-6, IL-17A and CXCLi2 
in caecal and caecal tonsil tissues during early 
infection time points (2 d.p.i) 
Chapter 2 
Prolonged C. jejuni challenge causes 
subsequent induction of regulatory 
responses 
Subsequent induction of IL-10 and TGFβ4 in caecal 
and caecal tonsil tissues during later stages of 




CMT derived from 'adult' broiler 
chicken microbiota is effective in 
reducing susceptibility of broiler 
chickens to experimental C. jejuni 
infection 
Reductions in flock shedding of C. jejuni within 
flocks treated with CMT preparations 
 
 
Chapters 3 & 4 
Reduced caecal burden of C. jejuni within birds of 
CMT treated flocks  
 
Percentage invasion of C. jejuni into avian 
intestinal cell lines in-vitro was reduced following 
prophylactic incubation with CMT filtrate 
Chapter 4 
Efficacy of CMT treatment is reliant 
on its administration to an early, 
naïve chick microbiota 
Administration of CMT to chicks at 7 d.p.h 
marginally disrupted C. jejuni flock transmission 
and showed no influence on caecal burden at 





Administration of CMT to newly 
hatched chicks modulates the caecal 
microbiota, creating a bacterial 
community more representative of 
an 'adult' chicken microbiota 
Early caecal content of CMT treated chicks shows 
considerably higher relative abundance of 
Firmicutes taxons compared to caecal content of 
untreated chicks, being predominantly 
Proteobacteria 
Chapter 5 
Increased representation of Ruminococcaceae 
within the caecal content of CMT treated chicks 
7 d.p.h 
Increased frequencies of observed ASVs within 
caecal content of CMT treated birds compared to 
other treatment groups 
CMT shows more taxonomic 
richness compared to Aviguard® 
preparation 
Increased number of ASVs identified within CMT 
preparation material compared to that of 
Aviguard® preparation  
Chapter 5 
CMT might be better able to cause 
prolonged modifications to the 
caecal microbiota than commercial 
CE products 
CMT preparation and caecal content of CMT 
treated chicks at both 3 & 7 d.p.h showed 
considerably more uniquely shared ASVs than seen 







STUDY LIMITATIONS  
 
Description of study limitations has been provided throughout this thesis in the discussion 
pertaining to each chapter. Crucial to the reliability of the results gained from in vivo 
experimental protocols, was use of a sufficient number of experimental animals per 
treatment group. A continued core limitation to this project was the ability to obtain 
expected treatment group sizes from eggs hatched within our experimental unit. Although it 
is difficult to ascertain exact causes of the reduced hatchability rates observed within a 
number of the experimental trials of this project, potential cause could lie with a low egg 
viability or exposure of eggs to incubation conditions that do not meet those required by the 
developing embryo. While not directly impacting the outcome of the associated 
experimental trials, treatment group sizes of lower magnitude might reduce the general 
power of the study. Confounding this, drawing accurate comparisons between treatment 
groups of differing sizes allows for introduction of bias into any conclusions drawn. 
Stemming from this, it would have been of perceivably greater importance to provide larger 
numbers of samples submitted for 16S rRNA per treatment groups, per sampling timepoint. 
This would also allow for increased sampling time points between hatch and C. jejuni 
infection potentially unearthing crucial stages in microbiota development. Increased 
sampling magnitude here could generate datasets better able to identify caecal microbiota 
alterations associated within specific therapy. Processing of such microbiota samples would 
also have gained a greater credibility from the inclusion of microbial mock communities to 
control for potential deleterious effects of DNA extraction techniques on certain bacterial 
communities.  
 
The ability to accurately assess the immunomodulatory effects of CMT might also be limited 
by the use of in vitro cell line monolayers within this project. While use of 2D cell monolayers 
are a commonly utilised tool in understanding the potential interactions between host cells 
and external stimuli, the in vivo relevance of these studies remains somewhat restricted. It 
has often been suggested that these cell models do not comprehend the complexity of living 
physiological systems and so are unable to accurately reflect a true biological picture 
(Langhans., 2018). Of further consideration should be the use of a more comprehensively 




infectious challenge. This would provide the results gained here a greater degree of biological 
relevance.  
 
Although undeniable that the administration of CMT at point-of-hatch resulted in biological 
manipulation of the avian intestinal tract, it is conceivable that the processing of CMT material 
following collection could be modified to reduce potential loss of oxygen-sensitive microbial 
species. Use of anaerobic workstations and pre-reduced diluent to prepare such material 





Experimental data gained within this project provides insight into how the broiler chicken 
immune system might respond to long-term Campylobacter colonisation. To develop in-depth 
understanding of this complex host-microbe interaction, data such as that obtained here can 
be collated with previous work focused on early innate responses to generate explanatory 
statistical models of interdependent immunological systems (Reid et al., 2016).  
 
 
With 16S rRNa sequencing tools heralding useful insight into how CMT and Aviguard® might 
influence patterns of microbial taxonomic community assembly within the broiler caecum, 
this project perhaps lacked further understanding in the functional outcomes of these shifts. 
Metabolomic tools might provide a useful means of assessing which, if any microbial 
metabolites might be differential represented within CMT treated birds, how this might be 
reflective of the caecal microbial community, and finally, how this might influence 
susceptibility to intestinal disease and dysbiosis. Additionally, the extensive use of whole-
genome sequencing as oppose to simply 16S rRNA tools would allow for not only deeper 
functional insight into the bacterial components of this environment, but also archaeal, 
fungal, viral and protozoan microbial groups. Using whole genome sequencing in this way 
would also allow for de novo taxonomic assignment, reducing researcher reliance on 
reference databases and thus allowing for the potential identification of novel species and 
strains previously overlooked. Such techniques could be applied in a regular fashion following 
CMT administration to provide a more comprehensive understanding of successional 




manner could also be used to create a more defined catalogue of the exact components found 
within the CMT inoculum material.   
 
Early work presented throughout this project has provided weight to the reproducible 
protective effect of CMT against Campylobacter within the broiler chicken. However, to allow 
us to refine its use as a viable prophylactic measure we must understand how we can tailor 
its use to complement modern day poultry farming practices. Further work into the efficacy 
implications of route, processing technique and timing of CMT administration could enable 
this comprehension. Such in vivo research should also incorporate an increased frequency of 
caecal swabbing following C. jejuni infection to gain a more consistent idea of infection 
dynamics within this replica-flock system. Any work in this regard should first determine the 
limit of detection for such techniques for improved accuracy. With products such as Aviguard, 
tested here, purporting maximal efficacy for prevention of colonisation from Salmonella 
species as oppose to Campylobacter  species, extension of current protocols to a wider range 
of enteric pathogenic bacterial taxa might increase the scope of CMT protocols within the 
poultry industry. However, to maximise this potential, all work should consistently and 
accurately assess impacts of treatment on both feed consumption and total body weight.  
 
 
With relatively limited information regarding the cell line utilised within the in vitro work 
described here, potential use of a widely described cell line (such as the macrophage HD11) 
might offer more viable results. To generate a more biologically relevant data set regarding 
immune response following CMT administration, and how this might subsequently impact C. 
jejuni colonisation, reliance on in vitro cell culture could also be superseded by use of 
gastrointestinal tissue sections collected from experimental birds. Performing RT-qPCR from 
RNA extracts of these tissues would enable complete characterisation of C. jejuni colonisation, 
microbiome composition and immune gene transcription for each individual experimental 
animal. Such information would prove invaluable in deciphering the complex biological 





To conclude, the commercial broiler chicken represents an important infection reservoir for 




evident risk to public health, the persistent intestinal, occasionally systemic, infection 
dynamics associated with Campylobacter in the broiler chicken are not as commensal as first 
believed and may also demonstrate important welfare indications for the chicken itself. The 
results presented here indicate that, at a time when effective Campylobacter control 
strategies are needed, early modulation of the chick microbiota may offer an effective means 
of protection. Although some-what rudimentary in concept, CMT shows promise in inducing 
rapid successional taxonomic changes in the chick microbiota to create an intestinal 
environment less susceptible to opportunistic infection. While it remains important to refine 
our understanding how CMT might influence both the intestinal microbiota and the immune 
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Appendix 1: Appendix to Chapter 2  
 
ELISA for the detection of serum antibodies  
Reagents: 
• Carbonate-bicarbonate tables (Sigma, Poole, Dorset, UK) 
• Nunc-immuno MicroWell flat-bottomed 96-well plates (sigma, Poole, Dorset, 
UK) 
• Tween-20 sachets (Sigma, Poole, Dorset, UK) 
• PBS 
• Skimmed milk powder (Supermarket) 
• Secondary antibody conjugated with alkaline phosphatase solution  
• P-nitrophenyl phosphate (Sigma, Poole, Dorset, UK) 
• NaOH tablets (FisherScientific, Loughborough, UK) 
 
To do one day prior to assay  
- Add 1 carbonate-bicarbonate tablet to 100ml deionised water 
- Tale 10 ml carbonate-bicarbonate buffer (prepared above) and add soluble 
antigen to a concentration of 10 µg/ml 
- Coat flat-bottomed 96-well plate with 100 µl antigen solution prepared and 
incubate overnight at 4°C 
 
Assay protocol  
- After overnight incubation, wash plates 3 x with a wash buffer (PBS + 0.05 % 
tween20; PBST) 
- Incubate the plates with 200 µl blocking buffer for 1 hour at 37°C. Keep plate 
covered [blocking buffer: 3 % (w/v) skimmed milk powder in PBST] 
- Wash plates once with wash buffer  
- In a separate normal microplate, dilute blood serum samples in blocking buffer 
to required dilution  
- Transfer 100 µl to each well of flat-bottomed plate in duplicate 
- Incubate for 1 hour at 37°C. Keep plate covered  
- Wash plates 3-5 times in wash buffer  
- Add 100 µl of diluted secondary antibody conjugated with alkaline 
phosphatase solution to each well [Secondary antibody conjugated with 
alkaline phosphatase diluted with blocking solution, dilution will depend on 
antibody type] 
- Incubate for 1 hour at 37°C.  
- Wash 3-5 times in wash buffer  
- Add 100 µl p-nitrophenyl phosphate to each well and incubate for 30 minutes 
at room temperature in the dark 
- Add 100 µl 3N NaOH to each well to stop reaction (NaOH tablets dissolved in 
distilled water to desired concentration] 
- Read absorbance at 405nm using microplate reader. 





Table 33. Bacteriological results corresponding to individual caecal content samples collected 















CFU/g Log CFU/g 
spot1 spot2 spot3 
Infected 1934 1.66 6 8 10 3 3.50E+08 8.54E+00 6.02E-01 2.11E+08 8.32E+00 
Infected 1935 0.64 1 2 3 3.00 1.33E+03 3.12E+00 1.56E+00 2.08E+03 3.32E+00 
Infected 1936 1.09 6 4 3 2.00 1.50E+08 8.18E+00 9.15E-01 1.37E+08 8.14E+00 
Infected 1937 0.94 - 0 0 0 N/A N/A - N/A N/A 
Infected 1938 1.15 4 3 2 1.00 1.00E+06 6.00E+00 8.73E-01 8.73E+05 5.94E+00 
Infected 1939 2.23 6 8 3 3.00 2.33E+08 8.37E+00 4.48E-01 1.04E+08 8.02E+00 
Infected 1940 1.50 6 7 7 1.00 2.50E+08 8.40E+00 6.66E-01 1.67E+08 8.22E+00 
Infected 1941 1.92 5 6 3 4.00 2.17E+07 7.34E+00 5.21E-01 1.13E+07 7.05E+00 
Infected 1942 1.01 5 7 2 5.00 2.33E+07 7.37E+00 9.95E-01 2.32E+07 7.37E+00 
Infected 1943 0.80 4 11 7 8.00 4.33E+06 6.64E+00 1.24E+00 5.39E+06 6.73E+00 
Infected 1944 3.10 4 9 13 13.00 5.83E+06 6.77E+00 3.23E-01 1.88E+06 6.27E+00 
Infected 1945 0.86 6 3 6 6.00 2.50E+08 8.40E+00 1.16E+00 2.91E+08 8.46E+00 
Infected 1946 0.76 - 0 0 0 N/A N/A - N/A N/A 
Infected 1947 0.75 5 14 5 6.00 4.17E+07 7.62E+00 1.33E+00 5.53E+07 7.74E+00 
Infected 1948 1.63 4 0 1 1.00 3.33E+05 5.52E+00 6.13E-01 2.04E+05 5.31E+00 
Infected 1949 1.76 6 0 1 5 1.00E+08 8.00E+00 5.68E-01 5.68E+07 7.75E+00 
Infected 1950 0.61 - 0 0 0 N/A N/A - N/A N/A 
Infected 1951 1.38 - 0 0 0 N/A N/A - N/A N/A 
Infected 1952 2.21 4 5 3 3 1.83E+06 6.26E+00 4.53E-01 8.31E+05 5.92E+00 
Infected 1953 1.82 7 0 3 2 8.33E+08 8.92E+00 5.51E-01 4.59E+08 8.66E+00 
Infected 1954 2.28 5 9 9 6 4.00E+07 7.60E+00 4.40E-01 1.76E+07 7.25E+00 
Infected 1955 1.11 2 13 9 0 3.67E+04 4.56E+00 9.03E-01 3.31E+04 4.52E+00 
Infected 1956 1.19 7 4 1 2 1.17E+09 9.07E+00 8.44E-01 9.85E+08 8.99E+00 
Infected 1957 2.01 5 2 4 4 1.67E+07 7.22E+00 4.97E-01 8.28E+06 6.92E+00 
Infected 1958 2.43 6 6 8 3 2.83E+08 8.45E+00 4.12E-01 1.17E+08 8.07E+00 
Infected 1959 0.56 3 2 1 2 8.33E+04 4.92E+00 1.77E+00 1.48E+05 5.17E+00 
Infected 1962 0.70 2 9 14 7 5.00E+04 4.70E+00 1.43E+00 7.15E+04 4.85E+00 
Infected 1963 1.16 5 11 7 12.00 5.00E+07 7.70E+00 8.62E-01 4.31E+07 7.63E+00 
Infected 1964 1.15 5 4 3 7.00 2.33E+07 7.37E+00 8.70E-01 2.03E+07 7.31E+00 
Infected 1965 1.34 4 6 2 10.00 3.00E+06 6.48E+00 7.47E-01 2.24E+06 6.35E+00 
Infected 1966 1.91 3 3 2 2.00 1.17E+05 5.07E+00 5.24E-01 6.11E+04 4.79E+00 
Infected 1967 1.00 5 4 2 2 1.33E+07 7.12E+00 1.00E+00 1.34E+07 7.13E+00 
Infected 1968 1.28 - 0 0 0 N/A N/A - N/A N/A 
Infected 1969 1.77 7 19 16 16.00 8.50E+09 9.93E+00 5.65E-01 4.80E+09 9.68E+00 
Infected 1970 0.94 4 5 5 8.00 3.00E+06 6.48E+00 1.07E+00 3.20E+06 6.50E+00 
Infected 1971 0.59 5 13 14 12.00 6.50E+07 7.81E+00 1.69E+00 1.10E+08 8.04E+00 
Infected 1972 2.36 4 12 8 17.00 6.17E+06 6.79E+00 4.24E-01 2.61E+06 6.42E+00 
Infected 1973 0.79 6 7 12 11.00 5.00E+08 8.70E+00 1.26E+00 6.32E+08 8.80E+00 
Infected 1974 1.11 6 13 7 8.00 4.67E+08 8.67E+00 8.99E-01 4.20E+08 8.62E+00 
Infected 1975 1.24 5 1 1 2.00 6.67E+06 6.82E+00 8.05E-01 5.37E+06 6.73E+00 
Infected 1976 2.75 4 9 13 8 5.00E+06 6.70E+00 3.64E-01 1.82E+06 6.26E+00 
Infected 1977 0.63 3 1 1 3.00 8.33E+04 4.92E+00 1.59E+00 1.32E+05 5.12E+00 
Infected 1978 2.19 6 16 15 13.00 7.33E+08 8.87E+00 4.56E-01 3.34E+08 8.52E+00 
Infected 1979 1.84 7 1 1 1.00 5.00E+08 8.70E+00 5.43E-01 2.71E+08 8.43E+00 
Infected 1980 1.65 5 9 2 6.00 2.83E+07 7.45E+00 6.06E-01 1.72E+07 7.23E+00 
Infected 1981 0.89 4 9 6 4.00 3.17E+06 6.50E+00 1.12E+00 3.55E+06 6.55E+00 
Infected 1982 0.75 4 6 13 8.00 4.50E+06 6.65E+00 1.33E+00 6.00E+06 6.78E+00 
Infected 1983 1.59 4 11 8 9 4.67E+06 6.67E+00 6.31E-01 2.94E+06 6.47E+00 
Infected 1984 1.29 - 0 0 0 N/A N/A - N/A N/A 
Infected 1985 1.25 7 4 1 3.0 1.33E+09 9.12E+00 7.99E-01 1.07E+09 9.03E+00 
Infected 1986 0.89 5 1 2 2.0 8.33E+06 6.92E+00 1.12E+00 9.36E+06 6.97E+00 
Infected 1987 1.66 6 3 3 1 1.17E+08 8.07E+00 6.02E-01 7.03E+07 7.85E+00 
Infected 1988 0.60 - 0 0 0 N/A N/A - N/A N/A 
Infected 1989 1.20 - 0 0 0 N/A N/A - N/A N/A 
Infected 1990 0.90 - 0 0 0 N/A N/A - N/A N/A 
Infected 1991 0.46 - 0 0 0 N/A N/A - N/A N/A 




Table 34. Bacteriological results corresponding to individual ileal content samples collected from 














CFU/g spot1 spot2 spot3 
Infected 1934 1.47 - 0 0 0 N/A N/A - N/A N/A 
Infected 1935 0.24 - 0 0 0 N/A N/A - N/A N/A 
Infected 1936 0.35 3 5 5 9.00 3.17E+05 5.50E+00 2.83E+00 8.97E+05 5.95E+00 
Infected 1937 0.47 - 0 0 0 N/A N/A - N/A N/A 
Infected 1938 0.94 - 0 0 0 N/A N/A - N/A N/A 
Infected 1939 0.68 4 2 2 4.00 1.33E+06 6.12E+00 1.47E+00 1.96E+06 6.29E+00 
Infected 1940 1.38 - 0 0 0 N/A N/A - N/A N/A 
Infected 1941 1.80 - 0 0 0 N/A N/A - N/A N/A 
Infected 1942 0.56 - 0 0 0 N/A N/A - N/A N/A 
Infected 1943 0.50 3 2 2 2.00 1.00E+05 5.00E+00 2.01E+00 2.01E+05 5.30E+00 
Infected 1944 1.06 - 0 0 0 N/A N/A - N/A N/A 
Infected 1945 0.75 2 10 0 0.00 1.67E+04 4.22E+00 1.33E+00 2.22E+04 4.35E+00 
Infected 1946 0.43 - 0 0 0 N/A N/A - N/A N/A 
Infected 1947 0.85 - 0 0 0 N/A N/A - N/A N/A 
Infected 1948 1.09 - 0 0 0 N/A N/A - N/A N/A 
Infected 1949 1.79 1 2 1 1 6.67E+02 2.82E+00 5.59E-01 3.72E+02 2.57E+00 
Infected 1950 0.64 - 0 0 0 N/A N/A - N/A N/A 
Infected 1951 0.54 - 0 0 0 N/A N/A - N/A N/A 
Infected 1952 0.76 2 3 4 2 1.50E+04 4.18E+00 1.31E+00 1.96E+04 4.29E+00 
Infected 1953 1.93 - 0 0 0 N/A N/A - N/A N/A 
Infected 1954 2.19 - 0 0 0 N/A N/A - N/A N/A 
Infected 1955 1.20 - 0 0 0 N/A N/A - N/A N/A 
Infected 1956 1.73 - 0 0 0 N/A N/A - N/A N/A 
Infected 1957 1.74 - 0 0 0 N/A N/A - N/A N/A 
Infected 1958 0.71 - 0 0 0 N/A N/A - N/A N/A 
Infected 1959 1.24 - 0 0 0 N/A N/A - N/A N/A 
Infected 1962 1.72 - 0 0 0 N/A N/A - N/A N/A 
Infected 1963 1.17 - 0 0 0 N/A N/A - N/A N/A 
Infected 1964 1.10 - 0 0 0 N/A N/A - N/A N/A 
Infected 1965 0.36 - 0 0 0 N/A N/A - N/A N/A 
Infected 1966 1.23 1 0 2 3.00 8.33E+02 2.92E+00 8.13E-01 6.78E+02 2.83E+00 
Infected 1967 1.23 5 0 2 2 6.67E+06 6.82E+00 8.14E-01 5.43E+06 6.73E+00 
Infected 1968 0.58 - 0 0 0 N/A N/A - N/A N/A 
Infected 1969 1.19 3 5 8 4 2.83E+05 5.45E+00 8.41E-01 2.38E+05 5.38E+00 
Infected 1970 0.58 - 0 0 0 N/A N/A - N/A N/A 
Infected 1971 0.48 - 0 0 0 N/A N/A - N/A N/A 
Infected 1972 1.18 - 0 0 0 N/A N/A - N/A N/A 
Infected 1973 0.71 - 0 0 0 N/A N/A - N/A N/A 
Infected 1974 0.61 2 2 3 2.00 1.17E+04 4.07E+00 1.64E+00 1.92E+04 4.28E+00 
Infected 1975 2.02 2 0 1 0.00 1.67E+03 3.22E+00 4.95E-01 8.24E+02 2.92E+00 
Infected 1976 0.93 2 2 4 3 1.50E+04 4.18E+00 1.07E+00 1.61E+04 4.21E+00 
Infected 1977 1.19 - 0 0 0 N/A N/A - N/A N/A 
Infected 1978 1.55 - 0 0 0 N/A N/A - N/A N/A 
Infected 1979 1.24 - 0 0 0 N/A N/A - N/A N/A 
Infected 1980 1.03 - 0 0 0 N/A N/A - N/A N/A 
Infected 1981 1.43 - 0 0 0 N/A N/A - N/A N/A 
Infected 1982 0.53 - 0 0 0 N/A N/A - N/A N/A 
Infected 1983 1.34 - 0 0 0 N/A N/A - N/A N/A 
Infected 1984 1.07 - 0 0 0 N/A N/A - N/A N/A 
Infected 1985 1.30 - 0 0 0 N/A N/A - N/A N/A 
Infected 1986 0.99 - 0 0 0 N/A N/A - N/A N/A 
Infected 1987 0.85 - 0 0 0 N/A N/A - N/A N/A 
Infected 1988 0.74 - 0 0 0 N/A N/A - N/A N/A 
Infected 1989 0.65 - 0 0 0 N/A N/A - N/A N/A 
Infected 1990 0.29 - 0 0 0 N/A N/A - N/A N/A 
Infected 1991 0.48 - 0 0 0 N/A N/A - N/A N/A 






Table 35. Bacteriological results corresponding to individual caecal content samples collected 














CFU/g log CFU/g 
spot1 spot2 spot3 
Infected 1 2.60 4 4 4 2 1.67E+06 6.22E+00 3.85E-01 6.41E+05 5.81E+00 
Infected 2 1.51 3 5 5 2 2.00E+05 5.30E+00 6.61E-01 1.32E+05 5.12E+00 
Infected 3 0.78 - 0 0 0 N/A N/A - N/A N/A 
Infected 4 2.59 5 2 3 3 1.33E+07 7.12E+00 3.87E-01 5.15E+06 6.71E+00 
Infected 5 1.76 3 6 4 5 2.50E+05 5.40E+00 5.67E-01 1.42E+05 5.15E+00 
Infected 6 2.59 6 9 7 7 3.83E+08 8.58E+00 3.86E-01 1.48E+08 8.17E+00 
Infected 7 1.92 6 3 9 8 3.33E+08 8.52E+00 5.21E-01 1.74E+08 8.24E+00 
Infected 8 2.10 7 2 5 3 1.67E+09 9.22E+00 4.76E-01 7.94E+08 8.90E+00 
Infected 9 1.44 5 17 6 3 4.33E+07 7.64E+00 6.94E-01 3.01E+07 7.48E+00 
Infected 10 1.61 5 6 6 0 2.00E+07 7.30E+00 6.20E-01 1.24E+07 7.09E+00 
Infected 11 2.31 6 1 11 10 3.67E+08 8.56E+00 4.33E-01 1.59E+08 8.20E+00 
Infected 12 1.56 6 3 0 2 8.33E+07 7.92E+00 6.39E-01 5.33E+07 7.73E+00 
Infected 13 1.66 1 2 4 3 1.50E+03 3.18E+00 6.01E-01 9.01E+02 2.95E+00 
Infected 14 1.32 - 0 0 0 N/A N/A - N/A N/A 
Infected 15 1.18 3 3 2 1 1.00E+05 5.00E+00 8.49E-01 8.49E+04 4.93E+00 
Infected 16 1.37 3 5 6 2 2.17E+05 5.34E+00 7.28E-01 1.58E+05 5.20E+00 
Infected 17 0.66 5 0 0 6 1.00E+07 7.00E+00 1.51E+00 1.51E+07 7.18E+00 
Infected 18 1.11 - 0 0 0 N/A N/A - N/A N/A 
Infected 19 1.99 5 6 3 8 2.83E+07 7.45E+00 5.03E-01 1.42E+07 7.15E+00 
Infected 20 2.83 6 4 4 8 2.67E+08 8.43E+00 3.54E-01 9.43E+07 7.97E+00 
Infected 21 1.86 6 6 5 5 2.67E+08 8.43E+00 5.38E-01 1.44E+08 8.16E+00 
Infected 22 1.48 5 11 7 8 4.33E+07 7.64E+00 6.76E-01 2.93E+07 7.47E+00 
Infected 23 1.77 5 7 14 9 5.00E+07 7.70E+00 5.65E-01 2.83E+07 7.45E+00 
Infected 24 2.11 3 3 4 5 2.00E+05 5.30E+00 4.74E-01 9.48E+04 4.98E+00 
Infected 25 2.61 4 7 12 10 4.83E+06 6.68E+00 3.83E-01 1.85E+06 6.27E+00 















Table 36. Bacteriological results corresponding to individual ileal content samples collected from 














CFU/g log CFU/g 
spot1 spot2 spot3 
Infected 1 0.8 - 0 0 0 N/A N/A - N/A N/A 
Infected 2 1.203 - 0 0 0 N/A N/A - N/A N/A 
Infected 3 0.939 - 0 0 0 N/A N/A - N/A N/A 
Infected 4 0.668 - 0 0 0 N/A N/A - N/A N/A 
Infected 5 1.177 1 0 2 0 3.33E+03 3.52E+00 8.50E-01 2.83E+03 3.45E+00 
Infected 6 0.726 - 0 0 0 N/A N/A - N/A N/A 
Infected 7 1.81 1 12 10 9 5.17E+04 4.71E+00 5.52E-01 2.85E+04 4.46E+00 
Infected 8 0.722 2 6 6 7 3.17E+05 5.50E+00 1.39E+00 4.39E+05 5.64E+00 
Infected 9 1.02 2 2 1 1 6.67E+04 4.82E+00 9.80E-01 6.54E+04 4.82E+00 
Infected 10 1.961 - 0 0 0 N/A N/A - N/A N/A 
Infected 11 1.3 - 0 0 0 N/A N/A - N/A N/A 
Infected 12 1.655 - 0 0 0 N/A N/A - N/A N/A 
Infected 13 0.35 - 0 0 0 N/A N/A - N/A N/A 
Infected 14 0.988 - 0 0 0 N/A N/A - N/A N/A 
Infected 15 1.722 - 0 0 0 N/A N/A - N/A N/A 
Infected 16 0.397 2 0 0 1 1.67E+04 4.22E+00 2.52E+00 4.20E+04 4.62E+00 
Infected 17 0.615 - 0 0 0 N/A N/A - N/A N/A 
Infected 18 1.77 - 0 0 0 N/A N/A - N/A N/A 
Infected 19 1.597 - 0 0 0 N/A N/A - N/A N/A 
Infected 20 0.486 - 0 0 0 N/A N/A - N/A N/A 
Infected 21 0.346 1 8 7 15 5.00E+04 4.70E+00 2.89E+00 1.45E+05 5.16E+00 
Infected 22 1.047 1 4 3 3 1.67E+04 4.22E+00 9.55E-01 1.59E+04 4.20E+00 
Infected 23 0.814 - 0 0 0 N/A N/A - N/A N/A 
Infected 24 2.181 - 0 0 0 N/A N/A - N/A N/A 
Infected 25 0.649 - 0 0 0 N/A N/A - N/A N/A 


















Appendix 2: Appendix to Chapter 3 
 
Table 37. MALDI-TOF MS identifications from single colonies grown on CAB agar. Table shows 




Organism (best match) 
Score 
Value 




A1 Bacillus pumilus 1.82 
No Organism Identification 
Possible 
1.59 
A2 Escherichia coli 2.46 Escherichia coli  2.35 
A3b Escherichia coli 2.45 Escherichia coli 2.33 
A4 Enterococcus faecium 2.31 Enterococcus faecium 2.22 
A5 Bacillus pumilus 1.99 Bacillus pumilus 1.83 
A6 Bacillus altitudinis 1.89 Bacillus altitudinis 1.84 
A7a Bacillus sp 1.91 Bacillus altitudinis 1.88 
A7b Enterococcus faecalis  2.30 Enterococcus faecalis  2.29 
A8a Bacillus cereus 2.31 Bacillus cereus 2.18 
A8b Escherichia coli 2.48 Escherichia coli 2.47 
A9a Bacillus subtilis N/A     
A10a Solibacillus silvestris N/A     
A10b Lactobacillus Paracesei 1.78 Staphylococcus cohnii 1.73 
Microaerobic 
M1a Bacillus subtilis 1.98 Bacillus subtilis 1.89 




1.88 Bacillus amyloliquefaciens 1.84 




M2a Bacillus subtilis 1.96 Bacillus subtilis 1.91 
M2c Escherichia coli 2.42 Escherichia coli 2.41 
M3 Escherichia coli 2.37 Escherichia coli 2.33 
M4a Enterococcus faecium 2.08 Enterococcus faecium 1.98 
M4b Clostridium perfringens 2.08 Clostridium perfringens 2.04 
M5 Enterococcus faecium 2.43 Enterococcus faecium 2.38 
M6a Bacillus subtilis 1.94 Bacillus subtilis 1.84 
M6b Escherichia coli 2.56 Escherichia coli 2.43 
M7 Bacillus cereus 2.42 Bacillus cereus 2.22 
M8 Bacillus pumilus 1.77 Bacillus pumilus 1.74 
M9a Bacillus megaterium  2.22 Bacillus megaterium 1.98 
M9b Clostridium perfringens 2.53 Clostridium perfringens 2.52 
M10a Bacillus megaterium  2.02 Bacillus megaterium 1.92 
M10b Bacillus megaterium  2.09 Bacillus megaterium 1.95 
M11 Bacillus pumilus 1.92 Bacillus pumilus 1.83 
Anaerobic 
An1 Clostridium perfringens 2.47 Clostridium perfringens 2.44 
An2 Clostridium perfringens 2.57 Clostridium perfringens 2.52 












Table 38. Bacteriological results corresponding to individual caecal content samples collected 




Group Bird ID Sample 
weight 
Dilution spot1 spot2 spot3 cfu/ml log 
cfu/ml 
Correction factor CFU/g Log CFU/g 
CMT 949 0.62 5 12 10 8 5.00E+08 8.70E+00 1.61E+00 8.06E+08 8.91E+00 
CMT 950 1.53 1 4 5 5 2.33E+04 4.37E+00 6.54E-01 1.53E+04 4.18E+00 
CMT 951 0.86 2 6 3 6 2.50E+05 5.40E+00 1.16E+00 2.90E+05 5.46E+00 
CMT 954 0.36 1 3 1 1 8.33E+03 3.92E+00 2.80E+00 2.33E+04 4.37E+00 
CMT 955 1.30 1 7 5 8 3.33E+04 4.52E+00 7.72E-01 2.57E+04 4.41E+00 
CMT 956 0.67 2 14 11 16 6.83E+05 5.83E+00 1.50E+00 1.03E+06 6.01E+00 
CMT 958 0.46 1 6 3 3 2.00E+04 4.30E+00 2.19E+00 4.39E+04 4.64E+00 
CMT 959 0.50 1 10 12 11 5.50E+04 4.74E+00 1.98E+00 1.09E+05 5.04E+00 
CMT 961 1.26 5 14 14 16 7.33E+08 8.87E+00 7.95E-01 5.83E+08 8.77E+00 
CMT 963 0.79 1 1 2 2 8.33E+03 3.92E+00 1.26E+00 1.05E+04 4.02E+00 
CMT 966 1.38 5 10 9 9 4.67E+08 8.67E+00 7.24E-01 3.38E+08 8.53E+00 
CMT 969 0.54 1 4 2 6 2.00E+04 4.30E+00 1.84E+00 3.68E+04 4.57E+00 
CMT 970 0.56 6 1 2 2 8.33E+08 8.92E+00 1.78E+00 1.48E+09 9.17E+00 
CMT 971 0.45 1 1 3 2 1.00E+04 4.00E+00 2.21E+00 2.21E+04 4.34E+00 
CMT 972 0.60 4 3 8 10 3.50E+07 7.54E+00 1.66E+00 5.81E+07 7.76E+00 
CMT 973 0.83 5 13 16 16 7.50E+08 8.88E+00 1.20E+00 9.04E+08 8.96E+00 
CMT 974 0.36 5 7 5 5 2.83E+08 8.45E+00 2.75E+00 7.78E+08 8.89E+00 
CMT 975 0.53 3 5 4 2 1.83E+06 6.26E+00 1.88E+00 3.45E+06 6.54E+00 
CMT 925 0.55 1 0 0 0 0.00E+00 N/A 1.81E+00 0.00E+00 N/A 
Ext. Control 1551 0.79 8 18 23 22 1.05E+12 1.20E+01 1.27E+00 1.33E+12 1.21E+01 
Ext. Control 1552 1.90 8 25 28 22 1.25E+12 1.21E+01 5.25E-01 6.57E+11 1.18E+01 
Ext. Control 1553 0.64 8 18 17 23 9.67E+11 1.20E+01 1.55E+00 1.50E+12 1.22E+01 
Ext. Control 1554 1.34 7 4 5 5 2.33E+10 1.04E+01 7.46E-01 1.74E+10 1.02E+01 
Ext. Control 1555 0.19 8 22 25 27 1.23E+12 1.21E+01 5.15E+00 6.36E+12 1.28E+01 
Ext. Control 1556 0.91 8 21 26 27 1.23E+12 1.21E+01 1.10E+00 1.35E+12 1.21E+01 
Ext. Control 1557 1.25 8 10 18 15 7.17E+11 1.19E+01 8.01E-01 5.74E+11 1.18E+01 
Ext. Control 1559 0.65 7 4 5 6 2.50E+10 1.04E+01 1.55E+00 3.87E+10 1.06E+01 
Ext. Control 1560 0.41 8 31 28 29 1.47E+12 1.22E+01 2.46E+00 3.60E+12 1.26E+01 
Ext. Control 1561 0.60 8 25 23 21 1.15E+12 1.21E+01 1.68E+00 1.93E+12 1.23E+01 
Ext. Control 1562 0.77 8 25 25 29 1.32E+12 1.21E+01 1.29E+00 1.70E+12 1.22E+01 
Ext. Control 1563 0.24 8 22 23 25 1.17E+12 1.21E+01 4.26E+00 4.96E+12 1.27E+01 
Ext. Control 1566 0.33 8 16 14 13 7.17E+11 1.19E+01 3.01E+00 2.16E+12 1.23E+01 
Ext. Control 1567 0.55 8 16 20 20 9.33E+11 1.20E+01 1.83E+00 1.71E+12 1.22E+01 
Ext. Control 1569 0.58 8 23 25 28 1.27E+12 1.21E+01 1.71E+00 2.17E+12 1.23E+01 
Ext. Control 1570 1.08 8 14 18 18 8.33E+11 1.19E+01 9.24E-01 7.70E+11 1.19E+01 
Ext. Control 1571 0.49 8 17 16 15 8.00E+11 1.19E+01 2.06E+00 1.65E+12 1.22E+01 
Ext. Control 1572 0.93 8 22 24 21 1.12E+12 1.20E+01 1.08E+00 1.20E+12 1.21E+01 




Table 39. Bacteriological results corresponding to individual ileal content samples collected from 











CMT 949 0.59 - 0 0 0 N/A N/A - N/A N/A 
CMT 950 0.42 - 0 0 0 N/A N/A - N/A N/A 
CMT 951 0.35 - 0 0 0 N/A N/A - N/A N/A 
CMT 954 0.43 - 0 0 0 N/A N/A - N/A N/A 
CMT 955 0.82 - 0 0 0 N/A N/A - N/A N/A 
CMT 956 0.37 - 0 0 0 N/A N/A - N/A N/A 
CMT 958 1.26 - 0 0 0 N/A N/A - N/A N/A 
CMT 959 0.80 - 0 0 0 N/A N/A - N/A N/A 
CMT 961 0.61 - 0 0 0 N/A N/A - N/A N/A 
CMT 963 0.35 - 0 0 0 N/A N/A - N/A N/A 
CMT 966 0.55 - 0 0 0 N/A N/A - N/A N/A 
CMT 969 0.62 - 0 0 0 N/A N/A - N/A N/A 
CMT 970 0.06 - 0 0 0 N/A N/A - N/A N/A 
CMT 971 0.34 - 0 0 0 N/A N/A - N/A N/A 
CMT 972 0.46 - 0 0 0 N/A N/A - N/A N/A 
CMT 973 0.56 - 0 0 0 N/A N/A - N/A N/A 
CMT 974 0.25 - 0 0 0 N/A N/A - N/A N/A 
CMT 975 0.40 - 0 0 0 N/A N/A - N/A N/A 
CMT 925 0.48 - 0 0 0 N/A N/A - N/A N/A 
Ext. Control 1551 0.82 - 0 0 0 N/A N/A - N/A N/A 
Ext. Control 1552 0.71 1 2 2 1 8.33E+03 3.92E+00 1.41E+00 1.18E+04 4.07E+00 
Ext. Control 1553 0.65 1 2 2 3 1.17E+04 4.07E+00 1.54E+00 1.80E+04 4.25E+00 
Ext. Control 1554 1.15 1 1 2 1 6.67E+03 3.82E+00 8.68E-01 5.79E+03 3.76E+00 
Ext. Control 1555 0.21 1 5 4 6 2.50E+04 4.40E+00 4.83E+00 1.21E+05 5.08E+00 
Ext. Control 1556 0.41 - 0 0 0 N/A N/A - N/A N/A 
Ext. Control 1557 0.50 1 8 2 5 2.50E+04 4.40E+00 2.00E+00 5.01E+04 4.70E+00 
Ext. Control 1559 0.45 1 2 1 1 6.67E+03 3.82E+00 2.21E+00 1.47E+04 4.17E+00 
Ext. Control 1560 0.74 2 4 2 2 1.33E+05 5.12E+00 1.35E+00 1.80E+05 5.26E+00 
Ext. Control 1561 0.79 - 0 0 0 N/A N/A - N/A N/A 
Ext. Control 1562 1.38 1 3 2 2 1.17E+04 4.07E+00 7.26E-01 8.47E+03 3.93E+00 
Ext. Control 1563 0.65 3 10 12 13 5.83E+06 6.77E+00 1.54E+00 8.96E+06 6.95E+00 
Ext. Control 1566 0.69 2 8 7 8 3.83E+05 5.58E+00 1.45E+00 5.57E+05 5.75E+00 
Ext. Control 1567 0.31 1 4 3 2 1.50E+04 4.18E+00 3.18E+00 4.78E+04 4.68E+00 
Ext. Control 1569 0.56 4 4 2 4 1.67E+07 7.22E+00 1.78E+00 2.97E+07 7.47E+00 
Ext. Control 1570 0.43 1 4 5 5 2.33E+04 4.37E+00 2.33E+00 5.43E+04 4.73E+00 
Ext. Control 1571 0.62 - 0 0 0 N/A N/A - N/A N/A 
Ext. Control 1572 0.55 1 5 5 5 2.50E+04 4.40E+00 1.83E+00 4.59E+04 4.66E+00 







Table 40. Bacteriological results corresponding to individual caecal content samples collected 









cfu/g log cfu/g 
spot1 spot2 spot3 
CMT 1801 1.964 - - - - - - 0.51 - - 
CMT 1802 1.156 - - - - - - 0.87 - - 
CMT 1803 1.593 - - - - - - 0.63 - - 
CMT 1804 1.053 - - - - - - 0.95 - - 
CMT 1805 1.871 - - - - - - 0.53 - - 
CMT 1806 0.575 - - - - - - 1.74 - - 
CMT 1808 1.51 - - - - - - 0.66 - - 
CMT 1809 0.81 - - - - - - 1.23 - - 
Ext. Control 3751 0.892 6 9 5 10 4.00E+09 9.60E+00 1.12 4.48E+09 9.65E+00 
Ext. Control 3752 1.143 3 2 4 6 2.00E+06 6.30E+00 0.87 1.75E+06 6.24E+00 
Ext. Control 3753 1.559 5 7 9 16 5.33E+08 8.73E+00 0.64 3.42E+08 8.53E+00 
Ext. Control 3754 1.031 4 8 10 5 3.83E+07 7.58E+00 0.97 3.72E+07 7.57E+00 
Ext. Control 3755 1.112 5 6 4 2 2.00E+08 8.30E+00 0.90 1.80E+08 8.25E+00 
Ext. Control 3756 0.935 6 4 3 4 1.83E+09 9.26E+00 1.07 1.96E+09 9.29E+00 
Ext. Control 3757 1.917 5 12 19 22 8.83E+08 8.95E+00 0.52 4.61E+08 8.66E+00 
Ext. Control 3758 0.677 6 5 7 8 3.33E+09 9.52E+00 1.48 4.92E+09 9.69E+00 
Ext. Control 3759 1.021 5 19 11 16 7.67E+08 8.88E+00 0.98 7.51E+08 8.88E+00 
Ext. Control 3760 1.555 5 9 7 12 4.67E+08 8.67E+00 0.64 3.00E+08 8.48E+00 
Ext. Control 3761 0.563 5 3 6 5 2.33E+08 8.37E+00 1.78 4.14E+08 8.62E+00 
Ext. Control 3762 0.634 4 11 6 9 4.33E+07 7.64E+00 1.58 6.83E+07 7.83E+00 
 
 
Table 41. Bacteriological results corresponding to individual ileal content samples collected from 









cfu/g log cfu/g 
spot1 spot2 spot3 
CMT 1801 0.41 - - - - - - 2.44 - - 
CMT 1802 1.167 - - - - - - 0.86 - - 
CMT 1803 0.794 - - - - - - 1.26 - - 
CMT 1804 0.878 - - - - - - 1.14 - - 
CMT 1805 0.598 - - - - - - 1.67 - - 
CMT 1806 0.303 - - - - - - 3.30 - - 
CMT 1808 0.807 - - - - - - 1.24 - - 
CMT 1809 0.816 - - - - - - 1.23 - - 
Ext. Control 3751 0.377 - - - - - - 2.65 - - 
Ext. Control 3752 1.115 - - - - - - 0.90 - - 
Ext. Control 3753 0.979 - - - - - - 1.02 - - 
Ext. Control 3754 0.52 1 0 1 1 3.33E+03 3.52E+00 1.92 6.41E+03 3.81E+00 
Ext. Control 3755 0.725 - - - - - - 1.38 - - 
Ext. Control 3756 0.587 - - - - - - 1.70 - - 
Ext. Control 3757 0.811 1 3 1 8 2.00E+04 4.30E+00 1.23 2.47E+04 4.39E+00 
Ext. Control 3758 0.688 2 7 1 7 2.50E+05 5.40E+00 1.45 3.63E+05 5.56E+00 
Ext. Control 3759 1.026 - - - - - - 0.97 - - 
Ext. Control 3760 1.708 - - - - - - 0.59 - - 
Ext. Control 3761 1.244 1 1 1 1 5.00E+03 3.70E+00 0.80 4.02E+03 3.60E+00 












Table 42. Bacteriological results corresponding to individual caecal content samples collected 









cfu/g log cfu/g 
spot1 spot2 spot3 
CMT 2251 1.074 6 1 1 3 8.33E+08 8.92E+00 0.93 7.76E+08 8.89E+00 
CMT 2252 1.588 6 13 11 9 5.50E+09 9.74E+00 0.63 3.46E+09 9.54E+00 
CMT 2253 0.694 7 8 4 5 2.83E+10 1.05E+01 1.44 4.08E+10 1.06E+01 
CMT 2254 1.871 4 3 2 4 1.50E+07 7.18E+00 0.53 8.02E+06 6.90E+00 
CMT 2255 1.92 5 7 6 10 3.83E+08 8.58E+00 0.52 2.00E+08 8.30E+00 
CMT 2256 1.662 5 7 9 11 4.50E+08 8.65E+00 0.60 2.71E+08 8.43E+00 
CMT 2257 1.335 4 6 6 5 2.83E+07 7.45E+00 0.75 2.12E+07 7.33E+00 
CMT 2258 0.875 6 7 6 7 3.33E+09 9.52E+00 1.14 3.81E+09 9.58E+00 
CMT 2259 0.808 5 2 5 5 2.00E+08 8.30E+00 1.24 2.48E+08 8.39E+00 
CMT 2260 0.691 5 7 4 8 3.17E+08 8.50E+00 1.45 4.58E+08 8.66E+00 
CMT 2261 1.712 5 1 1 3 8.33E+07 7.92E+00 0.58 4.87E+07 7.69E+00 
CMT 2262 2.118 5 7 8 9 4.00E+08 8.60E+00 0.47 1.89E+08 8.28E+00 
CMT 2263 1.07 6 25 21 28 1.23E+10 1.01E+01 0.93 1.15E+10 1.01E+01 
CMT 2264 1.661 5 11 17 13 6.83E+08 8.83E+00 0.60 4.11E+08 8.61E+00 
CMT 2265 1.387 5 3 2 3 1.33E+08 8.12E+00 0.72 9.61E+07 7.98E+00 
Ext. Control 1776 1.272 5 2 9 11 3.67E+08 8.56E+00 0.79 2.88E+08 8.46E+00 
Ext. Control 1777 1.342 6 1 1 2 6.67E+08 8.82E+00 0.75 4.97E+08 8.70E+00 
Ext. Control 1778 2.632 5 1 2 4 1.17E+08 8.07E+00 0.38 4.43E+07 7.65E+00 
Ext. Control 1779 1.129 3 7 5 5 2.83E+06 6.45E+00 0.89 2.51E+06 6.40E+00 
Ext. Control 1780 2.753 4 2 2 3 1.17E+07 7.07E+00 0.36 4.24E+06 6.63E+00 
Ext. Control 1781 1.264 6 7 7 4 3.00E+09 9.48E+00 0.79 2.37E+09 9.38E+00 
Ext. Control 1782 0.822 3 9 10 14 5.50E+06 6.74E+00 1.22 6.69E+06 6.83E+00 
Ext. Control 1783 1.497 6 3 1 1 8.33E+08 8.92E+00 0.67 5.57E+08 8.75E+00 
Ext. Control 1784 1.364 4 8 12 9 4.83E+07 7.68E+00 0.73 3.54E+07 7.55E+00 
Ext. Control 1785 1.496 5 4 8 9 3.50E+08 8.54E+00 0.67 2.34E+08 8.37E+00 
Ext. Control 1786 0.637 4 3 3 0 1.00E+07 7.00E+00 1.57 1.57E+07 7.20E+00 
Ext. Control 1788 0.895 5 3 3 1 1.17E+08 8.07E+00 1.12 1.30E+08 8.12E+00 
Ext. Control 1789 0.151 6 2 9 6 2.83E+09 9.45E+00 6.62 1.88E+10 1.03E+01 
Ext. Control 1790 1.949 3 30 28 37 1.58E+07 7.20E+00 0.51 8.12E+06 6.91E+00 
Ext. Control 1791 1.724 5 4 10 7 3.50E+08 8.54E+00 0.58 2.03E+08 8.31E+00 

























Table 43. Bacteriological results corresponding to individual ileal content samples collected from 









cfu/g log cfu/g 
spot1 spot2 spot3 
Ileum 2251 1.219 - - - - - - 0.82 -   
Ileum 2252 0.582 - - - - - - 1.72 -   
Ileum 2253 1.546 1 9 9 3 3.50E+04 4.54E+00 0.65 2.26E+04 4.35E+00 
Ileum 2254 1.194 - - - - - - 0.84 -   
Ileum 2255 1.521 - - - - - - 0.66 -   
Ileum 2256 1.854 1 2 7 6 2.50E+04 4.40E+00 0.54 1.35E+04 4.13E+00 
Ileum 2257 1.358 1 10 13 7 5.00E+04 4.70E+00 0.74 3.68E+04 4.57E+00 
Ileum 2258 1.082 1 41 40 36 1.95E+05 5.29E+00 0.92 1.80E+05 5.26E+00 
Ileum 2259 0.934 - - - - - - 1.07 -   
Ileum 2260 0.249 - - - - - - 4.02 -   
Ileum 2261 0.986 - - - - - - 1.01 -   
Ileum 2262 1.891 - - - - - - 0.53 -   
Ileum 2263 0.601 - - - - - - 1.66 -   
Ileum 2264 0.664 1 30 32 28 1.50E+05 5.18E+00 1.51 2.26E+05 5.35E+00 
Ileum 2265 0.942 1 9 11 12 5.33E+04 4.73E+00 1.06 5.66E+04 4.75E+00 
Ileum 1776 0.998 - - - - - - 1.00 -   
Ileum 1777 1.236 1 60 70 65 3.25E+05 5.51E+00 0.81 2.63E+05 5.42E+00 
Ileum 1778 0.535 - - - - - - 1.87 -   
Ileum 1779 0.869 - - - - - - 1.15 -   
Ileum 1780 1.305 1 70 66 63 3.32E+05 5.52E+00 0.77 2.54E+05 5.41E+00 
Ileum 1781 2.072 1 52 48 62 2.70E+05 5.43E+00 0.48 1.30E+05 5.11E+00 
Ileum 1782 0.544 - - - - - - 1.84 -   
Ileum 1783 1.361 - - - - - - 0.73 -   
Ileum 1784 0.895 - - - - - - 1.12 -   
Ileum 1785 2.098 1 3 11 11 4.17E+04 4.62E+00 0.48 1.99E+04 4.30E+00 
Ileum 1786 0.679 - - - - - - 1.47 -   
Ileum 1788 0.847 - - - - - - 1.18 -   
Ileum 1789 0.763 1 10 12 14 6.00E+04 4.78E+00 1.31 7.86E+04 4.90E+00 
Ileum 1790 0.797 - - - - - - 1.25 -   
Ileum 1791 0.943 - - - - - - 1.06 -   




















 Table 44. Bacteriological results corresponding to individual caecal content samples collected 












Group Bird Id Sample 
Weight 









1 2  3 
4 d.p.i CMT 1801 1.173 - - - -  - -  0.85 0.00E+00 NA 
1802 0.924 - - - -  -  - 1.08 0.00E+00 NA 
1803 1.074 - - - -  -  - 0.93 0.00E+00 NA 
1804 0.456 - - - -  -  - 2.19 0.00E+00 NA 
1805 1.793 - - - -  -  - 0.56 0.00E+00 NA 
1806 1.645 - - - -  -  - 0.61 0.00E+00 NA 
1814 0.828 - - - -  -  - 1.21 0.00E+00 NA 
1815 0.837 - - - -  -  - 1.19 0.00E+00 NA 
1816 1.968 - - - -  -  - 0.51 0.00E+00 NA 
1819 1.431 - - - -  -  - 0.70 0.00E+00 NA 
Ext. 
Control 
2151 0.571 - - - -  -  - 1.75 0.00E+00 NA 
2156 2.206 - - - -  -  - 0.45 0.00E+00 NA 
2157 2.257 - - - -  -  - 0.44 0.00E+00 NA 
2164 2.468 - - - -  -  - 0.41 0.00E+00 NA 
2168 1.682 - - - -  -  - 0.59 0.00E+00 NA 
2176 0.778 1 0 2 0 3.33E+03 3.52E+00 1.29 4.28E+03 3.63E+00 
2179 1.828 1 2 2 1 8.33E+03 3.92E+00 0.55 4.56E+03 3.66E+00 
2181 2.679 - - - -  -  - 0.37 0.00E+00 NA 
2183 0.508 - - - -  -  - 1.97 0.00E+00 NA 
2184 0.734 - - - -  -  - 1.36 0.00E+00 NA 
2189 0.73 1 1 2 3 1.00E+04 4.00E+00 1.37 1.37E+04 4.14E+00 
2191 0.8 - - - -    - 1.25 0.00E+00 NA 
10 
d.p.i 
CMT 1807 1.4 5 6 4 4 2.33E+08 8.37E+00 0.71 1.67E+08 8.22E+00 
1808 1.311 - - - -  -  - 0.76 0.00E+00 NA 
1809 1.973 6 0 2 4 1.00E+09 9.00E+00 0.51 5.07E+08 8.70E+00 
1810 0.355 6 3 1 2 1.00E+09 9.00E+00 2.82 2.82E+09 9.45E+00 
1811 0.731 6 1 1 1 5.00E+08 8.70E+00 1.37 6.84E+08 8.84E+00 
1812 0.616 6 2 2 2 1.00E+09 9.00E+00 1.62 1.62E+09 9.21E+00 
1813 0.879 4 6 8 4 3.00E+07 7.48E+00 1.14 3.41E+07 7.53E+00 
1817 1.831 4 2 1 1 6.67E+06 6.82E+00 0.55 3.64E+06 6.56E+00 
1820 1.313 3 1 1 4 1.00E+06 6.00E+00 0.76 7.62E+05 5.88E+00 
1821 1.833 - - - -  -  - 0.55 0.00E+00 NA 
Ext. 
Control 
2161 1.103 2 3 3 1 1.17E+05 5.07E+00 0.91 1.06E+05 5.02E+00 
2162 0.571 5 4 3 2 1.50E+08 8.18E+00 1.75 2.63E+08 8.42E+00 
2163 1.228 5 1 2 1 6.67E+07 7.82E+00 0.81 5.43E+07 7.73E+00 
2165 1.905 6 3 2 4 1.50E+09 9.18E+00 0.52 7.87E+08 8.90E+00 
2166 1.558 5 5 6 4 2.50E+08 8.40E+00 0.64 1.60E+08 8.21E+00 
2167 0.938 5 11 13 14 6.33E+08 8.80E+00 1.07 6.75E+08 8.83E+00 
2170 2.005 5 2 9 9 3.33E+08 8.52E+00 0.50 1.66E+08 8.22E+00 
2172 1.171 - - - -     0.85 0.00E+00 NA 
2178 1.34 4 1 4 3 1.33E+07 7.12E+00 0.75 9.95E+06 7.00E+00 
2180 0.776 6 5 1 3 1.50E+09 9.18E+00 1.29 1.93E+09 9.29E+00 
2182 0.908 6 5 6 5 2.67E+09 9.43E+00 1.10 2.94E+09 9.47E+00 




Table 45. Bacteriological results corresponding to individual ileal content samples collected from 




























spot1 spot2 spot3 
4 d.p.i CMT 1801 0.689 - - - -     1.45 0.00E+00 NA 
CMT 1802 0.855 - - - -     1.17 0.00E+00 NA 
CMT 1803 0.645 - - - -     1.55 0.00E+00 NA 
CMT 1804 0.569 - - - -     1.76 0.00E+00 NA 
CMT 1805 1.345 - - - -     0.74 0.00E+00 NA 
CMT 1806 0.718 - - - -     1.39 0.00E+00 NA 
CMT 1814 0.572 - - - -     1.75 0.00E+00 NA 
CMT 1815 0.97 - - - -     1.03 0.00E+00 NA 
CMT 1816 0.244 - - - -     4.10 0.00E+00 NA 
CMT 1819 0.783 - - - -     1.28 0.00E+00 NA 
Ext. Control 2151 0.804 1 1 0 0 1.67E+03 3.22E+00 1.24 2.07E+03 3.32E+00 
Ext. Control 2156 1.017 - - - -     0.98 0.00E+00 NA 
Ext. Control 2157 1.464 - - - -     0.68 0.00E+00 NA 
Ext. Control 2164 1.199 1 2 2 0 6.67E+03 3.82E+00 0.83 5.56E+03 3.75E+00 
Ext. Control 2168 1.23 - - - -     0.81 0.00E+00 NA 
Ext. Control 2176 0.709 - - - -     1.41 0.00E+00 NA 
Ext. Control 2179 0.817 - - - -     1.22 0.00E+00 NA 
Ext. Control 2181 1.007 - - - -     0.99 0.00E+00 NA 
Ext. Control 2183 0.522 - - - -     1.92 0.00E+00 NA 
Ext. Control 2184 1.287 - - - -     0.78 0.00E+00 NA 
Ext. Control 2189 0.301 - - - -     3.32 0.00E+00 NA 
Ext. Control 2191 0.642 - - - -     1.56 0.00E+00 NA 
10 d.p.i CMT 1807 1.085 1 2 2 2 1.00E+04 4.00E+00 0.92 9.22E+03 3.96E+00 
CMT 1808 0.621 - - - -     1.61 0.00E+00 NA 
CMT 1809 1.476 2 4 10 8 3.67E+05 5.56E+00 0.68 2.48E+05 5.40E+00 
CMT 1810 0.7 3 8 7 11 4.33E+06 6.64E+00 1.43 6.19E+06 6.79E+00 
CMT 1811 0.274 1 1 1 2 6.67E+03 3.82E+00 3.65 2.43E+04 4.39E+00 
CMT 1812 0.515 2 3 6 4 2.17E+05 5.34E+00 1.94 4.21E+05 5.62E+00 
CMT 1813 0.769 2 2 2 1 8.33E+04 4.92E+00 1.30 1.08E+05 5.03E+00 
CMT 1817 1.017 2 7 8 3 3.00E+05 5.48E+00 0.98 2.95E+05 5.47E+00 
CMT 1820 0.542 - - - -     1.85 0.00E+00 NA 
CMT 1821 0.965 - - - -     1.04 0.00E+00 NA 
Ext. Control 2161 1.079 - - - -     0.93 0.00E+00 NA 
Ext. Control 2162 1.179 1 0 1 0 1.67E+03 3.22E+00 0.85 1.41E+03 3.15E+00 
Ext. Control 2163 0.553 - - - -     1.81 0.00E+00 NA 
Ext. Control 2165 0.815 2 1 3 4 1.33E+05 5.12E+00 1.23 1.64E+05 5.21E+00 
Ext. Control 2166 1.17 1 4 3 4 1.83E+04 4.26E+00 0.85 1.57E+04 4.20E+00 
Ext. Control 2167 0.993 1 4 0 4 1.33E+04 4.12E+00 1.01 1.34E+04 4.13E+00 
Ext. Control 2170 0.932 1 0 2 0 3.33E+03 3.52E+00 1.07 3.58E+03 3.55E+00 
Ext. Control 2172 0.706 - - - -     1.42 0.00E+00 NA 
Ext. Control 2178 0.947 1 11 7 9 4.50E+04 4.65E+00 1.06 4.75E+04 4.68E+00 
Ext. Control 2180 0.395 2 3 2 3 1.33E+05 5.12E+00 2.53 3.38E+05 5.53E+00 
Ext. Control 2182 0.987 1 4 8 5 2.83E+04 4.45E+00 1.01 2.87E+04 4.46E+00 




Appendix 3: Appendix to Chapter 4 
Table 46. Bacteriological results corresponding to individual caecal content samples collected 











spot1 spot2 spot3 
CMT 1703 0.51 - 0 0 0 N/A N/A - N/A N/A 
CMT 1704 0.66 - 0 0 0 N/A N/A - N/A N/A 
CMT 1705 0.87 - 0 0 0 N/A N/A - N/A N/A 
CMT 1706 2.52 - 0 0 0 N/A N/A - N/A N/A 
CMT 1707 1.94 - 0 0 0 N/A N/A - N/A N/A 
CMT 1710 2.67 - 0 0 0 N/A N/A - N/A N/A 
CMT 1712 1.55 - 0 0 0 N/A N/A - N/A N/A 
CMT 1713 1.12 - 0 0 0 N/A N/A - N/A N/A 
CMT 1714 1.28 - 0 0 0 N/A N/A - N/A N/A 
CMT 1715 0.87 - 0 0 0 N/A N/A - N/A N/A 
CMT 1717 1.786 - 0 0 0 N/A N/A - N/A N/A 
CMT 1718* 2.54 1 0 1 0 1.67E+03 3.22E+00 3.94E-01 6.56E+02 2.82E+00 
CMT 1719* 1.61 - 0 0 0 N/A N/A - N/A N/A 
Aviguard 3651 3.04 5 3 2 4 1.50E+08 8.18E+00 3.29E-01 4.93E+07 7.69E+00 
Aviguard 3652* 2.64 5 1 2 1 6.67E+07 7.82E+00 3.79E-01 2.53E+07 7.40E+00 
Aviguard 3653 2.96 3 7 10 8 4.17E+06 6.62E+00 3.38E-01 1.41E+06 6.15E+00 
Aviguard 3654* 2.05 5 1 3 2 1.00E+08 8.00E+00 4.88E-01 4.88E+07 7.69E+00 
Aviguard 3655 2.25 6 3 2 2 1.17E+09 9.07E+00 4.44E-01 5.19E+08 8.71E+00 
Aviguard 3657 2.26 5 8 3 6 2.83E+08 8.45E+00 4.42E-01 1.25E+08 8.10E+00 
Aviguard 3659 0.79 5 2 1 3 1.00E+08 8.00E+00 1.27E+00 1.27E+08 8.10E+00 
Aviguard 3660 1.13 5 3 4 9 2.67E+08 8.43E+00 8.85E-01 2.36E+08 8.37E+00 
Aviguard 3661 1.64 6 2 3 2 1.17E+09 9.07E+00 6.10E-01 7.11E+08 8.85E+00 
Aviguard 3662 1.16 5 2 4 4 1.67E+08 8.22E+00 8.62E-01 1.44E+08 8.16E+00 
    Aviguard 3663 1.155 5 1 1 0 3.33E+07 7.52E+00 8.66E-01 2.89E+07 7.46E+00 
    Aviguard 3664 2.74 5 1 1 2 6.67E+07 7.82E+00 3.65E-01 2.43E+07 7.39E+00 
    Aviguard 3665 1.99 6 2 4 3 1.50E+09 9.18E+00 5.03E-01 7.54E+08 8.88E+00 
Int. Control 226 1.326 6 1 2 4 1.17E+09 9.07E+00 7.54E-01 8.80E+08 8.94E+00 
Int. Control 227 2.161 5 2 4 6 2.00E+08 8.30E+00 4.63E-01 9.25E+07 7.97E+00 
Int. Control 228 1.455 4 7 7 9 3.83E+07 7.58E+00 6.87E-01 2.63E+07 7.42E+00 
Int. Control 229 0.363 6 8 5 6 3.17E+09 9.50E+00 2.75E+00 8.72E+09 9.94E+00 
Int. Control 230 0.865 6 2 6 3 1.83E+09 9.26E+00 1.16E+00 2.12E+09 9.33E+00 
Int. Control 231* 1.394 7 2 5 4 1.83E+10 1.03E+01 7.17E-01 1.32E+10 1.01E+01 
Int. Control 232 1.619 6 4 1 4 1.50E+09 9.18E+00 6.18E-01 9.26E+08 8.97E+00 
Int. Control 233* 1.215 5 6 3 3 2.00E+08 8.30E+00 8.23E-01 1.65E+08 8.22E+00 
Int. Control 234 2.282 6 1 1 1 5.00E+08 8.70E+00 4.38E-01 2.19E+08 8.34E+00 
Int. Control 236 1.359 5 12 7 12 5.17E+08 8.71E+00 7.36E-01 3.80E+08 8.58E+00 
Int. Control 237 2.331 6 6 5 5 2.67E+09 9.43E+00 4.29E-01 1.14E+09 9.06E+00 
Int. Control 238 2.647 6 1 2 1 6.67E+08 8.82E+00 3.78E-01 2.52E+08 8.40E+00 
Int. Control 239 1.836 7 8 3 1 2.00E+10 1.03E+01 5.45E-01 1.09E+10 1.00E+01 
Ext. Control 802* 1.94 4 8 5 6 3.17E+07 7.50E+00 5.15E-01 1.63E+07 7.21E+00 
Ext. Control 803 2.11 5 4 8 9 3.50E+08 8.54E+00 4.74E-01 1.66E+08 8.22E+00 
Ext. Control 804 2.71 6 5 7 4 2.67E+09 9.43E+00 3.69E-01 9.84E+08 8.99E+00 
Ext. Control 805 2.068 5 9 8 11 4.67E+08 8.67E+00 4.84E-01 2.26E+08 8.35E+00 
Ext. Control 806 1.692 5 4 4 4 2.00E+08 8.30E+00 5.91E-01 1.18E+08 8.07E+00 
Ext. Control 807 1.58 2 13 9 6 4.67E+05 5.67E+00 6.33E-01 2.95E+05 5.47E+00 
Ext. Control 809 1.07 4 13 15 16 7.33E+07 7.87E+00 9.35E-01 6.85E+07 7.84E+00 
Ext. Control 810 1.92 5 14 12 8 5.67E+08 8.75E+00 5.21E-01 2.95E+08 8.47E+00 
Ext. Control 811 1.04 5 3 5 2 1.67E+08 8.22E+00 9.62E-01 1.60E+08 8.20E+00 
Ext. Control 812 1.71 - 0 0 0 N/A N/A - N/A N/A 
Ext. Control 813 2.66 6 2 1 5 1.33E+09 9.12E+00 3.76E-01 5.01E+08 8.70E+00 
Ext. Control 814* 0.885 3 2 4 5 1.83E+06 6.26E+00 1.13E+00 2.07E+06 6.32E+00 




Table 47. Bacteriological results corresponding to individual ileal content samples collected from 









CFU/g Log CFU/g 
spot1 spot2 spot3 
CMT 1703 1.216 - 0 0 0 N/A N/A - N/A N/A 
CMT 1704 1.288 - 0 0 0 N/A N/A - N/A N/A 
CMT 1705 0.841 - 0 0 0 N/A N/A - N/A N/A 
CMT 1706 1.194 - 0 0 0 N/A N/A - N/A N/A 
CMT 1707 0.916 - 0 0 0 N/A N/A - N/A N/A 
CMT 1710 1.527 - 0 0 0 N/A N/A - N/A N/A 
CMT 1712 0.94 - 0 0 0 N/A N/A - N/A N/A 
CMT 1713 0.904 - 0 0 0 N/A N/A - N/A N/A 
CMT 1714 1.405 - 0 0 0 N/A N/A - N/A N/A 
CMT 1715 0.899 - 0 0 0 N/A N/A - N/A N/A 
CMT 1717 1.029 - 0 0 0 N/A N/A - N/A N/A 
CMT 1718* 0.996 - 0 0 0 N/A N/A - N/A N/A 
CMT 1719* 0.805 - 0 0 0 N/A N/A - N/A N/A 
Aviguard 3651 1.169 - 0 0 0 N/A N/A - N/A N/A 
Aviguard 3652* 0.491 - 0 0 0 N/A N/A - N/A N/A 
Aviguard 3653 0.788 1 2 1 1 6.67E+03 3.82E+00 1.27E+00 8.46E+03 3.93E+00 
Aviguard 3654* 1.239 2 4 6 4 2.33E+05 5.37E+00 8.07E-01 1.88E+05 5.27E+00 
Aviguard 3655 1.374 1 3 4 7 2.33E+04 4.37E+00 7.28E-01 1.70E+04 4.23E+00 
Aviguard 3657 1.259 1 3 7 5 2.50E+04 4.40E+00 7.94E-01 1.99E+04 4.30E+00 
Aviguard 3659 0.966 1 4 5 3 2.00E+04 4.30E+00 1.04E+00 2.07E+04 4.32E+00 
Aviguard 3660 1.138 2 7 7 7 3.50E+05 5.54E+00 8.79E-01 3.08E+05 5.49E+00 
Aviguard 3661 0.808 2 2 4 3 1.50E+05 5.18E+00 1.24E+00 1.86E+05 5.27E+00 
Aviguard 3662 1.136 - 0 0 0 N/A N/A - N/A N/A 
Aviguard 3663 0.519 1 1 0 2 5.00E+03 3.70E+00 1.93E+00 9.63E+03 3.98E+00 
Aviguard 3664 0.701 2 1 3 2 1.00E+05 5.00E+00 1.43E+00 1.43E+05 5.15E+00 
Aviguard 3665 1.881 3 1 1 1 5.00E+05 5.70E+00 5.32E-01 2.66E+05 5.42E+00 
Int. Control 226 1.513 - 0 0 0 N/A N/A - N/A N/A 
Int. Control 227 1.059 - 0 0 0 N/A N/A - N/A N/A 
Int. Control 228 0.744 2 1 0 0 1.67E+04 4.22E+00 1.34E+00 2.24E+04 4.35E+00 
Int. Control 229 0.796 5 12 9 14 5.83E+08 8.77E+00 1.26E+00 7.33E+08 8.87E+00 
Int. Control 230 1.381 3 0 3 3 1.00E+06 6.00E+00 7.24E-01 7.24E+05 5.86E+00 
Int. Control 231* 1.544 3 7 8 6 3.50E+06 6.54E+00 6.48E-01 2.27E+06 6.36E+00 
Int. Control 232 1.131 - 0 0 0 N/A N/A - N/A N/A 
Int. Control 233* 0.986 2 2 5 2 1.50E+05 5.18E+00 1.01E+00 1.52E+05 5.18E+00 
Int. Control 234 0.886 - 0 0 0 N/A N/A - N/A N/A 
Int. Control 236 1.253 2 2 4 2 1.33E+05 5.12E+00 7.98E-01 1.06E+05 5.03E+00 
Int. Control 237 0.727 4 1 3 1 8.33E+06 6.92E+00 1.38E+00 1.15E+07 7.06E+00 
Int. Control 238 1.03 1 1 0 0 1.67E+03 3.22E+00 9.71E-01 1.62E+03 3.21E+00 
Int. Control 239 1.203 1 0 0 1 1.67E+03 3.22E+00 8.31E-01 1.39E+03 3.14E+00 
Ext. Control 802* 1.962 1 3 5 4 2.00E+04 4.30E+00 5.10E-01 1.02E+04 4.01E+00 
Ext. Control 803 1.476 1 5 8 7 3.33E+04 4.52E+00 6.78E-01 2.26E+04 4.35E+00 
Ext. Control 804 0.661 1 2 0 0 3.33E+03 3.52E+00 1.51E+00 5.04E+03 3.70E+00 
Ext. Control 805 0.748 1 3 1 1 8.33E+03 3.92E+00 1.34E+00 1.11E+04 4.05E+00 
Ext. Control 806 0.954 1 1 2 4 1.17E+04 4.07E+00 1.05E+00 1.22E+04 4.09E+00 
Ext. Control 807 1.356 - 0 0 0 N/A N/A - N/A N/A 
Ext. Control 809 1.083 1 6 6 3 2.50E+04 4.40E+00 9.23E-01 2.31E+04 4.36E+00 
Ext. Control 810 0.713 1 1 1 1 5.00E+03 3.70E+00 1.40E+00 7.01E+03 3.85E+00 
Ext. Control 811 1.192 1 1 2 3 1.00E+04 4.00E+00 8.39E-01 8.39E+03 3.92E+00 
Ext. Control 812 0.253 - 0 0 0 N/A N/A - N/A N/A 
Ext. Control 813 1.782 - 0 0 0 N/A N/A - N/A N/A 
Ext. Control 814* 1.425 - 0 0 0 N/A N/A - N/A N/A 

























1 Inoculate count N/A 4 27 30 29 28.67 1.43E+07 7.16 N/A 
MHB (Control) C1 2 19 83 43 48.33 2.42E+05 5.38 1.69 
C2 2 22 32 37 30.33 1.52E+05 5.18 1.06 
C3 2 23 22 36 27.00 1.35E+05 5.13 0.94 
C4 2 18 12 35 21.67 1.08E+05 5.03 0.76 
C5 2 21 12 10 14.33 7.17E+04 4.86 0.50 
C6 2 10 18 9 12.33 6.17E+04 4.79 0.43 
C7 2 13 24 17 18.00 9.00E+04 4.95 0.63 
C8 3 19 21 27 22.33 1.12E+06 6.05 7.79 
C9 2 29 16 17 20.67 1.03E+05 5.01 0.72 
C10 2 13 8 9 10.00 5.00E+04 4.70 0.35 
C11 2 24 34 28 28.67 1.43E+05 5.16 1.00 
C12 2 63 35 15 37.67 1.88E+05 5.27 1.31 
CMT FT1 2 10 18 10 12.67 6.33E+04 4.80 0.44 
FT2 2 14 10 16 13.33 6.67E+04 4.82 0.47 
FT3 2 8 7 11 8.67 4.33E+04 4.64 0.30 
FT4 2 13 13 18 14.67 7.33E+04 4.87 0.51 
FT5 2 7 12 13 10.67 5.33E+04 4.73 0.37 
FT6 2 16 16 12 14.67 7.33E+04 4.87 0.51 
FT7 2 13 13 19 15.00 7.50E+04 4.88 0.52 
FT8 2 15 8 16 13.00 6.50E+04 4.81 0.45 
FT9 2 13 15 8 12.00 6.00E+04 4.78 0.42 
FT10 2 15 11 10 12.00 6.00E+04 4.78 0.42 
Aviguard Avi1 2 16 14 13 14.33 7.17E+04 4.86 0.50 
Avi2 2 21 16 18 18.33 9.17E+04 4.96 0.64 
Avi3 2 19 19 19 19.00 9.50E+04 4.98 0.66 
Avi4 2 7 11 12 10.00 5.00E+04 4.70 0.35 
Avi5 2 12 10 10 10.67 5.33E+04 4.73 0.37 
Avi6 2 21 15 19 18.33 9.17E+04 4.96 0.64 
Avi7 2 14 16 10 13.33 6.67E+04 4.82 0.47 
Avi8 2 11 15 15 13.67 6.83E+04 4.83 0.48 
Avi9 2 15 6 12 11.00 5.50E+04 4.74 0.38 
Avi10 2 18 25 14 19.00 9.50E+04 4.98 0.66 
2 Inoculate count N/A 5 2 6 3 3.67 1.83E+07 7.26 N/A 
MHB (Control)) C1 4 1 2 2 1.67 8.33E+05 5.92 4.55 
C2 3 15 13 10 12.67 6.33E+05 5.80 3.45 
C3 3 13 12 10 11.67 5.83E+05 5.77 3.18 
C4 3 5 5 9 6.33 3.17E+05 5.50 1.73 
C5 3 10 14 11 11.67 5.83E+05 5.77 3.18 
C6 3 14 10 11 11.67 5.83E+05 5.77 3.18 
CMT CMT1 3 12 10 11 11.00 5.50E+05 5.74 3.00 
CMT2 3 12 6 10 9.33 4.67E+05 5.67 2.55 
CMT3 3 4 6 8 6.00 3.00E+05 5.48 1.64 
CMT4 3 9 10 10 9.67 4.83E+05 5.68 2.64 
CMT5 3 2 1 1 1.33 6.67E+04 4.82 0.36 
CMT6 3 10 4 10 8.00 4.00E+05 5.60 2.18 
Aviguard Avi1 4 4 5 4 4.33 2.17E+06 6.34 11.82 
Avi2 4 2 2 2 2.00 1.00E+06 6.00 5.45 
Avi3 3 5 5 9 6.33 3.17E+05 5.50 1.73 
Avi4 4 2 2 2 2.00 1.00E+06 6.00 5.45 
Avi5 3 3 2 3 2.67 1.33E+05 5.12 0.73 
Avi6 3 9 8 5 7.33 3.67E+05 5.56 2.00 
3 Inoculate count N/A 4 13 7 3 7.67 3.83E+06 6.58 N/A 
MHB (Control) C1 3 6 10 4 6.67 3.33E+05 5.52 8.70 
C2 3 7 4 3 4.67 2.33E+05 5.37 6.09 
C3 3 9 5 6 6.67 3.33E+05 5.52 8.70 
C4 3 7 3 4 4.67 2.33E+05 5.37 6.09 
C5 3 5 7 6 6.00 3.00E+05 5.48 7.83 
C6 3 7 5 4 5.33 2.67E+05 5.43 6.96 
C7 3 3 3 2 2.67 1.33E+05 5.12 3.48 
C8 3 4 3 2 3.00 1.50E+05 5.18 3.91 




C10 4 4 3 4 3.67 1.83E+06 6.26 47.83 
CMT FT1 3 3 3 6 4.00 2.00E+05 5.30 5.22 
FT2 3 3 4 3 3.33 1.67E+05 5.22 4.35 
FT3 3 5 4 7 5.33 2.67E+05 5.43 6.96 
FT4 2 15 16 16 15.67 7.83E+04 4.89 2.04 
FT5 3 6 6 4 5.33 2.67E+05 5.43 6.96 
FT6 3 1 3 3 2.33 1.17E+05 5.07 3.04 
FT7 2 6 5 8 6.33 3.17E+04 4.50 0.83 
FT8 2 8 6 8 7.33 3.67E+04 4.56 0.96 
FT9 2 10 12 9 10.33 5.17E+04 4.71 1.35 
FT10 2 13 12 14 13.00 6.50E+04 4.81 1.70 
Aviguard Avi1 3 14 14 14 14.00 7.00E+05 5.85 18.26 
Avi2 3 5 8 7 6.67 3.33E+05 5.52 8.70 
Avi3 3 4 1 1 2.00 1.00E+05 5.00 2.61 
Avi4 2 17 23 19 19.67 9.83E+04 4.99 2.57 
Avi5 3 5 4 4 4.33 2.17E+05 5.34 5.65 
Avi6 3 6 5 7 6.00 3.00E+05 5.48 7.83 
Avi7 3 4 3 4 3.67 1.83E+05 5.26 4.78 
Avi8 3 6 2 2 3.33 1.67E+05 5.22 4.35 
Avi9 3 3 2 4 3.00 1.50E+05 5.18 3.91 




















































1 Inoculate Count N/A 4 10 11 12 11.00 5.50E+06 6.74 N/A 
MHB (Control) C1 3 13 7 13 11.00 5.50E+05 5.74 10.00 
C2 3 2 2 3 2.33 1.17E+05 5.07 2.12 
C3 3 6 5 2 4.33 2.17E+05 5.34 3.94 
C4 3 19 21 25 21.67 1.08E+06 6.03 19.70 
C5 3 9 9 10 9.33 4.67E+05 5.67 8.48 
C6 3 4 3 6 4.33 2.17E+05 5.34 3.94 
C7 3 4 5 3 4.00 2.00E+05 5.30 3.64 
C8 3 4 2 2 2.67 1.33E+05 5.12 2.42 
C9 3 5 2 1 2.67 1.33E+05 5.12 2.42 
C10 3 19 17 14 16.67 8.33E+05 5.92 15.15 
CMT CMT1 3 3 5 5 4.33 2.17E+05 5.34 3.94 
CMT2 3 6 5 0 3.67 1.83E+05 5.26 3.33 
CMT3 3 3 3 2 2.67 1.33E+05 5.12 2.42 
CMT4 3 1 5 3 3.00 1.50E+05 5.18 2.73 
CMT5 3 5 7 1 4.33 2.17E+05 5.34 3.94 
CMT6 3 4 7 6 5.67 2.83E+05 5.45 5.15 
CMT7 3 4 4 4 4.00 2.00E+05 5.30 3.64 
CMT8 3 4 5 6 5.00 2.50E+05 5.40 4.55 
CMT9 3 4 2 5 3.67 1.83E+05 5.26 3.33 
CMT10 3 5 3 7 5.00 2.50E+05 5.40 4.55 
 Aviguard Avi1 3 5 7 2 4.67 2.33E+05 5.37 4.24 
Avi2 3 1 4 5 3.33 1.67E+05 5.22 3.03 
Avi3 3 5 5 6 5.33 2.67E+05 5.43 4.85 
Avi4 3 3 1 6 3.33 1.67E+05 5.22 3.03 
Avi5 3 7 18 17 14.00 7.00E+05 5.85 12.73 
Avi6 3 5 5 3 4.33 2.17E+05 5.34 3.94 
Avi7 3 8 4 21 11.00 5.50E+05 5.74 10.00 
Avi8 3 2 8 3 4.33 2.17E+05 5.34 3.94 
Avi9 3 2 2 5 3.00 1.50E+05 5.18 2.73 
2 Inoculate Count N/A 4 4 9 4 5.67 2.83E+06 6.45 N/A 
MHB (Control) C1 3 2 2 1 1.67 8.33E+04 4.92 2.94 
C2 2 10 10 12 10.67 5.33E+04 4.73 1.88 
C3 2 9 13 8 10.00 5.00E+04 4.70 1.76 
C4 3 5 8 3 5.33 2.67E+05 5.43 9.41 
C5 3 1 4 1 2.00 1.00E+05 5.00 3.53 
C6 3 4 3 2 3.00 1.50E+05 5.18 5.29 
C7 3 1 2 1 1.33 6.67E+04 4.82 2.35 
C8 3 2 4 2 2.67 1.33E+05 5.12 4.71 
C9 3 2 1 1 1.33 6.67E+04 4.82 2.35 
C10 3 2 1 1 1.33 6.67E+04 4.82 2.35 
CMT CMT1 2 13 18 9 13.33 6.67E+04 4.82 2.35 
CMT2 2 13 11 13 12.33 6.17E+04 4.79 2.18 
CMT3 2 6 11 8 8.33 4.17E+04 4.62 1.47 
CMT4 2 5 9 3 5.67 2.83E+04 4.45 1.00 
CMT5 2 6 9 9 8.00 4.00E+04 4.60 1.41 
CMT6 2 4 5 7 5.33 2.67E+04 4.43 0.94 
CMT7 3 1 4 2 2.33 1.17E+05 5.07 4.12 
CMT8 3 1 1 1 1.00 5.00E+04 4.70 1.76 
CMT9 3 3 2 3 2.67 1.33E+05 5.12 4.71 
CMT10 2 12 14 19 15.00 7.50E+04 4.88 2.65 
Aviguard Avi1 3 4 3 2 3.00 1.50E+05 5.18 5.29 
Avi2 3 6 3 4 4.33 2.17E+05 5.34 7.65 
Avi3 2 11 16 15 14.00 7.00E+04 4.85 2.47 
Avi4 3 3 1 1 1.67 8.33E+04 4.92 2.94 
Avi5 3 2 2 2 2.00 1.00E+05 5.00 3.53 
Avi6 2 12 17 24 17.67 8.83E+04 4.95 3.12 
Avi7 3 1 2 1 1.33 6.67E+04 4.82 2.35 
Avi8 3 3 2 1 2.00 1.00E+05 5.00 3.53 
Avi9 3 5 2 5 4.00 2.00E+05 5.30 7.06 




Table 50. Recovered S. Typhimurium 4/74 and % invasion for GPA protocols on 8E11 cell lines 
Infection 
strain 

















N/A 6 5 10 8 7.67 3.83E+08 8.58 N/A 
LB 
(Control) 
C1 5 16 18 8 14.00 7.00E+07 7.85 18.26 
C2 5 7 14 11 10.67 5.33E+07 7.73 13.91 
C3 5 7 5 4 5.33 2.67E+07 7.43 6.96 
C4 5 9 10 7 8.67 4.33E+07 7.64 11.30 
C5 5 7 8 6 7.00 3.50E+07 7.54 9.13 
C6 5 11 17 13 13.67 6.83E+07 7.83 17.83 
C7 5 14 16 19 16.33 8.17E+07 7.91 21.30 
C8 5 15 12 14 13.67 6.83E+07 7.83 17.83 
CMT FT1 5 9 10 3 7.33 3.67E+07 7.56 9.57 
FT2 5 10 9 6 8.33 4.17E+07 7.62 10.87 
FT3 5 7 9 3 6.33 3.17E+07 7.50 8.26 
FT4 5 1 1 0 0.67 3.33E+06 6.52 0.87 
FT5 5 7 4 11 7.33 3.67E+07 7.56 9.57 
FT6 5 4 4 6 4.67 2.33E+07 7.37 6.09 
FT7 5 4 6 8 6.00 3.00E+07 7.48 7.83 
FT8 5 13 14 14 13.67 6.83E+07 7.83 17.83 
FT9 5 1 1 0 0.67 3.33E+06 6.52 0.87 
FT10 5 3 4 3 3.33 1.67E+07 7.22 4.35 
Aviguard Avi1 5 9 9 11 9.67 4.83E+07 7.68 12.61 
Avi2 5 11 7 6 8.00 4.00E+07 7.60 10.43 
Avi3 5 10 5 4 6.33 3.17E+07 7.50 8.26 
Avi4 5 4 2 2 2.67 1.33E+07 7.12 3.48 
Avi5 5 5 4 1 3.33 1.67E+07 7.22 4.35 
Avi6 5 14 9 8 10.33 5.17E+07 7.71 13.48 
Avi7 5 4 4 2 3.33 1.67E+07 7.22 4.35 
Avi8 5 6 8 3 5.67 2.83E+07 7.45 7.39 
Avi9 5 2 5 6 4.33 2.17E+07 7.34 5.65 
Avi10 5 17 14 7 12.67 6.33E+07 7.80 16.52 
2 Inoculate 
Count 
N/A 6 17 23 16 18.67 9.33E+08 8.97 N/A 
LB 
(Control) 
C1 6 1 2 1 1.33 6.67E+07 7.82 7.14 
C2 6 1 3 3 2.33 1.17E+08 8.07 12.50 
C3 6 1 1 3 1.67 8.33E+07 7.92 8.93 
C4 5 10 10 5 8.33 4.17E+07 7.62 4.46 
C5 6 1 1 3 1.67 8.33E+07 7.92 8.93 
C6 6 2 5 2 3.00 1.50E+08 8.18 16.07 
C7 5 6 5 5 5.33 2.67E+07 7.43 2.86 
C8 5 4 4 2 3.33 1.67E+07 7.22 1.79 
C9 5 6 11 4 7.00 3.50E+07 7.54 3.75 
C10 5 7 10 10 9.00 4.50E+07 7.65 4.82 
CMT FT1 5 9 1 11 7.00 3.50E+07 7.54 3.75 
FT2 5 4 4 7 5.00 2.50E+07 7.40 2.68 
FT3 5 6 3 7 5.33 2.67E+07 7.43 2.86 
FT4 5 5 4 4 4.33 2.17E+07 7.34 2.32 
FT5 5 4 3 7 4.67 2.33E+07 7.37 2.50 
FT6 5 5 5 6 5.33 2.67E+07 7.43 2.86 
FT7 5 13 11 6 10.00 5.00E+07 7.70 5.36 
FT8 5 6 4 7 5.67 2.83E+07 7.45 3.04 
FT9 5 4 1 5 3.33 1.67E+07 7.22 1.79 
FT10 5 1 3 3 2.33 1.17E+07 7.07 1.25 
Aviguard Avi1 5 7 9 10 8.67 4.33E+07 7.64 4.64 
Avi2 5 6 5 6 5.67 2.83E+07 7.45 3.04 
Avi3 5 5 8 5 6.00 3.00E+07 7.48 3.21 
Avi4 5 2 4 9 5.00 2.50E+07 7.40 2.68 
Avi5 5 11 9 11 10.33 5.17E+07 7.71 5.54 
Avi6 5 2 4 8 4.67 2.33E+07 7.37 2.50 
Avi7 5 2 9 5 5.33 2.67E+07 7.43 2.86 
Avi8 5 12 8 6 8.67 4.33E+07 7.64 4.64 
Avi9 5 3 8 8 6.33 3.17E+07 7.50 3.39 





Appendix 4: Appendix to Chapter 5 
 
QIIME2™ commands for microbiota analysis 
 
#input manifest file into QIIME2™ software 
qiime tools import --type 'SampleData[PairedEndSequencesWithQuality]' --input-path manifest.csv --output-path 
Qiime2/paired-end-demux.qza --source-format PairedEndFastqManifestPhred33 
 
# Run DADA2 plugin 
qiime dada2 denoise-paired –i--demultiplexed-seqs paired-end-demux.qza --p-trunc-len-f 250 --p-trunc-len-r 250 --p-trim-left-f 
7 --p-trim-left-r 21 --output-dir DADA2 
 
# Visualise summary feature data  
qiime feature-table  summarize --i-table DADA2/table.qza --o-visualization table.qzv --m-sample-metadata-file mappingfile.tsv  
qiime feature-table tabulate-seqs --i-data DADA2/representative_sequences.qza --o-visualization rep-seqs.qzv 
qiime metadata tabulate --m-input-file DADA2/denoising_stats.qza --o-visualization denoising-stats.qzv 
 
# Run mafft pipeline 
qiime phylogeny align-to-tree-mafft-fasttree –i- sequences DADA2/representative_sequences.qza –o-alignment aligned-rep-
seqs.qza –o-masked-alignment masked-aligned-rep-seqs.qza –o- tree unrooted-tree.qza –o-rooted-tree rooted-tree.qza 
 
#Alpha and Beta diversity analysis 
qiime diversity core-metrics-phylogenetic --i-phylogeny rooted-tree.qza --i-table DADA2/table.qza --p-sampling-depth 44841 --
m-metadata-file mappingfile.tsv --output-dir core-metrics-results 
qiime diversity alpha-group-significance –i-alpha-diversity core-metrics-results/evenness_vector.qza –m-metadata-file 
mappingfile.tsv –o-visualization core-metrics-results/evenness-group-significance.qzv 
qiime diversity alpha-group-significance –i-alpha-diversity core-metrics-results/observed_otus_vector.qza –m-metadata-file 
mappingfile.tsv –o-visualization core-metrics-results/observed-otus-group-significance.qzv 
qiime diversity alpha-group-significance –i-alpha-diversity core-metrics-results/shannon_vector.qza –m-metadata-file 
mappingfile.tsv –o-visualization core-metrics-results/shannon-group-significance.qzv 
qiime diversity beta-group-significance –i-distance-matrix core-metrics-results/unweighted_unifrac_distance_matrix.qza –m-
metadata-file mappingfile.tsv –m-metadata-column Group –o-visualization core-metrics-results/unweighted-unifrac-group-
significance.qzv –p-pairwise 
qiime diversity beta-group-significance –i-distance-matrix core-metrics-results/weighted_unifrac_distance_matrix.qza –m-




qiime feature-classifier classify-sklearn --i-classifier gg-13-8-99-515-806-nb-classifier.qza --i-reads 
DADA2/representative_sequences.qza --o-classification taxonomy.qza 
qiime metadata tabulate --m-input-file taxonomy.qza --o-visualization taxonomy.qzv 






















Table 51. DNA quantities of samples for Illumina MiSEQ protocols. All samples are quantified using 
QuBit analysis 
Sample  Organism Quantification method Concentration (ng/µl) Sample volume (µl ) 
CMT1 Bacteria QuBit 16.2 20 
CMT2 Bacteria QuBit 49.7 20 
CMT3 Bacteria QuBit 18.3 20 
CMT4 Bacteria QuBit 14.3 20 
CMT5 Bacteria QuBit 19.9 20 
CMT6 Bacteria QuBit 12.3 20 
CMT7 Bacteria QuBit 8.66 20 
CMT8 Bacteria QuBit 8.77 20 
CMT9 Bacteria QuBit 6.66 20 
CMT10 Bacteria QuBit 5.25 20 
Ext. Control 1 Bacteria QuBit 24.9 20 
Ext. Control 2 Bacteria QuBit 14.7 20 
Ext. Control 3 Bacteria QuBit 7.34 20 
Ext. Control 4 Bacteria QuBit 9.63 20 
Ext. Control 5 Bacteria QuBit 10.7 20 
Ext. Control 6 Bacteria QuBit 27.8 20 
Ext. Control 7 Bacteria QuBit 7.77 20 
Ext. Control 8 Bacteria QuBit 4.32 20 
Ext. Control 9 Bacteria QuBit 8.06 20 
Ext. Control 10 Bacteria QuBit 6.9 20 
Int. Control 1 Bacteria QuBit 15.1 20 
Int. Control 2 Bacteria QuBit 16.1 20 
Int. Control 3 Bacteria QuBit 19.7 20 
Int. Control 4 Bacteria QuBit 22.2 20 
Int. Control 5 Bacteria QuBit 14.9 20 
Int. Control 6 Bacteria QuBit 11.8 20 
Int. Control 7 Bacteria QuBit 11.2 20 
Int. Control 8 Bacteria QuBit 16.1 20 
Int. Control 9 Bacteria QuBit 0.419 20 
Int. Control 10 Bacteria QuBit 9.68 20 
Aviguard 1 Bacteria QuBit 74.8 20 
Aviguard 2 Bacteria QuBit 7.92 20 
Aviguard 3 Bacteria QuBit 35 20 
Aviguard 4 Bacteria QuBit 22.2 20 
Aviguard 5 Bacteria QuBit 18.5 20 
Aviguard 6 Bacteria QuBit 29.6 20 
Aviguard 7 Bacteria QuBit 46.8 20 
Aviguard 8 Bacteria QuBit 49.2 20 
Aviguard 9 Bacteria QuBit 10.8 20 
Aviguard 10 Bacteria QuBit 17.4 20 
3d_CMT1 Bacteria QuBit 27.2 20 
3d_CMT2 Bacteria QuBit 14.9 20 
3d_CMT3 Bacteria QuBit 26.3 20 
3d_CMT4 Bacteria QuBit 35.8 20 
3d_Aviguard1 Bacteria QuBit 7.53 20 
3d_Aviguard2 Bacteria QuBit 33.8 20 
3d_Aviguard3 Bacteria QuBit 10.3 20 
3d_Ext. Control 1 Bacteria QuBit 32.7 20 
3d_Ext. Control 2 Bacteria QuBit 32.2 20 
3d_Ext. Control 3 Bacteria QuBit 20.7 20 
3d_Int. Control 1 Bacteria QuBit 23.6 20 
3d_Int. Control 2 Bacteria QuBit 2.39 20 
3d_Int. Control 3 Bacteria QuBit 27.1 20 
AV_MAT_2 Bacteria QuBit 3.21 20 
CMT_MAT_1 Bacteria QuBit 5.72 20 





Table 52. Number of sequences for each processed sample following Illumina MiSeq protocols.  
Sample ID Treatment Group Age Sequence Count 
CMTMAT1 - - 87207 
CMTMAT2 - - 64083 
AvMAT 1 - - 80457 
CMT1 CMT treated 7 d.p.h 111568 
CMT2 CMT treated 7 d.p.h 59022 
CMT3 CMT treated 7 d.p.h 55625 
CMT4 CMT treated 7 d.p.h 54917 
CMT5 CMT treated 7 d.p.h 100721 
CMT6 CMT treated 7 d.p.h 120917 
CMT7 CMT treated 7 d.p.h 94670 
CMT8 CMT treated 7 d.p.h 90632 
CMT9 CMT treated 7 d.p.h 100074 
CMT10 CMT treated 7 d.p.h 69917 
H1 Ext. Control 7 d.p.h 88073 
H2 Ext. Control 7 d.p.h 107988 
H3 Ext. Control 7 d.p.h 115389 
H4 Ext. Control 7 d.p.h 78548 
H5 Ext. Control 7 d.p.h 68204 
H6 Ext. Control 7 d.p.h 44841 
H7 Ext. Control 7 d.p.h 105395 
H8 Ext. Control 7 d.p.h 95182 
H9 Ext. Control 7 d.p.h 102740 
H10 Ext. Control 7 d.p.h 103356 
C1 Int. Control 7 d.p.h 101033 
C2 Int. Control 7 d.p.h 123989 
C3 Int. Control 7 d.p.h 77929 
C4 Int. Control 7 d.p.h 85493 
C5 Int. Control 7 d.p.h 106937 
C6 Int. Control 7 d.p.h 90290 
C7 Int. Control 7 d.p.h 82793 
C8 Int. Control 7 d.p.h 93334 
C9 Int. Control 7 d.p.h 44963 
C10 Int. Control 7 d.p.h 92565 
A1 Aviguard® Treated 7 d.p.h 96183 
A2 Aviguard® Treated 7 d.p.h 118325 
A3 Aviguard® Treated 7 d.p.h 75630 
A4 Aviguard® Treated 7 d.p.h 63201 
A5 Aviguard® Treated 7 d.p.h 60388 
A6 Aviguard® Treated 7 d.p.h 112800 
A7 Aviguard® Treated 7 d.p.h 111525 
A8 Aviguard® Treated 7 d.p.h 76378 
A9 Aviguard® Treated 7 d.p.h 49008 
A10 Aviguard® Treated 7 d.p.h 70109 
3d_CMT1 CMT Treated 3 d.p.h 96394 
3d_CMT2 CMT Treated 3 d.p.h 84915 
3d_CMT3 CMT Treated 3 d.p.h 105610 
3d_CMT4 CMT Treated 3 d.p.h 71829 
3d_A1 Aviguard® Treated 3 d.p.h 84743 
3d_A2 Aviguard® Treated 3 d.p.h 89610 
3d_A3 Aviguard® Treated 3 d.p.h 89320 
3d_H1 Ext. Control  3 d.p.h 91907 
3d_H2 Ext. Control  3 d.p.h 115061 
3d_H3 Ext. Control  3 d.p.h 79881 
3d_C1 Int. Control 3 d.p.h 71315 
3d_C2 Int. Control 3 d.p.h 66630 




Table 53. Alpha diversity statistics shown for observed out, Shannon and Pielou evenness metrics.  
Sample ID Treatment 
Group 
Age (d.p.h) Metric 
observed_otus Shannon Pielou 
CMT1 CMT 7 121 5.141849 0.743164 
CMT2 CMT 7 118 5.243579 0.761855 
CMT3 CMT 7 124 5.340499 0.767954 
CMT4 CMT 7 100 4.60395 0.692964 
CMT5 CMT 7 101 4.365535 0.655662 
CMT6 CMT 7 204 5.775629 0.752777 
CMT7 CMT 7 114 3.906736 0.571755 
CMT8 CMT 7 175 4.492313 0.602897 
CMT9 CMT 7 82 3.718769 0.584937 
CMT10 CMT 7 190 5.329622 0.704059 
Ext. Control 1 Ext. Control 7 31 2.646616 0.534217 
Ext. Control 2 Ext. Control 7 40 3.066644 0.576228 
Ext. Control 3 Ext. Control 7 28 2.941746 0.611926 
Ext. Control 4 Ext. Control 7 38 2.703969 0.515245 
Ext. Control 5 Ext. Control 7 33 2.575939 0.510654 
Ext. Control 6 Ext. Control 7 36 3.184915 0.616047 
Ext. Control 7 Ext. Control 7 33 2.792606 0.553606 
Ext. Control 8 Ext. Control 7 35 2.33315 0.454869 
Ext. Control 9 Ext. Control 7 42 2.97532 0.55177 
Ext. Control 10 Ext. Control 7 40 3.032399 0.569793 
Int. Control 1 Int. Control 7 42 2.570053 0.476614 
Int. Control 2 Int. Control 7 23 2.583275 0.571071 
Int. Control 3 Int. Control 7 76 2.365656 0.378631 
Int. Control 4 Int. Control 7 16 1.620137 0.405034 
Int. Control 5 Int. Control 7 18 1.93333 0.463637 
Int. Control 6 Int. Control 7 21 2.538704 0.577987 
Int. Control 7 Int. Control 7 22 2.710189 0.607743 
Int. Control 8 Int. Control 7 18 2.432929 0.583447 
Int. Control 9 Int. Control 7 32 2.742669 0.548534 
Int. Control 10 Int. Control 7 26 2.873798 0.611389 
Aviguard 1 Aviguard 7 54 3.857191 0.670246 
Aviguard 2 Aviguard 7 48 2.141492 0.383439 
Aviguard 3 Aviguard 7 56 4.19332 0.722071 
Aviguard 4 Aviguard 7 43 3.110422 0.573216 
Aviguard 5 Aviguard 7 60 4.143292 0.701434 
Aviguard 6 Aviguard 7 49 3.625462 0.645708 
Aviguard 7 Aviguard 7 52 3.408657 0.597964 
Aviguard 8 Aviguard 7 63 4.560059 0.762899 
Aviguard 9 Aviguard 7 61 4.558576 0.768636 
Aviguard 10 Aviguard 7 51 3.949838 0.696323 
3d_CMT1 CMT 3 58 3.196973 0.545747 
3d_CMT2 CMT 3 29 2.427429 0.499679 
3d_CMT3 CMT 3 114 4.3293 0.633597 
3d_CMT4 CMT 3 65 3.953652 0.656495 
3d_Aviguard1 Aviguard 3 39 3.27769 0.62014 
3d_Aviguard2 Aviguard 3 36 3.598092 0.695966 
3d_Aviguard3 Aviguard 3 43 3.553481 0.654867 
3d_Ext. Control 1 Ext. Control 3 26 2.336354 0.49705 
3d_Ext. Control 2 Ext. Control 3 23 1.612776 0.356528 
3d_Ext. Control 3 Ext. Control 3 22 2.04975 0.459644 
3d_Int. Control 1 Int. Control 3 15 2.203958 0.564121 
3d_Int. Control 2 Int. Control 3 8 1.441641 0.480547 
3d_Int. Control 3 Int. Control 3 19 2.344251 0.551858 
AV_MAT_1 AvMat N/A 92 4.665639 0.715198 
CMT_MAT_1 CMTMat N/A 362 6.458213 0.759804 
CMT_MAT_2 CMTMat N/A 343 6.529707 0.77531 
Appendices 
303 
 
 
